<SEC-DOCUMENT>0001628280-22-019309.txt : 20220722
<SEC-HEADER>0001628280-22-019309.hdr.sgml : 20220722
<ACCEPTANCE-DATETIME>20220722162805
ACCESSION NUMBER:		0001628280-22-019309
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20220430
FILED AS OF DATE:		20220722
DATE AS OF CHANGE:		20220722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11504
		FILM NUMBER:		221100204

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>csbr-20220430.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7,d:776cf0b85fdb44a193c88f4fc7063181--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:csbr="http://championsoncology.com/20220430" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>csbr-20220430</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV8yLTEtMS0xLTE0Mzky_f112a631-988e-4870-a340-4726d31ff2ff">0000771856</ix:nonNumeric><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV83LTEtMS0xLTE0Mzky_2e60382e-6889-487c-85b4-c8dbcead7b77">false</ix:nonNumeric><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV85LTEtMS0xLTE0Mzky_299884bf-a246-4353-8124-f9b867fde213">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV8xMC0xLTEtMS0xNDM5Mg_03154902-c643-4bce-8ed3-a1c5a7254321">2022</ix:nonNumeric><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_4f9d5fac-8fa3-4bdf-b216-6f35e4ad8cd6">http://fasb.org/us-gaap/2022#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_83245714-dbce-4c16-95f3-18378f367455">http://fasb.org/us-gaap/2022#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_4bd9ec76-9111-4d75-a50f-d39d93fb58f3">http://fasb.org/us-gaap/2022#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_f5fd1e33-d369-4f1c-8371-9f7463dbc1e1">http://fasb.org/us-gaap/2022#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="csbr-20220430.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579e3079125343b4ac0c1233280dec0b_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i848cb9d7336747e68cfca92323b68acd_I20220720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ied6c8b18575745c19253a47ee2b946cd_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca155caea5f443da349ba10a3f84e1c_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa0daba14924b7d8838223b79f88c5b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02f3872d53a43f0a007156fe38211da_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2374b15e0606422f934d250e545fd7fd_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75e18175028428b92779412b437c5ac_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54a1d7487da488cbb84e20d7806250c_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fbb1281510d4a9893e74a6b8dad4aa2_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide558d40319b4db7bc7ac08294103641_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003c4a752f33480a906e9a3da5091e95_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc700e99e614f63be6283f7eea85ac1_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad133947d589468393bb167e733a7f9e_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f8236966dfe48fdbde9087ecc55f047_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f31a264cd4f4bd691dfd8d18e642222_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id431aa7354ed4c17822b0e24b7a2d5f8_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f25fb6e99f4ed98158edec2f27704a_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>csbr:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>csbr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e22e4b5df54df1862ddd1cc4b4935a_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:FewContractsMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd7cd0ec9ba489bbd06b6da6761fbcc_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:FewContractsMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1df8ed1c598465da670d79e3593edc3_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e36386ee4d4a73a89948ef648fc5c7_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b6dabdf94b404eb4437550f85937c4_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b035faecffc4387a2253d46e038e904_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b1597843e04e4d850927f9e6336bec_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568b515a477e47eab0c4e0a329fa4bb3_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ad5abd59b8400788b5b367632d5473_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35ac20f4a06475fa1113e6fe75b4f85_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b0060bd8694b6fb702f24b7e796e2b_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1aaf64c59043568e7d5f17d579c269_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748895a7edfe4b3297a3b13b1255c579_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5aecbec4114718bfe16c50c87355f3_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f37c8ede37d417ea5b2dcff2fe06109_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">csbr:FinanceLeasedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c343591f7aa43e9bbf094ff48848b15_D20190501-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">csbr:FinanceLeasedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75381282e8854f8aa4162452573b81af_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37caf4f2f3b94b46a64f2e1ccc27d921_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603726853868452081ffb4f2ddec75af_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8779c4cdedb2440f85a3c8ca3a5b66f1_D20191201-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b7070af4eb4a99ab731259dead4896_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82b4636bcec43a581c7c41150e8c863_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb85b2ee4da64c099fc6a0fbbd34f4d4_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fa58ff128b48d4a12d943d7cb17020_D20190501-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i22b89d0c347047c4a863838d447fe6b2_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7944dc3e37d5471fac3e5aa26a76720a_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2022FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b3c65241cc4e8181694452a5e4d0eb_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2022FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbb55bcd7d8409f95ab07871b4f00eb_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PharmacologyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ae863a047f404ebf60eb56f8352be7_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PharmacologyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9d5b70c71944c3b1537441f0cba8e8_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e613c7ed7e462d8916e09de7dfd9b6_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75ddc90488642fe9524dca29561cb31_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PersonalizedOncologyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ace46fb73764dc580412ddfa1073ea4_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PersonalizedOncologyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">csbr:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c0dcae4e7d40d4b0fb1669660fdd03_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2997e8d60bcf46f9ba6c1f4ca4110249_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55eff6dffbf4ce19f35251ba3c322f6_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23746d0989e4145af18c84580ca48f6_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c8d68a641f4e3b847ea1ccfcd8e347_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43786c34b50d435293e7048f0d6fb091_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b63951e3c94191b0de18e0a98025b5_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">csbr:TranslationalOncologySolutionsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541e144c82554a4e88aec80277e945e8_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">csbr:TranslationalOncologySolutionsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c10eebe3ea442a931103ac31ce4af1_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1add8ac2df4b9ebbefa41994d6bc10_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a9f833a47649688056938280a6100a_D20110218-20110218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-02-18</xbrli:startDate><xbrli:endDate>2011-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f8fd968db64d9aab0a9c7ba34faf09_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:DirectorCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-12</xbrli:startDate><xbrli:endDate>2013-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0fa135aa62446eb639c81206006175_D20131212-20131212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:DirectorCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-12</xbrli:startDate><xbrli:endDate>2013-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2499764558fa4746ac056a1fff5047ae_D20131212-20131212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-12</xbrli:startDate><xbrli:endDate>2013-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98768c91edc344c293525a163b2ebfb6_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f86018505f24f40a948b8a3bda2f392_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5a1fb68099489386e300756890aabb_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0d1264a9d342c3a89311559d727593_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74600c6b29b46c4882983e3cc60d3ed_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e6f0d067d84392bf315f54788e6654_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8126402c4f4240ec950ef891d3d9bad6_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i494cc1892ba8486dadda4d692b680743_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabe360fb07c401a827aa2b65746f3bb_D20190501-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a6fd87cc4541c9b8207826c0d2619a_I20130430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2013-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9df412082144bbb11d4d6da935fb41_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee677f4c8194c56a69b04f0e5332d03_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d88492120f4baca21ed89485bb0844_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d9cbec92d244c1bbb79ddf79455794_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4a80baff484f72aa17c4f7022a0626_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06e952147154d71b46d16b5e28a9fbe_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:CorporateHeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a586d6407045b5b2f71a3e6734cb67_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:CorporateHeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ae521181894cad8b64e2c702464cd0_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic847c89affc44622b37366e5f79fce04_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia727ea5ecb214935b2eeee869e2b3b96_D20200501-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie013b3012171467f93337908fb07dbff_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2df47285234084835a949fca5c80c3_I20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d1b96629e44d2bb9a499800cbc3b4c_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690a0daa1ab0464ba51eacbabf4ce92b_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aea2d8b8182467a8e0b368c96d67fa9_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef7fbd4bc8c4f4aab264f5fd41fec64_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c506566730476cb94f0263057c0930_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1c7838e6524ef6b1bb93bf4114d1ba_D20210501-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43d4a95e25b464dacea18dbf70da83b_D20200501-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96bb2ef9275f46ac8d01edb098d08a40_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000771856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i776cf0b85fdb44a193c88f4fc7063181_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE5_1f0a56c5-228a-46bb-9941-e144d25aa94a">10-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:460.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8wLTEtMS0xLTE0Mzky_9398304f-48b6-4e91-b1f5-de708f9d94a0">&#254;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR 15(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8xLTItMS0xLTE0Mzky_ccf954ef-22ca-46ef-b328-13f5fd4583d1"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8xLTItMS0xLTE0Mzky_217066fe-8c6b-40e6-85ba-6cd6cfa2c74c">April 30</ix:nonNumeric>, 2022</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:460.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NmQyMzY5YzAyNjQ1NDZmNWIyYzEzNDc2ZDljOTMyMjIvdGFibGVyYW5nZTo2ZDIzNjljMDI2NDU0NmY1YjJjMTM0NzZkOWM5MzIyMl8wLTEtMS0xLTE0Mzky_ac738822-327a-44c8-8d0f-13d0427e2844">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 13 OR 15(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">to</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjIw_dc695d46-ff1c-4de5-80e4-e3fb477b76e4">001-11504</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE1_24443dc0-8006-4972-b47f-b1e1afb85c75">CHAMPIONS ONCOLOGY, INC.</ix:nonNumeric></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as defined in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF8wLTAtMS0xLTE0Mzky_4f264ee7-a439-4208-858c-e94ce0b6e393">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF8wLTEtMS0xLTE0Mzky_cf322bfd-7de0-4578-bda4-7ddc1765cd65">52-1401755</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF80LTAtMS0xLTE0Mzky_efc59d8e-4b65-443b-b010-11506dc0d3ec">One University Plaza, Suite 307</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF80LTEtMS0xLTE0Mzky_1f375ab8-790d-4e2e-ba14-a275abb1eefe">07601</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF81LTAtMS0xLTE0MzkyL3RleHRyZWdpb246ZmJkODk4ZmY1YTdiNDZjM2IzNjg5Y2VhYWRhMDY0ODRfNA_caaf0634-e681-4ce5-a45d-ab5fe6cd91ba">Hackensack</ix:nonNumeric>, <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF81LTAtMS0xLTE0MzkyL3RleHRyZWdpb246ZmJkODk4ZmY1YTdiNDZjM2IzNjg5Y2VhYWRhMDY0ODRfOA_fa4f145e-7e83-4a8a-b8e5-8b556c1db061">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE2_dac4ce2a-2170-49e0-bbf4-badcf131b615">201</ix:nonNumeric>) <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE3_513720f6-20fa-402f-a5ec-ce06d8092f36">808-8400</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTAtMS0xLTE0Mzky_ad1b369c-716d-41e4-afd3-cde40e2031d7">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTItMS0xLTE0Mzky_e52f043c-5add-469e-bc01-d036b6d2612e">CSBR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTQtMS0xLTE0MzkyL3RleHRyZWdpb246MjljNjc1ZGNmM2NiNDFlMGI5Y2FkZWE1MGZjNWY1Y2NfNA_b5f13ec0-72e9-4fd4-868d-40025c77ecb0">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjA4_fcef21a0-908a-4e91-b8e6-ce64d649b902">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjA5_42e320f1-4e25-466d-8f81-b41f01301ec5">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEw_ef97cc43-7559-4a01-8898-ce06cf212ce6">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEx_a532048a-0501-4478-8577-6a59c694f01f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8yLTAtMS0xLTE0Mzky_d087f40c-1a9d-40e1-babe-72da03705d4d">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8yLTYtMS0xLTE0Mzky_68f13ebb-0e63-473b-8a22-07c8a276cdaa">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8zLTYtMS0xLTE0Mzky_cf766b18-6cb1-4cb8-bc6a-6ed9c232be3c">&#168;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Indicate by checkmark whether the registrant has filed a report on the attestation to its management&#8217;s effectiveness of its internal control over financial reporting under section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262 (b) by the registered public accounting firm that prepared or issued its audit report.&#160; &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEy_45e57d83-889c-4863-b15e-8293611a6bf2">&#168;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEz_50564527-be3f-4068-afcd-bd557f2bd8ed">&#254;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate aggregate market value of the voting stock held by non-affiliates of the Registrant as of October 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i579e3079125343b4ac0c1233280dec0b_I20211031" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8yNzQ4Nzc5MDcyNzk1_cbb117d5-eede-4221-9b0a-e52e884014bc">44.0</ix:nonFraction>&#160;million based on the closing price of the Registrant&#8217;s common stock as quoted on the Nasdaq Capital Market as of that date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock of the Registrant outstanding as of July 20, 2022 was <ix:nonFraction unitRef="shares" contextRef="i848cb9d7336747e68cfca92323b68acd_I20220720" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8yMTk5MDIzMjU4OTIz_a2608d10-3bd5-41dd-9d49-b482087c6223">13,522,441</ix:nonFraction>.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE4_b97ec693-b2e5-4b97-99c9-1063450e4462" escape="true">Portions of the Registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, are incorporated by reference into Part III of this Form 10-K.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED APRIL 30, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_22">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_25">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_25">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_28">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_31">15</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_37">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_40">Reserved</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_40">16</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_43">16</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_58">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_58">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_61">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_64">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_64">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_67">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_67">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_70">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_70">22</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_73">PART III</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_76">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_76">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_79">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_79">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_82">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_82">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_85">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_85">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_88">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_88">23</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_91">PART IV</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_94">Exhibits, Financial Statement Schedules.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_94">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_97">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_97">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_100">26</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report on Form 10-K (the "Annual Report"), &#8220;Champions Oncology, Inc.,&#8221; &#8220;Champions,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Champions Oncology, Inc. and its subsidiaries, except where the context otherwise requires or as otherwise indicated.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") that inherently involve risk and uncertainties.&#160;&#160;Forward-looking statements may be identified by the words &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;likely&#8221; or similar expressions. Forward-looking statements in this Annual Report include statements about our business strategies and products development activities, including the anticipated benefits and risks associated with those strategies as well as statements about the sufficiency of our capital resources.&#160;&#160;One should not place undue reliance on these forward-looking statements.&#160;&#160;We cannot guarantee that we will achieve the plans, intentions or expectations expressed or implied in our forward-looking statement.&#160;&#160;There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make.&#160;&#160;These important factors are described under &#8220;Risk Factors&#8221; set forth below.&#160;&#160;In addition, any forward-looking statements we make in this Annual Report speak only as of the date of this document, and we do not intend to update any such forward-looking statements to reflect events or circumstances that occur after that date, except as required by law.&#160;&#160;As a result of these and other factors, our stock price may fluctuate dramatically.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The PDX bank is highly characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of data for our large oncology dataset (the &#8220;Datacenter&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Datacenter combines our proprietary dataset with other large publicly available datasets. This dataset currently includes approximately 3,500 molecular datasets (genomics, transcriptomics, proteomics, phosphor-proteomics), approximately 3,000 clinical drug responses, approximately 3,500 in vivo drug responses, and the accompanying clinical information on the patients from which they were derived (pre and post tumor sample acquisition of drug treatments and responses, age, gender, ethnicity, tumor stage, tumor grade, location of tumor biopsy, histology, etc.) derived from our TumorBank.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One unique feature of this proprietary dataset is the fact that it is derived from a living TumorBank. This allows us to continue characterizing the TumorBank over time, and increasing the depth of characterization of the accumulated data. The combination of the breadth and depth of the TumorBank, and associated characterization, drives the value of our Datacenter. The Datacenter also includes approximately 20,000 publicly available datasets including genomics, transcriptomics, proteomics, and functional genomics, and patient outcome. This Datacenter facilitates our computational approach to drug discovery and provides the foundation to our Software as a Service ("SaaS") offerings. Collectively, our computational and experimental research platforms enable a more rapid and precise approach to drug discovery and development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through our technology platforms, we have designed an ecosystem of business lines consisting of:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The sale of research services utilizing our innovative research platforms to biopharmaceutical companies</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The sale of oncology research Software as a Service ("SaaS") tools to cancer research scientists</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The discovery and development of novel oncology therapeutics</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translational Oncology Solutions (TOS) Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Services </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research services utilize our research center to assist pharmaceutical and biotechnology companies with their drug development process. We perform studies which we believe may predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with other drugs and can stimulate the results of human clinical trials. These studies include in vivo studies that rely on implanting multiple tumors from our TumorBank in mice and testing the therapy of interest on these tumors. Studies may also include bioinformatics analysis that reveal the differences in the genetic signatures of the tumors that responded to a therapy as compared to the tumors that did not respond. Our studies can be used to determine which types of cancer, if any, may be inhibited by a drug. The studies can also be used to identify specific sub-populations, often characterized by particular genetic mutations that are differentially sensitive or resistant to a drug or drug combination. Additionally, we provide computational or experimental support to identify novel therapeutic targets, select appropriate patient populations for clinical evaluation, identify potential therapeutic combination strategies, and develop biomarker hypothesis of sensitivity or resistance. These studies include the use of our in vivo, ex vivo, analytical and computational platforms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasing the breadth of the TumorBank is an important strategic effort of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest significant research and development resources to increase the number of PDX Models in our TumorBank and add unique and different sub-types of cancer that are not historically addressed. This effort also allows us to build highly valuable PDX models derived from patients with resistance to specific therapies or important molecular annotations. We also invest significant resources to increase the depth of characterization of the TumorBank. For each model, this characterization includes phenotypic analysis, molecular analyses, and pharmacologic analysis. This depth of characterization, in an individual tumor basis, is unique and not widely available.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have performed studies for approximately 500 different pharmaceutical and biotechnology companies over the past ten years, have a high rate of repeat business, and contract with pharmaceutical and biotechnology companies across North America, Europe and Asia. Studies are performed in a preclinical non-regulatory environment, as well as a Good Clinical Regulatory Practice (GCLP) regulatory environment for clinical evaluation. Typical studies are in the $125,000 price range, with an increasing number of studies in the $250,000 to $500,000 range. Studies performed in a regulatory environment can be much larger than those performed within a non-regulatory environment. Revenue from this business has grown at an average annual growth rate of 28% since 2016 and represents the primary source of our current revenue stream.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software As A Service (SaaS) Business</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our SaaS business, launched in fiscal year 2021, is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin&#8221;), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscriptions basis. Our software development teams consist of bioinformatics scientists, mathematicians as well as software engineers. Lumin leverages Champions&#8217; large Datacenter coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research. It is the combination of the Datacenter and the analytics that create a unique foundation for Lumin. Insights developed using Lumin can provide the basis for biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Development Business</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began investing in drug discovery in fiscal year 2021. Our nascent drug discovery and development business leverages the computational and experimental capabilities within our platforms. Our discovery strategy utilizes our Datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then employ the use of our proprietary experimental platforms to rapidly validate these targets for further drug development efforts. Our efforts center around three areas of focus:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Targeted therapy with drug conjugates</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Immune oncology</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Cell therapy</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug discovery and development business is dependent on a dedicated research and development team, made up of computational and experimental scientists.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, the scientific teams within our Drug Discovery and Development teams are appropriately segregated from our other businesses.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a rich pipeline of targets at various stages of discovery and validation, with a select group that has progressed to therapeutic development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial strategy for the validated targets and therapeutics established from this business is wide-ranging and still being developed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It will depend on many factors, and will be specific for each target or therapeutic area identified.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We regularly evaluate strategic options to create additional value from our drug discovery business, which may include, but are not limited to, potential spin-out transactions or capital raises.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and marketing efforts are dependent on a dedicated sales force of approximately 31 professionals that sell our services directly to pharmaceutical and biotechnology companies. Our research services team is focused on identifying and selling studies to new customers as well as increasing our revenue from our existing customer base. We spend significant resources in informing our customers and reaching out to new contacts within companies that we currently serve. These efforts are aimed at moving our customers along the adoption curve for our research platforms, thereby increasing the number of studies and the average study size. Our success in these efforts is demonstrated by the growing number of customers who have increased their annual spend on our services over the years.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SaaS business development team is focused on identifying and selling subscriptions to new customers, ensuring a high level of use from these subscribers, and increasing our revenue from existing customers through the use of our cloud computing environment. Our sales approach is based on in informing our current research services customers and reaching out to new contacts within companies that we currently serve.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended  April&#160;30, 2022, revenues from our products and services totaled approximately $49.1 million, an increase of approximately 20% from the previous year.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Current Strategy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to use our various platform technologies to drive multiple synergistic revenue streams. We continue to build upon this with investments in research and development. Our enterprise strategy consists of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Establish a global leadership position in oncology research</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">A focus on bringing better drugs to patients faster</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Leading innovation in oncology research and development platforms</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Cultivating a solid reputation for the quality of data acquisition and interpretation</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Collaborations across the global biopharma landscape</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Profitable growth across all business lines</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Growth and Expansion Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to continue to use our various platform technologies to drive multiple synergistic revenue streams. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for growth has multiple components: &#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Growing our TumorBank: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grow our TumorBank in two ways. First, leverage a medical affairs team that works with a well established clinical network to facilitate access to patients diagnosed with prioritized tumors subtypes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, we utilize our legacy Personalized Oncology Services business to establish novel PDX models from patients who use this service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PDX models are then deeply characterized at the phenotypic, molecular, and pharmacologic levels.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This data characterization is then added to our DataCenter. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Adding new experimental technologies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fields of oncology research and drug development are evolving rapidly. To keep up with new approaches, we continuously add new technologies to platform. We are currently investing in developing additional proprietary pharmacology platforms aimed at enhancing the scientific output and driving innovation in the oncology research sector. We are also investing in the development of sophisticated analytical platforms which allow scientists to derive deeper insights when using our pharmacology platforms. Once these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experimental technologies are established they are made available to our research and development and target discovery teams.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Continued development of computational power:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have developed sophisticated and innovative computational approaches. We continue to invest in the development of novel artificial intelligence, data structures, and analytics. Our goal is to leverage our unique Datacenter to establish elegant ways to better understand the molecular dynamics of cancer, and the development novel therapeutics.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Champions currently competes in three different markets: </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Pharmaceutical companies rely on outsourcing preclinical studies to Clinical Research Organizations ("CROs").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in this industry is intense and based significantly on scientific, technological, and market forces, which include the effectiveness of the technology and products and the ability to commercialize technological developments. The Company faces significant competition from other healthcare companies in the United States and abroad. The majority of these competitors are, and will be, substantially larger than the Company, and have substantially greater resources and operating histories. There can be no assurance that developments by other companies will not render our products or technologies obsolete or non-competitive or that we will be able to keep pace with the technological or product developments of our competitors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies, as well as academic institutions, governmental agencies, and private research organizations also compete with us in recruiting and retaining highly qualified scientific, technical and professional personnel and consultants. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SaaS:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two important components of Lumin Bioinformatics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Datacenter and the Analytics. While we feel our Datacenter is unique, there are a large number of publicly available datasets that can be accessed free of charge for computational research. This publicly available data repertoire is constantly growing as academic labs publish results. We continue to find ways to differentiate our dataset, however there can be no assurance that developments by other companies or academic institutions in data curation will not render our Datacenter obsolete or non-competitive. The second component of Lumin Bioinformatics is the data analytics. While there are a minimal number of software solutions that offer the degree of analytics available within Lumin Bioinformatics, the know-how and workflows of these analytics are well established in bioinformatics labs across academia and the biopharmaceutical industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the barrier to entry for developing a SaaS tool leveraging these analytics is relatively low. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Developmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">t: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Drug Discovery and Development business places us in a good position of also competing against the same customers of our Research Services and/or SaaS businesses: the global biopharmaceutical industry. The global oncology drug market is estimated to be $85B.  Competition in this industry is strong and based significantly on scientific and technological forces, which rely solely on the effectiveness of therapeutics designed to treat cancer. The Company faces significant competition from other biopharmaceutical companies in the United States and abroad. The competitors have a wide range of strategic and operational approaches. Our business strategy is to work with differentiated therapeutic targets and research areas. However, given the intense degree of privacy from our competitors, we cannot guarantee that others within the industry are not also working on these targets. Further, some competitors will operate with no laboratory or experimental operations, while others will have varying degrees of laboratory space and experimental capabilities. There can be no assurance that developments by other companies will not render experimental platforms obsolete or non-competitive or that we will be able to keep pace with the technological or product developments of our competitors. These companies, as well as academic institutions, governmental agencies, and private research organizations also compete with us in recruiting and retaining highly qualified scientific, technical and professional personnel and consultants. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended April 30, 2022 and 2021, we spent approximately $9.4 million and $7.2 million, respectively, to further develop our platforms. We continue to expand our TumorBank via the inclusion of tumor tissue and implanted models through research collaborations and relationships with hospitals and academic institutions. Our research and development efforts were focused on increasing our understanding of our TumorGraft models, their clinical predictability, improving growth and tumor take rates, and other biological and molecular characteristics of the models. We are investing in developing additional proprietary pharmacology platforms aimed at enhancing the scientific output and driving innovation in the oncology research sector.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also investing in the acquisition of sophisticated analytical platforms which allow scientists to derive deeper insights when using our pharmacology platforms. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, development, and marketing of&#160;our products, the performance of our legacy POS testing services, and the operation of our facilities are generally subject to federal, state, local, or foreign legislation, including licensure of our laboratory located in Rockville, Maryland by the State of Maryland  and compliance with federal, state, local or foreign legislation applicable to the use of live animals in scientific testing, research and education.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has claimed regulatory authority over laboratory developed tests such as our legacy POS products, but has generally not exercised it. The FDA has announced regulatory and guidance initiatives that could increase federal regulation of our business. We are subject to federal and international regulations with regard to shipment of hazardous materials, including the Department of Transportation and the International Air Transit Authority. These regulations require interstate, intrastate, and foreign shipments comply with applicable labeling, documentation, and training requirements.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 15, 2022, we had 230 full-time employees, including 78 with doctoral or other advanced degrees. Of our workforce, 181 employees are engaged in research and development and laboratory operations, 31 employees are engaged in sales and marketing, and 18 employees are engaged in finance and administration.&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success will depend, in part, on our ability to continue to attract, hire, and retain qualified personnel. We continue to seek additions to our science and technical staff, although the competition for such personnel in the pharmaceutical and biotechnology industries is intense. Attracting, developing, and retaining skilled and experienced employees in our industry is crucial to our ability to compete effectively. Our ability to recruit and retain such employees depends on a number of factors, including our corporate culture and work environment, our corporate philosophy, internal talent development and career opportunities, and compensation and benefits.  </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees are represented by a labor union or covered by collective bargaining agreements.&#160;&#160;We have never experienced a work stoppage and believe our relationship with our employees is good.  </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company History</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as a merger and acquisition company under the laws of the State of Delaware on June 4, 1985, under the name &#8220;International Group, Inc.&#8221;  In September 1985, the Company completed a public offering and shortly thereafter acquired the world-wide rights to the Champions sports theme restaurant concept and changed its name to &#8220;Champions Sports, Inc.&#8221;  In 1997, the Company sold its Champions service mark and concept to Marriott International, Inc. and until 2005, was a consultant to Marriott International, Inc. and operated one Champions Sports Bar Restaurant. In January 2007, the Company changed its business direction to focus on biotechnology and subsequently changed its name to Champions Biotechnology, Inc. On May 18, 2007, the Company acquired Biomerk, Inc., at which time we began focusing on our current line of business. In April 2011, the Company changed its name to Champions Oncology, Inc. to reflect the Company's new strategic focus on developing advanced technologies to personalize the development and use of oncology drugs.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.championsoncology.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Information on our website is not part of this Annual Report. Through our website, we make available, free of charge, access to all reports filed with the United States Securities and Exchange Commission, or SEC, including our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, our Proxy Statements on Schedules 14A and amendments to those reports, as filed with or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.&#160;&#160;Copies of any materials we file with, or furnish to, the SEC can also be obtained free of charge through the SEC&#8217;s website at http://www.sec.gov.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks described below together with all of the other information included in this Annual Report.&#160;&#160;The risks and uncertainties described below are not the only ones we face.&#160;&#160;Additional risks not presently known, or those we currently consider insignificant, may also impair our business operations in the future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended April 30, 2022 and 2021, the Company had net income of approximately $548,000 and $362,000, respectively.&#160;&#160;As of April&#160;30, 2022, the Company has an accumulated deficit of approximately $72.0 million. As of April&#160;30, 2022, we had working capital of $2.2 million and cash of $9.0 million. We believe that our cash on hand, together with  expected cash flows from operations, are adequate to fund our operations through at least August 2023.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of our income or losses and liquidity requirements may vary significantly from year-to-year and quarter-to-quarter and will depend on, among other factors:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of continuing to build out our TumorGraft bank;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and rate of progress toward growing our technology platforms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and rate of progress toward building our business units;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of increasing our research and development;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of renting our laboratory and animal testing facilities and payment for associated services;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of obtaining and maintaining any necessary regulatory approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of expanding and building out our infrastructure; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost incurred in hiring and maintaining qualified personnel.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company derives revenue primarily from research services, while pursuing efforts to further develop its SaaS and drug discovery business units. We are investing resources to further grow our sales of all of our business units.&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become sustainably profitable, we will need to generate revenues to offset our operating costs, including our research and development and general and administrative expenses. We may not achieve or sustain our revenue or profit objectives. If we incur losses in the future and/or we are unable to obtain sufficient capital either from operations or externals sources, ultimately, we may have to cease operations.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to grow revenues, we must invest capital to implement our sales and marketing efforts and to successfully develop our technology platforms. Our sales and marketing efforts&#160;may never generate significant increases in revenues or achieve profitability and it is possible that we will be required to raise additional capital to continue our operations. If we must devote a substantial amount of time to raising capital, it will delay our ability to achieve our business goals within the time frames that we now expect, which could increase the amount of capital we need. In addition, the amount of time expended by our management on fundraising distracts them from concentrating on our business affairs. If we require additional capital and are not successful in raising the needed capital, we may have to cease operations.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may incur greater costs than anticipated, which could result in sustained losses.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use reasonable efforts to assess and predict the expenses necessary to pursue our business strategies. However, implementing our business strategies may require more employees, capital equipment, supplies or other expenditure items than management has predicted.&#160;Similarly, the cost of compensating additional management, employees and consultants or other operating costs may be more than we estimate, which could result in ongoing and sustained losses.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to implement our business strategies which could impair our ability to continue operations.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of our business strategies will depend in large part on our ability to (i)&#160;attract and maintain a significant number of customers; (ii)&#160;effectively provide acceptable services to our customers; (iii)&#160;develop and license new products and technologies; (iv)&#160;&#160;maintain appropriate internal procedures, policies, and systems; (v)&#160;hire, train, and retain skilled employees and management; (vi)&#160;continue to operate despite increasing competition in our industry; and (vii) establish, develop and maintain our name recognition. Our inability to obtain or maintain any or all these factors could impair our ability to implement our business strategies successfully, which could have material adverse effects on our results of operations and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research services are performed in laboratories that are subject to state regulation and licensure requirements. Such regulation and requirements are subject to change, and may result in additional costs or delays in providing our products to our customers. In addition, the healthcare industry in general is highly regulated in the United States at both the federal and state </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">levels. We seek to conduct our business in compliance with all applicable laws, but many of the laws and regulations potentially applicable to us are vague or unclear. These laws and regulations may be interpreted or applied by an authority in a way that could require us to make changes in our business. We may not be able to obtain all regulatory approvals needed to operate our business or sell our products. If we fail to do so, we could be subject to civil and criminal penalties or fines or lose the authorizations necessary to operate our business, as well as incur additional liabilities from third parties. If any of these events happened, they could hurt our business and financial results.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently utilize several office suites where our laboratories are located within one facility in Rockville, Maryland.  If this facility was to be significantly damaged or destroyed, we could suffer a loss of our ongoing and future drug studies, as well as our TumorBank. In addition, we lease the laboratories from a third party. If we had a dispute with our landlord or otherwise could not utilize our space, it would take time to find and move to a new facility, which could negatively affect our results of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research services operations depend on having a colony of live mice available. If this population experienced a health crisis, such as a virus or other pathogen, such crisis would affect the success of our existing and future business, as we would have to rebuild the population and repeat current studies.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have limited experience marketing and selling our products&#160;and may need to rely on third parties to successfully market and sell our products and generate revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we rely on the internet, word of mouth, and a small sales force to market our services. We have to compete with other pharmaceutical, biotechnology and life science technology and service companies to recruit, hire, train, and retain marketing and sales personnel.  However, there can be no assurance that we will be able to develop in-house sales, and as a result, we may not be able to generate product revenue.&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will continue to be dependent upon key employees.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, currently, is dependent upon the efforts of several full-time key employees, the loss of the services of one or more of which would have a material adverse effect on our business and financial condition. We intend to continue to develop our management team and attract and retain qualified personnel in all functional areas to expand and grow our business. This may be difficult in the healthcare industry where competition for skilled personnel is intense.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">In fiscal 2021, we identified that there was a material weaknesses in our internal control over financial reporting, which if not remediated, could materially adversely affect our ability to timely and accurately report our results of operations and financial condition. We believe this material weakness has since been remediated as of the filing date of this Form 10-K. If we fail to maintain an effective system of internal controls, the accuracy and timing of our financial reporting may be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:25.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in &#8220;Part II, Item 9A - Controls and Procedures,&#8221; of this Form 10-K we have concluded that there was a material weakness in our internal control over financial reporting in our prior fiscal reporting year. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.  It is necessary for us to maintain effective internal control over financial reporting to prevent fraud and errors and to maintain effective disclosure controls and procedures so that we can provide timely and reliable financial and other information.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:25.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Specifically, our risk assessment procedures over certain of our contractual arrangements requiring the payment of royalties for the licensing of technology from third-parties did not adequately identify the risks and consider the Company's obligations based on the recognition of oncology services revenue for the prior fiscal year.  As a result, the Company had missing process level controls over the review of royalty arrangements and the timely determination and recognition of related liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:25.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As further described in Part II, Item 9A in this Annual Report on Form 10-K, while we believe that we have implemented and carried out a remediation plan to remediate this material weakness, there can be no assurance that this will not occur in future reports. We may identify additional material weaknesses in our internal control over financial reporting in the future. If </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we are unable to fully remediate this material weakness or we identify additional material weaknesses in our internal control over financial reporting in the future, we may not be able to analyze, record and report financial information accurately, and/or to prepare our financial statements within the time periods specified by the rules.</span></div><div style="text-align:justify;text-indent:25.3pt"><span><br/></span></div><div style="text-align:justify;text-indent:25.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in a rapidly changing and highly competitive field. Potential competitors in the United States and abroad are numerous and include providers of clinical research services, most of which have substantially greater capital resources and more experience in research and development capabilities. Furthermore, new companies will likely enter our market from the United States and abroad, as scientific developments surrounding other pre-clinical and clinical services grow in the multibillion dollar oncology marketplace.&#160;&#160;Our competitors may succeed in selling their products to our pharmaceutical and biotech customers more effectively than we sell our products. &#160;In addition, academic institutions, hospitals, governmental agencies, and other public and private research organizations also may conduct similar research, seek patent protection, and may develop and commercially introduce competing products or technologies on their own or through joint ventures. If one or more of our competitors succeeds in developing similar technologies and products that are more effective or successful than any of those that we currently sell or will develop, our results of operations will be significantly adversely affected.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, we may not be able to compete as effectively.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important in the healthcare industry to obtain patent and trade secret protection for new technologies, products, and processes. Our success will depend, in part, upon our ability to obtain, enjoy, and enforce protection for any products we have, develop or acquire under United States and foreign patent laws and other intellectual property laws, preserve the confidentiality of our trade secrets, and operate without infringing the proprietary rights of third parties. Where appropriate, we will seek patent protection for certain aspects of our technology. However, while our TumorGraft Technology Platform is proprietary and requires significant know-how to both initiate and operate, it is not patented. It is, therefore, possible for competitors to develop other implantation procedures, or to discover the same procedures utilized by us, that could compete with us in our market.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It also is unclear whether efforts to secure our trade secrets will provide useful protection. While we will use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose our proprietary information to competitors resulting in a loss of protection. Enforcing a claim that someone else illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Finally, our competitors may independently develop equivalent knowledge, methods and know-how.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also seek to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Patent applications are maintained in secrecy in the United States and also are maintained in secrecy outside the United States until the application is published. Accordingly, we can conduct only limited searches to determine whether our technology </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringes the patents or patent applications of others. Any claims of patent infringement asserted by third parties would be time-consuming and could likely:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research service studies are subject to cancellation based on changes in customer&#8217;s development plans.</span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is primarily derived from studies performed for pharmaceutical and biotechnology companies to assist in the development of oncology drugs. There are many factors that could result in the change of our customers development plans for specific drugs, including without limitation to their research and development budgets and drug development strategies. These changes could lead to the cancellation or modification of on-going or planned studies. This would have a negative impact on the Company&#8217;s revenue growth and profit margin.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face competition in the life science market for computational software and for bioinformatics products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The market for our computational software platform for the life science market is competitive. We currently face competition from other scientific software providers, larger technology and solutions companies, in-house development by our customers and academic and government institutions, and the open-source community. Some of our competitors and potential competitors have longer operating histories in certain segments of our industry than we do and could have greater financial, technical, marketing, research and development, and other resources.  We could also face competition from open-source software initiatives, in which developers provide software and intellectual property free over the Internet. In addition, some of our customers spend significant internal resources in order to develop their own software. There can be no assurance that our current or potential competitors will not develop products, services, or technologies that are comparable to, superior to, or render obsolete, the products, services, and technologies we offer. There can be no assurance that our competitors will not adapt more quickly than we do to technological advances and customer demands, thereby increasing such competitors' market share relative to ours. Any material decrease in demand for our technologies or services may have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Drug development programs, particularly those in early stages of development, may never be commercialized.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">    Our future success depends, in part, on our ability to select successful product candidates, complete preclinical development of these product candidates and advance them to and through clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Early-stage product candidates in particular require significant investment in development, preclinical studies and clinical trials, regulatory clearances and substantial additional investment before they can be commercialized, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">    Our research and development programs may not lead to commercially viable products for several reasons, and are subject to the risks and uncertainties associated with drug development. For example, we may fail to identify promising product candidates, our product candidates may fail to be safe and effective in preclinical tests or clinical trials, or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. From time to time, we may establish and announce certain development goals for our product candidates and programs.  However, given the complex nature of the drug discovery and development process, it is difficult to predict accurately if and when we will achieve these goals.  If we are unsuccessful in advancing our research and development programs into clinical testing or in obtaining regulatory approval, our long-term business prospects will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Drug discovery programs, particularly those in early stages of development, may never be commercialized.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">      Our future success in drug discovery depends, in part, on our ability to select successful product candidates, complete preclinical development of these product candidates and advance them to and through clinical trials.  Early-stage product candidates in particular require significant investment in development, preclinical studies and clinical trials, regulatory clearances and substantial additional investment before they can be commercialized, if at all.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">    Our research and development programs related to drug discovery may not lead to commercially viable products for several reasons, and are subject to the risks and uncertainties associated with drug development. For example, we may fail to identify promising product candidates, our product candidates may fail to be safe and effective in preclinical tests or clinical trials, or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. From time to time, we may establish and announce certain development goals for our product candidates and programs.  However, given the complex nature of the drug discovery and development process, it is difficult to predict accurately if and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">when we will achieve these goals.  If we are unsuccessful in advancing our research and development programs into clinical testing or in obtaining regulatory approval, our long-term business prospects will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">   Impairment of goodwill or other long term assets may adversely impact future results of operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We have intangible assets, including goodwill, and capitalized software development costs on our balance sheet. If the future growth and operating results of our business are not as strong as anticipated and/or our market capitalization declines, this could impact the assumptions used in calculating the fair value of goodwill or recoverability of our capitalized software development costs. To the extent impairment occurs, the carrying value of our assets will be written down to an implied fair value and an impairment charge will be made to our income from continuing operations. Such an impairment charge could materially and adversely affect our operating results. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Internal Revenue Code of 1986, as amended, referred to as the Internal Revenue Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carry-forwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We believe that our 2016 public offering, taken together with our private placements and other transactions that have occurred since then, may have triggered an &#8220;ownership change&#8221; limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carry-forwards to offset U.S. federal taxable income may be subject to limitations, which potentially could result in increased future tax liability to us.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have a limited market for our common stock, which makes our securities very speculative.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Trading activity in our common stock is and has been limited. As a result, an investor may find it difficult to dispose of, or to obtain accurate quotations of the price of our common stock. There can be no assurance that a more active market for our common stock will develop, or if one should develop, there is no assurance that it will be sustained. This could severely limit the liquidity of our common stock, and would likely have a material adverse effect on the market price of our common stock and on our ability to raise additional capital. Furthermore, like many stocks quoted on the Nasdaq Capital Market, trading in our common stock is thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated to operating performance.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment in our common stock may be diluted if we issue additional shares in the future.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue additional shares of common stock, which will reduce shareholders&#8217; percentage ownership and may dilute per share value. Our certificate of incorporation authorizes the issuance of 200,000,000 shares of common stock. As of July 20, 2022, we had 13,522,441 shares of common stock issued and outstanding. The future issuance of all or part of the remaining authorized common stock would result in substantial dilution in the percentage of the common stock held by existing shareholders. The issuance of common stock for future services, acquisitions, or other corporate actions may have the effect of diluting the value of the shares held by existing shareholders, and might have an adverse effect on any market for our common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional funds by issuing equity securities or convertible debt securities in the future, our stockholders may experience significant dilution. Sale of additional equity and/or convertible debt securities at prices below certain levels will trigger anti-dilution provisions with respect to certain securities we have previously sold. If additional funds are raised through a credit facility or the issuance of debt securities or preferred stock, lenders under the credit facility or holders of these debt securities or preferred stock would likely have rights that are senior to the rights of holders of our common stock, and any credit facility or additional securities could contain covenants that would restrict our operation.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential future sales or issuances of our common stock to raise capital, or the perception that such sales could occur, could cause dilution to our current stockholders and the price of our common stock to fall.</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically supported our operations through the issuance of equity and may continue to do so in the future. Although we may not be successful in obtaining financing through equity sales on terms that are favorable to us, if at all, any such sales that do occur could result in substantial dilution to the interests of existing holders of our common stock. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the sale of a substantial number of shares of our common stock or other equity securities to any new investors, or the anticipation of such sales, could cause the trading price of our common stock to fall.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the healthcare payment system overseas to the degree we receive revenue from such healthcare systems overseas;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us of significant acquisition, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of significant shares of stock by large investors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability, or other litigation against us; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other key facts described in this &#8220;Risk Factors&#8221; section.</span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our certificate of incorporation and bylaws, and our contractual agreements could make it difficult for or prevent a third party from acquiring control of us or changing our board of directors and management. These provisions include:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements that our stockholders comply with advance notice procedures in order to nominate candidates for election to our board of directors or to place stockholders&#8217; proposals on the agenda for consideration at meetings of stockholders; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in connection with private placements of our stock in 2011, 2013 and 2015, we covenanted that we would not merge or consolidate with another company unless either the transaction and the trading volume of our stock met certain thresholds and qualifications or we obtained the consent of certain of the investors who purchased our stock in those private placements.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">provisions of Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in the stockholders&#8217; interest.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware General Corporation Law contains provisions that may have the effect of making it more difficult or delaying attempts by others to obtain control of us, even when these attempts may be in the best interests of our stockholders. We also are subject to the anti-takeover provisions of the Delaware General Corporation Law, which prohibit us from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; unless the business combination is approved in a prescribed manner and prohibit the voting of shares held by persons acquiring certain numbers of shares without obtaining requisite approval. The statutes have the effect of making it more difficult to effect a change in control of a Delaware company.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our management and four significant stockholders collectively own a substantial majority of our common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Collectively, our officers, our directors and three significant stockholders own or exercise voting and investment control of approximately 67% of our outstanding common stock as of July 20, 2022. As a result, investors may be prevented from affecting matters involving our company, including:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the composition of our board of directors and, through it, any determination with respect to our business direction and policies, including the appointment and removal of officers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any determinations with respect to mergers or other business combinations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our acquisition or disposition of assets; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate financing activities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, this concentration of voting power could have the effect of delaying, deterring or preventing a change of control or other business combination that might otherwise be beneficial to our stockholders. This significant concentration of share </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership may also adversely affect the trading price for our common stock because investors may perceive disadvantages in owning stock in a company that is controlled by a small number of stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid any cash dividends on our common stock to date and do not anticipate any cash dividends being paid to holders of our common stock in the foreseeable future. While our dividend policy will be based on the operating results and capital needs of the business, it is anticipated that any earnings will be retained to finance our future expansion. As we have no plans to issue cash dividends in the future, our common stock could be less desirable to other investors and as a result, the value of our common stock may decline, or fail to reach the valuations of other similarly situated companies who have historically paid cash dividends in the past.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock may be influenced by the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our common stock adversely, or provide more favorable relative recommendations about our competitors, the price of our common stock would likely decline. If any analyst who may cover us was to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our common stock or trading volume to decline.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">  Our business operations could be disrupted if our information technology systems fail to perform adequately.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">    We rely on information technology networks and systems, including the Internet, to process, transmit, and store information, to manage and support a variety of business processes and activities, and to comply with regulatory, legal, and tax requirements. Our information technology systems, some of which are dependent on services provided by third parties, may be vulnerable to damage, interruption, or shutdown due to any number of causes outside of our control such as catastrophic events, natural disasters, fires, power outages, systems failures, telecommunications failures, employee error or malfeasance, security breaches, computer viruses or other malicious codes, ransomware, unauthorized access attempts, denial of service attacks, phishing, hacking, and other cyberattacks. While we have experienced threats to our data and systems, to date, we are not aware that we have experienced a material breach. Cyberattacks are occurring more frequently, are constantly evolving in nature and are becoming more sophisticated. Additionally, continued geopolitical turmoil, including the Russia-Ukraine military conflict, has heightened the risk of cyberattacks. While we attempt to continuously monitor and mitigate against cyber risks, we may incur significant costs in protecting against or remediating cyberattacks or other cyber incidents.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sophisticated cybersecurity threats pose a potential risk to the security and viability of our information technology systems, as well as the confidentiality, integrity, and availability of the data stored on those systems, including cloud-based platforms. In addition, new technology that could result in greater operational efficiency may further expose our computer systems to the risk of cyber-attacks. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure and associated automated and manual control processes, we could be subject to billing and collection errors, business disruptions, or damage resulting from security breaches. If any of our significant information technology systems suffer severe damage, disruption, or shutdown, and our business continuity plans do not effectively resolve the issues in a timely manner, our product sales, financial condition, and results of operations may be materially and adversely affected, and we could experience delays in reporting our financial results. In addition, there is a risk of business interruption, violation of data privacy laws and regulations, litigation, and reputational damage from leakage of confidential information. Any interruption of our information technology systems could have operational, reputational, legal, and financial impacts that may have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks related to public health crises such as the global pandemic associated with COVID-19. The global spread of COVID-19 resulted in the World Health Organization declaring the outbreak a &#8220;pandemic,&#8221; or a worldwide spread of a new disease, in early 2020.  This virus eventually spread world wide to most&#160;countries, and to all 50 states within the United States. In response, most countries around the world imposed quarantines and restrictions on travel and mass gatherings in an effort to contain the spread of the virus. Employers worldwide were also required to increase, as much as possible, the capacity </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and arrangement for employees to work remotely. More recently, many of the restrictions and travel bans have been eased or lifted completely as global society as a whole works to return to pre-pandemic business and personal practices.  Although, to date, these restrictions have not materially impacted our operations, the effect on our business, from the spread of COVID-19 and the actions implemented by the governments of the United States and elsewhere across the globe, may, once again, worsen over time and we are unable to predict the potential impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;Any outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations. These could include disruptions or restrictions on our ability to travel, pursue partnerships and other business transactions, receive shipments of biologic materials, as well as be impacted by the temporary closure of the facilities of suppliers.   The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver supplies to us on a timely basis. In addition, health professionals may reduce staffing and reduce or postpone meetings with clients in response to the spread of an infectious disease. Though we have not yet experienced such events, if they would occur, they could result in a period of business disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.  However, as of the date of this Annual Report on Form 10-K, we have not experienced a material adverse effect on our business nor the need for reduction in our work force; and, currently, we do not expect any material impact on our long-term activity. The extent to which COVID-19 impacts our business will depend on future developments which are highly uncertain and cannot be predicted, including, but not limited to, new information which may emerge concerning the increased severity of the COVID-19 virus, the actions to contain COVID-19, or treat its impact.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">  Deterioration in general economic conditions in the United States and globally, including the effect of prolonged periods of inflation on our customers and suppliers, could harm our business and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">   Our business and results of operations could be adversely affected by changes in national or global economic conditions.  These conditions include but are not limited to inflation, rising interest rates, availability of capital markets, energy availability and costs (including fuel surcharges), the negative impacts caused by pandemics and public health crises (including the COVID-19 pandemic), negative impacts resulting from the military conflict between Russia and the Ukraine, and the effects of governmental initiatives to manage economic conditions.  Impacts of such conditions could be passed on to our business in the form of a reduced customer base and/or potential for new bookings due to possible reductions in pharmaceutical and biotech industry-wide spend on research and development and/or economic pressure on our suppliers to pass on increased costs.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.9 million and $1.3 million for the years ended April&#160;30, 2022 and 2021, respectively. The Company considers its facilities adequate for its current operational needs.</span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases the following facilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company&#8217;s corporate headquarters. The lease was renewed during fiscal 2022 and expires in November 2026. The Company recognized $88,000 and $91,000 of rental costs relative to this lease for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1330 Piccard Drive, Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The lease expires February 28, 2029. The Company recognized $1.7 million and $1.2 million of rental costs for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1405 Research Boulevard, Suite 125, Rockville, Maryland 20850, which consisted of laboratory and office space where the Company conducted operations related to its primary service offerings. The Company executed this lease on November&#160;1, 2018 and it was set to expire in&#160;April 2024. The Company terminated this lease on June 30, 2020 and transitioned its activities from this location to the Piccard Drive location, as defined above, during the first quarter of fiscal 2021. The Company recognized zero and&#160;$43,000&#160;of rental costs for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed the lease for its laboratory space in June 2021, and commenced occupancy during the three months ended October 31, 2021. This lease expires May 2023. The Company </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executed the lease for its office space on October 1, 2021.  This lease expires in September 2027. The Company recognized rental costs associated with these leases of $81,000 and zero for fiscal years 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_37"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Matters and Issuer Purchases of Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Market or Markets</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock are currently quoted on the Nasdaq Capital Market under the symbol &#8220;CSBR.&#8221; Our common stock commenced trading on the Nasdaq Capital Market on August 21, 2015. Prior to such date, our shares of common stock were traded over-the-counter and quoted on the OTCQB Marketplace.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the high and low bid prices of our common stock, as reported on Nasdaq for the periods shown:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Year Ended April 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Year Ended April 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approximate Number of Holders of Common Stock</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 20, 2022 there were approximately 1,900 record holders of the Company&#8217;s common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to receive such dividends as may be declared by our Board of Directors.&#160;&#160;No dividends have been declared or paid with respect to our common stock and no dividends are anticipated to be paid in the foreseeable future.&#160;&#160;Any future decisions as to the payment of dividends will be at the discretion of our Board of Directors, subject to applicable law.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales by the Company of Unregistered Securities</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repurchases of Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserved</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_43"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our consolidated financial statements and the related notes included elsewhere in this Annual Report.&#160;This discussion contains forward-looking statements that are based on our current expectations, estimates, and projections about our business and operations.&#160;Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those we discuss under Item 1A &#8211; &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Developments</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. Our research center consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. We perform studies which we believe may predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with other drugs and can stimulate the results of human clinical trials. These studies include in vivo studies that rely on implanting multiple tumors from our TumorBank in mice and testing the therapy of interest on these tumors. Studies may also include bioinformatics analysis that reveal the differences in the genetic signatures of the tumors that responded to a therapy as compared to the tumors that did not respond. Additionally, we provide computational or experimental support to identify novel therapeutic targets, select appropriate patient populations for clinical evaluation, identify potential therapeutic combination strategies, and develop biomarker hypothesis of sensitivity or resistance. These studies include the use of our in vivo, ex vivo, analytical and computational platforms.  </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through our Translational Oncology Solutions ("TOS"). This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.&#160;Utilizing our TumorGraft Technology Platform ("The Platform"), a comprehensive Bank of unique, well characterized models, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.</span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our growth strategy, we launched Lumin Bioinformatics ("Lumin"), a new oncology data-driven software program, during fiscal 2021. Our Lumin software contains comprehensive information derived from our research services and clinical studies. Lumin leverages Champions&#8217; large Datacenter coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research. It is the combination of the Datacenter and the analytics that create a unique foundation for Lumin. Insights developed using Lumin can provide the basis for biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.  </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug discovery and development business leverages the computational and experimental capabilities within our platforms. Our discovery strategy utilizes our rich and unique Datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets. We then employ the use of our proprietary experimental platforms to rapidly validate these targets for further drug development efforts. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We have a rich pipeline of targets at various stages of discovery and validation, with a select group that has progressed to therapeutic development. Our commercial strategy for the validated targets and therapeutics established from this business is wide-ranging and still being developed. It will depend on many factors, and will be specific for each target or therapeutic area identified. Any expenses associated with this part of our business are research and development and are expensed as incurred.</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We regularly evaluate strategic options to create additional value from our drug discovery business, which may include, but are not limited to, potential spin-out transactions or capital raises.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating results for the periods presented below (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:42.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology services revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of oncology services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology Services Revenue</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology services revenue, which is primarily derived from research services, was $49.1 million and $41.0 million, for the years ended April&#160;30, 2022 and 2021, respectively, an increase of $8.1 million, or 19.7%. The increase in revenue was primarily due to the expansion of both our platform and product lines creating additional demand for our services, leading to larger pharmacology study sizes in both our in-vivo and ex-vivo platforms. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Oncology Services</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of oncology services were $23.6 million and $21.4 million for the years ended April&#160;30, 2022 and 2021, respectively, an increase of $2.2 million or 10.2%. The increase in cost of oncology services was primarily from an increase in compensation and supply expenses resulting from the larger study sizes, and compensation expense for our SaaS platform. These increases were offset by a decrease in outsourced lab services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Gross margin was </span><span style="color:#00000a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">52%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the twelve months ended April&#160;30, 2022 compared to </span><span style="color:#00000a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the twelve months ended April 30, 2021. The improvement in gross margin was the direct result of decreasing the Company&#8217;s reliance on outsourcing and leveraging revenue growth over the fixed cost component of cost of sales.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;Research and Development</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expense was $9.4 million and $7.2 million for the years ended April&#160;30, 2022 and 2021, respectively, an increase of $2.2 million or 30.3%. The increase was primarily due to the investments in new service capabilities and our drug discovery and development programs with the increase coming primarily from compensation and lab supply expenses. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense was $6.4 million and $5.5 million for the years ended April&#160;30, 2022 and 2021, respectively, an increase of $0.9 million or 15.6%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was mainly due to compensation expense. Additionally, travel expense increased for our business development team as Covid-19 travel related restrictions eased.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expense was $9.1 million and $6.5 million for the years ended April&#160;30, 2022 and 2021, respectively, a decrease of $2.6 million, or 40.0%. General and administrative expenses were primarily comprised of compensation, insurance, professional fees, IT, and depreciation and amortization expenses. The general and administrative expenses increase was primarily due to increases in non-cash expenses, compensation and IT expenses for data storage and to support the overall infrastructure growth of the company. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was $24,000 and other income was $71,000 for the years ended April&#160;30, 2022 and 2021, respectively. Other expense for the year ended April 30, 2022 resulted primarily from foreign currency transaction losses. Other income for the year ended April 30, 2021 was primarily attributable to a $75,000 gain on operating lease termination offset by foreign currency transaction losses. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash on hand, working capital management, proceeds from certain private placements and public offerings of our securities and sales of products and services. For the years ended April&#160;30, 2022 and 2021, the Company had net income of approximately $548,000 and $362,000, respectively.  As of April&#160;30, 2022, the Company had an accumulated deficit of approximately $72.0 million, working capital of $2.2 million and cash of $9.0 million. We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least August 2023. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion relates to the major components of our cash flows:</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by (used in) operating activities was $6.5 million and ($1.7) million for the years ended April&#160;30, 2022 and 2021, respectively. The increase in cash provided was primarily due to improving cash based operational results and an increase in deferred revenue. The increase in deferred revenue was primarily driven by cash received upon signing new studies, an indicator of the strength of the Company&#8217;s sales pipeline. Changes in our working capital accounts were in the ordinary course of business operating activities.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.4 million and $3.2 million for the years ended April&#160;30, 2022 and 2021, respectively. The cash used was for the investment in lab and computer equipment and software development. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $0.2 million and $1.2 million for the years ended April&#160;30, 2022 and 2021, respectively. Cash flows provided by financing activities was due to exercises of stock options and decreased from the prior year due to lower volume of exercises of options and warrants.</span></div><div style="text-align:justify;text-indent:11.25pt"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Critical Accounting Policies</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The following discussion of critical accounting policies identifies the accounting policies that require application of management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. It is not intended to be a comprehensive list of all of our significant accounting policies, which are more fully described in Note&#160;2 of the notes to the consolidated financial statements included in this document. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for management&#8217;s judgment in their application. There are also areas in which the selection of an available alternative policy would not produce a materially different result.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States or GAAP.&#160;The preparation of the consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.&#160;Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions. We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;Actual amounts could differ significantly from amounts previously estimated.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue under the Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers.  In accordance with ASC 606, revenue is now recognized when, or as, a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise (or a combination of promises) in a contract to transfer distinct goods or services to a customer and is the unit of accounting under ASC 606 for the purposes of revenue recognition. A contract's transaction price is allocated to each separate performance obligation based upon the standalone selling price and is recognized as revenue, when, or as, the performance obligation is satisfied. The majority of the Company's contracts have a single performance obligation because the promise to transfer individual services is not separately identifiable from other promises in the contracts, and therefore, is not distinct.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. In addition, in certain instances a customer contract may include forms of variable consideration such as performance incentives or other provisions that can increase or decrease the transaction price. This variable consideration is generally awarded upon achievement of certain performance metrics. For the purposes of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount to be recorded is estimated based on the assessment of the Company's anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The Company accounts for amendments as a separate contract when they meet the criteria under ASC 606-10-25-12.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Payments</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically recognize expense for stock-based payments based on the fair value of awards on the date of grant.&#160;We use the Black-Scholes option pricing model to estimate fair value. The option pricing model requires us to estimate certain key assumptions such as expected life, volatility, risk free interest rates, and dividend yield to determine the fair value of stock-based awards.&#160;These assumptions are based on historical information and management judgment.&#160;We expense stock-based payments over the period that the awards are expected to vest. In the event of forfeitures, compensation expense is adjusted.&#160;We report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows when the cash tax benefit is received.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Capitalized Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the cost of computer software obtained or developed for internal use as well as the software development and implementation costs associated with a hosting arrangement ("internal-use software") that is a service contract</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance and with ASC 350, Intangibles - Goodwill and Other ("ASC-350"). We capitalize certain costs in the development of our internal-use software when the preliminary project stage is completed and the software has reached the point of technological feasibility. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose and available for sale.  Capitalized costs are then amortized using the straight-line method over an estimated useful economic life of three years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized software development costs are stated at gross cost less accumulated amortization. Recoverability of these capitalized costs is determined at each balance sheet date by comparing the forecasted future revenues from the related product, based on management&#8217;s best estimates using appropriate assumptions and projections at the time, to the carrying amount of the capitalized software development costs. If the carrying value is determined not to be recoverable from future revenues, an impairment loss is recognized equal to the amount by which the carrying amount exceeds the future revenues.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Income Taxes</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability method to account for income taxes.&#160;Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets.&#160;&#160;In preparing the consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate.&#160;&#160;This process involves estimating the actual current tax liability together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, depreciation on property, plant and equipment, goodwill and losses for tax and accounting purposes.&#160;&#160;These differences result in deferred tax assets, which include tax loss carry-forwards, and liabilities, which are included within the consolidated balance sheet.&#160;&#160;We then assess the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;To the extent a valuation allowance is established or increased in a period, we include an expense within the tax provision of the consolidated statements of operations.&#160;As of&#160;April&#160;30, 2022&#160;and&#160;2021, we have established a full valuation allowance for all deferred tax assets.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;April&#160;30, 2022 and&#160;2021, we recognized a liability for uncertain tax positions on the balance sheet relative to foreign operations in the amount of&#160;$181,000. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.&#160;&#160;Any interest or penalties related to unrecognized tax benefits is recognized in income tax expense. The Company has not accrued penalties or interest during the year ended&#160;April&#160;30, 2022.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Being Evaluated</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management&#8217;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#8212; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance on May 1, 2021 and it did not have an impact on its consolidated financial statements.&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Financing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet debt or similar obligations.&#160;&#160;We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position.&#160;&#160;We do not guarantee any third-party debt.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements required pursuant to this item are included in Item&#160;15 of this annual report and are presented beginning on page&#160;F-1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements With Accountants on Accounting and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Disclosure</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_67"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Management's Report on  Disclosure Controls and Procedures </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management, under the supervision and with the participation of our Principal Executive Officer (our Chief Executive Officer) and Principal Financial Officer (our Chief Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures as of April&#160;30, 2022, the end of our fiscal year covered by this annual report. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of April&#160;30, 2022, that consider remediation efforts commenced by the Company as a result of the material weakness noted during the assessment of the effectiveness of the Company&#8217;s internal controls over financial reporting as of and for the year ended April 30, 2021, our Chief Executive Officer and Chief Financial Officer have concluded that, as of April&#160;30, 2022, our disclosure controls and procedures are effective.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. This rule defines internal control over financial reporting as a process designed by, or under the supervision of, Company management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Management has assessed the effectiveness of our internal control over financial reporting using the components established in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A system of internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A material weakness is any deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of April&#160;30, 2022, the year covered by this Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Remediation of Prior Year Material Weakness in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the year ended April 30, 2021, we identified a material weakness in the consolidated financial statements close process. Specifically, our risk assessment procedures over certain of our contractual arrangements requiring the payment of royalties for the licensing of technology from third-parties did not adequately identify the risks and consider the Company&#8217;s obligations based on the recognition of oncology services revenue.  As a result, the Company had missing process level controls over the review of royalty arrangements and the timely determination and recognition of related liabilities.   Although no material misstatements were identified in our consolidated financial statements, these control deficiencies resulted in immaterial misstatements to our previously issued consolidated financial statements which were corrected in the consolidated financial statements included in the Form 10-K for our fiscal year ended April 30, 2021. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2022, the Company&#8217;s management designed and implemented certain measures to address the above-described material weakness and enhance the Company&#8217;s internal controls which has included enhanced processes and controls such as ensuring adequate identification and review of royalty agreement terms and obligations which have been formalized as of the completion of its third fiscal quarter of fiscal 2022. As part of our remediation measures, the Company has continually monitored its control environment and management has concluded that the remediation plan was implemented, tested, effective, and completed as of April&#160;30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other than the remediation of the prior year material weakness, there were no other changes in the Company&#8217;s internal controls over financial reporting during the year ended April&#160;30, 2022, that materially affected, or were reasonably likely to materially affect the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The information required by this item will be contained in our 2022 Proxy Statement and such information is incorporated herein by this reference.</span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_79"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The information required by this item will be contained in our 2022 Proxy Statement and such information is incorporated herein by this reference.</span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and Related Stockholder Matters</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The information required by this item will be contained in our 2022 Proxy Statement and such information is incorporated herein by this reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independence</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The information required by this item will be contained in our 2022 Proxy Statement and such information is incorporated herein by this reference.</span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accounting Fees and Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The information required by this item will be contained in our 2022 Proxy Statement and such information is incorporated herein by this reference.</span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_91"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_94"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibits, Financial Statement Schedules</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)1. Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statement of Changes in Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-7</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)2. Financial Statement Schedules</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because they are not applicable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)3. Exhibits required to be filed by Item 601 of Regulation S-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000095012311022584/c13768def14c.htm">Amended and Restated Articles of Incorporation (incorporated by reference to Appendix A to the Company&#8217;s Information Statement on Schedule 14C filed March 7, 2011)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415025506/v408612_8-k.htm">Certificate of Amendment to Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3(i) to the Company&#8217;s Current Report on Form 8-K filed April 28, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000162828017005232/form8-kamendedbylawx2017.htm">Amended and Restated Bylaws, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 9, 2017)</a></span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="csbrex414302022.htm">Description of Registered Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">(incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed July 28, 2020)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420413060120/v360015_8k.htm">Employment Agreement, dated November 5, 2013, between the Company and Ronnie Morris, M.D. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed November 12, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415017569/v405128_8-k.htm">Amendment to Employment Agreement, dated March 16, 2015, between the Company and Ronnie Morris (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420413033041/v346872_8k.htm">Offer letter dated June 3, 2013 between the Company and David Miller (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed June 3, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000095012311022584/c13768def14c.htm">2010 Equity Incentive Plan (incorporated by reference to Appendix B to the Company&#8217;s Definitive Information Statement on Schedule 14C filed March 7, 2011)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420414072471/v395914_ex10-1.htm">Form of Note Purchase Agreement, dated December 1, 2014, between the Company and each of&#160;&#160;Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed December 5, 2014)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420414072471/v395914_ex10-2.htm">Form of Convertible Promissory Note, dated December 1, 2014, issued to each of Joel Ackerman and Ronnie Morris in connection with the Note Purchase Agreement, dated December 1, 2014 between the Company and each of Joel Ackerman and Ronnie Morris incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed December 5, 2014)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415013098/v403291_ex10-1.htm">Amendment No. 1 to Convertible Promissory Note, dated December 1, 2014 issued to Joel Ackerman in connection with the Note Purchase Agreement, dated December , 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 2, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415013098/v403291_ex10-2.htm">Amendment No. 1 to Convertible Promissory Note, dated December 1, 2014 issued to Ronnie Morris in connection with the Note Purchase Agreement, dated December , 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 2, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-3.htm">Amended and Restated 2011 Securities Purchase Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420413004606/v333302_ex10-3.htm">Form of warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 30, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-5.htm">Amendment No. 1 to warrants, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-4.htm">Amended and Restated 2013 Securities Purchase Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420413004606/v333302_ex10-3.htm">Form of warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 30, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-6.htm">Amendment No. 1 to warrants, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420414006273/v367400_ex10-3.htm">Put Right Agreement, dated January 29, 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed March 6, 2014)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415015531/v404178_ex10-1.htm">Securities Purchase Agreement, dated March 11, 2015, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 12, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-1.htm">Amended and Restated Registration Rights Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to (i) the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature page thereto, (ii) the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature page thereto, and (iii) the Securities Purchase Agreement, dated March 11, 2015, between the Company. And each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415016511/v404684_ex10-2.htm">Form of Investor Warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated March 11, 2015, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415017569/v405128_ex10-1.htm">Option Exchange Agreement, dated March 16, 2015, between the Company and Joel Ackerman (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415017569/v405128_ex10-2.htm">Option Exchange Agreement, dated March 16, 2015, between the Company and Ronnie Morris (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000114420415017569/v405128_ex10-4.htm">Option Exchange Agreement, dated March 16, 2015, between the Company and David Miller (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000129707708000084/cbio0729.htm">Code of Ethics (incorporated by reference to Exhibit 14 of the April 30, 2008 Form 10-KSB)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/771856/000162828017007429/csbrex214302017.htm">List of Subsidiaries (incorporated by reference to Exhibit 21 of the Company's Form 10-K filed July 28, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex2314302022.htm">Consent of Independent Registered Public Accounting Firm*</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3114302022.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3124302022.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3214302022.htm">Section 1350 Certifications**</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Furnished hereto.</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_97"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form 10-K Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Required.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHAMPIONS ONCOLOGY, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RONNIE MORRIS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronnie Morris</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div style="text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RONNIE MORRIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronnie Morris</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DAVID MILLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Miller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOEL ACKERMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joel Ackerman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DAVID SIDRANSKY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Sidransky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ROBERT BRAININ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Brainin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT R. TOBIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott R. Tobin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL MENDELSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Mendelson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PHILIP BREITFELD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 22, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philip Breitfeld</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_106">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID# <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDMvZnJhZzo3YmQ1MmZhNGNlYWQ0NTI4YWVhYjI5ZWUwNWNlZWNhYy90YWJsZToyN2FkNDFhMmFlY2U0ZTlhYWUzNjVkOTY3MWYyNDhjOC90YWJsZXJhbmdlOjI3YWQ0MWEyYWVjZTRlOWFhZTM2NWQ5NjcxZjI0OGM4XzAtMC0xLTEtMTc2NTYvdGV4dHJlZ2lvbjo5MWI1ODk5ZTE1OTU0YWU2YmQ2ZmZjODgxYzlkY2Q5Zl8yNzQ4Nzc5MDY5NjA0_be179926-e205-4bd2-94d9-a48e32002ff8">274</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_106">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_109">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_109">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_115">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_115">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_118">Consolidated Statements of Changes in Stockholders' Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_118">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_121">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_121">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_124">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i776cf0b85fdb44a193c88f4fc7063181_124">8</a></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Champions Oncology, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Champions Oncology, Inc. and Subsidiaries (the &#8220;Company") as of April&#160;30, 2022 and 2021, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of April&#160;30, 2022 and 2021, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.  Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described further in Note 2 to the consolidated financial statements, revenues are primarily derived from contracts with customers to provide pharmacology services with payments based on fixed fee arrangements. The Company recognizes revenue over time using a progress-based input method that depicts the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. Customer payments may be made in advance or on a schedule in the statement of work (&#8220;SOW&#8221;) unrelated to when revenue is recognized resulting in deferred revenue. The determination of the progress as the overall performance obligation is being completed is based on the worked performed in accordance with the SOW and requires management estimates.  Pharmacology services revenues for the year ended April 30, 2022 and 2021 were approximately $46.8 million and $39.5 million, respectively.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the accounting for revenue and the related deferred revenue recognized over time as a critical audit matter due to the complexity and subjectivity of management&#8217;s estimate of the progress towards completion of its projects. This in turn led to a high degree of auditor judgement and subjectivity and significant audit effort was required in performing procedures to evaluate management&#8217;s determination of the project completion progress, related costs incurred and deferred revenue. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. We obtained an understanding and evaluated the design of controls relating to the Company's revenue recognition and deferred revenue. Our audit procedures related to the recognition of revenue over time and deferred revenue included the following procedures, among others, (i) testing the Company&#8217;s estimates of project progress by evaluating the appropriate SOW and customer acceptance documentation, (ii) testing the significant assumptions used to develop the estimates of project progress pursuant to the SOW and (iii) testing completeness and accuracy of the underlying data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDYvZnJhZzo2YzYyN2FhOWY0OTg0MjliOTdjMWE1MjJjY2RmMTlkNy90ZXh0cmVnaW9uOjZjNjI3YWE5ZjQ5ODQyOWI5N2MxYTUyMmNjZGYxOWQ3XzIxOTkwMjMyNjEzNjE_dc1b83bb-5e18-4830-95cd-e41f29888fce">EisnerAmper LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EISNERAMPER LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDYvZnJhZzo2YzYyN2FhOWY0OTg0MjliOTdjMWE1MjJjY2RmMTlkNy90ZXh0cmVnaW9uOjZjNjI3YWE5ZjQ5ODQyOWI5N2MxYTUyMmNjZGYxOWQ3XzIxOTkwMjMyNjEzNjI_25a71d1b-3587-453b-8691-05a78160b7bd">Iselin, New Jersey</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July&#160;22, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS OF APRIL&#160;30 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands except for shares)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMtMS0xLTEtMTQzOTI_36938a8a-b5f7-491d-8629-7677cb73e3bd">9,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMtMy0xLTEtMTQzOTI_1202badd-7ec0-471f-be9a-835473b94608">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQtMS0xLTEtMTQzOTI_578a74e9-f0dd-4014-a76d-481d9094801a">9,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQtMy0xLTEtMTQzOTI_2feb43f1-c3b3-4371-88e2-8fdbc0f5ac26">6,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzUtMS0xLTEtMTQzOTI_ae921059-73e3-4e4d-aaa5-f5de0537d8cd">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzUtMy0xLTEtMTQzOTI_e71ec72c-f401-4101-b5bf-b31610d6f4f0">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzctMS0xLTEtMTQzOTI_b3c5d763-729a-4a63-aeb5-8cc556957164">19,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzctMy0xLTEtMTQzOTI_b9877828-5c51-4eed-a566-050c45bf6381">12,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzktMS0xLTEtMTQzOTI_7b235032-919e-4103-b79d-caa63d211fe6">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzktMy0xLTEtMTQzOTI_37a873e9-fa36-40d3-bb42-573a7c55e4fd">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEwLTEtMS0xLTE0Mzky_dc10a248-6aa9-48f6-a35a-ba1fd99be1dc">7,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEwLTMtMS0xLTE0Mzky_7b70c048-d2ae-4092-8417-9db0aee53c4a">6,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzExLTEtMS0xLTE0Mzky_91b95727-7cac-4152-a9ce-78fcb2f5b5e1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzExLTMtMS0xLTE0Mzky_edabbab8-60ae-4178-998c-60d4464d8f80">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEyLTEtMS0xLTE0Mzky_2f799c6e-c68e-47d9-821c-eb3dae36f9e7">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEyLTMtMS0xLTE0Mzky_7f22e920-adc1-4ef5-b240-d7048668036b">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE0LTEtMS0xLTE0Mzky_38d80e73-04a9-40a4-9d8a-4fdc1a05e61d">35,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE0LTMtMS0xLTE0Mzky_eac64ebd-56d5-40d5-b5da-59c7bafad1ff">27,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES<br/>AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE4LTEtMS0xLTE0Mzky_0315a1ef-6146-497f-8d08-f24f09dece83">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE4LTMtMS0xLTE0Mzky_9da2f92c-13b8-483b-8a02-7452df9507bd">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE5LTEtMS0xLTE0Mzky_f063f250-da6b-4202-b008-ebb0e8c26232">2,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE5LTMtMS0xLTE0Mzky_a583fa6e-f9a7-47bf-b635-f3d54990dd37">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIwLTEtMS0xLTE0Mzky_405995fb-89b7-4411-b815-0d8df1560400">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIwLTMtMS0xLTE0Mzky_fbe1bb70-8322-48bd-b0fa-5cecad315a81">818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIxLTEtMS0xLTE0Mzky_778f7cc8-00f8-43a4-a59c-b46a3863a6c8">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIxLTMtMS0xLTE0Mzky_5b278403-e275-4de8-b6d2-ddbfeb085e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIyLTEtMS0xLTE0Mzky_2d9f9353-dc94-45e6-8f5c-13a39006c295">11,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIyLTMtMS0xLTE0Mzky_6a031407-c29d-46c0-ad06-63f6a0f7a48d">6,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI0LTEtMS0xLTE0Mzky_6150bf62-026e-47de-a574-00f5ce3e34ad">17,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI0LTMtMS0xLTE0Mzky_26571182-c402-4e30-9fd9-90480c9dde1f">11,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI3LTEtMS0xLTE0Mzky_76709711-023a-42fe-9c39-ae61080bdeb9">8,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI3LTMtMS0xLTE0Mzky_9eb3ec37-c989-4711-811b-bca957ac2226">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI5LTEtMS0xLTE0Mzky_e853a4cd-8dcc-4925-9e82-fd7179f4ea64">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI5LTMtMS0xLTE0Mzky_bee8f3f9-e94f-4269-bbe1-34fc4768c4fa">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMxLTEtMS0xLTE0Mzky_df6fee05-776f-4656-8ce9-41556e5c786f">26,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMxLTMtMS0xLTE0Mzky_08cc8d85-6243-4dae-a646-f3882a7ae1e1">20,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMTg_1dfd5822-fca5-4fb3-bea0-a4ab251bb3be"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMTg_ff1b95da-2613-4e33-b163-277e1f306e95">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMzI_38dd9d4e-497b-4343-a3e9-4b00174e82fb"><ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMzI_55a84de0-dc24-4f7c-bc28-3426c46d23f2">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNTQ_23ced4c6-c5a3-4591-b145-6fc5b973c9b0"><ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNTQ_8c3e9b70-6707-4cc7-881a-78dfb674c242">13,522,441</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNjE_4fe54d5e-f4a8-4ea4-a757-ac71a1aa7c22"><ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNjE_ec9c2a7c-8809-424f-b327-00374f2ba9ef">13,414,066</ix:nonFraction></ix:nonFraction> shares issued and outstanding at April 30, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTEtMS0xLTE0Mzky_6e0fcfe4-c7a6-412f-af15-1a08efba0dde">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTMtMS0xLTE0Mzky_82355084-896d-40fc-ad43-7c69856ae13b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM1LTEtMS0xLTE0Mzky_8523a3a5-8827-43fe-8e58-d05e0d906efd">81,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM1LTMtMS0xLTE0Mzky_c4553774-5e77-4081-b5c5-e1036427f271">79,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM2LTEtMS0xLTE0Mzky_ff157e07-fd4f-44d1-8c69-c00f21652eda">71,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM2LTMtMS0xLTE0Mzky_e504ff9b-c358-41ef-86f4-59dae936c42b">72,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM4LTEtMS0xLTE0Mzky_3373fa73-02b8-4c76-b006-bfa37f470b56">9,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM4LTMtMS0xLTE0Mzky_bbb353e2-b893-466f-8269-0fc31aa0c896">7,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQwLTEtMS0xLTE0Mzky_4c5f9f77-1f73-4174-b949-3c3262fb9aae">35,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQwLTMtMS0xLTE0Mzky_05422523-80ac-4246-9368-65b0faee0049">27,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_115"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands Except Share and Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_4f9d5fac-8fa3-4bdf-b216-6f35e4ad8cd6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_83245714-dbce-4c16-95f3-18378f367455">Oncology services revenue</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMS0xLTEtMTQzOTI_b73448b3-0775-42ce-9aba-c46434278de8">49,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMy0xLTEtMTQzOTI_8a8cd345-7ad0-463f-a70e-368422e60bb1">41,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_4bd9ec76-9111-4d75-a50f-d39d93fb58f3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_f5fd1e33-d369-4f1c-8371-9f7463dbc1e1">Cost of oncology services</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMS0xLTEtMTQzOTI_b5141ca8-bd31-43ed-9581-8eda85fa6888">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMy0xLTEtMTQzOTI_77f810b8-12d9-4537-9847-e82218b3a4b8">21,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzktMS0xLTEtMTQzOTI_1d744928-a81c-4237-8793-8066be01eb1c">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzktMy0xLTEtMTQzOTI_60ebe0f5-8d25-4fff-a640-d6362c91c909">7,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzEwLTEtMS0xLTE0Mzky_a2886761-2eeb-46a6-9a2a-cea59fc75267">6,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzEwLTMtMS0xLTE0Mzky_6c79a509-e92f-494f-aa26-f1303647753c">5,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzExLTEtMS0xLTE0Mzky_a2ed3730-3a85-44e9-8e9b-aa7ab5098925">9,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzExLTMtMS0xLTE0Mzky_de816ba0-2c57-4d46-9f6c-8ed723a550cb">6,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE0LTEtMS0xLTE0Mzky_85a702aa-966b-4e8b-9fbe-bb0775e4f428">48,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE0LTMtMS0xLTE0Mzky_d7195193-e04d-4502-a3ad-029054fa2ae5">40,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE2LTEtMS0xLTE0Mzky_22acd847-0172-4f64-a3c3-2128bfbb9e23">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE2LTMtMS0xLTE0Mzky_79746e90-7cbd-4a4e-b3c7-3d62b01ad7c7">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzIxLTEtMS0xLTE0Mzky_d1121bd2-969f-435d-83de-74702d3b68c8">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzIxLTMtMS0xLTE0Mzky_8e6cfcc5-d432-4c6b-86a8-98b21c90d683">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI1LTEtMS0xLTE0Mzky_c7ebf73e-b4d8-47d7-b868-f5d950ba998c">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI1LTMtMS0xLTE0Mzky_35457165-2d4d-46fa-87b7-b8008c58b1e5">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI2LTEtMS0xLTE0Mzky_b378eced-533b-438e-93f7-6b9ebc82d926">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI2LTMtMS0xLTE0Mzky_c1ecf6cb-4e4e-4676-b9c8-b4a761bd69b7">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI4LTEtMS0xLTE0Mzky_3e1bb81b-f103-4cf6-87f7-131470487017">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI4LTMtMS0xLTE0Mzky_1d7b9136-cd5b-49f6-97da-a4dfc30a0b46">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMxLTEtMS0xLTE0Mzky_840f8ca1-a7af-409e-a969-2b6695ed2106">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMxLTMtMS0xLTE0Mzky_89c5f030-5129-4224-9053-05ccfd418962">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMyLTEtMS0xLTE0Mzky_5b6cc0e7-dab6-42bb-b8f5-11bbf15702fb">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMyLTMtMS0xLTE0Mzky_5a5d87aa-4afb-436b-b48f-cfa910718dad">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM1LTEtMS0xLTE0Mzky_a7693543-8a2d-4d32-8e59-a771eb3e3680">13,197,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM1LTMtMS0xLTE0Mzky_91c8ffd1-00e6-48a8-8127-d3431ff1824d">13,138,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM2LTEtMS0xLTE0Mzky_bacdf407-bec9-48ea-beec-413a224b9211">14,159,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM2LTMtMS0xLTE0Mzky_0b28a0d6-9b1d-46f8-a22e-cfda811a3d51">14,573,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands except for shares)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:35.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.890%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, April 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaa0daba14924b7d8838223b79f88c5b_I20200430" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMS0xLTEtMTQzOTI_caca578f-d6b1-470e-bde2-abab802d3a50">12,726,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa0daba14924b7d8838223b79f88c5b_I20200430" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMy0xLTEtMTQzOTI_8a8160ea-ca00-4600-8fab-97f6d63ac638">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430" xsi:nil="true" name="us-gaap:TreasuryStockCommonShares" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzItNS0xLTEtMTY3Mjc_3deff684-1da5-48a3-9eb3-93db847fbae5"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430" xsi:nil="true" name="us-gaap:StockholdersEquity" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzItNy0xLTEtMTY3Mjk_bfb349d3-7554-433b-a65c-b978e88d3e86"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02f3872d53a43f0a007156fe38211da_I20200430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtOS0xLTEtMTQzOTI_deafc48b-77a6-4cce-b7dc-4b03ee17528f">77,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2374b15e0606422f934d250e545fd7fd_I20200430" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMTEtMS0xLTE0Mzky_35a609a4-1ea4-4b16-a9b3-ddd9b48b02db">72,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMTUtMS0xLTE0Mzky_12ad006a-b1d7-4a00-b91a-e0ee3373f3fd">5,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzUtOS0xLTEtMTQzOTI_5b9665e7-7de2-40e3-8875-c3864c74b7f7">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzUtMTUtMS0xLTE0Mzky_69727759-7e95-4a79-b275-88c6987abe14">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock on exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib54a1d7487da488cbb84e20d7806250c_D20200501-20210430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTEtMS0xLTE0Mzky_fe72c419-15e2-4013-8a4c-c37e99f9f7b9">687,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTktMS0xLTE0Mzky_3a55ac35-df45-4723-b539-b25677169753">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTE1LTEtMS0xNDM5Mg_da1ce86b-64c5-4b8f-9f3a-27ff03e75a87">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbb1281510d4a9893e74a6b8dad4aa2_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEyLTExLTEtMS0xNDM5Mg_afb83b3c-5f4f-4ca3-ba94-342845165dc3">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEyLTE1LTEtMS0xNDM5Mg_849c6fbf-32cf-472b-8908-034d3ad5954a">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide558d40319b4db7bc7ac08294103641_I20210430" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTEtMS0xLTE0Mzky_68d71c9e-1529-4ced-b4f2-aa788228750d">13,414,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide558d40319b4db7bc7ac08294103641_I20210430" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTMtMS0xLTE0Mzky_05f1898d-e2db-4851-8937-0dde75861120">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i003c4a752f33480a906e9a3da5091e95_I20210430" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTUtMS0xLTE0Mzky_3753e97a-c187-4341-9fef-22e223cbaf0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003c4a752f33480a906e9a3da5091e95_I20210430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTctMS0xLTE0Mzky_b75de040-2ef3-4967-a2cd-5dd6df61ad2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc700e99e614f63be6283f7eea85ac1_I20210430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTktMS0xLTE0Mzky_9b79ac35-e838-4539-80b1-36c123df19c9">79,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad133947d589468393bb167e733a7f9e_I20210430" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTExLTEtMS0xNDM5Mg_21f824f4-b0e9-476b-8553-8626965089c4">72,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTE1LTEtMS0xNDM5Mg_9570ec40-91e1-4b41-9a20-d7dd7ae7d993">7,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE1LTktMS0xLTE0Mzky_b08b0bc1-c720-4f45-a514-102ce9cee50f">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE1LTE1LTEtMS0xNDM5Mg_eb243045-73be-4444-a562-2901b0aa4eab">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock on exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTEtMS0xLTE0Mzky_c8f9dacc-c815-4038-b204-dd34f926c42b">108,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTMtMS0xLTE0Mzky_a8b8e446-7116-4a66-97f0-43ea3415d41c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTktMS0xLTE0Mzky_613b4759-6526-4c16-8350-751ab0659ca2">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTE1LTEtMS0xNDM5Mg_ffb416a7-46f9-4bef-be55-03fcf1e3a117">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8236966dfe48fdbde9087ecc55f047_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE4LTExLTEtMS0xNDM5Mg_52ce5476-6ee3-4d2e-84bc-b480f88c5249">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE4LTE1LTEtMS0xNDM5Mg_0ad16013-bd0e-466d-8153-8925a049ed51">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, April 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTEtMS0xLTE0Mzky_54787cd8-5ec8-4d73-94d7-e5d5b0315784">13,522,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTMtMS0xLTE0Mzky_83dfb10a-66fc-45bc-aff7-0a260076c8bb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f31a264cd4f4bd691dfd8d18e642222_I20220430" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTUtMS0xLTE0Mzky_ac852d59-a4d2-4845-8ffe-b587e026773e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f31a264cd4f4bd691dfd8d18e642222_I20220430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTctMS0xLTE0Mzky_1bdf1583-441a-4920-8885-5bfa0a56c677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id431aa7354ed4c17822b0e24b7a2d5f8_I20220430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTktMS0xLTE0Mzky_516627a9-c0c0-49bf-a8bb-22d6b73c7926">81,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f25fb6e99f4ed98158edec2f27704a_I20220430" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTExLTEtMS0xNDM5Mg_f9aa0c9d-e888-4076-ac9a-a028f8eff3b7">71,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTE1LTEtMS0xNDM5Mg_cd3212ad-c2f3-4871-94d7-433a987e0245">9,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMtMS0xLTEtMTQzOTI_3e1bb81b-f103-4cf6-87f7-131470487017">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMtMy0xLTEtMTQzOTI_13b04685-c83a-4e88-ab36-a2aea127c4a4">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by&#160;(used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzYtMS0xLTEtMTQzOTI_265f90bb-920d-43df-be58-3e2717af7166">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzYtMy0xLTEtMTQzOTI_c0ff4af4-4acb-4603-a678-3784fbc92ae9">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzctMS0xLTEtMTQzOTI_3814fbb7-f390-449e-b9c7-0ffb3d8cbad9">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzctMy0xLTEtMTQzOTI_998c68f1-a524-4d00-8367-dda81a7961c6">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on disposal of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzEwLTEtMS0xLTE0Mzky_56db8d73-7b85-4a76-b947-08e44f3a63f4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzEwLTMtMS0xLTE0Mzky_636a9d02-727d-40e4-b466-d7705935856e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzExLTEtMS0xLTE0Mzky_ac099198-5c20-4211-a2b4-18b098062d09">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzExLTMtMS0xLTE0Mzky_dc8e0780-14b7-446b-a80b-59a67a1823f2">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on termination of operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE0LTEtMS0xLTE0Mzky_ddb4f27e-3bd3-434d-a71e-01193980c2d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE0LTMtMS0xLTE0Mzky_5a3affcb-3479-4785-b36c-d52e90b1d7cf">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE1LTEtMS0xLTE0Mzky_90b61f44-1680-459a-9e36-b1cec979d5dd">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE1LTMtMS0xLTE0Mzky_84fea443-8ed3-470f-8246-3183606d5b65">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE5LTEtMS0xLTE0Mzky_aa921b29-d00b-4950-901f-cbc83d7bb54c">2,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE5LTMtMS0xLTE0Mzky_adf89cb8-e8cf-45d3-b831-92231a101222">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIwLTEtMS0xLTE0Mzky_f510d5b2-4986-4e35-ad87-b0e6b6fa28e5">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIwLTMtMS0xLTE0Mzky_065ebb79-f55a-4470-ba68-6f3b6f12fb25">572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIzLTEtMS0xLTE0Mzky_e7bf831b-6bce-4957-9ce9-1ec2a2962651">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIzLTMtMS0xLTE0Mzky_9b579139-936f-41e3-8fb2-80e01fa3a220">1,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI0LTEtMS0xLTE0Mzky_e20314e7-7815-4a49-b8f8-bbc9f5abc346">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI0LTMtMS0xLTE0Mzky_3b745c7c-d758-42e9-acb2-635f310a15b7">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI1LTEtMS0xLTE0Mzky_87703635-9697-47a9-aa70-0db62ebcf350">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI1LTMtMS0xLTE0Mzky_3871f033-ae23-401f-9602-564818f9f994">242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI2LTEtMS0xLTE0Mzky_7ae7cb8e-562e-4017-a110-f9312240f6eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI2LTMtMS0xLTE0Mzky_97d97491-7b17-4308-b631-7c51211b3084">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI3LTEtMS0xLTE0Mzky_23d0536b-c0ec-43b0-950a-774a64e65581">4,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI3LTMtMS0xLTE0Mzky_9ea7576b-8c7a-443f-8df5-b440f38b7bcb">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI5LTEtMS0xLTE0Mzky_d38f9d89-6154-4bf0-acea-c66a4ed8f141">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI5LTMtMS0xLTE0Mzky_c19f5c39-c8d2-432d-897d-0fa2eb01d53f">1,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMyLTEtMS0xLTE0Mzky_a0e826fd-6ecc-4fe3-aa4d-ab5bf370adb0">2,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMyLTMtMS0xLTE0Mzky_8be9c912-ab93-45d0-baa3-df56e7ba1e09">3,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refund of security deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="csbr:ProceedsFromRefundOfSecurityDeposit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMzLTEtMS0xLTE0Mzky_119521bf-53b1-4e28-89fb-69ed521393c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="csbr:ProceedsFromRefundOfSecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMzLTMtMS0xLTE0Mzky_02a3cf5e-24d0-49ce-8919-8062288a72cc">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzM2LTEtMS0xLTE0Mzky_de5f37e5-e4a4-441d-bb84-1cc42276259b">2,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzM2LTMtMS0xLTE0Mzky_f569dfdf-9a40-4ae1-ba92-3412d04d444d">3,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="csbr:ProceedsFromExerciseOfOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQxLTEtMS0xLTE0Mzky_844ba755-150f-4f85-809d-e855b54604c0">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="csbr:ProceedsFromExerciseOfOptionsAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQxLTMtMS0xLTE0Mzky_f3d4b9f0-206d-499d-a9df-57ab84664332">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQzLTEtMS0xLTE0Mzky_5a1915f8-e44b-4d93-abf4-49b69a5c6a53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQzLTMtMS0xLTE0Mzky_f7976a9e-d770-4764-bc9f-72567dd854be">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQ3LTEtMS0xLTE0Mzky_81e70c10-01d0-4ef5-ab32-9c52dfe53105">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQ3LTMtMS0xLTE0Mzky_f5dd99d1-522c-4b7a-a1a1-c8dc01306e75">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUxLTEtMS0xLTE0Mzky_5b05605e-653e-4a26-ac2f-d6872e31756d">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUxLTMtMS0xLTE0Mzky_bd523da7-1d4a-46df-98a9-8723b7cdeeab">3,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUyLTEtMS0xLTE0Mzky_eff60053-56af-457b-b6cf-1d6d69ec7f43">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUyLTMtMS0xLTE0Mzky_88d80998-6b00-4279-a8e4-8e7e531aeacb">8,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, end of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU0LTEtMS0xLTE0Mzky_3f7fc325-f772-4202-b936-dab317a5ded6">9,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU0LTMtMS0xLTE0Mzky_14574fee-e4c4-4770-9a40-8700953256bc">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing and investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU4LTEtMS0xLTE0Mzky_0cb4489e-1149-4351-beb5-4101e6ed564e">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU4LTMtMS0xLTE0Mzky_c733905a-70e4-4197-8f42-29c69335d430">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE2MTk_ff2106b9-040b-425a-a23f-51d8872aa305" continuedAt="ibd0a2d7c5cd04f779f28555afd32085c" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ibd0a2d7c5cd04f779f28555afd32085c" continuedAt="i5a1d62b02d5b4bc1b906ae8d584f95e6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Champions Oncology, Inc. (the &#8220;Company&#8221;), is engaged in drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms.  The Company&#8217;s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. Utilizing the TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, the Company offers multiple services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform is designed to facilitate drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="subsidiary" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="csbr:NumberofOperatingSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzExNzI_aa562848-82a1-4aa2-b310-dee2454f794e">three</ix:nonFraction> operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited, and Champions Oncology S.R.L. For the years ended April&#160;30, 2022 and 2021, there were no revenues earned by these subsidiaries.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE2MTc_59b1907d-8700-49e3-a0c0-9cbd25929b0e" continuedAt="i835fbcc55aee46c4945ca37c876d65a3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5a1d62b02d5b4bc1b906ae8d584f95e6"><ix:continuation id="i835fbcc55aee46c4945ca37c876d65a3">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company operates in <ix:nonFraction unitRef="segment" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE1ODQ_6cbc86ee-85e0-44f7-b220-ea7628963475">one</ix:nonFraction> reportable business segment.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_130"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjk4_d2541ac9-04c1-48f7-b849-5f07e05a4185" continuedAt="i626f73ef9a5e464886034adf272db5d4" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i626f73ef9a5e464886034adf272db5d4" continuedAt="id80d683b39014a6e95887dd65bbdcef9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzI3_638018e5-7342-4f00-a848-a654ce6d8c13" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjcz_30ffef43-aac8-462f-8eeb-7b5f498de987" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations. Foreign currency balances are translated at each month end to US dollars, and any resulting gain or loss is recognized in our results of operations, as the amounts are not material.</span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY4_2f40bf97-4d87-4f25-a930-96cd888cf91e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.   Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions.&#160; We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzE0_5ca4a38a-45ac-4d4d-a6c6-0d6e1cbe2782" continuedAt="i82dca0b7a2b04e9490f64dad963904d9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82dca0b7a2b04e9490f64dad963904d9">The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents.</ix:continuation> As of&#160;April 30, 2022&#160;and 2021 the Company had cash balances of $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzM4NDgyOTA3MzUyODY_6ea7f44b-c4bd-4fa8-a4b7-74de2415656a">9.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzM4NDgyOTA3MzUzMDA_7547f912-7b00-4ddf-a4b6-8bdb5c6e748f">4.7</ix:nonFraction>&#160;million, respectively, and <ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQwNjI_acadbc8f-22e9-40ef-bbac-f9e85da4d14d"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQwNjI_f34ad310-30f1-42d3-b9dd-6f739d557cef">no</ix:nonFraction></ix:nonFraction> cash equivalents.</span></div></ix:continuation><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="id80d683b39014a6e95887dd65bbdcef9" continuedAt="i61070a92e5a347eda2fe8fa2c54de371"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash on hand, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services.  For the year ended April&#160;30, 2022, the Company had net income of approximately $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ1Nzg_15dbaa6f-4d30-48a4-a514-b85e207d34d2">548,000</ix:nonFraction>, an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2MjI_17d164de-f3cd-4e76-bf8d-6509722507c2">72.0</ix:nonFraction> million, working capital of $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="csbr:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2NDU_8adc4c4d-fb19-4c6f-9520-2584b5a6818e">2.2</ix:nonFraction> million and cash of $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2NjA_700e4eed-aeee-436f-92df-00574925d4cf">9.0</ix:nonFraction> million. We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least August 2023. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjU0_88808c5e-f541-4961-b862-4d1dd13296d9" continuedAt="if05f5fb870ca4a57aa7a76bec06c7574" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, accounts receivable, prepaid expenses, and other current assets, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted market prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than level one inputs that are either directly or indirectly observable; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if05f5fb870ca4a57aa7a76bec06c7574">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.</ix:continuation> The Company has no assets or liabilities that are measured at fair value on a recurring and/or non-recurring  during the years ended April&#160;30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjQz_2277304d-ec89-4eba-96a2-9a8911959848" continuedAt="ie113e840b80246048bcf85596fa75c22" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie113e840b80246048bcf85596fa75c22">Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, computer hardware and software, and internally developed software. Assets in progress include equipment or software not yet placed in service. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870">three</span> to <ix:nonNumeric contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjQ0_a73b6207-3226-407a-8fb2-2a7e3f49c506">seven years</ix:nonNumeric>.</ix:continuation> Refer to Footnote 4, "Property and Equipment" for a detailed discussion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzI2_383bde18-92df-4aea-a192-20a285f0b063" continuedAt="i231850d8830b4d8d9b415dc82aebe199" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i231850d8830b4d8d9b415dc82aebe199"> The Company accounts for its leases under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjc0_3b89e0c0-363c-4929-85ba-b97d8ba52d16" continuedAt="id3682e22d53a40fda4bae4ea7c97d4de" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3682e22d53a40fda4bae4ea7c97d4de">Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.</ix:continuation>&#160;&#160;The Company has <ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzgyOTQ_c47f4c34-4196-42fb-ac57-d832501a0963"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzgyOTQ_ff329aa6-2149-41c4-8c34-5a15d5b15b9e">no</ix:nonFraction></ix:nonFraction>t recognized any impairment losses for the Company&#8217;s long-lived assets for the years ending April&#160;30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i61070a92e5a347eda2fe8fa2c54de371" continuedAt="id2d2242ee7884a1b869e577806df4ade"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzAx_3e36c3b7-9a8c-45cd-a171-bb2767c42c6d" continuedAt="i1903331d36a148549cb04d8eccab54d7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors, market conditions, or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit&#8217;s carrying amount exceeds its fair value, referred to as a &#8220;step zero&#8221; approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. Under FASB's Accounting Standards Update ("ASU") 2014-02, Topic 350, "Intangibles&#8212;Goodwill and Other" goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairment evaluation test involves comparing the current fair value of each business unit to its carrying value, including goodwill. Fair value is typically estimated using a discounted cash flow analysis, which requires the Company to estimate the future cash flows anticipated to be generated by the business unit being tested for impairment as well as to select a risk-adjusted discount rate to measure the present value of the anticipated cash flows. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. The Company estimates cash flows for the business unit over a discrete period (typically four or five years) and the terminal period (considering expected long term growth rates and trends). Estimating future cash flows requires significant judgment by management in such areas as future economic conditions, industry-specific conditions, product pricing, and necessary capital expenditures. The use of different assumptions or estimates for future cash flows or significant changes in risk-adjusted discount rates due to changes in market conditions could produce substantially different estimates of the fair value of the business unit.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1903331d36a148549cb04d8eccab54d7">The Company has <ix:nonFraction unitRef="segment" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzExMTk2_58721803-65b4-4c80-aa05-aa53632b9abe">one</ix:nonFraction> reportable segment. The Company assesses goodwill impairment by business unit.  Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the businesses.&#160;&#160;Future events, including but not limited to continued declines in economic activity, loss of contracts or a significant number of customers, or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment indicators exist and that goodwill is impaired.</ix:continuation>&#160;For the year ended April 30, 2022, the Company's annual assessment did not result in any impairment indicators. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjcw_cf9d5ffb-7114-4ce1-b7e0-9406587b13a8" continuedAt="i66d31856ab1f4637a54a6f9c1f9d9b8d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received in advance of products to be delivered or services to be performed.&#160;&#160;When products are delivered and/or services are performed, deferred revenue is recognized as earned.  Deferred revenue is expected to be recognized within one year.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:OtherNoncurrentLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjkw_7a8dcbc2-4267-4bd3-8eae-aa876c34c08e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities represent amounts for uncertain tax positions relating to one of our foreign entities and a financing lease of laboratory equipment in exchange for a lab supplies purchasing commitment.</span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjk2_cdac3949-ba91-4cf0-be17-554702b06c14" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Oncology Services</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of oncology services relates primarily to our Translational Oncology Solutions ("TOS") business unit. TOS costs consist of direct costs related to laboratory supplies, mice purchases, and maintenance costs for studies completed internally as well as charges from Contract Research Organization's for studies handled externally. Indirect costs include salaries and other payroll related costs of compensation for personnel directly engaged in providing TOS products and services. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, are expensed when incurred.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY0_05723aba-5bfd-420b-ba4a-44cad142379c" continuedAt="i15dd3e09752a41a888521cb04ec52575" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15dd3e09752a41a888521cb04ec52575">Research and development costs represent both costs incurred internally for research and development activities, including personnel costs, mice purchases, and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="id2d2242ee7884a1b869e577806df4ade" continuedAt="ib59f6e90fd8541d099392b344c46ee1d"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:SalesAndMarketingExpensePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzA4_168fcdef-78f8-425a-865b-0dfd484e48f9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses represent costs incurred to promote the Company&#8217;s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzA5_13c1e20e-2efc-4b31-ab69-2de5178cfe40" continuedAt="i767ecc17c24c4a53b3972a303aa40915" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i767ecc17c24c4a53b3972a303aa40915">Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company&#8217;s common stock purchase warrants and stock options.</ix:continuation> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjg0_b6ee916c-80ec-49e6-b8bb-7622d9cde2fa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payments</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically recognizes expense for stock-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of stock-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved &#8220;simplified method&#8221; noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. &#160;Estimated volatility is based upon the historical volatility of the Company's common stock.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based payments over the period that the awards are expected to vest.&#160;&#160;In the event of forfeitures, compensation expense is adjusted.&#160;&#160;The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY2_c93355f0-0c1a-49e2-9865-b162f2019574" continuedAt="i4296b838d2324e4c81085f1fa477044f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of April&#160;30, 2022 and 2021, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;As of April&#160;30, 2022 and 2021 the Company has recorded $<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4MzA3_047c5512-63f0-4c4c-8839-feecc87e4924"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4MzA3_a845f159-7e5b-4a9f-8e7b-a6ff7569f1eb">181,000</ix:nonFraction></ix:nonFraction> of liabilities related to uncertain tax positions relative to one of its foreign operations.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4296b838d2324e4c81085f1fa477044f">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense.</ix:continuation> The Company accrued $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4NTY0_a0f1cddb-5c28-4fa8-bdda-890a9e58de2b">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4NTcx_a6b53cd0-7c23-4e0f-8b81-732792280b3a">3,000</ix:nonFraction>, for interest and penalties on the Company&#8217;s statement of operations for the years ended April&#160;30, 2022 and 2021, respectively. The Company does not anticipate any significant unrecognized tax benefits to be recorded during the next 12 months.&#160;&#160;For the year ended April 30, 2022 and 2021, the Company recognized a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ5NDc4MDIzNjMwOTE_3620ef18-9cde-406b-9d62-8a57be272716">35,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ5NDc4MDIzNjMxMDA_4e7f9a27-7ed0-44fb-90e0-16cefdb942f5">75,000</ix:nonFraction>, respectively.  These amounts are mainly attributable to taxable income earned in Israel relating to transfer pricing.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ib59f6e90fd8541d099392b344c46ee1d" continuedAt="ib29e80a47d954ec7a38226948c44859c"><ix:continuation id="i66d31856ab1f4637a54a6f9c1f9d9b8d" continuedAt="i4d38692f89504290be71286929b1950b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers.  The objective of the standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under this standard, companies recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue is generated from contracts with customers. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between <ix:nonNumeric contextRef="i21e22e4b5df54df1862ddd1cc4b4935a_I20220430" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzU0OTc1NTg1MzIxMA_7df82ab4-ff54-4a74-b995-3c9d0dd68996">1</ix:nonNumeric> and <ix:nonNumeric contextRef="i8bd7cd0ec9ba489bbd06b6da6761fbcc_I20220430" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzU0OTc1NTg1MzIxOA_ed6444d1-ee53-4ab9-a19f-3b2fa83fe708">3</ix:nonNumeric> years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacology Study and Other Services</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incremental Costs of Obtaining a Contract (Sales Commissions)</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the costs of obtaining a contract can be expensed immediately, rather than capitalized and amortized, if the amortization period is one year or shorter.  Sales commissions for the Company represent contract costs with a term of one year or less.  Therefore, under ASC 606, the Company elected the practical expedient to expense these costs as incurred.&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.  </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib29e80a47d954ec7a38226948c44859c"><ix:continuation id="i4d38692f89504290be71286929b1950b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, Unbilled Services and Deferred Revenue</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise when the revenue recognized exceeds the amount billed to the customer.  Such situations occur due to divergences between revenue recognition and the invoicing milestones which are based on predetermined payment terms.   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjc1_4e314a9a-55d3-46dd-87f1-02b87e0a8712" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Being Evaluated</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses".  This update requires immediate recognition of management&#8217;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#8212; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. We adopted this guidance on May 1, 2021. The adoption of this ASU did not have a material impact is reflected in the Company's current year consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4Ng_60e80525-eda8-4dae-83f4-a2e323c30234" continuedAt="id91971f714654bab9397cac9d00a6940" escape="true">Accounts Receivable, Unbilled Services and Deferred Revenue</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id91971f714654bab9397cac9d00a6940" continuedAt="i0ad9da5d91b346149d7b64ebffdbd2b1"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4OQ_0369a031-6239-496d-ab14-4df5a62fc083" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable and unbilled services were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:71.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="csbr:TradeAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzItMS0xLTEtMTQzOTI_0671c949-29a3-4fb0-9ce6-7961b2e58068">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="csbr:TradeAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzItMy0xLTEtMTQzOTI_1fce1761-88a8-4d8c-b5a5-3600fcb296d7">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzMtMS0xLTEtMTQzOTI_712978ef-3849-4f41-b0f0-f08ceb2ddb12">4,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzMtMy0xLTEtMTQzOTI_b7877830-bca9-4358-8d46-72df06277372">3,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and unbilled services</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzQtMS0xLTEtMTQzOTI_e3fa09c1-fca0-4ebf-975d-c46efe7d34cf">10,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzQtMy0xLTEtMTQzOTI_6b3858cf-4175-4576-98d2-c283c21cd57c">7,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzUtMS0xLTEtMTQzOTI_58db6c23-f85a-4bea-831c-b58f9fab2fae">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzUtMy0xLTEtMTQzOTI_1b655ec1-0898-4e23-bbd9-d3170bda941d">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzYtMS0xLTEtMTQzOTI_51f83738-0975-4b4e-9d43-72fa545c124d">9,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzYtMy0xLTEtMTQzOTI_cfeee966-93ba-446b-b2e6-f069d8f9f8f1">6,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4Mw_12fe5b2e-edc5-4b0e-82b3-f6704945eb5d" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:71.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZTo2MTBiNWQwNDI5YzM0NzEyOTBjOTA1ZjkzMThhY2NiZS90YWJsZXJhbmdlOjYxMGI1ZDA0MjljMzQ3MTI5MGM5MDVmOTMxOGFjY2JlXzItMS0xLTEtMTQzOTI_c7a00054-aee9-4338-bea3-f7a2f4c19faa">11,071</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZTo2MTBiNWQwNDI5YzM0NzEyOTBjOTA1ZjkzMThhY2NiZS90YWJsZXJhbmdlOjYxMGI1ZDA0MjljMzQ3MTI5MGM5MDVmOTMxOGFjY2JlXzItMy0xLTEtMTQzOTI_a8e975a6-6f0a-4b7a-a13c-24cebca6a3cf">6,256</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0ad9da5d91b346149d7b64ebffdbd2b1"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is shown as a current liability on the Company's balance sheet.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 30, 2020 unbilled services was $<ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzIxOTkwMjMyNTU5NjI_d3f34f3b-12d5-4f47-bf9f-31241423d3fc">2.4</ix:nonFraction>&#160;million and deferred revenue was $<ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzIxOTkwMjMyNTU5NzY_05c2d21e-a048-4b5f-8bf7-a0d90a57ca0a">5.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i776cf0b85fdb44a193c88f4fc7063181_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxODY_7da2f199-f416-4363-bada-78e85c260368" continuedAt="i2b3b5d286b364ca2b9877970c6de3d8a" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:continuation id="i2b3b5d286b364ca2b9877970c6de3d8a" continuedAt="ia812caf55e7d413e8401e518787610fc"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxODg_5370f90a-fb98-43c5-bc8a-ee760826a916" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1df8ed1c598465da670d79e3593edc3_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzItMS0xLTEtMTQzOTI_b4eae45f-1ea0-4229-9ad4-26adf7aeea62">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e36386ee4d4a73a89948ef648fc5c7_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzItMy0xLTEtMTQzOTI_77c992ac-5da7-446d-a0a9-67e62968ba08">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b6dabdf94b404eb4437550f85937c4_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzMtMS0xLTEtMTQzOTI_3e50f270-3060-47b6-bb78-a352f476d171">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b035faecffc4387a2253d46e038e904_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzMtMy0xLTEtMTQzOTI_b50b58b7-0cac-400a-bf04-eadba11e7dad">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b1597843e04e4d850927f9e6336bec_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzQtMS0xLTEtMTQzOTI_70650f41-8e14-43e2-8a41-58bb8184359e">8,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568b515a477e47eab0c4e0a329fa4bb3_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzQtMy0xLTEtMTQzOTI_a177dafe-816f-4198-8650-44f5e4835d1b">6,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ad5abd59b8400788b5b367632d5473_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzUtMS0xLTEtMTQzOTI_887f455a-63d6-43bf-be82-7f7b00e01437">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35ac20f4a06475fa1113e6fe75b4f85_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzUtMy0xLTEtMTQzOTI_70319f30-0ac9-4afc-8745-e09e5db4ef5e">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b0060bd8694b6fb702f24b7e796e2b_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzYtMS0xLTEtMTQzOTI_44eba336-18cb-4562-8e2b-c3abba7306ec">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1aaf64c59043568e7d5f17d579c269_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzYtMy0xLTEtMTQzOTI_ff342d2b-9026-4383-870d-d663ccd1b152">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748895a7edfe4b3297a3b13b1255c579_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzctMS0xLTEtMTQzOTI_356f6fb9-687d-4400-b61a-c3c02ecea309">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5aecbec4114718bfe16c50c87355f3_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzctMy0xLTEtMTQzOTI_f7d5a538-31b7-4bcc-8277-7671ad7a63f4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzktMS0xLTEtMTQzOTI_2d4ec75c-653d-4ebd-8a44-6bb26bc4259f">12,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzktMy0xLTEtMTQzOTI_a2fbd872-d5a8-413c-9246-9fc8c0818475">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEwLTEtMS0xLTE0Mzky_c6b033fa-e554-4c92-b635-0b740e5f72ad">5,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEwLTMtMS0xLTE0Mzky_e82ed26f-73a5-4050-bc9b-731b8d192a0d">3,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb">Property and equipment, net</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTEtMS0xLTE0Mzky_08d13fb7-001b-45ee-8cee-3c1cf51daeb5">7,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTMtMS0xLTE0Mzky_d38eea01-adf8-4cee-a415-05fe64381620">6,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3NTk_d8c7fb21-8443-46d1-9e47-a2120d220a0d">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzE1Nw_565186e4-bd0f-49c8-8abd-0765853dac87">1.2</ix:nonFraction> million for the years ended April&#160;30, 2022 and 2021, respectively.  Depreciation and amortization expense, excluding expense recorded under finance leases, was&#160;$<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzI5OQ_28464dea-6ecf-40d2-b45c-51e18942b999">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzMwNw_c5d291d9-4d67-48fc-98ac-dbf152b07c5c">925,000</ix:nonFraction>&#160;for the years ended&#160;April 30, 2022&#160;and&#160;2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of&#160;April 30, 2022&#160;and&#160;2021, property, plant and equipment included gross assets held under finance leases of&#160;$<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3NzM_521826e9-d7ef-41fb-9dc6-78850e615e94">713,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzIxOTkwMjMyNjY0Mzc_e51d8808-2710-4b86-b0db-1202b9dc2ed7">343,000</ix:nonFraction>, respectively. Related depreciation expense for these assets was $<ix:nonFraction unitRef="usd" contextRef="i0f37c8ede37d417ea5b2dcff2fe06109_D20200501-20210430" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzUzMg_c7b2b5f4-781e-4778-8a8c-8823bc631a3e">87,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1c343591f7aa43e9bbf094ff48848b15_D20190501-20200430" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzUzOQ_30a9d995-11c8-4153-b1dc-6f7e1cec54a3">124,000</ix:nonFraction> for the years ended&#160;April&#160;30, 2022&#160;and&#160;2021.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized software development costs under a hosting arrangement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the cost of computer software obtained or developed for internal use as well as the software development and implementation costs associated with a hosting arrangement ("internal-use software") that is a service contract in accordance and with ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC-350"). We capitalize certain costs in the development of our internal-use software when the preliminary project stage is completed and it is probable that the project itself will be completed and the software will perform as intended. These capitalized costs include personnel and related expenses for employees and costs of third-party consultants who are directly associated with and who devote time to these internal-use software projects. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs incurred for significant upgrades, increased functionality, and enhancements to the Company's internal-use software solutions are also capitalized. Costs incurred for training, maintenance, and minor modifications are expensed as incurred.  Capitalized software development costs are amortized using the straight-line method over an estimated useful economic life of <ix:nonNumeric contextRef="i75381282e8854f8aa4162452573b81af_D20210501-20220430" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzI0NjE_27e76dc8-4c2e-42b9-b819-b7165290a3ee">three years</ix:nonNumeric>.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has capitalized development and implementation costs in accordance with accounting guidance for its Lumin Bioinformatics platform ("Lumin").  Lumin is the Company's new oncology data-driven software program and data tool which is operates as Software as a Service (SaaS).  These capitalized costs represent salaries, including direct payroll-related costs, certain software development consultant expenses and molecular sequencing programming costs incurred in the engineering and coding of the software development.  Capitalized costs are classified as assets in progress during the development process until development is complete and the asset is available for sale. The initial version of the Lumin platform was launched during fiscal year 2021, at which time initial capitalization ceased and amortization commenced. The total Lumin assest placed into service and available for sale as of July 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i37caf4f2f3b94b46a64f2e1ccc27d921_I20200731" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzM1Njk_70f7d88b-ad95-4ced-b607-e972f6057123">484,000</ix:nonFraction>.   </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continued to develop increased functionality, expand product design and usability, and add enhancements to the Lumin platform.  In accordance with accounting guidance, these costs were capitalized. This developmental work did not render the initial released version to be obsolete or diminished in value but, rather, added to the base functionality of the existing platform.  During the third quarter of fiscal year 2022, these capitalized costs were placed into </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ia812caf55e7d413e8401e518787610fc" continuedAt="ia5ade9bf0dbc429aac99e56a41934719"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service as the enhanced version was launched and made available for sale. The total cost of the enhanced Lumin asset placed into service and available for sale as of January 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i603726853868452081ffb4f2ddec75af_I20220131" decimals="-5" name="us-gaap:ServicingAssetAtFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3ODQ_327e0791-efc4-4d89-a7e4-18562d929640">1.4</ix:nonFraction>&#160;million, bringing the total capitalized gross asset investment to $<ix:nonFraction unitRef="usd" contextRef="i603726853868452081ffb4f2ddec75af_I20220131" decimals="-5" name="us-gaap:ServicingAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3OTg_2b888d38-9025-4bfb-ab40-744175240e18">1.9</ix:nonFraction>&#160;million. Amortization expense related to this asset addition was $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MTI_352b2077-4d1c-41f5-a1ca-720b759ee84a">317,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MjI_42a8daab-da8c-4664-ba4e-e7dc82666e60">134,000</ix:nonFraction> for the years ended April 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During fiscal 2020, the Company entered into a finance lease for laboratory equipment. The lease had costs of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i8779c4cdedb2440f85a3c8ca3a5b66f1_D20191201-20201130" decimals="-3" name="csbr:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU2NzI_cbafb765-4071-4fa2-9e18-6f757fb8f025">231,000</ix:nonFraction>, at inception, through November 2020. This lease expired December 2020. Prior to expiration, the  monthly finance lease payment was approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ic0b7070af4eb4a99ab731259dead4896_D20191201-20191231" decimals="-3" name="csbr:FinanceLeaseMonthlyPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU4MjE_22bff57d-c7ef-44a2-b76d-54b92c49737d">19,000</ix:nonFraction>. The future minimum lease payments remaining under this finance lease at April 30, 2021 and 2020 were <ix:nonFraction unitRef="usd" contextRef="ia82b4636bcec43a581c7c41150e8c863_I20210430" decimals="INF" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU5MjY_e4a7d3d0-a3ce-4f5a-905f-301a9cd2a1f3">zero</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usd" contextRef="ieb85b2ee4da64c099fc6a0fbbd34f4d4_I20200430" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU5MzM_a10027f8-4f64-4e45-a3de-9aea875cf006">135,000</ix:nonFraction>, respectively. The present value of minimum future obligations was calculated based on interest rate of&#160;<ix:nonFraction unitRef="number" contextRef="i19fa58ff128b48d4a12d943d7cb17020_D20190501-20200430" decimals="INF" name="csbr:PresentValueMinimumFutureObligationsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYwNDA_c6253661-9cb6-430a-a0e2-281c22ffe498">4.75</ix:nonFraction>%. Depreciation and amortization expense related to this finance lease was <ix:nonFraction unitRef="usd" contextRef="i22b89d0c347047c4a863838d447fe6b2_D20210501-20220430" decimals="INF" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MzE_9dd68d41-081b-405d-971b-82cf714a7617">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7944dc3e37d5471fac3e5aa26a76720a_D20200501-20210430" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxMTY_ad01c50b-45c9-45be-8b7f-6fdbad99b0e2">124,000</ix:nonFraction> &#160;for the years ended April 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5ade9bf0dbc429aac99e56a41934719">During fiscal 2022, the Company recognized a finance lease for laboratory equipment.  This equipment was obtained as the result of a laboratory supplies purchase commitment with costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430" decimals="-3" name="csbr:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NDE_cc20b9df-de7c-4cab-9034-7b4b8e6ee565">370,000</ix:nonFraction> at inception through December 2025. Cash payments for this lease are in the form of consideration for purchasing lab supplies under a purchase commitment agreement. The present value of the minimum future obligations of $<ix:nonFraction unitRef="usd" contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430" decimals="-3" name="csbr:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzIxOTkwMjMyNjc2MTM_8f03a127-91d7-4fe7-8b58-9204b8031679">370,000</ix:nonFraction> was calculated based on an interest rate of <ix:nonFraction unitRef="number" contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430" decimals="INF" name="csbr:PresentValueMinimumFutureObligationsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NTE_aca7cbfb-9bb9-4384-8fc8-69e730a7026e">3.25</ix:nonFraction>%. Depreciation and amortization expense related to this finance lease was $<ix:nonFraction unitRef="usd" contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NTg_a716b649-5749-467b-8527-7cc76b0eb107">87,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="i11b3c65241cc4e8181694452a5e4d0eb_D20200501-20210430" decimals="INF" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NjY_7f54f734-da73-4b21-bc7f-7f41126f35d3">zero</ix:nonFraction> for the years ended April 30, 2022 and 2021, respectively.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90ZXh0cmVnaW9uOjIzNDA5NDViMDM0YTQ2MmRiN2UzZTM5NDA5M2M1OTFlXzQwNTk_a73331df-e731-41b1-8b25-b973aa452e3c" continuedAt="ib0811cf84a884f43b74e4b7638fd02f8" escape="true">Revenue from Contracts with Customers</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib0811cf84a884f43b74e4b7638fd02f8" continuedAt="i27266c62297b465cb61801717c8d863a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology Services Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90ZXh0cmVnaW9uOjIzNDA5NDViMDM0YTQ2MmRiN2UzZTM5NDA5M2M1OTFlXzQwNjA_231a2289-0fe2-4080-86a4-2a3519cdb58f" continuedAt="i09c1db656e26494bb3268929adb03c6b" escape="true">The following table represents disaggregated revenue for the twelve months ended April&#160;30, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i09c1db656e26494bb3268929adb03c6b" continuedAt="i2eff791c9f354205ab5c5df43746318b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:70.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacology services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccbb55bcd7d8409f95ab07871b4f00eb_D20210501-20220430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzItMS0xLTEtMTQzOTI_b72d47c1-e65e-4b95-a38a-12fec2d56ca4">46,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ae863a047f404ebf60eb56f8352be7_D20200501-20210430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzItMy0xLTEtMTQzOTI_98991520-cf68-414f-8bf7-130c462044b7">39,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other TOS revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9d5b70c71944c3b1537441f0cba8e8_D20210501-20220430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMS0xLTEtMTU1MDc_f6e1d08c-905e-4357-86bb-f5bc391ee889">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e613c7ed7e462d8916e09de7dfd9b6_D20200501-20210430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMy0xLTEtMTU1MDc_b83b8176-9352-481f-9492-cf22faf4e075">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personalized oncology services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75ddc90488642fe9524dca29561cb31_D20210501-20220430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMS0xLTEtMTQzOTI_742e0d22-8fa6-4224-86bb-2f3f53d87986">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ace46fb73764dc580412ddfa1073ea4_D20200501-20210430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMy0xLTEtMTQzOTI_4ac21d76-91d6-4485-92da-0e2ec24735ee">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology services revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzUtMS0xLTEtMTQzOTI_9c127d5d-dd33-4e32-a67f-5c29feaf561c">49,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzUtMy0xLTEtMTQzOTI_5d148589-4e2a-4a8a-be28-d96bf08b59d4">41,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2eff791c9f354205ab5c5df43746318b"> Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers,  specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software.</ix:continuation> </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div></ix:continuation><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27266c62297b465cb61801717c8d863a">Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.  Refer to Note 3 for related balances.</ix:continuation> </span></div><div><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDIvZnJhZzo1Yjk1ZGE0ODY2MTY0ZWNhOTZiYWFlYzlkMjg2OThhYi90ZXh0cmVnaW9uOjViOTVkYTQ4NjYxNjRlY2E5NmJhYWVjOWQyODY5OGFiXzI1OQ_49c372d9-1c52-45f7-a50b-dd31ad1c233c" continuedAt="i24c5500a2b1c4b04a5815f32c125616c" escape="true">Significant Customers</ix:nonNumeric></span></div><ix:continuation id="i24c5500a2b1c4b04a5815f32c125616c" continuedAt="i350a47e918c84bfebdef3ebc0556de14"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended April&#160;30, 2022 and 2021, one and none of our customers accounted for more than 10% of our total revenue, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i350a47e918c84bfebdef3ebc0556de14">As of April&#160;30, 2022, one customer accounted for <ix:nonFraction unitRef="number" contextRef="if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDIvZnJhZzo1Yjk1ZGE0ODY2MTY0ZWNhOTZiYWFlYzlkMjg2OThhYi90ZXh0cmVnaW9uOjViOTVkYTQ4NjYxNjRlY2E5NmJhYWVjOWQyODY5OGFiXzIxOTkwMjMyNTY0MzE_2b2f2aae-2213-4f03-af35-a5038485dfdc">17</ix:nonFraction>% of our total accounts receivable balance.  As of April 30, 2021, no customers accounted for 10% or more of our total accounts receivable balance.</ix:continuation> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzIwNjM_b9b51b27-d711-43aa-9f79-8e3b64fcceea" continuedAt="i460d2bc33c264325bdd20933fcf82c02" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i460d2bc33c264325bdd20933fcf82c02" continuedAt="i14020119440d409eb76a3d2427cad6e9"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company&#8217;s financial position or results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Payment Arrangements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company&#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company has not accrued any liquidated damages associated with the Amended and Restated Registration Right Agreement as the Company has filed the required registration statement and anticipates continued compliance with the agreement.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14020119440d409eb76a3d2427cad6e9">The Company contracts with third-party vendors to license tumor samples for development into PDX models and use in our TOS business. These types of arrangements have an upfront fee ranging from approximately <ix:nonFraction unitRef="usd" contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430" decimals="INF" name="csbr:CollaborationArrangementRoyaltyFee" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzEzNjc_7b7e818a-3434-427a-a018-a061b6b4df44">nil</ix:nonFraction>&#160;to $<ix:nonFraction unitRef="usd" contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430" decimals="-3" name="csbr:CollaborationArrangementRoyaltyFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5MTM_349047d4-a292-48d6-938d-357d5607ca36">30,000</ix:nonFraction> per tumor sample depending on the successful growth of the tumor model and ability to develop them into a sellable product. The upfront costs are expensed as incurred. In addition, under certain agreements, for a limited period of time, the Company is subject to royalty payments if the licensed tumor models are used for sale in&#160;our TOS business,&#160;ranging from <ix:nonFraction unitRef="number" contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430" decimals="INF" name="csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzE3Mzc_e60e187d-0822-4641-bf61-a6428d001b35">2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430" decimals="INF" name="csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5MjI_3e910b73-b97c-4a01-8c44-0de84540ce40">20</ix:nonFraction>% of the contract price&#160;after recouping certain initiation costs.  Some of these arrangements also set forth an annual minimum royalty due regardless of tumor models used for sale.   For the years ended April&#160;30, 2022 and 2021, we have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzIxOTkwMjMyNTc3Mjk_b1aa13c3-dd91-419e-b735-47e8f05846c5">401,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5Mjg_ddeb0548-5acd-4036-8bf4-94d0853dceb8">127,000</ix:nonFraction> in expense related to these royalty arrangements, respectively.</ix:continuation>  </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNjU_b396c0f4-706e-4d16-84c6-bb5361bd1efa" continuedAt="i3bb4739718554c0e8134f1014e282e1a" escape="true">Stock-based Payments</ix:nonNumeric></span></div><ix:continuation id="i3bb4739718554c0e8134f1014e282e1a" continuedAt="i613a91c656264cee8f3bf1dc2363df15"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation in the amount of $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzc4_1a0d76b2-d0c5-4758-8ee1-7d6eeb4c8a23">912,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzg1_8a12cfda-df64-44ed-8fac-1e44285f01cf">598,000</ix:nonFraction> was recognized for years ended April&#160;30, 2022 and 2021, respectively.&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzg_f81227eb-d75c-4d8e-8325-14a165cf7324" continuedAt="if4b5222e5c684b5094b91ff66101c193" escape="true">Stock-based compensation costs were recorded as follows (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="if4b5222e5c684b5094b91ff66101c193" continuedAt="iecfaddd4d15f4ccb88df01c4d8281d12"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c0dcae4e7d40d4b0fb1669660fdd03_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzItMS0xLTEtMTQzOTI_2f16afb0-4b36-4c9e-b88d-f89fb97762f6">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2997e8d60bcf46f9ba6c1f4ca4110249_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzItMy0xLTEtMTQzOTI_f85b18fb-6b0c-4b0c-b9cd-106803550ae0">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55eff6dffbf4ce19f35251ba3c322f6_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzMtMS0xLTEtMTQzOTI_9e5a3e16-a8e0-4dad-b1b0-276a3ef2e005">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23746d0989e4145af18c84580ca48f6_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzMtMy0xLTEtMTQzOTI_739701b4-9895-4dbe-b0cc-fdf250bd1b4c">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c8d68a641f4e3b847ea1ccfcd8e347_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzQtMS0xLTEtMTQzOTI_a41f5e71-4b1b-492c-9ea2-3f1a546be0ca">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43786c34b50d435293e7048f0d6fb091_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzQtMy0xLTEtMTQzOTI_609bedf0-c1ea-4174-9123-d02a3654cfad">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOS cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b63951e3c94191b0de18e0a98025b5_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzUtMS0xLTEtMTQzOTI_180d6a8d-2251-40ad-874a-8b8d4a76104c">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541e144c82554a4e88aec80277e945e8_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzUtMy0xLTEtMTQzOTI_4d1150fa-d9af-4297-8283-bd8daa8ce157">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzgtMS0xLTEtMTQzOTI_0dd6e012-f3a3-47dc-bbfe-f877d8a8b548">912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzgtMy0xLTEtMTQzOTI_e6b86154-94e6-4054-b047-9d4db5c0723e">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iecfaddd4d15f4ccb88df01c4d8281d12">The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan ("the Plans"). In general, these plans provide for stock-based compensation to the Company&#8217;s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (&#8220;2021 Equity Plan&#8221;). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed <ix:nonFraction unitRef="shares" contextRef="i72c10eebe3ea442a931103ac31ce4af1_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzEwMTY_c086f19b-72e7-43eb-aa06-4716590851a0">2</ix:nonFraction>&#160;million shares of common stock. Options and Stock Appreciation Rights expire no later than <ix:nonNumeric contextRef="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzA0Njc_c0738754-1e02-442e-b742-d194441df409">ten years</ix:nonNumeric> from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than <ix:nonFraction unitRef="number" contextRef="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzA0ODc_7fdc2693-e06d-4d8d-bda9-3dfbc18c1efe">100</ix:nonFraction>% of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i613a91c656264cee8f3bf1dc2363df15" continuedAt="icb112e550e8b489bb5b6f25234291735"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair market value of the common stock subject to the option or right at the date of grant.  As of April 30, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="ice1add8ac2df4b9ebbefa41994d6bc10_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzEwMjc_bc235863-37ef-412a-84d5-2b890dba9e8c">1.8</ix:nonFraction>&#160;million shares were left to issue under this plan. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2010 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed <ix:nonFraction unitRef="shares" contextRef="i94a9f833a47649688056938280a6100a_D20110218-20110218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzcyNw_ce69302b-64fb-4c1e-b93f-ea7745b708bc">30,000,000</ix:nonFraction> shares of common stock. Options and Stock Appreciation Rights expire no later than <ix:nonNumeric contextRef="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzgxMw_5ed02c4f-7781-42c5-8529-7f1b02f448fe">ten years</ix:nonNumeric> from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than <ix:nonFraction unitRef="number" contextRef="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzk3Mg_ab1487df-86ef-409b-b006-921785fe8b3b">100</ix:nonFraction>% of the fair market value of the common stock subject to the option or right at the date of grant.  After February 2021, no more shares were available to be issued from this plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &#8220;2008 Equity Plan&#8221;).&#160;&#160;Such awards may be granted by the Company&#8217;s Board of Directors.&#160;&#160;Options granted under the 2008 Equity Plan expire no later than <ix:nonNumeric contextRef="ic8f8fd968db64d9aab0a9c7ba34faf09_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzE1MTY_7af34e76-5f0c-47f4-928e-76f5166497a5">ten years</ix:nonNumeric> from the date of grant and the awards vest as determined by the Board of Directors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock-based payments to non-employee consultants under the Plans, the fair value of the stock-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.&#160;&#160;The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company&#8217;s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award. After 2018, no more shares were available to be issued from this plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2013, the Compensation Committee of the Board of Directors of the Company adopted changes to the Director Compensation Plan of 2010 (the &#8220;Director Plan&#8221;) effective December 1, 2013.&#160;&#160;Under the Director Plan, independent directors of the Company are entitled to an annual award of a <ix:nonNumeric contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212" name="csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzM_b288f478-9cdd-45b4-909e-c38a940927cc">five-year</ix:nonNumeric> option to purchase <ix:nonFraction unitRef="shares" contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212" decimals="INF" name="csbr:StockOptionsAwardSharesToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI2NTI_0d624ea7-7b9f-452d-8be3-168434fed5f9">8,333</ix:nonFraction> shares of the Company&#8217;s common stock, and the Chairman of the Board of the Company is entitled to an annual award of a <ix:nonNumeric contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212" name="csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI3NDg3NzkwODQ0NDA_19f34667-4fdf-4d6b-8f80-cb91dab7c334">five-year</ix:nonNumeric> option to purchase <ix:nonFraction unitRef="shares" contextRef="i2499764558fa4746ac056a1fff5047ae_D20131212-20131212" decimals="INF" name="csbr:StockOptionsAwardSharesToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI3OTY_7a5eba26-413d-465c-90f2-f7a0e30d7ced">16,667</ix:nonFraction> shares of the Company&#8217;s common stock.&#160;&#160;Independent directors who serve as chairperson of a committee will also receive an annual grant of a <ix:nonNumeric contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212" name="csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzOTA_a1197ec3-ece4-461d-94fe-db19b5b66f6f">five-year</ix:nonNumeric> option to purchase <ix:nonFraction unitRef="shares" contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212" decimals="INF" name="csbr:StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI5NjY_ef66f921-3577-41ef-866f-e5dc3893217e">1,667</ix:nonFraction> shares of the Company&#8217;s common stock. All options issued under the Director Plan vest quarterly at a rate of <ix:nonFraction unitRef="number" contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzMwNzg_e3c79d48-84ae-4bfe-a473-73d63e40d175">25</ix:nonFraction>%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in October of each year. New directors will receive a grant upon joining the Board equal to the pro-rata annual grant for the remainder of the year.&#160;Options issued under the Director Plan are now issued pursuant to the 2021 Equity Plan.&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzA_828780ac-8a0b-4cba-b02d-c1f68b5d1152" escape="true"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April&#160;30, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjozYWZlZDM0YjNiZjQ0ZGJhYmVlYmRlYWNkNzA3NjhkNF83_e71164db-7be6-4651-ab4d-511fbdb93d25">6</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98768c91edc344c293525a163b2ebfb6_D20200501-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxOGZmYWI5M2U1YTU0ZDhkOGJhNDg3ZDQ5NWFhNmQzYl80_b5cf204e-1f38-4328-9af3-7e7b59f206be">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i5f86018505f24f40a948b8a3bda2f392_D20200501-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxOGZmYWI5M2U1YTU0ZDhkOGJhNDg3ZDQ5NWFhNmQzYl85_7de1bb72-8966-46f4-a781-88b29ea7a6e2">6</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4MmE1NWI1MmUxODU0MWRkODc0NDQyNjg1MGRjYTkzNF80_d145cdfa-c205-44b4-b4df-350506f39b9d">0.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4MmE1NWI1MmUxODU0MWRkODc0NDQyNjg1MGRjYTkzNF85_f2f96b6e-d6e6-4b8f-afc5-17836f3e88a0">1.2</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4NWY4MjgxYmMwNGE0YjJhYTAxZmFjN2MxNTJhYmM4Nl80_9cf6f864-535d-418a-ac66-a111419bd4e2">0.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4NWY4MjgxYmMwNGE0YjJhYTAxZmFjN2MxNTJhYmM4Nl85_525dabd2-f0dd-4b5c-ac7d-9a2acda24ea8">0.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo0NTQ0NmU5NDg1MDU0NjIyYTE1OGM3YjAxNDM3MWNjZl80_06b8a958-a22d-4a08-bb6d-c30b0c4be8a8">64</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo0NTQ0NmU5NDg1MDU0NjIyYTE1OGM3YjAxNDM3MWNjZl85_5279c083-f3c3-42d0-9b4a-521b7fe6c4e1">66</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4OGM3NWNiY2VjOGM0NjQ2YWYxNGNmYzYzMjE1YjljOV80_cade790b-0915-4585-8462-5ac2dfc7095e">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4OGM3NWNiY2VjOGM0NjQ2YWYxNGNmYzYzMjE1YjljOV85_0a984fa9-851b-4049-b95d-c2abab03a446">75</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzUtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxNTU4NTRhMzZkNTg0ZjFiOWEzYzk4NDNiYmU5ODY5Ml80_366ac487-8454-4a1e-bf71-3b8251969708">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzUtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjplMTU2YmMwZmI0ODI0NTNmYmI3Mzk2NGM2NTJiNzJlMF80_49d5c643-cd26-4727-b85f-6ff4b7563dc8">&#8212;</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="icb112e550e8b489bb5b6f25234291735"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted during the years ending April&#160;30, 2022 and 2021, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzM2NzI_8af8fe08-4e0f-4817-97e2-387701b7873e">5.56</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzM2Nzk_d508d9eb-2ac9-4f2d-abad-18b12e367d6a">5.11</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNjk_f289196d-f508-4245-9967-c2eba67d1e3f" continuedAt="i10f1dde4a1ea493d997aecc0dc1843f4" escape="true">The Company&#8217;s stock options activity and related information as of and for the years ended April&#160;30, 2022 and 2021 is as follows:</ix:nonNumeric></span></div><ix:continuation id="i10f1dde4a1ea493d997aecc0dc1843f4"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a5a1fb68099489386e300756890aabb_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMS0xLTEtMTQzOTI_c57c2542-2dac-4a2e-9896-74d4cfb884d2">1,618,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMy0xLTEtMTQzOTI_8e7ff568-7f06-4b69-a0c1-1e8884f305b7">35,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtNS0xLTEtMTQzOTI_2929cb73-48c4-4f1f-b079-eeb39ba8f866">1,653,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtNy0xLTEtMTQzOTI_28a686a2-32de-4e6d-9c9a-34cafcc23993">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtOS0xLTEtMTQzOTI_cec3c2fa-ce68-4a4f-8bdd-38f8e80e6c67">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMTEtMS0xLTE0Mzky_fe823878-1c23-453e-a8a3-385173c9c97a">11,384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMS0xLTEtMTQzOTI_6195a6c5-6a19-4a17-89ab-0602592b3246">155,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMy0xLTEtMTQzOTI_23f18af5-5e48-4891-989a-35d51c9e87c7">10,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItNS0xLTEtMTQzOTI_1bead16a-da1c-4cb0-98f8-2641bd93d088">166,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItNy0xLTEtMTQzOTI_d59025a0-7377-4c7d-a66d-dd945b138dc9">9.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItOS0xLTEtMTQzOTI_6776fb2f-fa7e-4b11-8dd2-69b23774b739">9.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMTEtMS0xLTE0Mzky_e009e3dd-1434-4cee-94a5-e49bf7acd692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtMS0xLTEtMTQzOTI_22f4093a-1620-4038-aa49-5efd9de989f1">108,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtMy0xLTEtMTQzOTI_a8b1eb71-6354-4de2-a0d8-b2399d64d307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtNS0xLTEtMTQzOTI_2ca1898e-5bb0-42cc-afc0-850efbbf344a">108,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtNy0xLTEtMTQzOTI_7a95cf2a-3fb8-4034-ac84-5aca6323a67c">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtMS0xLTEtMTQzOTI_b8d57de2-81a7-461a-96bb-d98f512202b7">11,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtMy0xLTEtMTQzOTI_6f3430cf-c8e1-4d4e-a282-0f1e5893fbc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtNS0xLTEtMTQzOTI_06825931-460f-4746-a8bb-ea6a7d069cf5">11,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtNy0xLTEtMTQzOTI_0f2ed7d3-2de7-4096-91e6-4ed3cb50514b">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtMS0xLTEtMTQzOTI_25215710-22e9-4b99-a806-7d277569c398">36,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtMy0xLTEtMTQzOTI_08dde4b8-4d6a-4b36-9727-55085c07308c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtNS0xLTEtMTQzOTI_ff0f469e-d956-412a-9119-521d4dfd020b">36,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtNy0xLTEtMTQzOTI_3117469c-b137-4ab6-af7f-999a96bc1cf6">7.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtMS0xLTEtMTQzOTI_fd081bd7-f845-4a48-8069-760d10558714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtMy0xLTEtMTQzOTI_cf685b44-e447-487a-b810-e98c9f6d62d9">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtNS0xLTEtMTQzOTI_feb31345-5672-40a3-b6b9-7395def2020c">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtNy0xLTEtMTQzOTI_3c43cb91-ba18-42dd-8c1a-30abaee6c944">9.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMS0xLTEtMTQzOTI_111d3699-03a2-4805-b301-e9c28a0f82f0">1,617,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMy0xLTEtMTQzOTI_551f1142-4b8f-4e8c-a270-07d558e28104">40,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtNS0xLTEtMTQzOTI_b17ebfb8-f13e-40b0-9672-5a9033e4b367">1,658,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtNy0xLTEtMTQzOTI_9a533378-6aba-4b39-a07d-a4f19a2106fd">4.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtOS0xLTEtMTQzOTI_20adfb8e-3fae-4b65-84b9-04f0504d20b3">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMTEtMS0xLTE0Mzky_b252c5ce-9fa8-407d-961e-8b21281b09b5">6,131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTEtMS0xLTE0Mzky_54c002d5-4aae-4cc4-8f68-6f84dfcd6330">1,617,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTMtMS0xLTE0Mzky_19d3ca21-30f2-468e-99f2-54074c8a9585">40,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTUtMS0xLTE0Mzky_ee94b29d-895f-42b8-8fe0-bcdab6662761">1,658,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTctMS0xLTE0Mzky_63cf99ba-e103-42e7-88d3-8dd23ce397e8">4.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTktMS0xLTE0Mzky_f9d5f22e-2d67-46f3-825d-34b6c88c8a31">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTExLTEtMS0xNDM5Mg_cb7a1d52-7c02-47e6-8386-9ad3de2ba83b">6,131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTEtMS0xLTE0Mzky_e8a4dbc7-2f23-466a-8057-6af60b12ab99">1,349,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTMtMS0xLTE0Mzky_2d67853f-5595-41fc-af26-0ad7ca15b3f7">4,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTUtMS0xLTE0Mzky_d3081440-21a7-4dc7-88aa-9487868e465a">1,354,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTctMS0xLTE0Mzky_f653ebf8-9835-4a63-bb57-a36a193ee271">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTktMS0xLTE0Mzky_a18f6e28-20cd-4111-9d5b-989b54f2d099">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTExLTEtMS0xNDM5Mg_d3540097-a1f5-4a62-8807-fa0ccce575d5">5,778,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8126402c4f4240ec950ef891d3d9bad6_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMS0xLTEtMTQzOTI_03071b1b-f142-48fa-885a-6889e11081e8">2,228,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i494cc1892ba8486dadda4d692b680743_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMy0xLTEtMTQzOTI_a6744b7a-1c29-4d98-9cb5-8803b8acd88c">43,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtNS0xLTEtMTQzOTI_64973144-f343-42d2-8be0-2ae40121ae18">2,271,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtNy0xLTEtMTQzOTI_444d6b53-251d-4189-be72-f512b01ab1a2">3.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idabe360fb07c401a827aa2b65746f3bb_D20190501-20200430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtOS0xLTEtMTQzOTI_301506d8-cf43-420a-8d35-fad75e134abd">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMTEtMS0xLTE0Mzky_6e79d1d9-b9d6-45d8-a244-576add36efd8">10,663,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMS0xLTEtMTQzOTI_056b7e96-1cba-4508-aaa3-dd88db9614ca">135,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMy0xLTEtMTQzOTI_550cd9df-b924-4f98-9661-86b0240dffe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItNS0xLTEtMTQzOTI_f92e80c2-39cb-46bc-876e-ce30e6866bdb">135,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItNy0xLTEtMTQzOTI_7ef06f09-b2d9-46b3-8c5f-3af02fed5376">9.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItOS0xLTEtMTQzOTI_5aba6a70-f083-4d42-b053-9b2911d1c882">7.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMTEtMS0xLTE0Mzky_bfbb2d7c-b0fe-4d3e-a8de-08787f5b383a">259,000</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtMS0xLTEtMTQzOTI_ec507dc1-abe2-416d-aadd-1bbcb8f7bb38">686,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtMy0xLTEtMTQzOTI_0bad998b-e8ef-45a4-926a-d9821ae4bd60">1,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtNS0xLTEtMTQzOTI_4ce07c30-a09f-44e2-a628-f8deaf041142">687,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtNy0xLTEtMTQzOTI_3cb3a167-f2ba-4ab4-aa8a-4a14b2617dc5">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtMS0xLTEtMTQzOTI_9d92cdaa-7ca9-47dd-9c7e-db0696a4a344">47,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtMy0xLTEtMTQzOTI_0aa2d49c-a06c-4bf4-80c3-7cfe10a2be74">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtNS0xLTEtMTQzOTI_7b2b4b36-107a-438a-9de5-f0886e1e3bf8">48,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtNy0xLTEtMTQzOTI_f7a2b717-018e-4e59-9bbe-620fc76a107d">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtMS0xLTEtMTQzOTI_e47267ee-24e8-4b5a-886f-b7ab8ce68702">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtMy0xLTEtMTQzOTI_720e9d52-0139-426c-aead-05fcfae019cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtNS0xLTEtMTQzOTI_f253882d-04f7-460f-85a0-37fd5d94e396">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtNy0xLTEtMTQzOTI_2d4b4526-ec6f-4732-9c2f-277a885f7dae">7.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtMS0xLTEtMTQzOTI_f101f2c9-b247-4701-876f-fbb44af970fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtMy0xLTEtMTQzOTI_6c09fabb-b13d-43d7-88ce-5b662e893fc0">5,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtNS0xLTEtMTQzOTI_9f1876cc-4940-4629-829f-dfab8838e68e">5,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtNy0xLTEtMTQzOTI_276a5259-99cc-4778-a819-132a358adbc5">10.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a5a1fb68099489386e300756890aabb_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMS0xLTEtMTQzOTI_a74e1388-d589-417e-881f-4e2943374ac1">1,618,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMy0xLTEtMTQzOTI_11cb6de8-9153-4fda-906e-2f0ab9520301">35,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtNS0xLTEtMTQzOTI_98b35815-b47d-4ccb-aafa-a421da71fac9">1,653,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtNy0xLTEtMTQzOTI_b7e313c7-b2c3-4883-84ca-a77d2404eace">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtOS0xLTEtMTQzOTI_d525927c-d33f-4c8e-91fe-5dd85724d5d8">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMTEtMS0xLTE0Mzky_8a70154b-14d7-420a-92be-5afa671cf282">11,384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a5a1fb68099489386e300756890aabb_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTEtMS0xLTE0Mzky_ed5f85c0-591f-41b0-8cd1-8c7ac6f2abc6">1,618,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTMtMS0xLTE0Mzky_d4b223a3-07a6-4db9-9d45-b05c0294f241">35,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTUtMS0xLTE0Mzky_0ec6eb2d-a1ac-482c-ae57-1145c411e513">1,653,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTctMS0xLTE0Mzky_c39e9034-b7db-4740-af53-f41963f9c969">3.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTktMS0xLTE0Mzky_00e938ad-f58e-4ef1-9d10-96204b084dee">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTExLTEtMS0xNDM5Mg_0c9d6888-8a9b-404c-9eb8-ec6bb091cdea">11,384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a5a1fb68099489386e300756890aabb_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTEtMS0xLTE0Mzky_7fe3e1a9-a75b-4485-a017-be1ac0428459">1,323,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTMtMS0xLTE0Mzky_c29c2213-cedc-47c2-8e67-fa1bf5b2fa14">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTUtMS0xLTE0Mzky_32e999f0-8f6f-4474-922d-bd4bc14b564b">1,332,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTctMS0xLTE0Mzky_8007d0ff-613c-4fdd-b823-7989d1b7166f">3.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTktMS0xLTE0Mzky_79a6a43a-4939-4618-bd4e-2014808959a1">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTExLTEtMS0xNDM5Mg_b7839d9d-fd77-47b2-9f66-c6d36f5f497c">9,995,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_154"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMTc_721bcafc-2bbc-4cab-a4c8-32144ae65f90" continuedAt="i8dbfa86f19294328b8eb5ecc524ab7b5" escape="true">Provision for Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i8dbfa86f19294328b8eb5ecc524ab7b5" continuedAt="ide08dd3b7d0e4469b2fa84e37680168b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMDA_bbeb7da4-bd70-471b-aba9-30ff89e4ab36" continuedAt="i2950a296897347858d00e8ef92f5966f" escape="true">The components of the provision for income taxes are as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ide08dd3b7d0e4469b2fa84e37680168b" continuedAt="i56e03463d30f4f0ea3f16c68c9cf2aae"><ix:continuation id="i2950a296897347858d00e8ef92f5966f"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItMS0xLTEtMTQzOTI_a7b12bb6-69fb-4a7d-8fb3-afdd665f0a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItMy0xLTEtMTQzOTI_41785e85-65ed-4d73-bd39-71c4006366db">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItNS0xLTEtMTQzOTI_49358809-a1b0-45fa-afe8-cc83b3938186">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItNy0xLTEtMTQzOTI_68dc4af7-5572-4716-aed4-51c5e0285697">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtMS0xLTEtMTQzOTI_0047d9ce-e2ca-4e75-82d1-26c372f8c3b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtMy0xLTEtMTQzOTI_a7d5339a-badb-4b32-9125-6db8d2b08740">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtNS0xLTEtMTQzOTI_1c86d8d1-e4f1-47df-bc7d-3e26b7eac1cb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtNy0xLTEtMTQzOTI_0c420a93-016e-417d-8cf0-67ea29b072dc">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItMS0xLTEtMTQzOTI_847402bf-71ad-4c0b-a7aa-3ce724a27405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItMy0xLTEtMTQzOTI_34a50949-ce99-4442-81d7-6a637afcc20f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItNS0xLTEtMTQzOTI_197d9a75-d7e6-428f-b183-f1be7b748950">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItNy0xLTEtMTQzOTI_ac0a25c0-7871-47d4-bd08-1c37c7fd896d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtMS0xLTEtMTQzOTI_4110cc2b-53b3-4c3b-bcc2-3e739a7f881a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtMy0xLTEtMTQzOTI_daa7e3bd-6506-4f7a-a159-6e71124b2577">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtNS0xLTEtMTQzOTI_6b3c84b8-52df-44ba-8695-45010dcbc29a">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtNy0xLTEtMTQzOTI_e2e13f42-f26a-4bf2-8ca8-9caad73eca19">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:center;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMDg_9ae53cd3-0675-457f-a3e8-18295b61a1d4" escape="true"><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the Company&#8217;s effective tax rate and the United States statutory tax rate for the years ended April&#160;30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzItMS0xLTEtMTQzOTI_33f5bd5c-8211-491f-ba21-cf4939f6f5d6">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzItMy0xLTEtMTQzOTI_9d012278-c307-40e3-82c7-ae1e88428cec">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US vs. foreign tax rate difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzMtMS0xLTEtMTQzOTI_ac001ffb-93c5-40c2-a085-c80a2d3e4655">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzMtMy0xLTEtMTQzOTI_4ef88ea2-c783-4c5d-a3b2-438a63815087">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzQtMS0xLTEtMTQzOTI_dffc60ad-475b-44c2-8850-7530f8d92687">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzQtMy0xLTEtMTQzOTI_9d5337c1-94fb-4b33-88b0-b528fbc9139d">80.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzUtMS0xLTEtMTQzOTI_cde7e92e-a090-46b2-953c-fde10c843fb9">47.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" name="csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzUtMy0xLTEtMTQzOTI_5e981d3b-ad31-40c3-b00f-7ff8f0fc10f6">61.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzYtMS0xLTEtMTQzOTI_b50e5dff-6b2a-4192-8ca4-e8c0634ecbe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" sign="-" name="csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzYtMy0xLTEtMTQzOTI_122c76bf-7bde-40c3-b8d6-1ddf2f0d6757">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzktMS0xLTEtMTQzOTI_8af0dbe1-eaec-4bcc-9458-e0cec786aec4">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzktMy0xLTEtMTQzOTI_bfc15079-2821-4148-8723-2bedef86437b">24.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzEyLTEtMS0xLTE0Mzky_b846d564-c285-415d-b03b-f6ab2a454bff">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzEyLTMtMS0xLTE0Mzky_286890bd-c1cb-4e21-bfae-35808c0c4a1f">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&#160;&#160;<ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyOTc_f6db584a-e441-4576-b1bd-da01c766bc18" continuedAt="i1eb6661e570149b9b240e09e06d30d30" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities as of April&#160;30, 2022 and 2021 consist of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="i1eb6661e570149b9b240e09e06d30d30"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzItMS0xLTEtMTQzOTI_f362c055-1cbb-41a2-91c5-434f1d1669a4">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzItMy0xLTEtMTQzOTI_fab70c8f-6945-41f5-b152-d2da4b4c70ab">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use, net asset/liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzMtMS0xLTEtMTQzOTI_98a61b8c-a8eb-45ed-95a4-4699086fff92">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzMtMy0xLTEtMTQzOTI_a6ca8ca5-5a71-4cc7-95c3-04fd20ab2158">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzQtMS0xLTEtMTQzOTI_db720f30-ecf9-4e48-bda3-87f7db2cee68">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzQtMy0xLTEtMTQzOTI_031409d5-cde3-4a32-9ae7-ee7b6b81efa6">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzYtMS0xLTEtMTQzOTI_b5413a9f-fa37-4c15-8d5b-622c916c459f">3,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzYtMy0xLTEtMTQzOTI_20374af0-4b52-4f3f-b5b8-d49d83bc49d6">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzktMS0xLTEtMTQzOTI_c85078ab-b6c8-40b0-9e3b-5ee0b1ab2995">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzktMy0xLTEtMTQzOTI_faf53332-0c37-4f62-9922-61e3b560e4a5">11,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzExLTEtMS0xLTE0Mzky_c94933de-bd3f-4563-9858-17b28e07747b">15,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzExLTMtMS0xLTE0Mzky_96745b75-6454-4ca7-b7a8-9d247eae8e8b">15,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzEyLTEtMS0xLTE0Mzky_5543820b-3c3e-431a-bb21-6cd9d0152dd6">15,502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzEyLTMtMS0xLTE0Mzky_2fd57a73-db60-4686-95d7-d0cd87914270">15,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzE0LTEtMS0xLTE0Mzky_67462a09-f858-427b-99ac-ec95790a6256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzE0LTMtMS0xLTE0Mzky_4d4f0c2d-f934-4077-8f7d-03a339d771c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.730%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense; class life changes to qualified improvements (in general, from 39 years to 15 years); and the ability to carry back net operating losses incurred from tax years 2018 through 2020 up to the five preceding tax years. The Company has evaluated the new tax provisions of the CARES Act and determined the impact to be either immaterial or not applicable. </span></div></ix:continuation><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i56e03463d30f4f0ea3f16c68c9cf2aae"><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the available evidence about future tax planning strategies, taxable income, and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of&#160;April&#160;30, 2022&#160;and&#160;2021.&#160;&#160;For the years ended&#160;April&#160;30, 2022&#160;and&#160;2021, the Company recorded a valuation allowance of&#160;$<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzYwNDczMTM5NTYzNTI_0c70d770-1343-4456-97dd-ea9cca824b0b">15.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-5" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzE2MzQ_7437a908-0695-46e6-a563-d4700cbeaf41">15.3</ix:nonFraction>&#160;million, respectively.&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;April&#160;30, 2022&#160;and&#160;2021, the Company&#8217;s estimated U.S. net operating loss carry-forwards were approximately $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzYwNDczMTM5NTYzNjc_b990d1cf-6f40-4d31-b412-a2416bf70425">48.0</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzE3NTM_79b86755-3731-4508-9e35-fdcd894b50e4">46.9</ix:nonFraction>&#160;million, respectively. Net operating losses generated prior to May 1, 2018 have a 20-year carryforward and will begin expiring in&#160;2025&#160;for federal and&#160;2031&#160;for state purposes. Losses generated in the fiscal years since the year ended April 30, 2019 may be carried forward indefinitely.&#160;&#160;A valuation allowance has been recorded against all of these loss carryforwards.</span></div><div style="text-align:justify;text-indent:33.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership may result in a limitation on the amount of net operating losses that may be utilized in future years. During the fiscal year ended April 30, 2013, approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i69a6fd87cc4541c9b8207826c0d2619a_I20130430" decimals="-5" name="csbr:OperatingLossCarryforwardsLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzIzODc_470bda35-7d37-4564-8d77-58a4caf403ab">12.0</ix:nonFraction> million&#160;of the Company&#8217;s net operating losses became subject to limitation under Internal Revenue Code Section 382 in connection with an ownership change on January 28, 2013. As a result of the ownership change, the Company&#8217;s annual limitation on its use of net operating loss carry-forwards is approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="csbr:OperatingLossCarryforwardsLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzI2NDM_7440d984-b17d-4c0e-a021-ec81ed2a54e8">432,000</ix:nonFraction>.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company files income tax returns in various jurisdictions with varying statutes of limitations.&#160;&#160;As of&#160;April&#160;30, 2022, the earliest tax year still subject to examination for state purposes is fiscal 2018.&#160;&#160;The Company&#8217;s tax years for periods ending April 30, 2002 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMjA_8419ec3f-a728-46a8-8506-ebfeaa7723b0" escape="true"><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the changes to the Company&#8217;s uncertain tax positions for the period and years ended April&#160;30, 2022 and 2021 in thousands:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzItMS0xLTEtMTQzOTI_e8553d57-0357-4b3b-9c82-7142c48a5979">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e18175028428b92779412b437c5ac_I20200430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzItMy0xLTEtMTQzOTI_60acc6b0-9c5b-41b5-a1e0-7960e7376203">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzMtMS0xLTEtMTQzOTI_bd2ee991-9405-40de-b786-06c05307df5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzMtMy0xLTEtMTQzOTI_92d96220-1b53-4164-964c-e2b9ae4136fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment made on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzQtMS0xLTEtMTQzOTI_4c453b53-b642-4dcc-9394-fdda45aed46e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzQtMy0xLTEtMTQzOTI_3439a649-16f8-44df-a3e2-fe9fb3ccde1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzUtMS0xLTEtMTQzOTI_874ae9c2-9e1f-4be1-a607-ce1b82293e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzUtMy0xLTEtMTQzOTI_28c6c9fc-b13a-44ed-8317-7741a6f1f1bb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMS0xLTEtMTQzOTI_4fc183ea-4154-42d9-8ecc-3c5a8750dee8"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMS0xLTEtMTQzOTI_82a07bf0-7a59-41c1-8964-55fc4e867370">181</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMy0xLTEtMTQzOTI_bfdcc759-eb1d-45a0-be39-f0853c198d5d">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;30, 2022 and 2021, the above amounts of $<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyNDA_4fc183ea-4154-42d9-8ecc-3c5a8750dee8"><ix:nonFraction unitRef="usd" contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyNDA_82a07bf0-7a59-41c1-8964-55fc4e867370">181,000</ix:nonFraction></ix:nonFraction>  for each fiscal year were included in other long-term liabilities.</span></div></ix:continuation><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_157"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1Mg_cd9c3bac-8b95-48b1-98f5-d9171f68d830" continuedAt="ic4fce7433693456494506366d1854976" escape="true">Earnings Per Share</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4fce7433693456494506366d1854976" continuedAt="i56928999c5da403b84ebaefb18674da9"><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1NA_2d731b77-8872-4357-ba7b-885be60c8961" continuedAt="id0ab46256b994b4a9c81610f42c7c1ab" escape="true">A reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i56928999c5da403b84ebaefb18674da9"><div style="margin-top:5pt"><ix:continuation id="id0ab46256b994b4a9c81610f42c7c1ab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net income per share computation (dollars in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzMtMS0xLTEtMTQzOTI_34719ea6-f5b3-42a0-b00c-f2c563965cfe">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzMtMy0xLTEtMTQzOTI_32297808-c2a4-4601-a897-e42383aff7d7">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzQtMS0xLTEtMTQzOTI_ee0275f2-1f37-464c-9925-561d06716bdf">13,197,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzQtMy0xLTEtMTQzOTI_653e1f67-5fad-41ee-89d1-409a4dbbd94b">13,138,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzUtMS0xLTEtMTQzOTI_34d0cbe4-e60c-411b-916f-4285d46dcd46">0.04</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzUtMy0xLTEtMTQzOTI_e7853e11-27c9-4914-a3dc-9afaaef648cb">0.03</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per share computation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzgtMS0xLTEtMTQzOTI_53c792b9-d685-4e1f-b74d-56dad7834ada">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzgtMy0xLTEtMTQzOTI_34b06d3f-459c-47da-9928-09668db03acf">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEwLTEtMS0xLTE0Mzky_178f4009-4106-477e-945f-75b5e7ea3579">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEwLTMtMS0xLTE0Mzky_3d3ff591-130e-4a96-9428-ff8404592e00">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEyLTEtMS0xLTE0Mzky_121127e3-d777-414d-85c6-f76d3b48ead0">13,197,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEyLTMtMS0xLTE0Mzky_4d394b36-819f-4896-a781-ce4b762d84d3">13,138,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental shares from assumed exercise of warrants and stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEzLTEtMS0xLTE0Mzky_3cc9c8dd-f454-4a2d-9cd7-64339ec8d7e4">962,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEzLTMtMS0xLTE0Mzky_6a3e2020-5008-4577-8f13-bc3362a6b504">1,434,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average share &#8211; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE0LTEtMS0xLTE0Mzky_ef049a85-a4a3-4e79-bada-d530d60c6b0f">14,159,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE0LTMtMS0xLTE0Mzky_82c91c04-8232-4620-a064-cec861d5300c">14,573,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE2LTEtMS0xLTE0Mzky_87a014dc-cc33-4481-a86a-916add3ece98">0.04</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE2LTMtMS0xLTE0Mzky_b9cab68a-ee44-48eb-9027-3a35c8e353cc">0.02</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1Ng_7a57eb3b-b0b5-4d86-a938-a2c77c44b6d8" escape="true"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total potential stock-based instruments outstanding at April&#160;30, 2022 and 2021 that could have an effect on the future computation of dilution per common share.  These figures were not included in the above calculation as, to do so, would be antidilutive:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a9df412082144bbb11d4d6da935fb41_D20210501-20220430" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzItMS0xLTEtMTQzOTI_2d275c3c-4ee0-41f2-8828-59e7b9d13539">1,332,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ee677f4c8194c56a69b04f0e5332d03_D20200501-20210430" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzItMy0xLTEtMTQzOTI_bbe3f28d-7e17-4f3f-9605-d0011db32df4">1,653,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzUtMS0xLTEtMTQzOTI_560b7ccc-bce7-4e7b-9c72-3ee6abce4eb2">1,332,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzUtMy0xLTEtMTQzOTI_fa826ca4-28bb-499b-a0f2-7ab5113ba8c5">1,653,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_160"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzgyNg_81e65756-d0c2-4580-8d3f-84fe4300e81f" continuedAt="ic481016f9aaa4aa9b968038baa113222" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ic481016f9aaa4aa9b968038baa113222"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions include transactions between the Company and its shareholders, management, or affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both years ended April&#160;30, 2022 and 2021, the Company paid a member of its Board of Directors $<ix:nonFraction unitRef="usd" contextRef="idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2NjM_02a7a78a-bdc8-4199-a6f5-cb11a300a648">36,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id4d88492120f4baca21ed89485bb0844_D20200501-20210430" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2NzI_8c4d3302-fc42-4ea8-8da0-00bfb19ebc12">54,000</ix:nonFraction> for consulting services unrelated to his duties as a board member.  During the years ended April&#160;30, 2022 and 2021, the Company paid another board member $<ix:nonFraction unitRef="usd" contextRef="i25d9cbec92d244c1bbb79ddf79455794_D20210501-20220430" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2ODE_4e90ae8b-b447-4835-be30-4e7a1a3e88ac">17,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifb4a80baff484f72aa17c4f7022a0626_D20200501-20210430" decimals="-2" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM3MTk_bf2ddcab-0622-419c-934d-86fee1d1c496">5,500</ix:nonFraction>, respectively, for consulting services unrelated to his duties as a board member.  All of the amounts paid to these related parties have been recognized in expense in the period the services were performed.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzY_a07747be-48bd-426b-acde-e59ecd1ad13f" continuedAt="ided22f6b484a4b24bdb1336f4c9f7245" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ided22f6b484a4b24bdb1336f4c9f7245" continuedAt="i991c28a362ec420192b488a221bb2123">The Company accounts for its leases under ASC 842.&#160;Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both an operating lease ROU asset and operating lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company has elected to apply the short-term lease exemption practical expedient for each class of underlying assets and excludes short-term leases having initial terms of 12 months or less. The Company recognizes rent </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i991c28a362ec420192b488a221bb2123" continuedAt="i05fc86b9b0244e0bb66e2cc1651cb62e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense on a straight-line basis over the lease term for these short-term leases. The Company has determined that no material embedded leases exist. Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $<ix:nonFraction unitRef="usd" contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMDE4OQ_df401ebd-ed64-4c3b-95ec-efca69fd702b">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzIwODM_5b451219-d229-4ce4-9710-5ddc7114f797">1.3</ix:nonFraction> million for the years ended April&#160;30, 2022 and 2021, respectively. </span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases the following facilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company&#8217;s corporate headquarters. The lease was renewed during fiscal 2022 and expires in November 2026. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="if06e952147154d71b46d16b5e28a9fbe_D20210501-20220430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzI0NDg_1324c636-6157-4f86-af9e-fd1009eda226">88,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i80a586d6407045b5b2f71a3e6734cb67_D20200501-20210430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzI0NTU_d12b1e1e-9f29-45a3-92d7-afd387a2ed26">91,000</ix:nonFraction> of rent expense relative to this lease for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease (the "Original Premises") on January 11, 2017. The operating commencement date was August 11, 2017. This lease originally expired in August 2028.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by <ix:nonNumeric contextRef="i85ae521181894cad8b64e2c702464cd0_I20200330" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjExOTQ_27ebb077-bb04-48f6-8245-bb2380aeb309">six months</ix:nonNumeric>. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In accordance with ASC 842, the Company evaluated the first amendment and also performed a reassessment of the existing lease for Suite 025 to determine the impact of the <ix:nonNumeric contextRef="i85ae521181894cad8b64e2c702464cd0_I20200330" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzM_e6b6c7cd-8690-4aa9-84f2-0a606691271f">six-month</ix:nonNumeric> term extension. As a result of this assessment, the Company recognized an additional operating ROU asset and related operating lease liability for Suite 025 of $<ix:nonFraction unitRef="usd" contextRef="ic847c89affc44622b37366e5f79fce04_I20200731" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2MjY_633cff9c-db35-44c7-93b9-603ce06f1519">118,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic847c89affc44622b37366e5f79fce04_I20200731" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2MzM_e9f30ad1-f157-4e3f-b517-f2ee50403842">125,000</ix:nonFraction>, respectively, as well as an incremental net rent expense of $<ix:nonFraction unitRef="usd" contextRef="ia727ea5ecb214935b2eeee869e2b3b96_D20200501-20200731" decimals="-3" name="csbr:OperatingLeaseIncrementalRentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2OTc_bd8e2a05-c048-48bc-8628-2a8c3c1dc1ef">8,000</ix:nonFraction> during the three months ended July 31, 2020. The Company did not recognize the incremental rental expense under this amendment during fiscal 2020 as the Expansion Premises lease commencement date was during fiscal 2021.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $<ix:nonFraction unitRef="usd" contextRef="ie013b3012171467f93337908fb07dbff_I20200601" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzQxMDg_05e15ed3-4a0b-4de0-9a96-eed2ed0f836a">3.8</ix:nonFraction>&#160;million, each, respectively.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">On December 22, 2020, the Company executed the second amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suites 025, 050, and 104 ("Additional Expansion Premises") and add on Suite 201. The Additional Expansion Premises operating lease commencement date was April 1, 2021 and, under the second amendment, reaffirms that all three leases expire February 28, 2029. Upon the Additional Expansion Premises operating lease commencement date (April 1, 2021), the Company also recognized an operating ROU asset and related operating lease liability for Suite 201 of $<ix:nonFraction unitRef="usd" contextRef="i0c2df47285234084835a949fca5c80c3_I20210401" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMDcwMg_17afcd00-c2e5-4af2-8c96-89d38d587796">3.3</ix:nonFraction>&#160;million, each, respectively. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">For the leases related to the premises at Piccard Drive, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i29d1b96629e44d2bb9a499800cbc3b4c_D20210501-20220430" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMjAyNw_e37f8539-cc26-4793-8ff3-79d50e748aa2">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i690a0daa1ab0464ba51eacbabf4ce92b_D20200501-20210430" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMjAzNQ_02298f8b-42de-442c-b1a3-4b86e06c6c20">1.2</ix:nonFraction>&#160;million of rental expense for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1405 Research Boulevard, Suite 125, Rockville, Maryland 20850 (&#8220;New Location&#8221;), which consisted of laboratory and office space where the Company conducted operations related to its primary service offerings. The Company executed this lease on November&#160;1, 2018. The operating commencement date was January&#160;17, 2019. This lease was set to expire in&#160;April 2024. The Company terminated this lease on June 30, 2020 and transitioned its activities from this location to the Expansion Premises, as defined above, during the first quarter of fiscal 2021. Upon lease termination, the Company recognized a decrease in the related operating ROU asset and operating lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU2NDM_6d217f9f-22b0-479a-8810-14b588ac9b90">850,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU2NTA_f39fd0df-6842-4ddf-9250-bbb692beb830">926,000</ix:nonFraction>, respectively, as well as a gain on lease termination of $<ix:nonFraction unitRef="usd" contextRef="i8aea2d8b8182467a8e0b368c96d67fa9_D20200630-20200630" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3MTA_501547b9-c750-41ab-9760-70c0c405d167">76,000</ix:nonFraction>.  The Company recognized <ix:nonFraction unitRef="usd" contextRef="i2ef7fbd4bc8c4f4aab264f5fd41fec64_D20210501-20220430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3NDM_5f5c6bfb-16a8-42a3-8cae-67687c0b8d47">zero</ix:nonFraction>&#160;and&#160;$<ix:nonFraction unitRef="usd" contextRef="i99c506566730476cb94f0263057c0930_D20200501-20210430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3NTA_ec151935-cffe-44b7-8c8f-7b32fc1b8604">43,000</ix:nonFraction>&#160;of rental expense for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed the lease for its laboratory space in June 2021, and commenced occupancy during the three months ended October 31, 2021. This lease expires May 2023. The Company executed the lease for its office space on October 1, 2021. This lease expires September 2027. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Company recognized an operating ROU asset and related operating lease liability for the lab and office space of $<ix:nonFraction unitRef="usd" contextRef="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMjQ_a035e70b-4fbe-48b9-a5b0-534877a700e8"><ix:nonFraction unitRef="usd" contextRef="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMjQ_b155ae00-da2b-4df6-93bd-8c07f9dc1cba">205,000</ix:nonFraction></ix:nonFraction> each, respectively.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Company recognized rental costs associated with these leases of $<ix:nonFraction unitRef="usd" contextRef="i8f1c7838e6524ef6b1bb93bf4114d1ba_D20210501-20220430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMzQ_36161eee-9b2f-4a56-b6ca-2e840d12a94e">81,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="ib43d4a95e25b464dacea18dbf70da83b_D20200501-20210430" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyNDI_b902bf24-75ab-44dc-aa4c-aa25ceb8261a">zero</ix:nonFraction> for fiscal 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHAMPIONS ONCOLOGY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i05fc86b9b0244e0bb66e2cc1651cb62e"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="csbr:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzQ_2420d765-b22f-4b8e-8e32-15c778fde7ef" continuedAt="ia4a45a2fa0c341bfb457447c16730981" escape="true">ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ia4a45a2fa0c341bfb457447c16730981"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:48.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net<br/></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzEtMS0xLTEtMTQzOTI_7b235032-919e-4103-b79d-caa63d211fe6">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzEtMi0xLTEtMTQzOTI_aff07cdd-42f1-4ec8-ac24-a06d1a26bb10">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities<br/></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzItMS0xLTEtMTQzOTI_405995fb-89b7-4411-b815-0d8df1560400">1,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzItMi0xLTEtMTQzOTI_54968638-7798-4eae-95c1-75d7d97e8fad">818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzMtMS0xLTEtMTQzOTI_76709711-023a-42fe-9c39-ae61080bdeb9">8,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzMtMi0xLTEtMTQzOTI_6b7c5502-df86-4cfc-9eaa-719efee6b078">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 30, 2022, the weighted average remaining operating lease term and the weighted average discount rate were&#160;<ix:nonNumeric contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMTU_dd0023e8-a4bc-4c27-87de-a67b4a72abf1">6.7</ix:nonNumeric> years and&#160;<ix:nonFraction unitRef="number" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMTc_b56ddc53-3962-4da8-866b-006e1d192bae">5.73</ix:nonFraction>%, respectively.  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzU_6c40d289-315e-475a-abdd-742ecd85e801" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments due each fiscal year as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"></td><td style="width:74.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzAtMS0xLTEtMTQzOTI_b5aaed20-780d-462c-9bfd-396f7222f096">2,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzEtMS0xLTEtMTQzOTI_60ceda94-693d-41bf-8fa1-94c4fce250ba">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzItMS0xLTEtMTQzOTI_976580c1-91d6-469c-b76d-209277fff326">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzMtMS0xLTEtMTQzOTI_920c21c0-bdfd-4e76-a916-0599751ac7fd">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzQtMS0xLTEtMTQzOTI_d67bdeb0-eb28-4edb-8d91-90a4e6eb0e14">2,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzUtMS0xLTEtMTQzOTI_cfdc5f71-f936-4995-a33a-ff818929a8a7">5,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total undiscounted liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzYtMS0xLTEtMTQzOTI_6e7ae5ba-b3c8-4e6f-bf6f-eeaca6338c1e">19,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzctMS0xLTEtMTg2Nzk_58f4fc3a-7504-4080-b4b7-6bdc35b5ef0a">9,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzgtMS0xLTEtMTg2ODM_f1880fc0-021f-4d28-b1ff-0c9020ccef2d">9,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, Property and Equipment, for more information on financing leases.</span></div></ix:continuation><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span><br/></span></div><div id="i776cf0b85fdb44a193c88f4fc7063181_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i776cf0b85fdb44a193c88f4fc7063181_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%;text-decoration:underline">Exhibit Index</span></div><div style="margin-bottom:7pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Articles of Incorporation (incorporated by reference to Appendix A to the Company&#8217;s Information Statement on Schedule 14C filed March 7, 2011)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3(i) to the Company&#8217;s Current Report on Form 8-K filed April 28, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 9, 2017)<br/></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of Registered Securities </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">(incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed July 28, 2020)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated November 5, 2013, between the Company and Ronnie Morris, M.D. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed November 12, 2013)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Employment Agreement, dated March 16, 2015, between the Company and Ronnie Morris (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offer letter dated June 3, 2013 between the Company and David Miller (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed June 3, 2013)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010 Equity Incentive Plan (incorporated by reference to Appendix B to the Company&#8217;s Definitive Information Statement on Schedule 14C filed March 7, 2011)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Note Purchase Agreement, dated December 1, 2014, between the Company and each of&#160;&#160;Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed December 5, 2014)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Convertible Promissory Note, dated December 1, 2014, issued to each of Joel Ackerman and Ronnie Morris in connection with the Note Purchase Agreement, dated December 1, 2014 between the Company and each of Joel Ackerman and Ronnie Morris incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed December 5, 2014)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Convertible Promissory Note, dated December 1, 2014 issued to Joel Ackerman in connection with the Note Purchase Agreement, dated December , 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 2, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Convertible Promissory Note, dated December 1, 2014 issued to Ronnie Morris in connection with the Note Purchase Agreement, dated December , 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 2, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2011 Securities Purchase Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 30, 2013)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to warrants, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2013 Securities Purchase Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 30, 2013)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to warrants, dated March 13, 2015, between the Company and each person or entities that are signatories to the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put Right Agreement, dated January 29, 2014, between the Company and each of Joel Ackerman and Ronnie Morris (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed March 6, 2014)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Purchase Agreement, dated March 11, 2015, between the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 12, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Registration Rights Agreement, dated March 13, 2015, between the Company and each person or entities that are signatories to (i) the Securities Purchase Agreement, dated March 24, 2011, between the Company and each investor identified on the signature page thereto, (ii) the Securities Purchase Agreement, dated January 28, 2013, between the Company and each investor identified on the signature page thereto, and (iii) the Securities Purchase Agreement, dated March 11, 2015, between the Company. And each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Investor Warrant issued to each person or entities that are signatories to the Securities Purchase Agreement, dated March 11, 2015, between the Company and each investor identified on the signature page thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 17, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Exchange Agreement, dated March 16, 2015, between the Company and Joel Ackerman (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Exchange Agreement, dated March 16, 2015, between the Company and Ronnie Morris (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Exchange Agreement, dated March 16, 2015, between the Company and David Miller (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed March 20, 2015)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code of Ethics (incorporated by reference to Exhibit 14 of the April 30, 2008 Form 10-KSB)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of Subsidiaries (incorporated by reference to Exhibit 21 of the Company's Form 10-K filed July 28, 2017)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex2314302022.htm">Consent of Independent Registered Public Accounting Firm*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3114302022.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3124302022.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="csbrex3214302022.htm">Section 1350 Certifications**</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">* Filed herewith</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">** Furnished hereto.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>csbrex414302022.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ice5caf159a3749f1877f1b2c0be2ec0b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RIDER X</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the April 30, 2022, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to one vote per share. Our certificate of incorporation, as amended, does not provide for cumulative voting. Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all of our assets which are legally available for distribution, after payment of our provision for all liabilities.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>csbrex2314302022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iabb9b197f14f4ed4ac24d9f3ba3492df_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statement of Champions Oncology, Inc. on Form S-8 (No. 333-182747) of our report dated July 22, 2022, on our audits of the consolidated financial statements as of April&#160;30, 2022 and 2021 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about July 22, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; EisnerAmper LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EISNERAMPER LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July&#160;22, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>csbrex3114302022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if8bdc7a9435348729f03e32b8f992043_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Ronnie Morris, certify that&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Champions Oncology, Inc., a Delaware corporation&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;Ronnie Morris</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronnie Morris</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July 22, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>csbrex3124302022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iead38f06c9244fa18595756699948425_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Miller, certify that&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Champions Oncology, Inc., a Delaware corporation&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;David Miller</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Miller</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July 22, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>csbrex3214302022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i650f76782a9a43329296e0d7ca834d46_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Champions Oncology, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended April 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the U.S. Sarbanes-Oxley Act of 2002, that to the best of our knowledge&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;Ronnie Morris</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronnie Morris</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;David Miller</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Miller</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July 22, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>csbr-20220430.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:csbr="http://championsoncology.com/20220430" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://championsoncology.com/20220430">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="csbr-20220430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="csbr-20220430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="csbr-20220430_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="csbr-20220430_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://championsoncology.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://championsoncology.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://championsoncology.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationNarrativeDetails" roleURI="http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1" roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableUnbilledServicesandDeferredRevenue" roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue">
        <link:definition>2107103 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableUnbilledServicesandDeferredRevenueTables" roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables">
        <link:definition>2308301 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails" roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails">
        <link:definition>2409404 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails" roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails">
        <link:definition>2410405 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails" roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails">
        <link:definition>2411406 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://championsoncology.com/role/PropertyandEquipment">
        <link:definition>2112104 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://championsoncology.com/role/PropertyandEquipmentTables">
        <link:definition>2313302 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetails" roleURI="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
        <link:definition>2414407 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2415408 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomers" roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomers">
        <link:definition>2116105 - Disclosure - Revenue from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersTables" roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomersTables">
        <link:definition>2317303 - Disclosure - Revenue from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersDetails" roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomersDetails">
        <link:definition>2418409 - Disclosure - Revenue from Contracts with Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomers" roleURI="http://championsoncology.com/role/SignificantCustomers">
        <link:definition>2119106 - Disclosure - Significant Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersDetails" roleURI="http://championsoncology.com/role/SignificantCustomersDetails">
        <link:definition>2420410 - Disclosure - Significant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://championsoncology.com/role/CommitmentsandContingencies">
        <link:definition>2121107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2422411 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPayments" roleURI="http://championsoncology.com/role/StockbasedPayments">
        <link:definition>2123108 - Disclosure - Stock-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPaymentsTables" roleURI="http://championsoncology.com/role/StockbasedPaymentsTables">
        <link:definition>2324304 - Disclosure - Stock-based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPaymentsNarrativeDetails" roleURI="http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails">
        <link:definition>2425412 - Disclosure - Stock-based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails" roleURI="http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails">
        <link:definition>2426413 - Disclosure - Stock-based Payments - Allocation of Stock-based Compensation Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPaymentsStockOptionGrantsAssumptionsDetails" roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails">
        <link:definition>2427414 - Disclosure - Stock-based Payments - Stock Option Grants Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedPaymentsStockOptionActivityDetails" roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails">
        <link:definition>2428415 - Disclosure - Stock-based Payments - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxes" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxes">
        <link:definition>2129109 - Disclosure - Provision for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesTables" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesTables">
        <link:definition>2330305 - Disclosure - Provision for Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails">
        <link:definition>2431416 - Disclosure - Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1">
        <link:definition>2431416 - Disclosure - Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails">
        <link:definition>2432417 - Disclosure - Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2433418 - Disclosure - Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesNarrativeDetails" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails">
        <link:definition>2434419 - Disclosure - Provision for Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails" roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails">
        <link:definition>2435420 - Disclosure - Provision for Income Taxes - Change in Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://championsoncology.com/role/EarningsPerShare">
        <link:definition>2136110 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://championsoncology.com/role/EarningsPerShareTables">
        <link:definition>2337306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>2438421 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails" roleURI="http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails">
        <link:definition>2439422 - Disclosure - Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://championsoncology.com/role/RelatedPartyTransactions">
        <link:definition>2140111 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2441423 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://championsoncology.com/role/Leases">
        <link:definition>2142112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://championsoncology.com/role/LeasesTables">
        <link:definition>2343307 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://championsoncology.com/role/LeasesDetails">
        <link:definition>2444424 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesROUAssetsandLeaseLiabilitiesDetails" roleURI="http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails">
        <link:definition>2445425 - Disclosure - Leases - ROU Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2446426 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2446426 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="csbr_EquityIncentivePlan2021Member" abstract="true" name="EquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" abstract="false" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_ProceedsFromRefundOfSecurityDeposit" abstract="false" name="ProceedsFromRefundOfSecurityDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" abstract="false" name="CollaborationArrangementRoyaltyFeePercentOfContractPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="csbr_CollaborationArrangementRoyaltyFee" abstract="false" name="CollaborationArrangementRoyaltyFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_TwoThousandEightEquityIncentivePlanMember" abstract="true" name="TwoThousandEightEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="csbr_EquityIncentivePlan2010Member" abstract="true" name="EquityIncentivePlan2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_PharmacologyServicesMember" abstract="true" name="PharmacologyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" abstract="false" name="AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="csbr_NonEmployeesMember" abstract="true" name="NonEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_TradeAccountsReceivable" abstract="false" name="TradeAccountsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="csbr_StockOptionsAwardSharesToPurchaseCommonStock" abstract="false" name="StockOptionsAwardSharesToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="csbr_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="csbr_FinanceLeaseAxis" abstract="true" name="FinanceLeaseAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="csbr_BoardMemberTwoMember" abstract="true" name="BoardMemberTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="csbr_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="csbr_FewContractsMember" abstract="true" name="FewContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="csbr_FinanceLeaseMonthlyPayment" abstract="false" name="FinanceLeaseMonthlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" abstract="false" name="StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="csbr_DirectorCompensationPlanMember" abstract="true" name="DirectorCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_PresentValueMinimumFutureObligationsInterestRate" abstract="false" name="PresentValueMinimumFutureObligationsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="csbr_TranslationalOncologySolutionsCostOfSalesMember" abstract="true" name="TranslationalOncologySolutionsCostOfSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_CorporateHeadquartersMember" abstract="true" name="CorporateHeadquartersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_FinanceLeaseDomain" abstract="true" name="FinanceLeaseDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_MilanItalyMember" abstract="true" name="MilanItalyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_ProceedsFromExerciseOfOptionsAndWarrants" abstract="false" name="ProceedsFromExerciseOfOptionsAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_NumberofOperatingSubsidiaries" abstract="false" name="NumberofOperatingSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="csbr_RockvilleMDNewLocationMember" abstract="true" name="RockvilleMDNewLocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_DirectorsAndEmployeesMember" abstract="true" name="DirectorsAndEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_OperatingLeaseIncrementalRentExpense" abstract="false" name="OperatingLeaseIncrementalRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_A2020FinanceLeaseMember" abstract="true" name="A2020FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" abstract="false" name="SalesAndMarketingExpensePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="csbr_A2022FinanceLeaseMember" abstract="true" name="A2022FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="csbr_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="csbr_PersonalizedOncologyServicesMember" abstract="true" name="PersonalizedOncologyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" abstract="false" name="OtherNoncurrentLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="csbr_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" abstract="false" name="DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="csbr_OneCustomerMember" abstract="true" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_BoardMemberOneMember" abstract="true" name="BoardMemberOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_FinanceLeasedAssetsMember" abstract="true" name="FinanceLeasedAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="csbr_RockvilleMDMember" abstract="true" name="RockvilleMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>csbr-20220430_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6042ec2-244b-42a0-b73d-3b703d598a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:to="loc_us-gaap_AssetsCurrent_e6042ec2-244b-42a0-b73d-3b703d598a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e61adc01-8c41-4fa9-af58-b50e01836c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e61adc01-8c41-4fa9-af58-b50e01836c8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_01af9c89-8be0-4eee-ac5a-a3006e350967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:to="loc_us-gaap_Goodwill_01af9c89-8be0-4eee-ac5a-a3006e350967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5a6eb4c7-02d3-476c-82e6-71f63723908b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5a6eb4c7-02d3-476c-82e6-71f63723908b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6aabedba-e137-4d60-bb9d-c4be44127793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a3da8999-848b-4f91-9838-8943eb631d04" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6aabedba-e137-4d60-bb9d-c4be44127793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_78009e14-0310-4e93-9fd4-f93f4f0c3f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:to="loc_us-gaap_AccountsPayableCurrent_78009e14-0310-4e93-9fd4-f93f4f0c3f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bce0e01e-4a41-4f25-b9be-fafa22cae31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bce0e01e-4a41-4f25-b9be-fafa22cae31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca6449af-739d-47e5-a833-a0742c904043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca6449af-739d-47e5-a833-a0742c904043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a47db57d-47ee-4aeb-914a-a16abc41fed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a47db57d-47ee-4aeb-914a-a16abc41fed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3363a0e6-d2d9-4450-b15a-a14ee881c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d9db470-5773-44cf-b522-0e92f8bb0d76" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3363a0e6-d2d9-4450-b15a-a14ee881c8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_912dceef-aca4-4f84-a648-2c091edbdf24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_43ea7d4c-8ce7-417d-b758-3e5b181c1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_912dceef-aca4-4f84-a648-2c091edbdf24" xlink:to="loc_us-gaap_LiabilitiesCurrent_43ea7d4c-8ce7-417d-b758-3e5b181c1ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c1d310f4-6328-477a-a4fe-3cce85d78c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_912dceef-aca4-4f84-a648-2c091edbdf24" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c1d310f4-6328-477a-a4fe-3cce85d78c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f145786e-c63b-439a-8234-1391e7aa686d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_912dceef-aca4-4f84-a648-2c091edbdf24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f145786e-c63b-439a-8234-1391e7aa686d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f8c56f5-e52b-42f5-9996-3a298419ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f8751fb1-5e57-4d6a-88c6-595d9c9b4789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f8c56f5-e52b-42f5-9996-3a298419ede9" xlink:to="loc_us-gaap_Liabilities_f8751fb1-5e57-4d6a-88c6-595d9c9b4789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff3c49b2-e288-4fae-a690-4dc2d22d112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f8c56f5-e52b-42f5-9996-3a298419ede9" xlink:to="loc_us-gaap_StockholdersEquity_ff3c49b2-e288-4fae-a690-4dc2d22d112d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5688190c-0752-432f-a55e-d7902e491ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_9f87fc82-8701-4f97-ae23-504039b0c060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5688190c-0752-432f-a55e-d7902e491ae7" xlink:to="loc_us-gaap_Cash_9f87fc82-8701-4f97-ae23-504039b0c060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d2a16db7-0d67-4b4a-afca-35521d7721e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5688190c-0752-432f-a55e-d7902e491ae7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d2a16db7-0d67-4b4a-afca-35521d7721e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d6a835-347e-4a26-a836-1a388a2e3e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5688190c-0752-432f-a55e-d7902e491ae7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d6a835-347e-4a26-a836-1a388a2e3e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_80bd283b-94ec-4046-a78e-e7254193da8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ebc2a5e-af0f-400a-ad11-9dfe47f15a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80bd283b-94ec-4046-a78e-e7254193da8f" xlink:to="loc_us-gaap_CommonStockValue_3ebc2a5e-af0f-400a-ad11-9dfe47f15a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0e3ca6ca-db34-4097-b88e-1ceaa242108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80bd283b-94ec-4046-a78e-e7254193da8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0e3ca6ca-db34-4097-b88e-1ceaa242108f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d44a9e58-8afe-4809-867e-aca57b0c963f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80bd283b-94ec-4046-a78e-e7254193da8f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d44a9e58-8afe-4809-867e-aca57b0c963f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f3edb5af-8c8d-4690-8f06-edfb5053c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_54630bc4-1734-40eb-bd75-32d159d5e46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f3edb5af-8c8d-4690-8f06-edfb5053c5fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_54630bc4-1734-40eb-bd75-32d159d5e46b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54c7deff-6d52-427a-88da-6a55533ea932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f3edb5af-8c8d-4690-8f06-edfb5053c5fe" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54c7deff-6d52-427a-88da-6a55533ea932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_aa8544b9-ba75-4172-8cfa-2a39b0b85c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2986df3b-b682-4cec-aaf2-3f5578214574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_aa8544b9-ba75-4172-8cfa-2a39b0b85c36" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2986df3b-b682-4cec-aaf2-3f5578214574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36498453-2c8c-4307-bcef-1910504ad7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_aa8544b9-ba75-4172-8cfa-2a39b0b85c36" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_36498453-2c8c-4307-bcef-1910504ad7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_3dd0f540-9e64-449c-b036-d98c64823342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_aa8544b9-ba75-4172-8cfa-2a39b0b85c36" xlink:to="loc_us-gaap_SellingAndMarketingExpense_3dd0f540-9e64-449c-b036-d98c64823342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_99c4e94b-0a88-49b2-9075-a98ea698b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_aa8544b9-ba75-4172-8cfa-2a39b0b85c36" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_99c4e94b-0a88-49b2-9075-a98ea698b2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e09e8d38-04a2-411b-ab0c-eddf2b46657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acb8c6c0-21a3-4747-a763-1d12093f4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e09e8d38-04a2-411b-ab0c-eddf2b46657b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acb8c6c0-21a3-4747-a763-1d12093f4205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_e3620994-a3b8-488d-a649-9f0ed0f251de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e09e8d38-04a2-411b-ab0c-eddf2b46657b" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_e3620994-a3b8-488d-a649-9f0ed0f251de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e549dc3-9112-444d-9c32-fc97c9b0ffe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46c8248c-e669-46b8-bb37-96ef7c7b07a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7e549dc3-9112-444d-9c32-fc97c9b0ffe7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46c8248c-e669-46b8-bb37-96ef7c7b07a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d204e1a3-e9e5-4b4a-b9c4-1849854a17f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7e549dc3-9112-444d-9c32-fc97c9b0ffe7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d204e1a3-e9e5-4b4a-b9c4-1849854a17f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ac60c90-df88-46ef-b50d-1552b03ede50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_NetIncomeLoss_0ac60c90-df88-46ef-b50d-1552b03ede50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d4bc98c5-947f-4d5c-a942-939ec9b0ab62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_ShareBasedCompensation_d4bc98c5-947f-4d5c-a942-939ec9b0ab62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ce94c07b-87e3-489f-a643-56d873140af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_DepreciationAndAmortization_ce94c07b-87e3-489f-a643-56d873140af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_02fa7b64-31c9-4717-8d5a-654910908a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_02fa7b64-31c9-4717-8d5a-654910908a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_b118f8f3-4f31-462a-b729-fe4497b1acab" xlink:href="csbr-20220430.xsd#csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_b118f8f3-4f31-462a-b729-fe4497b1acab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_963ce793-c140-4765-9835-9801e40d1ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_963ce793-c140-4765-9835-9801e40d1ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11f0e26a-7649-401c-b6ab-91834fe741f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11f0e26a-7649-401c-b6ab-91834fe741f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02956f00-227d-4093-81eb-9710ccfb138a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02956f00-227d-4093-81eb-9710ccfb138a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_170c21e1-7dd9-4ffb-9c08-8e584bc18855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_170c21e1-7dd9-4ffb-9c08-8e584bc18855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc23e0b6-063c-4fe4-b6c7-4e93d258fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc23e0b6-063c-4fe4-b6c7-4e93d258fdc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e3d8c548-4376-478c-83d8-482965f4c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e3d8c548-4376-478c-83d8-482965f4c15c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3514f4c6-a2b8-412f-b4fa-84fc911600c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3514f4c6-a2b8-412f-b4fa-84fc911600c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cc59fc14-1661-4d97-b884-2e4117b51af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cc59fc14-1661-4d97-b884-2e4117b51af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1936d935-48b0-4269-bfd1-9199958c8e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f719ed1a-ca16-4b40-a3bd-0a809b5e3355" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1936d935-48b0-4269-bfd1-9199958c8e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf320310-33dc-493a-b2ad-450a52e4bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d017d4e-cb6d-43b6-8ad1-bf130edb34a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf320310-33dc-493a-b2ad-450a52e4bfd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d017d4e-cb6d-43b6-8ad1-bf130edb34a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f75faf3f-f048-4e6d-a561-68d16db39cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf320310-33dc-493a-b2ad-450a52e4bfd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f75faf3f-f048-4e6d-a561-68d16db39cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cebd5009-49ce-4d71-a52b-6d5d0b1e475f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf320310-33dc-493a-b2ad-450a52e4bfd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cebd5009-49ce-4d71-a52b-6d5d0b1e475f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c2ff05a-a0b4-456e-a65c-76f72bcfaa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_843872e7-60d1-4cc9-9506-6c41f47513c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c2ff05a-a0b4-456e-a65c-76f72bcfaa0d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_843872e7-60d1-4cc9-9506-6c41f47513c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants_b0fb35f9-b47f-4add-95da-3383332d870e" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromExerciseOfOptionsAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c2ff05a-a0b4-456e-a65c-76f72bcfaa0d" xlink:to="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants_b0fb35f9-b47f-4add-95da-3383332d870e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7652b2b4-8d57-421f-aec2-e8ef51195a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_297ca286-f9e8-4919-8556-c257814e3ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7652b2b4-8d57-421f-aec2-e8ef51195a6f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_297ca286-f9e8-4919-8556-c257814e3ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromRefundOfSecurityDeposit_243aba65-f6a4-4356-a43a-b1424947328d" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromRefundOfSecurityDeposit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7652b2b4-8d57-421f-aec2-e8ef51195a6f" xlink:to="loc_csbr_ProceedsFromRefundOfSecurityDeposit_243aba65-f6a4-4356-a43a-b1424947328d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1b930b74-7f75-4d23-ab74-12494bea7030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_5b3c65d7-d112-46db-b527-70eea2e448f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b930b74-7f75-4d23-ab74-12494bea7030" xlink:to="loc_us-gaap_AccountsReceivableGross_5b3c65d7-d112-46db-b527-70eea2e448f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3c0c3087-3efc-4ddf-a1c7-f0b68237d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b930b74-7f75-4d23-ab74-12494bea7030" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3c0c3087-3efc-4ddf-a1c7-f0b68237d211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_dcd91d5e-eec8-48e1-bff2-c1491f40bffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TradeAccountsReceivable_3453f1c5-c30f-4608-a40f-fc9da00e12e2" xlink:href="csbr-20220430.xsd#csbr_TradeAccountsReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGross_dcd91d5e-eec8-48e1-bff2-c1491f40bffa" xlink:to="loc_csbr_TradeAccountsReceivable_3453f1c5-c30f-4608-a40f-fc9da00e12e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_d3cb5d4e-1cee-40d3-b42e-086fb0ba9dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGross_dcd91d5e-eec8-48e1-bff2-c1491f40bffa" xlink:to="loc_us-gaap_UnbilledContractsReceivable_d3cb5d4e-1cee-40d3-b42e-086fb0ba9dec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_99715c2c-7674-44b9-9e06-d19a6be75a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4fef0088-70af-4cb7-9daa-b66ff1e9f504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_99715c2c-7674-44b9-9e06-d19a6be75a39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4fef0088-70af-4cb7-9daa-b66ff1e9f504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2cf8d967-21c7-455e-8612-4ea14b7623e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_99715c2c-7674-44b9-9e06-d19a6be75a39" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2cf8d967-21c7-455e-8612-4ea14b7623e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_b6575740-3772-4772-b5fd-b44021029831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_55d73ac2-bfda-4bd7-8dda-f0410537317a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_b6575740-3772-4772-b5fd-b44021029831" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_55d73ac2-bfda-4bd7-8dda-f0410537317a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_e7b7f8b9-4a3c-4bbe-a179-44bfd98f54b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1d8fde4b-27b2-4ebc-a276-0755cd6fb811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_e7b7f8b9-4a3c-4bbe-a179-44bfd98f54b1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1d8fde4b-27b2-4ebc-a276-0755cd6fb811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fc3572dd-7058-405f-b23f-6e375fe4f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_402a01ba-ae5b-49a6-8ac8-bac071230500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fc3572dd-7058-405f-b23f-6e375fe4f36e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_402a01ba-ae5b-49a6-8ac8-bac071230500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_143e2f0d-3f17-494a-a81e-fc21867132b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_18db08f5-ad8f-41d4-a603-7cbef9cc60e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_143e2f0d-3f17-494a-a81e-fc21867132b9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_18db08f5-ad8f-41d4-a603-7cbef9cc60e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_92038701-795c-408f-977a-3ed6bc2f81b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_143e2f0d-3f17-494a-a81e-fc21867132b9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_92038701-795c-408f-977a-3ed6bc2f81b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d9e250d-f177-4f2d-985c-e62a4354e1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_143e2f0d-3f17-494a-a81e-fc21867132b9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d9e250d-f177-4f2d-985c-e62a4354e1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_d596cfed-1c58-43c5-8a0b-a4f899b6f728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_97748881-9192-441b-beb2-57a99ba226dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_d596cfed-1c58-43c5-8a0b-a4f899b6f728" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_97748881-9192-441b-beb2-57a99ba226dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0532c07f-ccad-4fc6-9526-ec4e44942dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_0b993d18-add7-48ba-9fed-791e67f2eb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0532c07f-ccad-4fc6-9526-ec4e44942dcb" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_0b993d18-add7-48ba-9fed-791e67f2eb19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1af184b3-7908-47c2-9782-0456b0766c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0532c07f-ccad-4fc6-9526-ec4e44942dcb" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1af184b3-7908-47c2-9782-0456b0766c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_b0e066ee-2bd9-4695-8e1d-eb4a9f28d24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0532c07f-ccad-4fc6-9526-ec4e44942dcb" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_b0e066ee-2bd9-4695-8e1d-eb4a9f28d24e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8f954bc8-f743-4e8f-aa48-35621a99270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8f954bc8-f743-4e8f-aa48-35621a99270c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e6583d32-8b55-41c5-8335-a7a05e51b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e6583d32-8b55-41c5-8335-a7a05e51b64c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5be4f04b-d0c1-4432-871d-ff27ee3e27dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5be4f04b-d0c1-4432-871d-ff27ee3e27dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e532aa2f-786f-4502-bf2e-d7891c321a93" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e532aa2f-786f-4502-bf2e-d7891c321a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_3278dd15-b691-4f04-8854-7d8e16cb08be" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_3278dd15-b691-4f04-8854-7d8e16cb08be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f10b02ca-9851-481d-822b-a7cba7e85a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6de1a2aa-6ee1-4c4a-bbb8-a6161980046e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f10b02ca-9851-481d-822b-a7cba7e85a14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3448aa44-7663-4f18-89e1-34f2328ed29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3448aa44-7663-4f18-89e1-34f2328ed29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_098b13a7-3e04-448a-9b6e-bd5e0bc479d7" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:to="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_098b13a7-3e04-448a-9b6e-bd5e0bc479d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_874c64d4-0ad6-48d5-8df2-32bf0f841a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_874c64d4-0ad6-48d5-8df2-32bf0f841a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e10c42f8-d866-4e37-b687-1d9cb6c794ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e10c42f8-d866-4e37-b687-1d9cb6c794ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_24136f54-3c54-481e-ba35-7b73c42ff9eb" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f9b214c3-43e7-4eaf-8ded-9fd2dfc92d4e" xlink:to="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_24136f54-3c54-481e-ba35-7b73c42ff9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_48dc3b7e-3798-4d1f-8564-44c71e82dcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_11335ce7-e420-4fce-b244-9c8d15adce59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_48dc3b7e-3798-4d1f-8564-44c71e82dcb7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_11335ce7-e420-4fce-b244-9c8d15adce59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dacd4d2c-adfb-419e-8214-ea58a247ef04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_48dc3b7e-3798-4d1f-8564-44c71e82dcb7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dacd4d2c-adfb-419e-8214-ea58a247ef04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8068f66-3e2c-4da7-8747-69d2746fa778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3fe31e6-88ea-44d1-b141-4e1ac3d66678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8068f66-3e2c-4da7-8747-69d2746fa778" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3fe31e6-88ea-44d1-b141-4e1ac3d66678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_ed4623f5-b6ac-413e-bd8d-f50ed6c2f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8068f66-3e2c-4da7-8747-69d2746fa778" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_ed4623f5-b6ac-413e-bd8d-f50ed6c2f34c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9eb80824-e3fc-44aa-b207-6641308d1ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9eb80824-e3fc-44aa-b207-6641308d1ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ac73661-7126-4731-bd9c-ba8c9cddb125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ac73661-7126-4731-bd9c-ba8c9cddb125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6246264f-7072-46af-ac49-eccce5656abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6246264f-7072-46af-ac49-eccce5656abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dd75461f-80fd-4694-98d4-3fa2d7450ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dd75461f-80fd-4694-98d4-3fa2d7450ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_15595278-07b7-4488-a6e3-5d1d448a9590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_15595278-07b7-4488-a6e3-5d1d448a9590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1fab2ee3-f1ef-4ba1-a4be-0e9652779137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3a67f5c-bb6b-4d88-8005-e2d581c88dc3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1fab2ee3-f1ef-4ba1-a4be-0e9652779137" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a522b5c-584c-44f4-b250-0a6e470d21e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9081c3a7-c888-4dbe-815b-cf68573e0ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a522b5c-584c-44f4-b250-0a6e470d21e8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9081c3a7-c888-4dbe-815b-cf68573e0ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7bbd2eee-5e1f-487d-833f-d359268e6b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a522b5c-584c-44f4-b250-0a6e470d21e8" xlink:to="loc_us-gaap_OperatingLeaseLiability_7bbd2eee-5e1f-487d-833f-d359268e6b50" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>csbr-20220430_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="if92a7ae9583a4393b87c99b923e2b7d4_CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c705fec4-1451-4e50-8e2d-790ca955ed04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c705fec4-1451-4e50-8e2d-790ca955ed04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a7cc3afb-4e6b-4c33-bf85-917b2d4dcc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a7cc3afb-4e6b-4c33-bf85-917b2d4dcc60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2de13e47-ffe0-42c1-8e77-4aae2dc8b97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockholdersEquity_2de13e47-ffe0-42c1-8e77-4aae2dc8b97c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_395cb9d7-732c-4e27-ac75-1e1940808a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_395cb9d7-732c-4e27-ac75-1e1940808a1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c5572dad-3951-4799-bfce-df746daa0ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c5572dad-3951-4799-bfce-df746daa0ff9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce8cf35a-82d7-4982-a2f9-2b4fb83ca7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce8cf35a-82d7-4982-a2f9-2b4fb83ca7c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45974354-a605-4569-ac8f-9ad606ecf639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_NetIncomeLoss_45974354-a605-4569-ac8f-9ad606ecf639" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_edae235e-0c45-4282-8b54-7070556cb671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ea553679-3db3-4929-b77e-f43ced348e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e0d79ff-12a4-4ee6-ad1a-3082d52a7d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:to="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ad5718e-4f6f-4d91-8c26-5347c07896bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:to="loc_us-gaap_EquityComponentDomain_2ad5718e-4f6f-4d91-8c26-5347c07896bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:to="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d2a90cf-480a-42d0-b230-7e09fd9298d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_CommonStockMember_7d2a90cf-480a-42d0-b230-7e09fd9298d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_74010539-301a-48a1-83b0-fbda43bade3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_TreasuryStockCommonMember_74010539-301a-48a1-83b0-fbda43bade3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_56251e28-772a-4a6c-9f31-72d0262c58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_56251e28-772a-4a6c-9f31-72d0262c58a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff8584b1-fa35-4bc1-a8a3-996870ca58d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_RetainedEarningsMember_ff8584b1-fa35-4bc1-a8a3-996870ca58d6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="iae405cc1223f4e15bf5d4573e24352a2_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ba265a77-1d6a-41bc-9a52-aba5e1084849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_Cash_ba265a77-1d6a-41bc-9a52-aba5e1084849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_190008fc-617e-4c1f-9dc0-357713dfa490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_190008fc-617e-4c1f-9dc0-357713dfa490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92fcf9b0-b9dd-4452-a7ab-73bbc2daa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_NetIncomeLoss_92fcf9b0-b9dd-4452-a7ab-73bbc2daa2cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44bf47fb-1a61-4e8f-9f08-42cfda157744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44bf47fb-1a61-4e8f-9f08-42cfda157744" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_WorkingCapital_527091c9-7df2-480d-88bd-0b8520c15e21" xlink:href="csbr-20220430.xsd#csbr_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_csbr_WorkingCapital_527091c9-7df2-480d-88bd-0b8520c15e21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_27f2565a-d5e5-42a4-af7a-33acad22e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_27f2565a-d5e5-42a4-af7a-33acad22e334" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8f60dfe8-6e50-4152-8174-e44e35b0f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8f60dfe8-6e50-4152-8174-e44e35b0f419" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c8a1b10e-33d7-45db-a85e-a20591431089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_NumberOfReportableSegments_c8a1b10e-33d7-45db-a85e-a20591431089" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5cfbe987-cb12-4aba-8c20-a935cb9ce9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5cfbe987-cb12-4aba-8c20-a935cb9ce9fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b5b67ce2-3d27-4c0f-8c66-18a925179596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b5b67ce2-3d27-4c0f-8c66-18a925179596" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4537bb9-486d-41f4-a63d-01b7e7407015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e4537bb9-486d-41f4-a63d-01b7e7407015" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:to="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_109f733c-05d3-4cf1-861e-3563dcaa8330_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:to="loc_srt_RangeMember_109f733c-05d3-4cf1-861e-3563dcaa8330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:to="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_687423e7-cfdf-4d86-b09b-0cd729a1d8be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:to="loc_srt_MinimumMember_687423e7-cfdf-4d86-b09b-0cd729a1d8be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d0ff344-0e3f-4ca0-9029-a5ac3e6f8741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:to="loc_srt_MaximumMember_1d0ff344-0e3f-4ca0-9029-a5ac3e6f8741" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" id="ic4d8b3a7bae146c79e33f8ad5ce171aa_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7dd497ec-990c-499e-b5e2-a4025ae8402c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:to="loc_srt_ProductsAndServicesDomain_7dd497ec-990c-499e-b5e2-a4025ae8402c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:to="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:href="csbr-20220430.xsd#csbr_FewContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:to="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_903787dc-b202-4053-89f2-e1c8e1544494_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:to="loc_srt_RangeMember_903787dc-b202-4053-89f2-e1c8e1544494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:to="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6a1f29b9-4f74-4e68-b5a3-02db9e18f911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6a1f29b9-4f74-4e68-b5a3-02db9e18f911" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1" xlink:type="extended" id="i9bc846daeb9d4743a9e5d12b370394f5_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7dd497ec-990c-499e-b5e2-a4025ae8402c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:to="loc_srt_ProductsAndServicesDomain_7dd497ec-990c-499e-b5e2-a4025ae8402c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:to="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:href="csbr-20220430.xsd#csbr_FewContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:to="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_903787dc-b202-4053-89f2-e1c8e1544494_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:to="loc_srt_RangeMember_903787dc-b202-4053-89f2-e1c8e1544494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:to="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="i15db3daac428408cb9ab9642f1603939_PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_61fd2d6c-5e1a-4e1e-b473-95c3609fdaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_61fd2d6c-5e1a-4e1e-b473-95c3609fdaeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8ede47f-530a-4c85-99a9-53ee7490af1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8ede47f-530a-4c85-99a9-53ee7490af1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74f91630-ad74-4bfc-b301-2f191920a5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74f91630-ad74-4bfc-b301-2f191920a5a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6cfa8478-67a2-466d-aefc-2efa02a8c2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6cfa8478-67a2-466d-aefc-2efa02a8c2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84ff311b-a445-47ef-9dbc-5a6210506a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84ff311b-a445-47ef-9dbc-5a6210506a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2360c8af-c89c-4e16-8e00-5924859129bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2360c8af-c89c-4e16-8e00-5924859129bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_51cff27a-6eff-4f6e-9ddf-530ca748c041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_ComputerEquipmentMember_51cff27a-6eff-4f6e-9ddf-530ca748c041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_c98a23b8-866c-4889-83b1-9cd632df56d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_c98a23b8-866c-4889-83b1-9cd632df56d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ef36abd5-afc7-44b4-a1f5-47db0aa4f20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ef36abd5-afc7-44b4-a1f5-47db0aa4f20e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_864a2983-88bf-4021-97b8-5dfc3a12f216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_AssetUnderConstructionMember_864a2983-88bf-4021-97b8-5dfc3a12f216" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ed5bfd33-771a-40d8-807a-e2314adcf0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ed5bfd33-771a-40d8-807a-e2314adcf0d0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="i3b57c17d81cc4c899c8fb4bcf726d7cc_PropertyandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9a6d23af-1c3e-4030-8a23-b8d1b250b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9a6d23af-1c3e-4030-8a23-b8d1b250b26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747fe6f6-37e1-42fc-8fab-94829805b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747fe6f6-37e1-42fc-8fab-94829805b87d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_dc427644-1853-4519-a0ae-e2ee1eddd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_dc427644-1853-4519-a0ae-e2ee1eddd6b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_66bf3163-37f1-4d7a-b4c6-3fc38ce0b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_Depreciation_66bf3163-37f1-4d7a-b4c6-3fc38ce0b667" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2ce89af-04ed-47da-8b43-8e0da9176f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2ce89af-04ed-47da-8b43-8e0da9176f4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a0363c50-e123-4b5f-b02f-021bc0a8bbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a0363c50-e123-4b5f-b02f-021bc0a8bbe2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmount_e444cc73-0dfb-4b6e-98a7-9fc7772df8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAssetAtFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_ServicingAssetAtFairValueAmount_e444cc73-0dfb-4b6e-98a7-9fc7772df8f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAsset_46262427-7fbc-40ad-b2f5-d0a996c54f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_ServicingAsset_46262427-7fbc-40ad-b2f5-d0a996c54f1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_ca93411f-528a-4f53-a3bf-ff38277e90de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_ca93411f-528a-4f53-a3bf-ff38277e90de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseCost_b6aeb8a7-8401-4531-b851-1533384099a7" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_FinanceLeaseCost_b6aeb8a7-8401-4531-b851-1533384099a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseMonthlyPayment_e9a65063-34dc-4fe6-8c68-d751a109bbfc" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseMonthlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_FinanceLeaseMonthlyPayment_e9a65063-34dc-4fe6-8c68-d751a109bbfc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2938a91d-4918-4856-ba73-a105c9dcbb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2938a91d-4918-4856-ba73-a105c9dcbb63" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PresentValueMinimumFutureObligationsInterestRate_d06bf2be-543c-4359-a44c-b74d30b6d329" xlink:href="csbr-20220430.xsd#csbr_PresentValueMinimumFutureObligationsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_PresentValueMinimumFutureObligationsInterestRate_d06bf2be-543c-4359-a44c-b74d30b6d329" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d8314ec7-a961-4d89-af20-caae28553a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d8314ec7-a961-4d89-af20-caae28553a78" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3de20ac0-62ba-4e07-8d25-345e91b5628d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3de20ac0-62ba-4e07-8d25-345e91b5628d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeasedAssetsMember_c5603476-33a1-4991-aa10-b952c30eccc7" xlink:href="csbr-20220430.xsd#csbr_FinanceLeasedAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_csbr_FinanceLeasedAssetsMember_c5603476-33a1-4991-aa10-b952c30eccc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b64cb20a-9878-486c-b986-c0abdf5420a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b64cb20a-9878-486c-b986-c0abdf5420a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_4879428a-8950-49d2-83b4-298da1d2a311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_us-gaap_AssetUnderConstructionMember_4879428a-8950-49d2-83b4-298da1d2a311" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:to="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseDomain_14bed8d7-dcdf-4282-96e9-15faab51918d_default" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:to="loc_csbr_FinanceLeaseDomain_14bed8d7-dcdf-4282-96e9-15faab51918d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:to="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2020FinanceLeaseMember_2c87aa5a-7114-4c40-98aa-7b5c79afa28d" xlink:href="csbr-20220430.xsd#csbr_A2020FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:to="loc_csbr_A2020FinanceLeaseMember_2c87aa5a-7114-4c40-98aa-7b5c79afa28d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2022FinanceLeaseMember_b3a0bd26-091d-4863-bcee-bcb602317c34" xlink:href="csbr-20220430.xsd#csbr_A2022FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:to="loc_csbr_A2022FinanceLeaseMember_b3a0bd26-091d-4863-bcee-bcb602317c34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended" id="i6409fa674ba4404d8433ed973c99bcf5_RevenuefromContractswithCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbb55896-6e5d-41b0-90c3-22e47568246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbb55896-6e5d-41b0-90c3-22e47568246d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:to="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:to="loc_srt_ProductsAndServicesDomain_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:to="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PharmacologyServicesMember_7181c135-9f39-4880-9c6c-52c75863f7ed" xlink:href="csbr-20220430.xsd#csbr_PharmacologyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_PharmacologyServicesMember_7181c135-9f39-4880-9c6c-52c75863f7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OtherServicesMember_9f13726b-bc7a-475c-a821-2de24c0eb6f5" xlink:href="csbr-20220430.xsd#csbr_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_OtherServicesMember_9f13726b-bc7a-475c-a821-2de24c0eb6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PersonalizedOncologyServicesMember_005f4822-18b3-4956-ad28-0bce82526732" xlink:href="csbr-20220430.xsd#csbr_PersonalizedOncologyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_PersonalizedOncologyServicesMember_005f4822-18b3-4956-ad28-0bce82526732" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SignificantCustomersDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SignificantCustomersDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/SignificantCustomersDetails" xlink:type="extended" id="if5731c92081441edaf5d75c437b5ba2d_SignificantCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c2802642-3655-4b3b-a253-5c6df3412a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c2802642-3655-4b3b-a253-5c6df3412a8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e4f4477e-44ac-434f-ba27-d060ca085b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:to="loc_us-gaap_AccountsReceivableMember_e4f4477e-44ac-434f-ba27-d060ca085b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1b65d478-4f93-4b02-ba48-f5d8609d1f9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1b65d478-4f93-4b02-ba48-f5d8609d1f9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b90aa7a2-5e4e-4c01-a8d3-6240a36551a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b90aa7a2-5e4e-4c01-a8d3-6240a36551a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f84bd8e6-324f-4d63-a042-f0145d3b7158_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:to="loc_srt_NameOfMajorCustomerDomain_f84bd8e6-324f-4d63-a042-f0145d3b7158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:to="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OneCustomerMember_340742ca-eb6b-4df6-9735-1c6cd62f0439" xlink:href="csbr-20220430.xsd#csbr_OneCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:to="loc_csbr_OneCustomerMember_340742ca-eb6b-4df6-9735-1c6cd62f0439" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i130d5f86e561426c8fb64013275d6df0_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFee_2fc6a6b3-b01a-4ca4-afb0-2658c0cb37ab" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_csbr_CollaborationArrangementRoyaltyFee_2fc6a6b3-b01a-4ca4-afb0-2658c0cb37ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_3bca0cec-7f73-4175-a8fc-9a74720ccec2" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_3bca0cec-7f73-4175-a8fc-9a74720ccec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_109c738f-537f-447a-98a6-ca11e7f758ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_us-gaap_RoyaltyExpense_109c738f-537f-447a-98a6-ca11e7f758ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:to="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0ad0471-280e-4117-88b1-7619cd2f52ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:to="loc_srt_RangeMember_b0ad0471-280e-4117-88b1-7619cd2f52ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:to="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b9282fba-4eed-4668-87d9-7e96db704c44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:to="loc_srt_MinimumMember_b9282fba-4eed-4668-87d9-7e96db704c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_867cab37-f447-4250-ba44-ede79b8adff9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:to="loc_srt_MaximumMember_867cab37-f447-4250-ba44-ede79b8adff9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails" xlink:type="extended" id="i5095cdf40cd145c59447a8ccc2daf5e6_StockbasedPaymentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_07b3f52b-cf80-4ce8-9c7f-e0de50ba1e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_07b3f52b-cf80-4ce8-9c7f-e0de50ba1e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff727d38-91e5-488e-a751-32d6a343af51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff727d38-91e5-488e-a751-32d6a343af51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f98ffcf7-34dd-4477-9bb0-244140c90508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f98ffcf7-34dd-4477-9bb0-244140c90508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_bc1777e4-9ece-4c9f-a335-93445b0fde70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_bc1777e4-9ece-4c9f-a335-93445b0fde70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50cc4eec-626a-48e4-89f6-2c09869e750c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50cc4eec-626a-48e4-89f6-2c09869e750c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock_53a74485-001e-41c6-9119-29c565711ddc" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock_53a74485-001e-41c6-9119-29c565711ddc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_c1d90910-6918-4ce6-99ac-0b6a13147832" xlink:href="csbr-20220430.xsd#csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_c1d90910-6918-4ce6-99ac-0b6a13147832" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_ec48bf0b-0873-4442-8f3a-ab8d322852cf" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_ec48bf0b-0873-4442-8f3a-ab8d322852cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_8bb2e537-2fb5-4229-a546-fc8972a2286b" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_8bb2e537-2fb5-4229-a546-fc8972a2286b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d3bbae68-5756-4b9c-b027-3285c948d7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d3bbae68-5756-4b9c-b027-3285c948d7d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9700ba2b-32e4-4ec3-bddb-892393eff1d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:to="loc_us-gaap_PlanNameDomain_9700ba2b-32e4-4ec3-bddb-892393eff1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:to="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2021Member_49364bcb-c730-4536-ad38-c4ba12459745" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_EquityIncentivePlan2021Member_49364bcb-c730-4536-ad38-c4ba12459745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2010Member_2e7fff1d-29b2-4b34-83b6-c7bd2a637a12" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_EquityIncentivePlan2010Member_2e7fff1d-29b2-4b34-83b6-c7bd2a637a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TwoThousandEightEquityIncentivePlanMember_df70930b-1c39-41c1-a439-d1aba0b19443" xlink:href="csbr-20220430.xsd#csbr_TwoThousandEightEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_TwoThousandEightEquityIncentivePlanMember_df70930b-1c39-41c1-a439-d1aba0b19443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorCompensationPlanMember_aa018b55-1469-404d-a60d-373a47b8891c" xlink:href="csbr-20220430.xsd#csbr_DirectorCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_DirectorCompensationPlanMember_aa018b55-1469-404d-a60d-373a47b8891c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ddf61173-147f-4b52-87d5-da69cc0d0892_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:to="loc_srt_RangeMember_ddf61173-147f-4b52-87d5-da69cc0d0892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:to="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f4f00a9-8c8d-47cb-9b97-4b13cec8394e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:to="loc_srt_MaximumMember_5f4f00a9-8c8d-47cb-9b97-4b13cec8394e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_930f285e-86de-4ac4-94bd-60ecb4042c6f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_930f285e-86de-4ac4-94bd-60ecb4042c6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8ffd6816-36b3-4c8e-888e-7649a73a9c32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8ffd6816-36b3-4c8e-888e-7649a73a9c32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails" xlink:type="extended" id="ic32b9220c4de4a56b534cd15b6bdbbc1_StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_192e64d6-ef4c-43bb-be34-e1233ba33079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_192e64d6-ef4c-43bb-be34-e1233ba33079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ed96c7c-2eb7-4511-887a-5b031499aa87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ed96c7c-2eb7-4511-887a-5b031499aa87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711cc2ef-b470-4919-80d3-be9507568965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711cc2ef-b470-4919-80d3-be9507568965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_5d563a25-1812-4505-a9ae-644e25eb9a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_5d563a25-1812-4505-a9ae-644e25eb9a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01cc7549-68a1-43fc-9789-c4e575608b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01cc7549-68a1-43fc-9789-c4e575608b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember_a53dcb6d-52d0-4a9e-9cbd-c9a2ebc7243a" xlink:href="csbr-20220430.xsd#csbr_TranslationalOncologySolutionsCostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember_a53dcb6d-52d0-4a9e-9cbd-c9a2ebc7243a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsStockOptionGrantsAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails" xlink:type="extended" id="i1570bd4f07b2414884106545f590fc80_StockbasedPaymentsStockOptionGrantsAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ab96009-fad4-4005-a701-78ad5c647977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ab96009-fad4-4005-a701-78ad5c647977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9557d828-2e5f-4381-a660-ece9944da74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9557d828-2e5f-4381-a660-ece9944da74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c3b26804-aa55-4070-a0b2-585b5c9bda97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c3b26804-aa55-4070-a0b2-585b5c9bda97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3c95b346-cd22-45bb-9383-9c986a1d7119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3c95b346-cd22-45bb-9383-9c986a1d7119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a002a1d9-3d61-4e46-abdc-3793efb944c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a002a1d9-3d61-4e46-abdc-3793efb944c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b71c1f6-8fdf-4b9d-b79d-a985d07c93bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b71c1f6-8fdf-4b9d-b79d-a985d07c93bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:to="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bdf6b27-c66c-4c3f-a120-f206f7ee623b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:to="loc_srt_RangeMember_6bdf6b27-c66c-4c3f-a120-f206f7ee623b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:to="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eddea9c-1bbd-49f6-a683-3e1eb70d7db5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:to="loc_srt_MinimumMember_7eddea9c-1bbd-49f6-a683-3e1eb70d7db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78b51f7e-3e74-4044-965c-7327a866c11c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:to="loc_srt_MaximumMember_78b51f7e-3e74-4044-965c-7327a866c11c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails" xlink:type="extended" id="i7e9a00a9802544b1999512d382f7282d_StockbasedPaymentsStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acfb2bce-a24f-4084-ab15-f7270b8cd397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acfb2bce-a24f-4084-ab15-f7270b8cd397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_265be27a-4a24-41a5-836e-a76c82fa0620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_265be27a-4a24-41a5-836e-a76c82fa0620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_219c18ca-c1c6-4102-8aad-f531cf7a401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_219c18ca-c1c6-4102-8aad-f531cf7a401c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_2658f81f-f0c2-488e-bf7f-4a6e0f430bc3" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_2658f81f-f0c2-488e-bf7f-4a6e0f430bc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e9a877b-73c7-4bce-b5d3-810f406bd127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e9a877b-73c7-4bce-b5d3-810f406bd127" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b610bfe4-de97-44fa-a812-1cbe1c5f8235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b610bfe4-de97-44fa-a812-1cbe1c5f8235" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6cd1984-d626-40c6-806e-9545e678be90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0c226c82-15a1-4eb9-b455-8f36703414b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0c226c82-15a1-4eb9-b455-8f36703414b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5227e88-8e17-44f2-91d5-682a19440856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5227e88-8e17-44f2-91d5-682a19440856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5921a48a-4f5c-4fcb-a6ba-dbd94be06f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5921a48a-4f5c-4fcb-a6ba-dbd94be06f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8ecada82-3079-41b4-874a-d789a3aece84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8ecada82-3079-41b4-874a-d789a3aece84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc4c0063-e4a8-430d-ac33-fee9d92d019f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc4c0063-e4a8-430d-ac33-fee9d92d019f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_575fd4fc-5f44-4c0f-b4cc-140681ad1cca" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_575fd4fc-5f44-4c0f-b4cc-140681ad1cca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6000d9a0-234d-48e6-8022-f1a607bd9804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6000d9a0-234d-48e6-8022-f1a607bd9804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7c28961f-487b-44ed-b426-8159d28eec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7c28961f-487b-44ed-b426-8159d28eec2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbd62fc0-8448-488a-a79b-3e19a662f131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_24935cba-0072-46dc-b82e-2ac743717aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_24935cba-0072-46dc-b82e-2ac743717aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f4155753-cbc4-42df-9c16-f3527bddecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f4155753-cbc4-42df-9c16-f3527bddecab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72e96f3b-12b7-464d-97cd-f79a9e1c42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72e96f3b-12b7-464d-97cd-f79a9e1c42f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_a42b4047-64e6-4b5a-882e-b43922925d56" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_a42b4047-64e6-4b5a-882e-b43922925d56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_7d79d916-a69d-4e80-a435-2ef2aa6e9540" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_7d79d916-a69d-4e80-a435-2ef2aa6e9540" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f8ac8a57-2eee-4212-8236-6a18559a7729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f8ac8a57-2eee-4212-8236-6a18559a7729" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_843aeced-2be0-46ae-97b2-800857dfa379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_843aeced-2be0-46ae-97b2-800857dfa379" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a5587e89-434a-4e84-83d8-56634624e9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a5587e89-434a-4e84-83d8-56634624e9f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_ea35a163-8597-4548-8578-57fd4f760b15" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_ea35a163-8597-4548-8578-57fd4f760b15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b40a98f-b333-4b66-83fc-5694338714e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5249ba42-7957-4685-8935-704a418fd8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5249ba42-7957-4685-8935-704a418fd8ed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6223bab1-ef8c-4fca-878b-66b26cc60f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6223bab1-ef8c-4fca-878b-66b26cc60f20" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:to="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55ebda19-761b-4b8b-aa26-251238a7c082_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55ebda19-761b-4b8b-aa26-251238a7c082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorsAndEmployeesMember_4b8cee61-8fa3-4902-9926-bf31b619cb79" xlink:href="csbr-20220430.xsd#csbr_DirectorsAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:to="loc_csbr_DirectorsAndEmployeesMember_4b8cee61-8fa3-4902-9926-bf31b619cb79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_NonEmployeesMember_936ede18-9904-42b9-b567-1a975d8dafba" xlink:href="csbr-20220430.xsd#csbr_NonEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:to="loc_csbr_NonEmployeesMember_936ede18-9904-42b9-b567-1a975d8dafba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails" xlink:type="extended" id="ia2d0b95e40bc4fa3a63a3b6012952440_EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74d22d7e-6574-483b-aebb-80caa94f1244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74d22d7e-6574-483b-aebb-80caa94f1244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6068c378-af2d-4173-9677-b5cf27833519_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6068c378-af2d-4173-9677-b5cf27833519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_02e744a6-01cd-47ea-9c6e-62231e1d0a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:to="loc_us-gaap_EmployeeStockOptionMember_02e744a6-01cd-47ea-9c6e-62231e1d0a96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="ia5d34db308064269b76ff305231631ab_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_01f87a86-4bd4-4af3-9a28-43b1adba4845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_01f87a86-4bd4-4af3-9a28-43b1adba4845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:to="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberOneMember_c11d5e4a-cd6d-471c-b455-f50fe06daea2" xlink:href="csbr-20220430.xsd#csbr_BoardMemberOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:to="loc_csbr_BoardMemberOneMember_c11d5e4a-cd6d-471c-b455-f50fe06daea2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberTwoMember_fae1418f-ddc1-402d-9c91-4f6faf760805" xlink:href="csbr-20220430.xsd#csbr_BoardMemberTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:to="loc_csbr_BoardMemberTwoMember_fae1418f-ddc1-402d-9c91-4f6faf760805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:to="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ca7015f-05fa-4880-aefa-8a3e242d0091_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ca7015f-05fa-4880-aefa-8a3e242d0091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_429a3ddd-d0ce-4de6-9779-2e0c444e41cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_429a3ddd-d0ce-4de6-9779-2e0c444e41cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://championsoncology.com/role/LeasesDetails" xlink:type="extended" id="i61e5ca4baa124b7b9157b15875c0e513_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_82a8cbab-1b9c-412d-9d91-44decd472f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseExpense_82a8cbab-1b9c-412d-9d91-44decd472f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_078d5f1b-f715-4efd-9084-eb79d92c649e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_078d5f1b-f715-4efd-9084-eb79d92c649e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2bafe0c-0b70-4629-94ef-06f011403631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2bafe0c-0b70-4629-94ef-06f011403631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e9e025d4-9a5d-41fb-a596-e1dbaa4ef43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseLiability_e9e025d4-9a5d-41fb-a596-e1dbaa4ef43d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OperatingLeaseIncrementalRentExpense_f9025c30-0a1c-4136-a1ae-b957a1d1a70e" xlink:href="csbr-20220430.xsd#csbr_OperatingLeaseIncrementalRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_csbr_OperatingLeaseIncrementalRentExpense_f9025c30-0a1c-4136-a1ae-b957a1d1a70e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1c78538b-5923-4147-adf1-7f94947294e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1c78538b-5923-4147-adf1-7f94947294e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c611cf0-24d0-4851-9aaa-92f510f79e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c611cf0-24d0-4851-9aaa-92f510f79e76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_402c257e-95ea-4456-879f-cb978dbf3eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_402c257e-95ea-4456-879f-cb978dbf3eec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a6f6b1a-ade7-4b37-836f-064b94ddc71b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a6f6b1a-ade7-4b37-836f-064b94ddc71b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CorporateHeadquartersMember_afb7d5a8-9e03-456f-8671-9f247e5af10d" xlink:href="csbr-20220430.xsd#csbr_CorporateHeadquartersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_CorporateHeadquartersMember_afb7d5a8-9e03-456f-8671-9f247e5af10d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDMember_323d30e1-a677-4873-aa56-381686d42f07" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_RockvilleMDMember_323d30e1-a677-4873-aa56-381686d42f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDNewLocationMember_c1e84433-72ab-4ac9-8d6f-4da64423ccd4" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDNewLocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_RockvilleMDNewLocationMember_c1e84433-72ab-4ac9-8d6f-4da64423ccd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_MilanItalyMember_70b5606e-44ec-418b-b459-e37e971c782c" xlink:href="csbr-20220430.xsd#csbr_MilanItalyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_MilanItalyMember_70b5606e-44ec-418b-b459-e37e971c782c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>csbr-20220430_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_b60ea1a8-be34-467f-90df-dd25caef1241_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:to="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_305d6d84-07a8-46ee-9658-388f6c5438fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6a03c977-353c-42df-a094-71fe0f663e7d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;Total undiscounted liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6cfad1df-7b2a-41be-9cd8-fe521ed7fd73_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4de2637a-9ffc-4dd5-a8e0-040116f5196c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c2ec825c-59ff-43fc-84d4-ab893890baec_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_50977adc-ca1e-4d70-b79e-23f81d20cc92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_fcec3704-377a-4d09-8de5-53aba50cafc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9cbc65e7-3b8d-4363-8577-1e63a272e881_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_2b11375b-2756-4b91-923e-0fbf299a332c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_70dc39aa-b787-4319-b1a1-97caf15f48c4_totalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7fb4bb7e-f8bf-45c8-93f5-8a28d22e8893_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_67a9c995-de60-401f-ad34-0885dd680324_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_46b74a4b-bf08-45ec-a6ee-313ff425c175_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on termination of operating lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_4a5bf78c-dda4-4e57-af84-3fb50fc5bf36_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on termination of operating lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_31631b81-324e-459f-b067-4d572d2f4ec2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6c79469d-4d5a-4787-bd1c-58d2c2e18461_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e5fbc09b-8e8b-4e0c-91b8-3021f57309ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_092b66ba-dd0c-4376-a861-b445b60d38d9_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_DirectorCompensationPlanMember_171ca708-5f88-408e-9a6d-a82661346891_terseLabel_en-US" xlink:label="lab_csbr_DirectorCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Compensation Plan</link:label>
    <link:label id="lab_csbr_DirectorCompensationPlanMember_label_en-US" xlink:label="lab_csbr_DirectorCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorCompensationPlanMember" xlink:href="csbr-20220430.xsd#csbr_DirectorCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DirectorCompensationPlanMember" xlink:to="lab_csbr_DirectorCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FinanceLeaseAxis_45301322-2a89-4909-abe9-26d312b85c53_terseLabel_en-US" xlink:label="lab_csbr_FinanceLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Axis]</link:label>
    <link:label id="lab_csbr_FinanceLeaseAxis_label_en-US" xlink:label="lab_csbr_FinanceLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Axis]</link:label>
    <link:label id="lab_csbr_FinanceLeaseAxis_documentation_en-US" xlink:label="lab_csbr_FinanceLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseAxis" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FinanceLeaseAxis" xlink:to="lab_csbr_FinanceLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_72d26665-c13a-4ce7-961a-23571adafab2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e1de47b2-30ba-48e8-bf7e-580de89c6169_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_587551e1-71ea-487d-b47f-0534519bb47a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf816a46-e353-45dd-801f-61fbdf860019_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9553603e-8cbc-46ca-a18c-28402bfc3aeb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62660252-7d24-457b-9f72-ff9137879d9f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_98cfd2e8-0734-4f13-869f-70e471f173ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_30048892-3cb5-44bb-9e5c-9f958aca43a4_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable and unbilled services</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_316b1104-0c53-43b3-ac41-8d7eff418761_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4c38a997-87bc-4e0d-83c1-a20848df2c34_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_550d2c02-3cde-4b85-9566-bad7b1019e93_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_69b2848a-e6ed-4f76-a694-7d580168ac2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c20fada8-9a9b-49fc-bf4a-512068a82b2c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_cf6f02e9-8e4a-4c63-adab-f4d74a6b979e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1f54841-e85e-4816-9cbf-eebdaa063331_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_37007793-2392-4eee-8c14-98e0d756f6f6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5222c30a-2a86-4689-b36b-5c59a62e2090_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock equivalents</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFee_51982a91-8977-40dc-96e9-2c02e66a426f_terseLabel_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fee per tumor sample</link:label>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFee_label_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Royalty Fee</link:label>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFee_documentation_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Royalty Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFee" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CollaborationArrangementRoyaltyFee" xlink:to="lab_csbr_CollaborationArrangementRoyaltyFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7dcbce1-bc93-41f0-98b7-e1116e6d7fd3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a235d1a3-c202-42e6-b297-e34a9cdd4264_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_71d3228b-4c15-4760-96a3-eaa9704fc03c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_53371e94-db10-4191-a880-259a5416764a_terseLabel_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting arrangement, amortization expense</link:label>
    <link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_label_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Expense, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:to="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_04daa59a-fd43-45ff-9a38-626d322a49a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f6aa0c73-937b-4a8b-8084-cf3de45135f8_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_PharmacologyServicesMember_ebc6489a-dece-4fa4-811e-d0d8c2993eaa_terseLabel_en-US" xlink:label="lab_csbr_PharmacologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacology services</link:label>
    <link:label id="lab_csbr_PharmacologyServicesMember_label_en-US" xlink:label="lab_csbr_PharmacologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacology Services [Member]</link:label>
    <link:label id="lab_csbr_PharmacologyServicesMember_documentation_en-US" xlink:label="lab_csbr_PharmacologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacology Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PharmacologyServicesMember" xlink:href="csbr-20220430.xsd#csbr_PharmacologyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_PharmacologyServicesMember" xlink:to="lab_csbr_PharmacologyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_90ea6bf3-a979-4fc9-bc8e-0718c6768724_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_46c60836-c129-481e-ab72-03315ee03f33_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f0f26e6d-ccb5-4aa0-b094-400754edc7de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6c370052-cbbc-4620-b5f6-4385f460f2d0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FinanceLeaseCost_d4b64f83-00d7-4658-86cf-00abf188eb80_terseLabel_en-US" xlink:label="lab_csbr_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs</link:label>
    <link:label id="lab_csbr_FinanceLeaseCost_label_en-US" xlink:label="lab_csbr_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_csbr_FinanceLeaseCost_documentation_en-US" xlink:label="lab_csbr_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseCost" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FinanceLeaseCost" xlink:to="lab_csbr_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_BoardMemberTwoMember_c0aff898-f385-40ad-945d-771be0e1ca80_terseLabel_en-US" xlink:label="lab_csbr_BoardMemberTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member Two</link:label>
    <link:label id="lab_csbr_BoardMemberTwoMember_label_en-US" xlink:label="lab_csbr_BoardMemberTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member Two [Member]</link:label>
    <link:label id="lab_csbr_BoardMemberTwoMember_documentation_en-US" xlink:label="lab_csbr_BoardMemberTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberTwoMember" xlink:href="csbr-20220430.xsd#csbr_BoardMemberTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_BoardMemberTwoMember" xlink:to="lab_csbr_BoardMemberTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b0f3a877-6f89-46e8-8f02-5430c673f879_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_59992bdb-d329-4e0a-8b3c-7a531bb6548b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0c9c59b8-18d8-4923-8be6-86c4453244b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0b413be1-2b5c-4779-8bb6-922567d62d72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c9089d4b-ee3b-441a-ab72-ac229652139a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueAmount_a4dcb1a0-0e32-48f7-ab68-deb81c0de019_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing asset</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueAmount_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing Asset at Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAssetAtFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmount" xlink:to="lab_us-gaap_ServicingAssetAtFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_3903ca68-0dc6-40c1-b78c-38583bb01388_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_06c555cd-407f-46a4-91dc-63e7ce3de015_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_WorkingCapital_35cd4790-429b-40b2-9583-a0e0a83c294b_terseLabel_en-US" xlink:label="lab_csbr_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_csbr_WorkingCapital_label_en-US" xlink:label="lab_csbr_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_csbr_WorkingCapital_documentation_en-US" xlink:label="lab_csbr_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_WorkingCapital" xlink:href="csbr-20220430.xsd#csbr_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_WorkingCapital" xlink:to="lab_csbr_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b2d1617a-3b8b-4fc5-87a9-9f6b55fd551d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_09387bf7-be23-4cbe-b35e-fff9f153c5d2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_83e60ad9-1091-456b-9aa4-e354726f7a51_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_07fc57f2-7632-418c-9e4f-8600b116da16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_01ed0f6d-1ddd-4e23-b779-3f6a871ae71d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_cca839cd-baf4-43d5-b32a-e8258f966261_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_55e9faad-2821-4958-9726-c5704818453c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_OperatingLeaseIncrementalRentExpense_b7b7c61c-7c5e-4c49-afa0-955f7acd329a_terseLabel_en-US" xlink:label="lab_csbr_OperatingLeaseIncrementalRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease incremental rent expense</link:label>
    <link:label id="lab_csbr_OperatingLeaseIncrementalRentExpense_label_en-US" xlink:label="lab_csbr_OperatingLeaseIncrementalRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Incremental Rent Expense</link:label>
    <link:label id="lab_csbr_OperatingLeaseIncrementalRentExpense_documentation_en-US" xlink:label="lab_csbr_OperatingLeaseIncrementalRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Incremental Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OperatingLeaseIncrementalRentExpense" xlink:href="csbr-20220430.xsd#csbr_OperatingLeaseIncrementalRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_OperatingLeaseIncrementalRentExpense" xlink:to="lab_csbr_OperatingLeaseIncrementalRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_648254d2-3187-4e7b-b485-8b4ec0afc5b8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_527143d2-491e-400c-b3f4-f64f5dbcc5a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44b9e899-a93d-40f5-bd21-e50efe67b863_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a6a15a71-0292-443a-ae3d-baa42fb30673_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_8daa625d-e55f-443f-9a86-812c43bbee93_terseLabel_en-US" xlink:label="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right Of Use Assets</link:label>
    <link:label id="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="csbr-20220430.xsd#csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c9baa993-7989-4b48-a8de-d1dae37a2f5e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_12cb24d7-3988-4b82-9121-c458b570ff3e_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0c22cc83-bd51-4bc9-97bf-b164c793643e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2bc09641-7628-4bce-81da-15d1238c0be7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cbff93d9-f039-4a81-b074-03fb1a0a78a8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12350a24-87cf-4173-976e-137144c0b04b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c40e65b2-7cd6-479d-8e03-dc360aea756d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c0f8ec62-6842-4e09-8c71-ec5e227a56ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3895e045-ca9f-44b7-8915-db33bf6cf8f5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42e68870-862c-46ed-bec0-62e9c5d8cd2c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_19b58c42-34e8-4402-b0eb-5ff412a2b927_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_fa604d66-3ab1-4def-a83e-b7d9c8acbbfc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ec1553cd-7cba-4a58-8d93-f9cb9188b48e_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8e768118-1ec6-4ea8-8099-f5fdc45dc61b_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a4a72403-8a37-4dc0-a98f-9a2630012495_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of advanced billings</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9956527c-7410-476a-8482-d7c718efbd3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_EquityIncentivePlan2010Member_ba1e678c-fdce-4826-85b5-ae8abb17ac50_terseLabel_en-US" xlink:label="lab_csbr_EquityIncentivePlan2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2010</link:label>
    <link:label id="lab_csbr_EquityIncentivePlan2010Member_label_en-US" xlink:label="lab_csbr_EquityIncentivePlan2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2010Member" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_EquityIncentivePlan2010Member" xlink:to="lab_csbr_EquityIncentivePlan2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants_c30acb05-16a9-4810-8878-69bd7d99d10e_terseLabel_en-US" xlink:label="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
    <link:label id="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants_label_en-US" xlink:label="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Of Options And Warrants</link:label>
    <link:label id="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants_documentation_en-US" xlink:label="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow associated with the amount received from holders exercising their stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromExerciseOfOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:to="lab_csbr_ProceedsFromExerciseOfOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8908ceed-72d2-4337-80d5-9885cb1d9656_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e2cbbed8-834e-4c69-a564-aa9e4506c159_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f5f365df-622e-49bf-b572-a3935b0c5b34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_16cf9747-2f3d-4b8d-bdc5-0fb3e186fca6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1ccdfd34-8e03-428c-bce8-1e05fd92e2f4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5dd48021-ec57-4b16-a65e-3f539c83ff48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ad9cc91b-378a-436e-a44b-93e083354a52_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net income per share computation (dollars in thousands):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d11e8d05-1cf0-400e-a501-857c647a0841_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b55a514-796e-454d-ae24-5ac4c199583c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_217d5756-d191-4a4e-adfc-25bd6a30eb1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46013909-6ac0-4bfb-8ede-05f74c9fe374_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_214e7107-9369-4087-8ba4-d2dd8844ced7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_364d1767-5f18-4991-bb02-deb4b178604d_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_59309bb0-8f84-4761-bd15-50093a4878ff_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US vs. foreign tax rate difference</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d66c3ce3-1808-441b-a16c-19bc9ceb2f20_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a653bcd3-26a3-4d4a-b2ad-34bd7f8c4649_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e68e8b78-fcb1-4627-b5ee-0aa7eda25651_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_a7c20d3f-4d55-4137-bbe9-66abf792c1fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental shares from assumed exercise of warrants and stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_c4080feb-7eb3-4e06-aa46-f1cd8855ae55_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FewContractsMember_a693bc1f-fc87-4311-bd23-3fe297f84e06_terseLabel_en-US" xlink:label="lab_csbr_FewContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Few Contracts</link:label>
    <link:label id="lab_csbr_FewContractsMember_label_en-US" xlink:label="lab_csbr_FewContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Few Contracts [Member]</link:label>
    <link:label id="lab_csbr_FewContractsMember_documentation_en-US" xlink:label="lab_csbr_FewContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Few contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FewContractsMember" xlink:href="csbr-20220430.xsd#csbr_FewContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FewContractsMember" xlink:to="lab_csbr_FewContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b1141eae-31b1-4c4f-864e-8ab9aaf8a7bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4728c6fc-7025-40f6-a82e-1f20023658aa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a5e8838b-9c0a-44f4-b21e-c948d632f9e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bb99b79e-1d1a-4191-a211-8ee67511bd21_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ec81ac26-71cc-46da-83c0-24165d050b36_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b8e028bc-9eb1-4281-9ea3-d1a0e8b55a24_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_77b788c5-bc5f-4ff1-bf07-3cb47b3e97f0_terseLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested percent</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Vested Percentage</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock vested for share based compensation arrangement by share based payment award options during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:to="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3e769331-eba5-48ee-aa8d-72baf5fa62ee_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_87f9ec37-fd74-4626-a003-247454a4a4e1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted income per share computation</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_RockvilleMDNewLocationMember_9a594164-56fe-45ab-8465-f24f803e1802_terseLabel_en-US" xlink:label="lab_csbr_RockvilleMDNewLocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD New Location</link:label>
    <link:label id="lab_csbr_RockvilleMDNewLocationMember_label_en-US" xlink:label="lab_csbr_RockvilleMDNewLocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD New Location [Member]</link:label>
    <link:label id="lab_csbr_RockvilleMDNewLocationMember_documentation_en-US" xlink:label="lab_csbr_RockvilleMDNewLocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD New Location [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDNewLocationMember" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDNewLocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RockvilleMDNewLocationMember" xlink:to="lab_csbr_RockvilleMDNewLocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_68b0eb6e-8b87-431a-9e28-55c5bfebf530_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4973bf90-7e01-453f-b81a-2566d2b4c94e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_OtherServicesMember_5e2d7677-b409-4704-b86c-24d5460dc6fc_terseLabel_en-US" xlink:label="lab_csbr_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other TOS revenue</link:label>
    <link:label id="lab_csbr_OtherServicesMember_label_en-US" xlink:label="lab_csbr_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_csbr_OtherServicesMember_documentation_en-US" xlink:label="lab_csbr_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OtherServicesMember" xlink:href="csbr-20220430.xsd#csbr_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_OtherServicesMember" xlink:to="lab_csbr_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e0bc1f7d-30b1-4b2b-b48f-d2cfb3358014_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_546d6dcb-4388-4d8b-b4c8-7be8f99fa1b5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_625dee4c-e500-46c4-91a8-1287d7bb544e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry-forward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_20c15263-eaf1-4027-b254-a28871f22674_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_40b4fbe7-1e63-462a-8843-c0efa5e11c6d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_111dd211-05f2-45be-9846-e178f5b36325_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e5940389-dde6-422b-934f-9cd909fb689f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ceb658c9-bae8-467b-8e37-8b59398f2d44_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock_2bd95b19-7fe5-4adb-8770-fc36517ddbe1_terseLabel_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options award shares to purchase common stock (in shares)</link:label>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock_label_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options award Shares to purchase common Stock</link:label>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock_documentation_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares to purchase common stock option awards during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:to="lab_csbr_StockOptionsAwardSharesToPurchaseCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_734df5f4-caef-40dc-815c-ee6d81f2d8c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_8b56a3a6-e94b-4c2e-a902-79a27c6f52ea_terseLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Granted</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_cbf89ef9-0d40-422c-94ca-08d466aba728_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_4b191890-a500-4468-bcfa-b780d907e841_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_e99dc29e-2e04-4317-b87f-dc7dbbf18366_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8e2bfcb4-69f9-4d76-8e00-070b0b5ed059_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fdd19171-643c-41b7-8360-670bbb5f11bb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_40a7c7c2-8d61-4670-9535-1fea7c111d9b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_22f95bcc-aac7-4455-9972-147ec0601e5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_fa77c6b4-f547-4607-9f02-7fc3d425f200_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_12db1377-9251-4c2b-a0ec-5d6bde06facb_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5cd71a73-6b0d-4c61-813a-551425ff213e_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3e92950d-3274-421b-8ff0-a079fd635999_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_PersonalizedOncologyServicesMember_45874530-9819-42a3-b77b-6a27bc2b1a43_terseLabel_en-US" xlink:label="lab_csbr_PersonalizedOncologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized oncology services</link:label>
    <link:label id="lab_csbr_PersonalizedOncologyServicesMember_label_en-US" xlink:label="lab_csbr_PersonalizedOncologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized Oncology Services [Member]</link:label>
    <link:label id="lab_csbr_PersonalizedOncologyServicesMember_documentation_en-US" xlink:label="lab_csbr_PersonalizedOncologyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized Oncology Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PersonalizedOncologyServicesMember" xlink:href="csbr-20220430.xsd#csbr_PersonalizedOncologyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_PersonalizedOncologyServicesMember" xlink:to="lab_csbr_PersonalizedOncologyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_A2022FinanceLeaseMember_71440b6f-3c70-423a-ae20-3d4133457f2a_terseLabel_en-US" xlink:label="lab_csbr_A2022FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Finance Lease</link:label>
    <link:label id="lab_csbr_A2022FinanceLeaseMember_label_en-US" xlink:label="lab_csbr_A2022FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Finance Lease [Member]</link:label>
    <link:label id="lab_csbr_A2022FinanceLeaseMember_documentation_en-US" xlink:label="lab_csbr_A2022FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2022FinanceLeaseMember" xlink:href="csbr-20220430.xsd#csbr_A2022FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_A2022FinanceLeaseMember" xlink:to="lab_csbr_A2022FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_CorporateHeadquartersMember_8a6750a1-55ec-480b-9fde-a20a2889e8ab_terseLabel_en-US" xlink:label="lab_csbr_CorporateHeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters</link:label>
    <link:label id="lab_csbr_CorporateHeadquartersMember_label_en-US" xlink:label="lab_csbr_CorporateHeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CorporateHeadquartersMember" xlink:href="csbr-20220430.xsd#csbr_CorporateHeadquartersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CorporateHeadquartersMember" xlink:to="lab_csbr_CorporateHeadquartersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9288586d-9de2-403e-81d5-192179715e20_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_0569e6e8-3d5f-47cb-b213-ca8920ba7943_negatedTerseLabel_en-US" xlink:label="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Deferred Expense Depreciation And Amortization</link:label>
    <link:label id="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_documentation_en-US" xlink:label="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax liability attributable to deductible temporary differences from depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:to="lab_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d9ddd338-e7ad-4e29-89a6-b3c562eab89c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_44a6437c-b52e-49e7-949b-41a07473f71a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e24ef6d-1f8d-463f-ae34-7887c279d39c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c68b147f-23b2-418e-b868-77ce91e2fb17_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1419dd13-b879-42d8-885d-29b0c3a3f305_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6fd6d0cd-d3d5-47d1-8ce9-6ed096d69e32_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_186ed1bd-36a3-491a-b686-cd60c157049a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility Maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8075a6ee-7647-4a45-a9d1-0d3dc6ac8179_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_2fd1708e-c3fb-4d54-99bb-d6afa300fd56_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_dfffee6d-9919-4158-87ad-eacbbec2a955_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7c92539b-558b-4acc-91db-c7cadf962f89_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per common share outstanding, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_76a0ded3-7f92-4458-a697-b5851dabe9bf_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_570a9785-c961-46d8-985f-90512ec2590a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_TranslationalOncologySolutionsCostOfSalesMember_9f19b963-4c77-4ad9-b0ed-bc18657d598e_verboseLabel_en-US" xlink:label="lab_csbr_TranslationalOncologySolutionsCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOS cost of sales</link:label>
    <link:label id="lab_csbr_TranslationalOncologySolutionsCostOfSalesMember_label_en-US" xlink:label="lab_csbr_TranslationalOncologySolutionsCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Oncology Solutions Cost Of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember" xlink:href="csbr-20220430.xsd#csbr_TranslationalOncologySolutionsCostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember" xlink:to="lab_csbr_TranslationalOncologySolutionsCostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_dcd83e22-5c92-4e7a-8ff5-ed6a23256fca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f717a8c4-9593-437c-8ce3-345e59dd8c94_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_9e7b01c0-f58e-45e5-9529-6e535ee3860d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_512d6f62-afa5-452e-9f4f-f0b1696d13da_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4615fabd-119e-4077-a584-fcaa35ea6138_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_72d6cdd8-982c-43c0-82eb-6d0d4a4c2f5e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ce621e7e-5d5d-4f13-ae94-c41b8b08a5ca_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c18c8069-35aa-4257-9016-6a3699f63bc6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b56899ab-6354-45aa-9889-1d277d9ea136_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_95b6763f-22e6-40a4-8cd5-b78a8d775642_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9809bee7-d2df-4ae1-825e-50c2aa25e68c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_29807743-7ad1-45e2-8b52-130b69df10cc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Stock-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2a682cb0-0997-4370-817e-5986059e300a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4e5ff90-af6b-4b85-acf3-9cc86b9d1e78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_68dff122-2adc-4361-b28d-629c1b5d72fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a8c3d139-bcfd-4bb6-8d76-c3775b37f471_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_68c890ce-05c0-4274-904f-eaf2f8e314dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4434aac4-15ab-4b26-a3b5-fc5810c37f5c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_56fe0a8c-ceaa-4faa-ae77-517816726d18_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_15b89fe2-8fb6-4bf6-82fb-c14861b8b61e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ac2de218-923a-45c5-8d8d-034bb5981b78_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_743b8970-ef55-47fc-9c6f-c7d2dd1d31c9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_95dfbd07-5f68-41fd-986f-cfadce4b7638_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_12199e86-3668-4a67-9046-b868e139cd7a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dd6c4ece-6cf5-4749-858c-b58581d8237d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2bb542c2-9164-467a-a13a-37bce217799e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_EquityIncentivePlan2021Member_c4bc2285-9309-4534-9d22-87c1eda8c73f_terseLabel_en-US" xlink:label="lab_csbr_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:label id="lab_csbr_EquityIncentivePlan2021Member_label_en-US" xlink:label="lab_csbr_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021 [Member]</link:label>
    <link:label id="lab_csbr_EquityIncentivePlan2021Member_documentation_en-US" xlink:label="lab_csbr_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2021Member" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_EquityIncentivePlan2021Member" xlink:to="lab_csbr_EquityIncentivePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_006706f2-bab8-4a9c-bf59-a83691f85562_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_780ad894-1159-4bea-81f6-f34788e6d10c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7d4f4021-439d-43c8-91f2-f6e0d1c5a105_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8e6e3bb4-92d4-4782-bb7d-4c3e12889fd3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_11a094ec-f4f2-4b01-a240-311a1f767e8d_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_af0d4285-b1ba-426a-a5ea-27aa10ca0255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ec8c97ea-df5a-42f9-9166-dc22d90c5d3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a5af9810-7174-4f30-acfe-c096a9b8989f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c29ba5-7cde-444b-bf65-6f89710d3f07_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a6f3ec11-5971-48ba-9743-f6320e9bf1ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_fb272c1c-1137-4e46-a919-2ad6f54e4ed0_terseLabel_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option award shares to purchase unregistered common stock (in shares)</link:label>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_label_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Award Shares To Purchase Unregistered Common Stock</link:label>
    <link:label id="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_documentation_en-US" xlink:label="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares to purchase of unregistered common stock option awards during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:to="lab_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f33589c0-1dea-40c9-9eca-0997c4a3df23_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6b9a3aef-9311-4505-a91c-54dbe7365707_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_89075689-3809-4628-80b1-7a1b8f342f6d_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current, total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_56916342-ec30-4b93-9bda-214fccfc0e85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b1fa9170-915f-4f91-98bc-2168634a2224_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_83b2b816-6a93-426e-9981-edd7f4a52e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_b26fbdd2-067e-4d3d-bf6d-b0884da3b422_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_PresentValueMinimumFutureObligationsInterestRate_c56facf6-b18a-4273-84e3-877e1ad6f01d_terseLabel_en-US" xlink:label="lab_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum future obligations interest rate</link:label>
    <link:label id="lab_csbr_PresentValueMinimumFutureObligationsInterestRate_label_en-US" xlink:label="lab_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value Minimum Future Obligations Interest Rate</link:label>
    <link:label id="lab_csbr_PresentValueMinimumFutureObligationsInterestRate_documentation_en-US" xlink:label="lab_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value Minimum Future Obligations Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:href="csbr-20220430.xsd#csbr_PresentValueMinimumFutureObligationsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:to="lab_csbr_PresentValueMinimumFutureObligationsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_e25826a6-7474-4bf9-bfef-cb00d2bd4aa5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_05c1215c-2c46-4cb5-8fe2-88471a055552_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Vested and Expected to Vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_TradeAccountsReceivable_253549f5-a804-42d1-a7e9-9122602afe96_terseLabel_en-US" xlink:label="lab_csbr_TradeAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_csbr_TradeAccountsReceivable_label_en-US" xlink:label="lab_csbr_TradeAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_csbr_TradeAccountsReceivable_documentation_en-US" xlink:label="lab_csbr_TradeAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TradeAccountsReceivable" xlink:href="csbr-20220430.xsd#csbr_TradeAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_TradeAccountsReceivable" xlink:to="lab_csbr_TradeAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6d7162d6-0bf6-41cb-901e-f155ab090d1e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_873e9366-5c99-401c-b452-c4a123f534be_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8955ce40-663a-442b-9806-029b1e43a780_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_08f764a3-352b-4832-8d92-920f85459578_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1fd3ab48-a072-48c6-a072-60c7fed005aa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Being Evaluated and Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_94b4f1eb-d899-4820-88a2-13e651f09230_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_67bac89c-cbba-4958-a947-5df225d216fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_341275fb-a5d8-4e73-b596-98c26b69a3c1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4ede6c1f-84f1-4e84-b661-5a69c536dc2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e7539b30-b31b-4767-a6f7-6dc47eab2235_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a8a899a6-f758-4867-b6f6-26bb2526ecae_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cf937b2f-3372-4f91-ac33-41974590335c_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_MilanItalyMember_eec7a6f0-2f0b-4473-b5fc-16b1c2a96893_terseLabel_en-US" xlink:label="lab_csbr_MilanItalyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milan Italy</link:label>
    <link:label id="lab_csbr_MilanItalyMember_label_en-US" xlink:label="lab_csbr_MilanItalyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milan Italy [Member]</link:label>
    <link:label id="lab_csbr_MilanItalyMember_documentation_en-US" xlink:label="lab_csbr_MilanItalyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milan Italy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_MilanItalyMember" xlink:href="csbr-20220430.xsd#csbr_MilanItalyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_MilanItalyMember" xlink:to="lab_csbr_MilanItalyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_62a1ff95-cf34-44ff-a58f-71fd166df8f4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_698a66b6-0883-43a7-a722-ba52bfba1b8e_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfb52b1c-5b98-4259-8c01-f4bfd8692152_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by&#160;(used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_86e1375f-9a22-4bfa-9f29-5641fd9f93bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_683f0101-22b2-4ab2-9544-c6a4e4c460b3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit) from income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f7d749e0-8cfc-4def-bb91-1ef8a2ccdd84_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4e7f4e47-5da0-4f14-b021-c85849d38bb2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a94dd69b-0091-4532-acb4-8ae815e9fb21_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5c286502-0c7f-4519-876f-3ae459790903_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b9ac1acd-2797-454e-88ab-4e6ef7a20039_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b17e73b3-dc85-446e-99bc-850628c0b9a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34aa81ef-ba9b-4367-b727-74ec37af025e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_66a7be3e-7832-49a7-9fdd-ab23f48d1c96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4e48f9b7-93b4-4173-831f-adf8788ee279_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c8cb960-8491-472b-b7e9-4a3102ba35e5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d6d93fa7-4932-49bc-81c3-f2435f69569d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4e057ea1-edf6-4425-ab23-691388d99419_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ProceedsFromRefundOfSecurityDeposit_b1abcce2-fe71-435b-b1ec-db11d03df286_terseLabel_en-US" xlink:label="lab_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund of security deposit</link:label>
    <link:label id="lab_csbr_ProceedsFromRefundOfSecurityDeposit_label_en-US" xlink:label="lab_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Refund Of Security Deposit</link:label>
    <link:label id="lab_csbr_ProceedsFromRefundOfSecurityDeposit_documentation_en-US" xlink:label="lab_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Refund Of Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromRefundOfSecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:to="lab_csbr_ProceedsFromRefundOfSecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ded06322-3d26-4b9b-b6c9-09cd5688dfbe_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of oncology services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6050722-578b-4e2f-b6ba-406197dbd779_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f1e401e-d832-45b7-b765-740807afa7e7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted weighted average share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3b8f5f15-ece7-4fb2-b2df-2d3079f0e89b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility Minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_a99bacff-0fb9-40de-a12b-99309f31ed3f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5cf7ad14-e776-419f-b3f3-9071122a66b6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56c0ab0b-b29d-46ae-acd5-02fb1571adcb_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ddb77e33-109b-4fae-ad7d-b5eb8e01f7ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_d0161032-6d15-42e4-8665-cfefb2d7d652_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_32ea7186-feaa-42d5-b8f3-5511ed3cb098_terseLabel_en-US" xlink:label="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_label_en-US" xlink:label="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosure [Abstract]</link:label>
    <link:label id="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_documentation_en-US" xlink:label="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:href="csbr-20220430.xsd#csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:to="lab_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_79dbb1c5-fe15-405a-8563-8ba594211be8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 200,000,000 shares authorized; 13,522,441 and 13,414,066 shares issued and outstanding at April 30, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_CommitmentsAndContingenciesLineItems_2d73df81-9506-45ac-8f8c-f189b4992f93_verboseLabel_en-US" xlink:label="lab_csbr_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_csbr_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_csbr_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesLineItems" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems" xlink:to="lab_csbr_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e44b8805-c7d2-4520-9375-db0c8739b705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_23d76d51-3b40-47b6-b9e9-08a6d49cc2f9_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4ae448c-872b-4239-997f-821efa1aa017_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d31b3cd5-7106-40e4-a07b-ea22f85cbfb8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62d613cc-ce62-4d25-b1dd-3577693bab4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_263657e6-7e64-43bd-b0cd-c0d25d66393f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_CommitmentsAndContingenciesTable_7b8f1bfe-11bc-4517-b0a2-f1c8bd9ed2de_terseLabel_en-US" xlink:label="lab_csbr_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_csbr_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_csbr_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesTable" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CommitmentsAndContingenciesTable" xlink:to="lab_csbr_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_37fbeaf1-7162-49f1-971f-acf43339f468_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_76eeb7b1-8894-4870-b475-e11288728f64_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_930cab3a-d84d-4792-be52-13dbc77342c7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_363622a1-b172-4052-a310-fdc6be092d4a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8063d434-c0c0-4435-ba38-cd95b2fa7ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_af5ce9d4-b7d9-4cc0-862b-1025daded2f3_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_a14d2d21-e535-4eb1-8781-f87f5b304efd_verboseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock_5f12502c-2c2f-4ee3-99c8-4986180c68d2_terseLabel_en-US" xlink:label="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Marketing</link:label>
    <link:label id="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock_label_en-US" xlink:label="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales And Marketing Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales And Marketing Expense, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:href="csbr-20220430.xsd#csbr_SalesAndMarketingExpensePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:to="lab_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f1790ce4-a4ac-4a3d-bc55-e6aeaca5e690_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_90982773-3f9e-453f-81b4-412d3af3e3c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ad922c89-84cc-4d31-a8d0-5a4db4a60719_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f54ba7a-39a0-4ffa-8daf-fc8ce186d620_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock_ebb133a1-862e-4cfe-9f15-126d54365f5b_terseLabel_en-US" xlink:label="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Liabilities</link:label>
    <link:label id="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-current Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-current Liabilities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:href="csbr-20220430.xsd#csbr_OtherNoncurrentLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:to="lab_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_50ef7370-615f-45a8-86a9-dac65c6021a5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f31b1485-63da-4fd8-9e26-3ddb75fdb636_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_TwoThousandEightEquityIncentivePlanMember_f10065cb-43f1-4313-8581-125ac4b1a8d6_terseLabel_en-US" xlink:label="lab_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Equity Incentive Plan</link:label>
    <link:label id="lab_csbr_TwoThousandEightEquityIncentivePlanMember_label_en-US" xlink:label="lab_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eight Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_csbr_TwoThousandEightEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eight Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:href="csbr-20220430.xsd#csbr_TwoThousandEightEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:to="lab_csbr_TwoThousandEightEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_76a955b9-5ec3-4c0e-aa57-5b672511400a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78eb3bd9-a096-4c34-8dde-f1d3c770bcb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock_fda13552-2412-4369-9261-30a7e045938d_terseLabel_en-US" xlink:label="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services and Deferred Revenue</link:label>
    <link:label id="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock_label_en-US" xlink:label="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services And Deferred Revenue [Text Block]</link:label>
    <link:label id="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock_documentation_en-US" xlink:label="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services And Deferred Revenue [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:href="csbr-20220430.xsd#csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:to="lab_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_eb073c07-32dc-4c4f-b96b-6cecee31ca61_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ea89bb5f-2226-47d0-8f86-8ce69d4e50e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price as percent of market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_efc63539-1137-4394-ab45-b8e4f2ccb985_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5712cced-3164-440c-a2f7-6fd476b702cb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock_bdbd0d40-b855-4e8f-b89d-5d9ef003a63d_terseLabel_en-US" xlink:label="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities</link:label>
    <link:label id="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="csbr-20220430.xsd#csbr_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_csbr_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_56c4178d-2b7f-43a3-9871-fdb7ba4c0563_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c53b8705-67da-4031-8ef0-a7e8d0840995_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27dab147-676e-4747-abf4-3a3909ef2c5d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_AuditorInformationAbstract_label_en-US" xlink:label="lab_csbr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_csbr_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_csbr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AuditorInformationAbstract" xlink:href="csbr-20220430.xsd#csbr_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_AuditorInformationAbstract" xlink:to="lab_csbr_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_A2020FinanceLeaseMember_82787b65-fed7-479a-b8ad-90486241005d_terseLabel_en-US" xlink:label="lab_csbr_A2020FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Finance Lease</link:label>
    <link:label id="lab_csbr_A2020FinanceLeaseMember_label_en-US" xlink:label="lab_csbr_A2020FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Finance Lease [Member]</link:label>
    <link:label id="lab_csbr_A2020FinanceLeaseMember_documentation_en-US" xlink:label="lab_csbr_A2020FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2020FinanceLeaseMember" xlink:href="csbr-20220430.xsd#csbr_A2020FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_A2020FinanceLeaseMember" xlink:to="lab_csbr_A2020FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_12646699-f180-4aab-99ea-8189b844ea23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f4d3a0fc-4073-4aa5-9886-85c74d804fab_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1dc87921-f09b-4a70-8c45-9d1517bc1d77_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b75a7981-cc53-456b-a16b-53535ec803e6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_2420babf-af31-4165-b828-a0e680e799ec_terseLabel_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, as percent of contract price</link:label>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_label_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Royalty Fee, Percent Of Contract Price</link:label>
    <link:label id="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_documentation_en-US" xlink:label="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Royalty Fee, Percent Of Contract Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:to="lab_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f4e5139d-ade5-47c7-8ea6-36557aa607c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_d6b7d1dc-f66f-40c5-b5aa-727df99888a5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_a33edbb4-abea-493d-9237-c6e5d2d4648d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c2c6bf36-e732-45fc-9307-02f2567d5127_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b950ce7c-a4c3-47f3-8029-0d61536b17be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_aba9a4ad-745f-48a9-af62-be81d4654cda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9a9e1bdc-2245-40d7-bdc0-5f018010ffc1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_66b02fd1-0ed3-49d4-8945-03358f3c3395_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_42e63e95-c657-482b-9c43-adeeac6be16c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2d8ef8be-8fdb-4478-a70a-f0be87825c3f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_50e073aa-3528-4e4a-84bd-1b5f52b73f26_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_803318a3-d9fb-4472-8b48-bfd06aa1ca99_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue arrangements by service contract period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_f43cfcc8-4b28-468f-bd85-a8aa666a7adb_terseLabel_en-US" xlink:label="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option to purchase</link:label>
    <link:label id="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_label_en-US" xlink:label="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Term of Option to Purchase</link:label>
    <link:label id="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_documentation_en-US" xlink:label="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Term of Option to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:href="csbr-20220430.xsd#csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:to="lab_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_6e966589-b079-45f9-ac30-5875b93cdcee_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Oncology Services</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5b7a2bb5-ce8d-4be7-98db-1f9731c28524_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_BoardMemberOneMember_26a840df-25cb-4531-b2ec-afc4c11d16f8_terseLabel_en-US" xlink:label="lab_csbr_BoardMemberOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member One</link:label>
    <link:label id="lab_csbr_BoardMemberOneMember_label_en-US" xlink:label="lab_csbr_BoardMemberOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member One [Member]</link:label>
    <link:label id="lab_csbr_BoardMemberOneMember_documentation_en-US" xlink:label="lab_csbr_BoardMemberOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberOneMember" xlink:href="csbr-20220430.xsd#csbr_BoardMemberOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_BoardMemberOneMember" xlink:to="lab_csbr_BoardMemberOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_158343d7-33ac-4cb7-80e3-d5d0d6c86119_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b3296f4e-5dd8-4171-9974-3c9581805994_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_cc483164-9923-4c27-af71-4d82a36a7263_negatedLabel_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc24c087-48e9-40ff-8c98-9a34cff5579f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8ec71095-72b4-453d-8702-7fd3bed9f402_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_15dd79c3-7229-41c3-9d29-3ed88c28fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6cfeba8d-fcc0-4c84-a3aa-d618f1c0d037_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_df899119-0dbc-4853-9ec4-f1646a40b986_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_be15357f-ce07-47a8-af9b-e57ecfe29bd6_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_2b0caac0-c4ee-4a37-9ed1-5a33b6046948_totalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e96118fa-2ea1-4b1b-802c-6e415fc30d23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_522af6c7-9be8-4efb-afd4-80be0c7427f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_e71d471e-bfc5-4cc6-8ff3-32d5f3b0388f_negatedLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:to="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9d39fdb1-99d9-46ab-a5ae-c7d51709297a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_735b5c0f-2596-4990-9257-c531c2b88682_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0ca79ee7-9041-4775-a5db-cf3671609171_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_32593f23-388e-4adf-87f9-87e5928d4b8a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, payment, due</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c910ea5-4541-4399-b9a6-4b0f7d16eeca_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a544867b-1aa2-4469-82b1-8c318c8186c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount_1fdd08a3-2ba0-4373-a232-5b9449817687_terseLabel_en-US" xlink:label="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss, limitations on use</link:label>
    <link:label id="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount_label_en-US" xlink:label="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limitations On Use, Amount</link:label>
    <link:label id="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limitations On Use, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:href="csbr-20220430.xsd#csbr_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="lab_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FinanceLeasedAssetsMember_e10d7d17-f448-487e-9453-42081a0ee5b3_terseLabel_en-US" xlink:label="lab_csbr_FinanceLeasedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leased Assets</link:label>
    <link:label id="lab_csbr_FinanceLeasedAssetsMember_label_en-US" xlink:label="lab_csbr_FinanceLeasedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leased Assets [Member]</link:label>
    <link:label id="lab_csbr_FinanceLeasedAssetsMember_documentation_en-US" xlink:label="lab_csbr_FinanceLeasedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leased Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeasedAssetsMember" xlink:href="csbr-20220430.xsd#csbr_FinanceLeasedAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FinanceLeasedAssetsMember" xlink:to="lab_csbr_FinanceLeasedAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4df34758-1ab7-4e8b-8708-3f9a2ad41d28_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e06f042a-7ba7-4eb7-8393-0d13e274ff4a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_5547c02b-e967-46e9-a033-367219d0f299_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_202d5d53-f42b-4d48-aab1-393427765d1d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_NonEmployeesMember_cdee06cd-c11e-484a-8a18-739fe656fa3b_verboseLabel_en-US" xlink:label="lab_csbr_NonEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Employees</link:label>
    <link:label id="lab_csbr_NonEmployeesMember_label_en-US" xlink:label="lab_csbr_NonEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_NonEmployeesMember" xlink:href="csbr-20220430.xsd#csbr_NonEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_NonEmployeesMember" xlink:to="lab_csbr_NonEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5960abe2-028c-470b-9b84-2f21e3ad6fe1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_712465f5-7b1a-43c4-bcb7-cd1609963112_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69e78600-a941-494e-9598-129abd1a290f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_70ea3208-0081-4bc0-af51-9d8487e17cbe_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_69c9bc06-05dd-4ba7-8438-87f3ae4122a4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cb8d4e9a-fd9e-40cf-969e-19e66de0e71f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing and investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_OneCustomerMember_e718a68f-9326-4b23-aca1-f50fd03a2a58_terseLabel_en-US" xlink:label="lab_csbr_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_csbr_OneCustomerMember_label_en-US" xlink:label="lab_csbr_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer [Member]</link:label>
    <link:label id="lab_csbr_OneCustomerMember_documentation_en-US" xlink:label="lab_csbr_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OneCustomerMember" xlink:href="csbr-20220430.xsd#csbr_OneCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_OneCustomerMember" xlink:to="lab_csbr_OneCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0191c510-8275-467d-9c6f-f76008f577c8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_564d33e9-32ae-48a2-a46c-c010ff0e074e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_af29bad3-faea-4d69-8768-4d9ec760c72f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_NumberofOperatingSubsidiaries_7199ac49-a39a-46d0-9628-efb50c06814e_terseLabel_en-US" xlink:label="lab_csbr_NumberofOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating subsidiaries</link:label>
    <link:label id="lab_csbr_NumberofOperatingSubsidiaries_label_en-US" xlink:label="lab_csbr_NumberofOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Subsidiaries</link:label>
    <link:label id="lab_csbr_NumberofOperatingSubsidiaries_documentation_en-US" xlink:label="lab_csbr_NumberofOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_NumberofOperatingSubsidiaries" xlink:href="csbr-20220430.xsd#csbr_NumberofOperatingSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_NumberofOperatingSubsidiaries" xlink:to="lab_csbr_NumberofOperatingSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_BasicAndDilutedEarningsPerShareAbstract_6ca5f1d0-9106-4747-8c47-74f3200dde0d_terseLabel_en-US" xlink:label="lab_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per common share outstanding</link:label>
    <link:label id="lab_csbr_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted, Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_csbr_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted, Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:href="csbr-20220430.xsd#csbr_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_csbr_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FinanceLeaseMonthlyPayment_a8b4de36-3a57-449b-90b4-a0781495860e_terseLabel_en-US" xlink:label="lab_csbr_FinanceLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases monthly payments</link:label>
    <link:label id="lab_csbr_FinanceLeaseMonthlyPayment_label_en-US" xlink:label="lab_csbr_FinanceLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Monthly Payment</link:label>
    <link:label id="lab_csbr_FinanceLeaseMonthlyPayment_documentation_en-US" xlink:label="lab_csbr_FinanceLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Monthly Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseMonthlyPayment" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseMonthlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FinanceLeaseMonthlyPayment" xlink:to="lab_csbr_FinanceLeaseMonthlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_30377e18-e21a-4b3d-9672-283938d69b44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_06dc7c28-d105-44a0-900b-541460387275_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50a7d91c-4b89-4bb9-92b2-59ecb623066c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology services revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b1d1f04-d005-4de5-816d-41eb221a85e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total oncology services revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8111a879-3eec-4960-b705-1ab16a7d0651_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0e6dc153-950f-4b23-b816-62f6e3676b84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f3e2f041-94c2-413a-baf1-27faca614941_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_716a1594-687e-47a4-b094-e95fd84237cb_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_894ff5b1-52a0-4c95-b0ac-6d8e01d7e313_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_b5d6942c-00b8-4665-9d6e-6207cfbf253c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_76fa84f1-9d26-40fc-85ea-bb8ca087570a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_f450ec53-85b8-46bf-9803-f11952eabab5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_28d76178-6f2f-44f7-ae0c-fbedad279986_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0261674e-b22f-4a60-bb30-5eb27edbb626_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a93f5007-d066-40e2-ad96-8fae56fc8747_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_b07714b6-e308-454b-a72b-c885b3a74ab6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_61d7ab85-22b6-4c3f-9916-06e17a5b5627_verboseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_8efea6e5-1620-47e9-940a-bac32b5c4dbb_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5aac60f9-5c73-445c-bc8e-073f2a397360_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_77611cc4-7a87-4122-877a-d2f759550265_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f54c78a-ed78-42ca-bc03-7d9ad1276387_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_dc64816e-2ad4-4fd3-8729-fc385f0069bd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d4736c92-72da-4a86-ae82-ca30d18ff765_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6bbfccc5-4800-4808-935e-decf3092caec_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d3681eac-d678-4d6f-bd6b-6bddcfb04df3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per common share outstanding, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6fdc5669-d258-4be6-b56f-b9a18567aa94_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_897041ab-58f1-4f11-afe6-37dd6e22528c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9e8cc57f-e62c-4461-850b-cbb19f46e0bf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_67829360-9a00-46cf-82c1-42b04cd52bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_17bb5a39-698d-4e60-b364-dcc78ee5c6f1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d19e1252-3d22-4177-b885-60165f24b8cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rates Minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_072d9a49-240f-453f-bbd5-3e0cd106b7d2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_c3f87813-f2a0-4334-8506-39721c879877_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of accounts receivable, unbilled services, and advanced billings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_703808f6-5bd1-4184-a15a-a28ac8238c68_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c43e217a-e154-4270-a12c-2324b55fa6bb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_941bb3a1-6e14-434b-9b8e-1f608f6f9b2d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ba6e5e4e-801c-46ae-955a-fecbc34d01fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27448436-1b8b-45b7-9568-1d182709361c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration term of awards</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_11994437-b50e-4920-b125-0641730cee4c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_15902c0e-1152-44e5-9a97-f612f65cb367_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rates Maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_501ade63-2636-4418-b5cc-0a708a36421f_verboseLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Canceled (in usd per share)</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:to="lab_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3a4f102e-2760-407b-8591-a74e6d61cb4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_733894e2-52a8-4201-9623-f3bc9e0919a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_RockvilleMDMember_d357a013-e7ce-4679-945f-34168b5ba1d7_terseLabel_en-US" xlink:label="lab_csbr_RockvilleMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD</link:label>
    <link:label id="lab_csbr_RockvilleMDMember_label_en-US" xlink:label="lab_csbr_RockvilleMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD [Member]</link:label>
    <link:label id="lab_csbr_RockvilleMDMember_documentation_en-US" xlink:label="lab_csbr_RockvilleMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, MD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDMember" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_RockvilleMDMember" xlink:to="lab_csbr_RockvilleMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4a116ca7-5546-4790-8d34-0faa4f59bb4f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_a60662a9-01ad-4d42-b8d3-dd1cf8803af7_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled services</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_d76c3a50-74af-4c4e-81e3-6ce9f808b829_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related related party transaction, amounts of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_a2ed1138-dea1-4c67-aeb3-4b13f038a712_verboseLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant in Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_12be3009-e2d2-4f07-8e60-e5c759d675f3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_b8ea67ae-febb-49e8-834d-924658d1a4f9_terseLabel_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Granted</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_label_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted</link:label>
    <link:label id="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_documentation_en-US" xlink:label="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of equity-based compensation awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:to="lab_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_14b3cc1f-371e-4673-8d3a-ae0890f9b9e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_05e6fec3-563d-430d-99aa-9f87279fdd21_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_DirectorsAndEmployeesMember_ca945e7c-2d5f-4c0b-ba97-fb7508d069cd_terseLabel_en-US" xlink:label="lab_csbr_DirectorsAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors and Employees</link:label>
    <link:label id="lab_csbr_DirectorsAndEmployeesMember_label_en-US" xlink:label="lab_csbr_DirectorsAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors and Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorsAndEmployeesMember" xlink:href="csbr-20220430.xsd#csbr_DirectorsAndEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DirectorsAndEmployeesMember" xlink:to="lab_csbr_DirectorsAndEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_3e0cdc7d-6f4a-4f5c-911b-b9bb9532d028_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b152ebcb-c164-420a-af06-01adf8f494e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb5e313b-e8ed-43ce-ba3e-c1515186e538_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b2368a89-1966-42a3-b1e4-a334f1e96dac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_17cda94d-4a39-4e90-89f4-88b599af8209_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_295b5315-8717-4bb6-853d-00f24bd2c500_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a57e15f-2cfa-4447-9f34-daa6e667920b_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30ec2bdb-863b-4a34-9920-80d93b8079f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_71ce4c5b-ab25-418f-8ba3-4f22dcb1b785_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3d059d17-689c-47e4-989a-7fb38f55ca4d_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5ec0d616-4d2a-4893-9875-6e1f57761a3a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_663491b5-df57-4a82-8888-81b818d3c71d_negatedLabel_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in uncertain tax position</link:label>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_label_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Increase in uncertain tax position</link:label>
    <link:label id="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_documentation_en-US" xlink:label="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Increase in uncertain tax position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:to="lab_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServicingAsset_df7d7279-5167-4641-9ba3-2ec16095efe5_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing asset at gross capitalized amount</link:label>
    <link:label id="lab_us-gaap_ServicingAsset_label_en-US" xlink:label="lab_us-gaap_ServicingAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAsset" xlink:to="lab_us-gaap_ServicingAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_edfdce7d-12ec-48f0-b2b5-3b17abebabf1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_b8492f04-9269-405e-80a3-bc4c958b1cea_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_34a388d9-38f4-44b3-9d27-4329ad35e2ff_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a72d5953-826b-431e-951f-94997ccf219a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_347baeb6-49e5-41b5-834e-455d1cb22e71_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60457d7b-dc8a-4525-82f2-0e07c4fe2ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_118f22e5-c483-440e-9dc5-a095ea6fde36_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b61da5a4-cebf-4371-8db8-923257e7202f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_5c2a436b-0a5b-440d-8ea8-bd2124c79e3e_terseLabel_en-US" xlink:label="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use, net asset/liability</link:label>
    <link:label id="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_label_en-US" xlink:label="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Right Of Use Asset (Liability)</link:label>
    <link:label id="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_documentation_en-US" xlink:label="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Right Of Use Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:to="lab_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c19ad64f-188d-45d8-89da-3673260889ae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_51a358dc-1496-41fe-8bf8-89ed686ad70a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets in progress</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7abe6904-fb38-4880-aca2-716690ca9f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_1c2be47f-9339-41f9-b84d-f8a7bb427a46_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d8d3eac1-e32f-49b3-a056-b5135cb622f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_csbr_FinanceLeaseDomain_e297d495-1f8c-4d4b-a066-cbba53907b86_terseLabel_en-US" xlink:label="lab_csbr_FinanceLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Domain]</link:label>
    <link:label id="lab_csbr_FinanceLeaseDomain_label_en-US" xlink:label="lab_csbr_FinanceLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Domain]</link:label>
    <link:label id="lab_csbr_FinanceLeaseDomain_documentation_en-US" xlink:label="lab_csbr_FinanceLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseDomain" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_csbr_FinanceLeaseDomain" xlink:to="lab_csbr_FinanceLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9606f7cf-89e8-40d7-acb3-8a2f7c9cd3cd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_256c8e34-ea35-49f8-b7b1-00d07fc1ef84_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>csbr-20220430_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6af2fab7-d215-4985-a85a-7cb6b627a689,g:06743d58-53e9-4b4b-98dc-83b9bba193f7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://championsoncology.com/role/Cover" xlink:type="simple" xlink:href="csbr-20220430.xsd#Cover"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_61267f49-32bb-4c20-b4df-7e460038d9fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentType_61267f49-32bb-4c20-b4df-7e460038d9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9fb359b5-c580-4f87-a689-61d902c382d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentAnnualReport_9fb359b5-c580-4f87-a689-61d902c382d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_221c9c60-26b3-4049-bb2c-df9ce83ee788" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentPeriodEndDate_221c9c60-26b3-4049-bb2c-df9ce83ee788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_796280ca-6d4f-41e6-80a9-af8569a90c03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_CurrentFiscalYearEndDate_796280ca-6d4f-41e6-80a9-af8569a90c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e3177dc0-3117-442d-9ff5-7af9a5436579" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentTransitionReport_e3177dc0-3117-442d-9ff5-7af9a5436579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2bc6116d-2348-4178-8a69-08fa7b9655ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityFileNumber_2bc6116d-2348-4178-8a69-08fa7b9655ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_99338448-11a9-433f-99bd-2e2c276c9740" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityRegistrantName_99338448-11a9-433f-99bd-2e2c276c9740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d301ae96-a0b3-46d6-b59a-f15862f92bdf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d301ae96-a0b3-46d6-b59a-f15862f92bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_776141ee-f66b-4c42-a2ad-24ad772e3b76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityTaxIdentificationNumber_776141ee-f66b-4c42-a2ad-24ad772e3b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_52f12fbf-e1ef-41c9-946a-cc58205b704c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityAddressAddressLine1_52f12fbf-e1ef-41c9-946a-cc58205b704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a00f09d0-ea0f-498a-8423-b2ada01b11ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityAddressPostalZipCode_a00f09d0-ea0f-498a-8423-b2ada01b11ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_617b99f4-71d7-4900-87e6-cae3db844e5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityAddressCityOrTown_617b99f4-71d7-4900-87e6-cae3db844e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_43042a61-ebda-41f3-835d-40ef39015f71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityAddressStateOrProvince_43042a61-ebda-41f3-835d-40ef39015f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e4c2bf69-51a5-4bbe-b8b7-d4c0467d599e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_CityAreaCode_e4c2bf69-51a5-4bbe-b8b7-d4c0467d599e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_805c2f15-4b57-4dc9-872b-75c11f0c9f7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_LocalPhoneNumber_805c2f15-4b57-4dc9-872b-75c11f0c9f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_95b6e659-6357-4a70-ae8b-93ffe62698e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_Security12bTitle_95b6e659-6357-4a70-ae8b-93ffe62698e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fcf942ed-eeed-42de-a1ee-69269809274f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_TradingSymbol_fcf942ed-eeed-42de-a1ee-69269809274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_78e72b6a-0149-4b99-843f-7346891c00d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_SecurityExchangeName_78e72b6a-0149-4b99-843f-7346891c00d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7e26c137-e902-4d92-82f4-83114e31c6fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7e26c137-e902-4d92-82f4-83114e31c6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_af315cbb-468c-418a-b697-f3f96a88b92b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityVoluntaryFilers_af315cbb-468c-418a-b697-f3f96a88b92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_48412d99-6096-4d86-9b7d-84adc5f121fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityCurrentReportingStatus_48412d99-6096-4d86-9b7d-84adc5f121fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_19aca8a4-df7d-4340-871f-3e160a831050" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityInteractiveDataCurrent_19aca8a4-df7d-4340-871f-3e160a831050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3f254df9-6437-4552-b223-610fad099ab1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityFilerCategory_3f254df9-6437-4552-b223-610fad099ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1515f992-e410-4fd9-b0bb-6a7ba42960c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntitySmallBusiness_1515f992-e410-4fd9-b0bb-6a7ba42960c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_35219474-39bb-406b-86f2-df04e7487b7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityEmergingGrowthCompany_35219474-39bb-406b-86f2-df04e7487b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_23913b99-a337-4991-933c-3b5313224f71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_IcfrAuditorAttestationFlag_23913b99-a337-4991-933c-3b5313224f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f97bd7c9-13b5-4689-a208-1bc58ce0709e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityShellCompany_f97bd7c9-13b5-4689-a208-1bc58ce0709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d2ed2a25-b78c-4582-a3d1-0bc0d4f923ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityPublicFloat_d2ed2a25-b78c-4582-a3d1-0bc0d4f923ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a1c3c1f4-8180-4aa1-b20a-0278ea63452b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a1c3c1f4-8180-4aa1-b20a-0278ea63452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_97aea6dd-6143-40b2-bbf8-ba43708f460c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_97aea6dd-6143-40b2-bbf8-ba43708f460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd83655a-df15-44da-aca3-a695f06bbabb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_EntityCentralIndexKey_dd83655a-df15-44da-aca3-a695f06bbabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_81ac3647-c101-4976-bd6d-886da0ed0527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_AmendmentFlag_81ac3647-c101-4976-bd6d-886da0ed0527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_01452950-cb7a-4604-a277-cb33d8475305" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_01452950-cb7a-4604-a277-cb33d8475305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0dca72e1-e943-472c-85b8-1a2b6b49e62c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c053ef5-52c8-44a7-b5db-5239c7bf76a9" xlink:to="loc_dei_DocumentFiscalYearFocus_0dca72e1-e943-472c-85b8-1a2b6b49e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AuditInformation" xlink:type="simple" xlink:href="csbr-20220430.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AuditorInformationAbstract_56a2cac6-e159-480d-85d2-4df68b76602c" xlink:href="csbr-20220430.xsd#csbr_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_02163a14-2e45-46ee-b9a3-ee9a8db07792" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_AuditorInformationAbstract_56a2cac6-e159-480d-85d2-4df68b76602c" xlink:to="loc_dei_AuditorFirmId_02163a14-2e45-46ee-b9a3-ee9a8db07792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_951e66a3-7d18-4685-b1bc-4ed2ec204e84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_AuditorInformationAbstract_56a2cac6-e159-480d-85d2-4df68b76602c" xlink:to="loc_dei_AuditorName_951e66a3-7d18-4685-b1bc-4ed2ec204e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d00b2b89-9104-4347-ae94-d0bc04783e61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_AuditorInformationAbstract_56a2cac6-e159-480d-85d2-4df68b76602c" xlink:to="loc_dei_AuditorLocation_d00b2b89-9104-4347-ae94-d0bc04783e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8d77ca13-220c-42fd-932b-12c0193e9890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d77ca13-220c-42fd-932b-12c0193e9890" xlink:to="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_59a0f754-a678-4fa3-9ac6-fc4e18bfcb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:to="loc_us-gaap_Cash_59a0f754-a678-4fa3-9ac6-fc4e18bfcb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39d740d7-c72b-4a2e-bd59-eba311a9d972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39d740d7-c72b-4a2e-bd59-eba311a9d972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135cea93-9c56-495f-af54-4e7d83b0e44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135cea93-9c56-495f-af54-4e7d83b0e44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8ada7c87-4a1f-4694-b277-0d305df5f45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_395fce0e-fa0c-4f59-a5c1-1f55ae2f9abf" xlink:to="loc_us-gaap_AssetsCurrent_8ada7c87-4a1f-4694-b277-0d305df5f45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0eb044f6-51f4-47e0-b6fc-848bbe0adb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0eb044f6-51f4-47e0-b6fc-848bbe0adb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b38421cb-001d-4411-aaf8-704943e122e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b38421cb-001d-4411-aaf8-704943e122e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7cb597d8-b339-4219-aed2-1b64079c9d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7cb597d8-b339-4219-aed2-1b64079c9d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0a62636e-5cfb-487b-9e38-08f351df33d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_Goodwill_0a62636e-5cfb-487b-9e38-08f351df33d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_574546f3-4365-4fc3-be2d-f17681723ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3424c050-291a-449e-a96e-17f1e539e374" xlink:to="loc_us-gaap_Assets_574546f3-4365-4fc3-be2d-f17681723ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d77ca13-220c-42fd-932b-12c0193e9890" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6d13b8c5-1d5f-40d9-a6a6-5cae27687a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_AccountsPayableCurrent_6d13b8c5-1d5f-40d9-a6a6-5cae27687a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e9720dfe-427f-45d8-a474-6ab09a8e8f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e9720dfe-427f-45d8-a474-6ab09a8e8f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4433ab21-f6cd-487b-8743-bf4856a7043e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4433ab21-f6cd-487b-8743-bf4856a7043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5236a14b-46bd-4448-b396-22e076ba6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5236a14b-46bd-4448-b396-22e076ba6890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4d4fdbfd-dafa-4d9c-a2c7-dcec69478c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4d4fdbfd-dafa-4d9c-a2c7-dcec69478c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3303f4b7-60f5-4147-8b88-ce5b3fefaeec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8b3f909-275e-4821-9411-869a0e29e851" xlink:to="loc_us-gaap_LiabilitiesCurrent_3303f4b7-60f5-4147-8b88-ce5b3fefaeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3809d1ef-f88d-4e43-871c-da08e5276c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3809d1ef-f88d-4e43-871c-da08e5276c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_01275b8b-c07d-49d1-b1fb-a15648372164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_01275b8b-c07d-49d1-b1fb-a15648372164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_85f37b3f-9373-4c13-ae95-7a2747c0f1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_Liabilities_85f37b3f-9373-4c13-ae95-7a2747c0f1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0ea61a02-d98c-45c2-b5ac-58ee4e9d573b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:to="loc_us-gaap_CommonStockValue_0ea61a02-d98c-45c2-b5ac-58ee4e9d573b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_92bc985f-fc89-4a2c-938d-e905b4efd5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_92bc985f-fc89-4a2c-938d-e905b4efd5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2982b69d-351e-4551-a3ec-d2239bebc51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2982b69d-351e-4551-a3ec-d2239bebc51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4c9be39-c7f2-4810-8eb6-4f79b65bcf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_121b14c9-adfe-4e9f-90c2-7c55fab274b6" xlink:to="loc_us-gaap_StockholdersEquity_c4c9be39-c7f2-4810-8eb6-4f79b65bcf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aceeab8e-3f1a-43d9-94b0-88f4d509fca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_483113b0-8f56-41b8-bd3a-a9beb806a3e6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_aceeab8e-3f1a-43d9-94b0-88f4d509fca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ebb21091-760e-4675-a8ef-c260c83ee175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d2a53ba-de5a-43dd-8a03-166ff6c3cf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebb21091-760e-4675-a8ef-c260c83ee175" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d2a53ba-de5a-43dd-8a03-166ff6c3cf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bed4716b-1aa0-498e-a780-77ca8477bd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebb21091-760e-4675-a8ef-c260c83ee175" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bed4716b-1aa0-498e-a780-77ca8477bd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_76dd5d51-542b-4a34-9150-d3eb02a4eff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebb21091-760e-4675-a8ef-c260c83ee175" xlink:to="loc_us-gaap_CommonStockSharesIssued_76dd5d51-542b-4a34-9150-d3eb02a4eff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d73a2884-8dee-4e45-a659-d22edef9fcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebb21091-760e-4675-a8ef-c260c83ee175" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d73a2884-8dee-4e45-a659-d22edef9fcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0670828e-8bd4-46ca-9bd4-d903da8ad188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0670828e-8bd4-46ca-9bd4-d903da8ad188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e9546992-485c-4ab8-990f-10ea0531b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e9546992-485c-4ab8-990f-10ea0531b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6c79ae5-5b07-4044-a69a-6bb39a768b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6c79ae5-5b07-4044-a69a-6bb39a768b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_e997945e-574e-4672-b25d-a6637a83594a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:to="loc_us-gaap_SellingAndMarketingExpense_e997945e-574e-4672-b25d-a6637a83594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_556b325b-64c0-4f18-935f-74dd4b257ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_556b325b-64c0-4f18-935f-74dd4b257ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_de4f9746-4ff8-48e2-836b-85e9f28c8776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_291ea88e-2c6e-4bb0-a5f5-5e26335d92ac" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_de4f9746-4ff8-48e2-836b-85e9f28c8776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3576036-2bce-4233-9a40-c591f481fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_OperatingIncomeLoss_f3576036-2bce-4233-9a40-c591f481fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_17b3c81d-19bd-42c5-96da-2626231bb7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_17b3c81d-19bd-42c5-96da-2626231bb7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1ccf14b1-9187-4138-a2a5-ea0b5f7eaa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_17b3c81d-19bd-42c5-96da-2626231bb7f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1ccf14b1-9187-4138-a2a5-ea0b5f7eaa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b30a2c5f-894b-46eb-a21b-ff49ab7ddd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b30a2c5f-894b-46eb-a21b-ff49ab7ddd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70330ff3-6871-4246-b4ce-1af6fb501a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70330ff3-6871-4246-b4ce-1af6fb501a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa7ea71a-a977-4c6e-b341-b403ffc10b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_NetIncomeLoss_fa7ea71a-a977-4c6e-b341-b403ffc10b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BasicAndDilutedEarningsPerShareAbstract_3d64e865-c3a2-42e4-b4e9-62f276d44c13" xlink:href="csbr-20220430.xsd#csbr_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_csbr_BasicAndDilutedEarningsPerShareAbstract_3d64e865-c3a2-42e4-b4e9-62f276d44c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_852e731a-ef48-4f3f-9770-2d21d04405ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_BasicAndDilutedEarningsPerShareAbstract_3d64e865-c3a2-42e4-b4e9-62f276d44c13" xlink:to="loc_us-gaap_EarningsPerShareBasic_852e731a-ef48-4f3f-9770-2d21d04405ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a779a70c-c1a7-45d7-acb8-5257f6bd2fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_BasicAndDilutedEarningsPerShareAbstract_3d64e865-c3a2-42e4-b4e9-62f276d44c13" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a779a70c-c1a7-45d7-acb8-5257f6bd2fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_8b35b22a-42ab-4bb6-9e96-d37c7834d009" xlink:href="csbr-20220430.xsd#csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_8b35b22a-42ab-4bb6-9e96-d37c7834d009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7c56e6a3-3e33-4086-a178-bb106e4a3fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_8b35b22a-42ab-4bb6-9e96-d37c7834d009" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7c56e6a3-3e33-4086-a178-bb106e4a3fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad22407c-7f46-4879-8159-a3406b3b6b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_8b35b22a-42ab-4bb6-9e96-d37c7834d009" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad22407c-7f46-4879-8159-a3406b3b6b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList_aa497382-03ac-4667-9fbc-08dadd4fd367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_TypeOfRevenueExtensibleList_aa497382-03ac-4667-9fbc-08dadd4fd367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_905912b5-095d-462b-9dcb-c3e17e73f7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c870f3ee-4834-477e-94de-3961d40d813f" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_905912b5-095d-462b-9dcb-c3e17e73f7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4d22caae-bead-4e9e-8405-b21be8bbac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4d22caae-bead-4e9e-8405-b21be8bbac1b" xlink:to="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad5718e-4f6f-4d91-8c26-5347c07896bb" xlink:to="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d2a90cf-480a-42d0-b230-7e09fd9298d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_CommonStockMember_7d2a90cf-480a-42d0-b230-7e09fd9298d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_74010539-301a-48a1-83b0-fbda43bade3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_TreasuryStockCommonMember_74010539-301a-48a1-83b0-fbda43bade3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_56251e28-772a-4a6c-9f31-72d0262c58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_56251e28-772a-4a6c-9f31-72d0262c58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff8584b1-fa35-4bc1-a8a3-996870ca58d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67f53746-c1fe-4ae2-b717-baf0a3a616b5" xlink:to="loc_us-gaap_RetainedEarningsMember_ff8584b1-fa35-4bc1-a8a3-996870ca58d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f347f4e-16c2-400b-8e57-d2c7df0a9af7" xlink:to="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba7539b-00a8-4b43-b239-6202b18ba0fd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c705fec4-1451-4e50-8e2d-790ca955ed04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c705fec4-1451-4e50-8e2d-790ca955ed04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a7cc3afb-4e6b-4c33-bf85-917b2d4dcc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a7cc3afb-4e6b-4c33-bf85-917b2d4dcc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2de13e47-ffe0-42c1-8e77-4aae2dc8b97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockholdersEquity_2de13e47-ffe0-42c1-8e77-4aae2dc8b97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_395cb9d7-732c-4e27-ac75-1e1940808a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_395cb9d7-732c-4e27-ac75-1e1940808a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c5572dad-3951-4799-bfce-df746daa0ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c5572dad-3951-4799-bfce-df746daa0ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce8cf35a-82d7-4982-a2f9-2b4fb83ca7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce8cf35a-82d7-4982-a2f9-2b4fb83ca7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45974354-a605-4569-ac8f-9ad606ecf639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_NetIncomeLoss_45974354-a605-4569-ac8f-9ad606ecf639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_edae235e-0c45-4282-8b54-7070556cb671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_edae235e-0c45-4282-8b54-7070556cb671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ea553679-3db3-4929-b77e-f43ced348e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_ea553679-3db3-4929-b77e-f43ced348e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e0d79ff-12a4-4ee6-ad1a-3082d52a7d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21efd505-3a30-4e87-b8c1-cf1a4719f36c" xlink:to="loc_us-gaap_StockholdersEquity_0e0d79ff-12a4-4ee6-ad1a-3082d52a7d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="csbr-20220430.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df8d4ad8-cac3-4af5-a721-061328896cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df8d4ad8-cac3-4af5-a721-061328896cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bf3878f-62d8-46a8-bed3-e793ab2bc560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df8d4ad8-cac3-4af5-a721-061328896cdf" xlink:to="loc_us-gaap_NetIncomeLoss_6bf3878f-62d8-46a8-bed3-e793ab2bc560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df8d4ad8-cac3-4af5-a721-061328896cdf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5baefbba-c08a-47c4-ab2c-bc9b5096c210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_ShareBasedCompensation_5baefbba-c08a-47c4-ab2c-bc9b5096c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2a2601fe-c363-4c4f-88a3-608781be3be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_DepreciationAndAmortization_2a2601fe-c363-4c4f-88a3-608781be3be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c17a40bb-10af-41d4-bfe2-eb1b842d7327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c17a40bb-10af-41d4-bfe2-eb1b842d7327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_2ed5d456-5684-4ab3-b949-73689b6b32e7" xlink:href="csbr-20220430.xsd#csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_2ed5d456-5684-4ab3-b949-73689b6b32e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_6ba58a42-1b66-46c9-bd9b-3a8d4432c336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_6ba58a42-1b66-46c9-bd9b-3a8d4432c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0c66c80c-19db-40a6-93d6-b31873e448d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0c66c80c-19db-40a6-93d6-b31873e448d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9cf9ee33-b4bd-4f9c-ac04-219371989ca2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74bf9879-3d9a-46b9-be4f-5be903632fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74bf9879-3d9a-46b9-be4f-5be903632fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba4bc0ae-a511-4fe2-9589-3d71ad94985b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba4bc0ae-a511-4fe2-9589-3d71ad94985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef6b3213-8dd4-44b1-9059-283952b130d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef6b3213-8dd4-44b1-9059-283952b130d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07709fd1-7fe7-45bb-b039-4d1de7521945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07709fd1-7fe7-45bb-b039-4d1de7521945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_47c2e40a-bf4c-46bd-b62f-60dfa18aa2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_47c2e40a-bf4c-46bd-b62f-60dfa18aa2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_becb9820-35bb-409f-97c1-a52025f31e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_becb9820-35bb-409f-97c1-a52025f31e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a1d3ba02-f201-47e1-917f-1005d2a4519e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_6187089e-3bf3-4ea8-a21e-a6d2bc46c983" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a1d3ba02-f201-47e1-917f-1005d2a4519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95640a8c-7f82-47ca-8bab-5f448751bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df8d4ad8-cac3-4af5-a721-061328896cdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95640a8c-7f82-47ca-8bab-5f448751bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db8f76ae-d74f-4c6b-be94-f0bce77c4154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db8f76ae-d74f-4c6b-be94-f0bce77c4154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1b69098-0ed9-4487-bca7-3d13ee108ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db8f76ae-d74f-4c6b-be94-f0bce77c4154" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1b69098-0ed9-4487-bca7-3d13ee108ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromRefundOfSecurityDeposit_d1144e45-901c-468a-946b-0cb1971c2cae" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromRefundOfSecurityDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db8f76ae-d74f-4c6b-be94-f0bce77c4154" xlink:to="loc_csbr_ProceedsFromRefundOfSecurityDeposit_d1144e45-901c-468a-946b-0cb1971c2cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09c360f1-9c4b-4fc8-9d25-1d5ada435d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db8f76ae-d74f-4c6b-be94-f0bce77c4154" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09c360f1-9c4b-4fc8-9d25-1d5ada435d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9fb6ff7-eb80-444f-bb04-af04d120d2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9fb6ff7-eb80-444f-bb04-af04d120d2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants_57b7d911-0931-4d27-b606-87e42bceab48" xlink:href="csbr-20220430.xsd#csbr_ProceedsFromExerciseOfOptionsAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9fb6ff7-eb80-444f-bb04-af04d120d2c1" xlink:to="loc_csbr_ProceedsFromExerciseOfOptionsAndWarrants_57b7d911-0931-4d27-b606-87e42bceab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_185def85-b60c-4d60-82dc-5a9d597209ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9fb6ff7-eb80-444f-bb04-af04d120d2c1" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_185def85-b60c-4d60-82dc-5a9d597209ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9aae0061-a2f6-4a00-a44d-fa82401b363e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9fb6ff7-eb80-444f-bb04-af04d120d2c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9aae0061-a2f6-4a00-a44d-fa82401b363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee1481b4-e164-4065-82a1-462305c64397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee1481b4-e164-4065-82a1-462305c64397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03b2c8f1-905d-4621-a83a-7a017a86046b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03b2c8f1-905d-4621-a83a-7a017a86046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b5fc055-d7b2-4489-81cc-09487c0a460f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b5fc055-d7b2-4489-81cc-09487c0a460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3e60eb04-6d3c-45ad-82e6-b9020f23f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fc09d6a4-bc3a-4f27-a2fe-aefd88e98aa4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3e60eb04-6d3c-45ad-82e6-b9020f23f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1af6d9d8-27a9-4d00-ae33-d3a8da5178ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3e60eb04-6d3c-45ad-82e6-b9020f23f37b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1af6d9d8-27a9-4d00-ae33-d3a8da5178ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="csbr-20220430.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e304e2-dd5f-472c-87cc-2f6040abbba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c6e8b65f-ad95-4fb7-a51e-761c0cf01e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e304e2-dd5f-472c-87cc-2f6040abbba2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c6e8b65f-ad95-4fb7-a51e-761c0cf01e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#OrganizationandBasisofPresentationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e9ed74c-7a05-485e-905d-ad539ab92738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_NumberofOperatingSubsidiaries_c54ee9f3-db24-4d61-9d3b-4062ec968ad1" xlink:href="csbr-20220430.xsd#csbr_NumberofOperatingSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e9ed74c-7a05-485e-905d-ad539ab92738" xlink:to="loc_csbr_NumberofOperatingSubsidiaries_c54ee9f3-db24-4d61-9d3b-4062ec968ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c5d7ea7e-57c8-4873-b166-e2b9743eddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e9ed74c-7a05-485e-905d-ad539ab92738" xlink:to="loc_us-gaap_NumberOfReportableSegments_c5d7ea7e-57c8-4873-b166-e2b9743eddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b667fb09-9bea-434b-a33a-e3da392091eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a2a3cea0-bb7b-492a-ae24-3163f2368daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b667fb09-9bea-434b-a33a-e3da392091eb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a2a3cea0-bb7b-492a-ae24-3163f2368daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5cf092f1-2a8b-4014-801a-82c3ec4eefed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5cf092f1-2a8b-4014-801a-82c3ec4eefed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a56c5142-73de-4a12-b8a2-9e7232b8715e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a56c5142-73de-4a12-b8a2-9e7232b8715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5b4c2764-ae11-4e25-a05d-b66aaf7fed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5b4c2764-ae11-4e25-a05d-b66aaf7fed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7630551e-3204-4b1e-9e85-eb47e676b5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_UseOfEstimates_7630551e-3204-4b1e-9e85-eb47e676b5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0a76cb98-f3c7-4cb3-a5a4-66912716fc13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0a76cb98-f3c7-4cb3-a5a4-66912716fc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f3cc8620-264b-451a-9156-37c692f6e5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f3cc8620-264b-451a-9156-37c692f6e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3808e146-5403-46e4-a960-473bb91651fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3808e146-5403-46e4-a960-473bb91651fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f38d93f5-1600-4cf1-92e3-1c4bf99d8c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f38d93f5-1600-4cf1-92e3-1c4bf99d8c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_86003092-af3d-4d5d-9c6c-0c6e5bf02912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_86003092-af3d-4d5d-9c6c-0c6e5bf02912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_398135ac-a605-4d54-8b69-007e403c388a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_398135ac-a605-4d54-8b69-007e403c388a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4db22031-190f-48c2-8d54-049da60d6443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4db22031-190f-48c2-8d54-049da60d6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock_09c1a547-b3d3-4248-822c-fc1b9c196a3c" xlink:href="csbr-20220430.xsd#csbr_OtherNoncurrentLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock_09c1a547-b3d3-4248-822c-fc1b9c196a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_8c5dbd3f-7e71-4fd9-aa0a-ff4b3c6a5160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_8c5dbd3f-7e71-4fd9-aa0a-ff4b3c6a5160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0dd0d013-a4ff-4b18-bfde-4ff9539b26ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0dd0d013-a4ff-4b18-bfde-4ff9539b26ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock_7970c4fe-3ac0-42b6-9148-34438166c080" xlink:href="csbr-20220430.xsd#csbr_SalesAndMarketingExpensePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock_7970c4fe-3ac0-42b6-9148-34438166c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ed08e4aa-054b-43c3-8481-98a9d3e7da97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ed08e4aa-054b-43c3-8481-98a9d3e7da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f8cc8f9b-b061-4135-ad74-a786035b073e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f8cc8f9b-b061-4135-ad74-a786035b073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0c92bd1c-93cb-4a33-b11d-1c5949ed3cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0c92bd1c-93cb-4a33-b11d-1c5949ed3cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3c3c0b02-d127-4c61-9211-e92c54230256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4be84d35-dac5-456f-9b6d-3ee6f504348e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3c3c0b02-d127-4c61-9211-e92c54230256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_06b50a9b-451f-4769-a7c9-95ca70e55cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06b50a9b-451f-4769-a7c9-95ca70e55cdd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:to="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_109f733c-05d3-4cf1-861e-3563dcaa8330" xlink:to="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_687423e7-cfdf-4d86-b09b-0cd729a1d8be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:to="loc_srt_MinimumMember_687423e7-cfdf-4d86-b09b-0cd729a1d8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d0ff344-0e3f-4ca0-9029-a5ac3e6f8741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0abea814-57a6-47ec-b1df-5d5198d0ff18" xlink:to="loc_srt_MaximumMember_1d0ff344-0e3f-4ca0-9029-a5ac3e6f8741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483afac5-28d5-49c3-8305-2efeb9e84ac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ba265a77-1d6a-41bc-9a52-aba5e1084849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_Cash_ba265a77-1d6a-41bc-9a52-aba5e1084849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_190008fc-617e-4c1f-9dc0-357713dfa490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_190008fc-617e-4c1f-9dc0-357713dfa490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92fcf9b0-b9dd-4452-a7ab-73bbc2daa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_NetIncomeLoss_92fcf9b0-b9dd-4452-a7ab-73bbc2daa2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44bf47fb-1a61-4e8f-9f08-42cfda157744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44bf47fb-1a61-4e8f-9f08-42cfda157744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_WorkingCapital_527091c9-7df2-480d-88bd-0b8520c15e21" xlink:href="csbr-20220430.xsd#csbr_WorkingCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_csbr_WorkingCapital_527091c9-7df2-480d-88bd-0b8520c15e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_27f2565a-d5e5-42a4-af7a-33acad22e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_27f2565a-d5e5-42a4-af7a-33acad22e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8f60dfe8-6e50-4152-8174-e44e35b0f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8f60dfe8-6e50-4152-8174-e44e35b0f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c8a1b10e-33d7-45db-a85e-a20591431089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_NumberOfReportableSegments_c8a1b10e-33d7-45db-a85e-a20591431089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5cfbe987-cb12-4aba-8c20-a935cb9ce9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5cfbe987-cb12-4aba-8c20-a935cb9ce9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b5b67ce2-3d27-4c0f-8c66-18a925179596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b5b67ce2-3d27-4c0f-8c66-18a925179596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4537bb9-486d-41f4-a63d-01b7e7407015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80fcd576-89ff-4c26-bede-209802ec2a0a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e4537bb9-486d-41f4-a63d-01b7e7407015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86d76028-23a5-4bc7-98dd-343c743061dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86d76028-23a5-4bc7-98dd-343c743061dc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7dd497ec-990c-499e-b5e2-a4025ae8402c" xlink:to="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:href="csbr-20220430.xsd#csbr_FewContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_df5098ef-1e3f-4266-98c7-8af5907e325e" xlink:to="loc_csbr_FewContractsMember_95bf5c36-a43f-498d-8cbe-f850bd4cd34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_903787dc-b202-4053-89f2-e1c8e1544494" xlink:to="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MinimumMember_a7100a99-1e40-4099-9143-449711bb6a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4c8aede-a9a6-48f7-8602-bdea0c49ef95" xlink:to="loc_srt_MaximumMember_db6f0f7c-7460-4c43-92f8-203ec1ac4835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6a1f29b9-4f74-4e68-b5a3-02db9e18f911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6a1f29b9-4f74-4e68-b5a3-02db9e18f911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_331acff8-a62d-4e33-a143-6d6c0abc93c2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_738badc3-e6f1-4647-8541-92cb4223e3d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa34afe0-6512-4fd2-bc2a-b2ede75e754b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenue"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_3352b2eb-920c-4b93-b7c0-f22420a06731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock_29cc384d-a1ef-405b-9607-b8e949e3dd92" xlink:href="csbr-20220430.xsd#csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_3352b2eb-920c-4b93-b7c0-f22420a06731" xlink:to="loc_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock_29cc384d-a1ef-405b-9607-b8e949e3dd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenueTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2efd1227-ff68-406c-a0d0-6f71fe6ce0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4c7a4dfd-f6aa-4307-923f-c6cc641ad4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2efd1227-ff68-406c-a0d0-6f71fe6ce0ab" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4c7a4dfd-f6aa-4307-923f-c6cc641ad4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d21a0fd0-9073-4cd3-a3e4-d832189db6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2efd1227-ff68-406c-a0d0-6f71fe6ce0ab" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d21a0fd0-9073-4cd3-a3e4-d832189db6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TradeAccountsReceivable_bd4195e7-211f-4a51-8e4e-dc4d2c902871" xlink:href="csbr-20220430.xsd#csbr_TradeAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:to="loc_csbr_TradeAccountsReceivable_bd4195e7-211f-4a51-8e4e-dc4d2c902871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_2a7fd82e-70c5-4786-b8ef-1c0d97845875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:to="loc_us-gaap_UnbilledContractsReceivable_2a7fd82e-70c5-4786-b8ef-1c0d97845875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_d2fb2175-33f5-4fdd-8f8d-6e1f93cb96a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:to="loc_us-gaap_AccountsReceivableGross_d2fb2175-33f5-4fdd-8f8d-6e1f93cb96a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8dbdeac8-a4a5-4127-a1ce-2189209b1994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8dbdeac8-a4a5-4127-a1ce-2189209b1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b0f214dd-265f-4954-9414-72541b4933bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_691df437-4db5-4b61-83ae-a74bd7ab0605" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b0f214dd-265f-4954-9414-72541b4933bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_965d40bc-08dc-4153-9dd7-20d3844c1aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_815d0046-34e1-463d-a626-54bc26d62d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_965d40bc-08dc-4153-9dd7-20d3844c1aac" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_815d0046-34e1-463d-a626-54bc26d62d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_82a0fef6-fbb9-419c-bbf4-ef56320a01af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_3c2cf5f0-1f01-45a2-98b5-1f922de88fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_82a0fef6-fbb9-419c-bbf4-ef56320a01af" xlink:to="loc_us-gaap_UnbilledContractsReceivable_3c2cf5f0-1f01-45a2-98b5-1f922de88fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8504444e-a646-4963-9a53-db5fdca74b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_82a0fef6-fbb9-419c-bbf4-ef56320a01af" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8504444e-a646-4963-9a53-db5fdca74b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d26ae28d-1f4a-4148-bcdf-033f1e80b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_45e89d3d-183a-404a-9f23-756938d56e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d26ae28d-1f4a-4148-bcdf-033f1e80b88a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_45e89d3d-183a-404a-9f23-756938d56e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba03a4d5-6b72-402c-bdab-e22fdead83c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_99c35529-158f-4755-af29-6b49f81dc15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba03a4d5-6b72-402c-bdab-e22fdead83c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_99c35529-158f-4755-af29-6b49f81dc15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c8fe7040-3242-44a7-bea4-e90705570fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c8fe7040-3242-44a7-bea4-e90705570fcd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84ff311b-a445-47ef-9dbc-5a6210506a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2360c8af-c89c-4e16-8e00-5924859129bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2360c8af-c89c-4e16-8e00-5924859129bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_51cff27a-6eff-4f6e-9ddf-530ca748c041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_ComputerEquipmentMember_51cff27a-6eff-4f6e-9ddf-530ca748c041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_c98a23b8-866c-4889-83b1-9cd632df56d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_c98a23b8-866c-4889-83b1-9cd632df56d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ef36abd5-afc7-44b4-a1f5-47db0aa4f20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ef36abd5-afc7-44b4-a1f5-47db0aa4f20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_864a2983-88bf-4021-97b8-5dfc3a12f216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_AssetUnderConstructionMember_864a2983-88bf-4021-97b8-5dfc3a12f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ed5bfd33-771a-40d8-807a-e2314adcf0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c336629d-4eff-4877-abe9-c2373200806d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ed5bfd33-771a-40d8-807a-e2314adcf0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_483326b8-34eb-4066-be3f-e93361075053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_61fd2d6c-5e1a-4e1e-b473-95c3609fdaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_61fd2d6c-5e1a-4e1e-b473-95c3609fdaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8ede47f-530a-4c85-99a9-53ee7490af1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8ede47f-530a-4c85-99a9-53ee7490af1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74f91630-ad74-4bfc-b301-2f191920a5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74f91630-ad74-4bfc-b301-2f191920a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6cfa8478-67a2-466d-aefc-2efa02a8c2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25fec7f5-37c8-4cbb-b885-e45e6095f18e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6cfa8478-67a2-466d-aefc-2efa02a8c2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0ae6e63c-9c88-40ed-9a68-6193f90578a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0ae6e63c-9c88-40ed-9a68-6193f90578a2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3de20ac0-62ba-4e07-8d25-345e91b5628d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeasedAssetsMember_c5603476-33a1-4991-aa10-b952c30eccc7" xlink:href="csbr-20220430.xsd#csbr_FinanceLeasedAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_csbr_FinanceLeasedAssetsMember_c5603476-33a1-4991-aa10-b952c30eccc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b64cb20a-9878-486c-b986-c0abdf5420a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b64cb20a-9878-486c-b986-c0abdf5420a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_4879428a-8950-49d2-83b4-298da1d2a311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6419fbdc-6267-4922-95a3-7b7a7c71be45" xlink:to="loc_us-gaap_AssetUnderConstructionMember_4879428a-8950-49d2-83b4-298da1d2a311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:to="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_FinanceLeaseAxis_14bed8d7-dcdf-4282-96e9-15faab51918d" xlink:to="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2020FinanceLeaseMember_2c87aa5a-7114-4c40-98aa-7b5c79afa28d" xlink:href="csbr-20220430.xsd#csbr_A2020FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:to="loc_csbr_A2020FinanceLeaseMember_2c87aa5a-7114-4c40-98aa-7b5c79afa28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_A2022FinanceLeaseMember_b3a0bd26-091d-4863-bcee-bcb602317c34" xlink:href="csbr-20220430.xsd#csbr_A2022FinanceLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_FinanceLeaseDomain_43ca31cc-521e-4346-98f9-035d70831742" xlink:to="loc_csbr_A2022FinanceLeaseMember_b3a0bd26-091d-4863-bcee-bcb602317c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20834c4-9216-4241-a472-bec7fbf6247a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9a6d23af-1c3e-4030-8a23-b8d1b250b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9a6d23af-1c3e-4030-8a23-b8d1b250b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747fe6f6-37e1-42fc-8fab-94829805b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747fe6f6-37e1-42fc-8fab-94829805b87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_dc427644-1853-4519-a0ae-e2ee1eddd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_dc427644-1853-4519-a0ae-e2ee1eddd6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_66bf3163-37f1-4d7a-b4c6-3fc38ce0b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_Depreciation_66bf3163-37f1-4d7a-b4c6-3fc38ce0b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2ce89af-04ed-47da-8b43-8e0da9176f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b2ce89af-04ed-47da-8b43-8e0da9176f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a0363c50-e123-4b5f-b02f-021bc0a8bbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a0363c50-e123-4b5f-b02f-021bc0a8bbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmount_e444cc73-0dfb-4b6e-98a7-9fc7772df8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAssetAtFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_ServicingAssetAtFairValueAmount_e444cc73-0dfb-4b6e-98a7-9fc7772df8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAsset_46262427-7fbc-40ad-b2f5-d0a996c54f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_ServicingAsset_46262427-7fbc-40ad-b2f5-d0a996c54f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_ca93411f-528a-4f53-a3bf-ff38277e90de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_ca93411f-528a-4f53-a3bf-ff38277e90de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseCost_b6aeb8a7-8401-4531-b851-1533384099a7" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_FinanceLeaseCost_b6aeb8a7-8401-4531-b851-1533384099a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_FinanceLeaseMonthlyPayment_e9a65063-34dc-4fe6-8c68-d751a109bbfc" xlink:href="csbr-20220430.xsd#csbr_FinanceLeaseMonthlyPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_FinanceLeaseMonthlyPayment_e9a65063-34dc-4fe6-8c68-d751a109bbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2938a91d-4918-4856-ba73-a105c9dcbb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2938a91d-4918-4856-ba73-a105c9dcbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PresentValueMinimumFutureObligationsInterestRate_d06bf2be-543c-4359-a44c-b74d30b6d329" xlink:href="csbr-20220430.xsd#csbr_PresentValueMinimumFutureObligationsInterestRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_csbr_PresentValueMinimumFutureObligationsInterestRate_d06bf2be-543c-4359-a44c-b74d30b6d329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d8314ec7-a961-4d89-af20-caae28553a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1273485c-5ebd-4cff-9fcd-0f8db259978e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d8314ec7-a961-4d89-af20-caae28553a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomers" xlink:type="simple" xlink:href="csbr-20220430.xsd#RevenuefromContractswithCustomers"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/RevenuefromContractswithCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b4da204-8aba-4c67-af08-a592da3dc4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e85b0d27-0e30-4232-94ad-c4e66a5c34f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b4da204-8aba-4c67-af08-a592da3dc4c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e85b0d27-0e30-4232-94ad-c4e66a5c34f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomersTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#RevenuefromContractswithCustomersTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/RevenuefromContractswithCustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7d98914-fe6c-4c9f-af03-3fb34472dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_18425e4c-63ec-4ee5-a8c0-2e04f15969d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7d98914-fe6c-4c9f-af03-3fb34472dc51" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_18425e4c-63ec-4ee5-a8c0-2e04f15969d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9f7b7fd6-4510-4d41-81a5-124313cdf2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9f7b7fd6-4510-4d41-81a5-124313cdf2bb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:to="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2a8a2bc2-1c0f-47c1-b862-e1c09adf5ebd" xlink:to="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PharmacologyServicesMember_7181c135-9f39-4880-9c6c-52c75863f7ed" xlink:href="csbr-20220430.xsd#csbr_PharmacologyServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_PharmacologyServicesMember_7181c135-9f39-4880-9c6c-52c75863f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OtherServicesMember_9f13726b-bc7a-475c-a821-2de24c0eb6f5" xlink:href="csbr-20220430.xsd#csbr_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_OtherServicesMember_9f13726b-bc7a-475c-a821-2de24c0eb6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_PersonalizedOncologyServicesMember_005f4822-18b3-4956-ad28-0bce82526732" xlink:href="csbr-20220430.xsd#csbr_PersonalizedOncologyServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cbf547d0-8642-475b-a806-fd232aba7109" xlink:to="loc_csbr_PersonalizedOncologyServicesMember_005f4822-18b3-4956-ad28-0bce82526732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b98bd019-653e-4879-8dae-c846082e80c3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbb55896-6e5d-41b0-90c3-22e47568246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2cad89f-8270-47e8-97e8-908148ecee0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbb55896-6e5d-41b0-90c3-22e47568246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SignificantCustomers" xlink:type="simple" xlink:href="csbr-20220430.xsd#SignificantCustomers"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SignificantCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2288cc9b-6aca-4698-b814-77bbe78f83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_dd3532bf-0427-4a86-9b2d-2c782417c0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2288cc9b-6aca-4698-b814-77bbe78f83f0" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_dd3532bf-0427-4a86-9b2d-2c782417c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/SignificantCustomersDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#SignificantCustomersDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/SignificantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_24d9633f-3a8c-44f8-a757-4988bc5be145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_24d9633f-3a8c-44f8-a757-4988bc5be145" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e1a86bf-2a01-4267-8fd6-2cafaf545cfd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e4f4477e-44ac-434f-ba27-d060ca085b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_818d7ea1-7e3a-4a9e-a514-83054f641503" xlink:to="loc_us-gaap_AccountsReceivableMember_e4f4477e-44ac-434f-ba27-d060ca085b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b65d478-4f93-4b02-ba48-f5d8609d1f9a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b90aa7a2-5e4e-4c01-a8d3-6240a36551a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_759e8c0b-42dc-4152-b9e0-2a1b668c9c22" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b90aa7a2-5e4e-4c01-a8d3-6240a36551a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f84bd8e6-324f-4d63-a042-f0145d3b7158" xlink:to="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OneCustomerMember_340742ca-eb6b-4df6-9735-1c6cd62f0439" xlink:href="csbr-20220430.xsd#csbr_OneCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1f9574b5-10b4-4794-a95f-f325bfb4ba87" xlink:to="loc_csbr_OneCustomerMember_340742ca-eb6b-4df6-9735-1c6cd62f0439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2b3d610b-0984-483d-b195-6913a97e508f" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c2802642-3655-4b3b-a253-5c6df3412a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e6936f98-2f6d-4152-9126-1015e2acef55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c2802642-3655-4b3b-a253-5c6df3412a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="csbr-20220430.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60ea3cc8-0f2c-4d77-9aea-9d3c6b9e4e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_73bef116-8195-4126-b770-a0b4f77ae634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60ea3cc8-0f2c-4d77-9aea-9d3c6b9e4e73" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_73bef116-8195-4126-b770-a0b4f77ae634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a2edfb8b-1fab-40ea-b248-9a10052173bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a2edfb8b-1fab-40ea-b248-9a10052173bd" xlink:to="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:to="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b0ad0471-280e-4117-88b1-7619cd2f52ef" xlink:to="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b9282fba-4eed-4668-87d9-7e96db704c44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:to="loc_srt_MinimumMember_b9282fba-4eed-4668-87d9-7e96db704c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_867cab37-f447-4250-ba44-ede79b8adff9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9f3964e-8270-4d09-aab8-740115c3af12" xlink:to="loc_srt_MaximumMember_867cab37-f447-4250-ba44-ede79b8adff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:href="csbr-20220430.xsd#csbr_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CommitmentsAndContingenciesTable_6e74d311-dde8-432f-a5db-ba90d59920a1" xlink:to="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFee_2fc6a6b3-b01a-4ca4-afb0-2658c0cb37ab" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_csbr_CollaborationArrangementRoyaltyFee_2fc6a6b3-b01a-4ca4-afb0-2658c0cb37ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_3bca0cec-7f73-4175-a8fc-9a74720ccec2" xlink:href="csbr-20220430.xsd#csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice_3bca0cec-7f73-4175-a8fc-9a74720ccec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_109c738f-537f-447a-98a6-ca11e7f758ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_csbr_CommitmentsAndContingenciesLineItems_47e6b480-82b2-44f1-b9ae-0779b16be55b" xlink:to="loc_us-gaap_RoyaltyExpense_109c738f-537f-447a-98a6-ca11e7f758ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPayments" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPayments"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0de7481d-ec38-48b0-a0e9-385cd1a89467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_91448350-edd1-4695-be52-b6c9bdeed3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0de7481d-ec38-48b0-a0e9-385cd1a89467" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_91448350-edd1-4695-be52-b6c9bdeed3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110551ca-c185-471f-b814-ebec97b67051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f584241c-ff82-4aa4-9904-12a062b6576d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110551ca-c185-471f-b814-ebec97b67051" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f584241c-ff82-4aa4-9904-12a062b6576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d55104eb-7b87-468d-b907-b6477200ba81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110551ca-c185-471f-b814-ebec97b67051" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d55104eb-7b87-468d-b907-b6477200ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5458ceb-801c-41f1-a5eb-9ae9a53c6089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_110551ca-c185-471f-b814-ebec97b67051" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5458ceb-801c-41f1-a5eb-9ae9a53c6089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d00f3c99-c45f-4a39-a09f-e483a9fc2507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d00f3c99-c45f-4a39-a09f-e483a9fc2507" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9700ba2b-32e4-4ec3-bddb-892393eff1d3" xlink:to="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2021Member_49364bcb-c730-4536-ad38-c4ba12459745" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_EquityIncentivePlan2021Member_49364bcb-c730-4536-ad38-c4ba12459745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EquityIncentivePlan2010Member_2e7fff1d-29b2-4b34-83b6-c7bd2a637a12" xlink:href="csbr-20220430.xsd#csbr_EquityIncentivePlan2010Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_EquityIncentivePlan2010Member_2e7fff1d-29b2-4b34-83b6-c7bd2a637a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TwoThousandEightEquityIncentivePlanMember_df70930b-1c39-41c1-a439-d1aba0b19443" xlink:href="csbr-20220430.xsd#csbr_TwoThousandEightEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_TwoThousandEightEquityIncentivePlanMember_df70930b-1c39-41c1-a439-d1aba0b19443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorCompensationPlanMember_aa018b55-1469-404d-a60d-373a47b8891c" xlink:href="csbr-20220430.xsd#csbr_DirectorCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0516770-656e-4bea-a8e6-c122106151c2" xlink:to="loc_csbr_DirectorCompensationPlanMember_aa018b55-1469-404d-a60d-373a47b8891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ddf61173-147f-4b52-87d5-da69cc0d0892" xlink:to="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f4f00a9-8c8d-47cb-9b97-4b13cec8394e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d70820d-da08-4458-a44e-7443d8d6a9ff" xlink:to="loc_srt_MaximumMember_5f4f00a9-8c8d-47cb-9b97-4b13cec8394e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_930f285e-86de-4ac4-94bd-60ecb4042c6f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8ffd6816-36b3-4c8e-888e-7649a73a9c32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c6870d8-4035-468b-8598-85a36a67b47c" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8ffd6816-36b3-4c8e-888e-7649a73a9c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6857d90d-4a25-42b2-9d5f-0f38a4467443" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_07b3f52b-cf80-4ce8-9c7f-e0de50ba1e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_07b3f52b-cf80-4ce8-9c7f-e0de50ba1e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff727d38-91e5-488e-a751-32d6a343af51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff727d38-91e5-488e-a751-32d6a343af51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f98ffcf7-34dd-4477-9bb0-244140c90508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f98ffcf7-34dd-4477-9bb0-244140c90508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_bc1777e4-9ece-4c9f-a335-93445b0fde70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_bc1777e4-9ece-4c9f-a335-93445b0fde70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50cc4eec-626a-48e4-89f6-2c09869e750c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50cc4eec-626a-48e4-89f6-2c09869e750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock_53a74485-001e-41c6-9119-29c565711ddc" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_StockOptionsAwardSharesToPurchaseCommonStock_53a74485-001e-41c6-9119-29c565711ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_c1d90910-6918-4ce6-99ac-0b6a13147832" xlink:href="csbr-20220430.xsd#csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase_c1d90910-6918-4ce6-99ac-0b6a13147832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_ec48bf0b-0873-4442-8f3a-ab8d322852cf" xlink:href="csbr-20220430.xsd#csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock_ec48bf0b-0873-4442-8f3a-ab8d322852cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_8bb2e537-2fb5-4229-a546-fc8972a2286b" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_8bb2e537-2fb5-4229-a546-fc8972a2286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d3bbae68-5756-4b9c-b027-3285c948d7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a8d3e35-ce33-4229-bab0-e2f8f9fdfffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d3bbae68-5756-4b9c-b027-3285c948d7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2bdcf80-70cc-453b-ba0d-ced23f9df690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2bdcf80-70cc-453b-ba0d-ced23f9df690" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ed96c7c-2eb7-4511-887a-5b031499aa87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711cc2ef-b470-4919-80d3-be9507568965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711cc2ef-b470-4919-80d3-be9507568965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_5d563a25-1812-4505-a9ae-644e25eb9a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_5d563a25-1812-4505-a9ae-644e25eb9a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01cc7549-68a1-43fc-9789-c4e575608b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01cc7549-68a1-43fc-9789-c4e575608b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember_a53dcb6d-52d0-4a9e-9cbd-c9a2ebc7243a" xlink:href="csbr-20220430.xsd#csbr_TranslationalOncologySolutionsCostOfSalesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7eca8420-8440-40da-8005-703c9b444d7d" xlink:to="loc_csbr_TranslationalOncologySolutionsCostOfSalesMember_a53dcb6d-52d0-4a9e-9cbd-c9a2ebc7243a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5369795f-9cbe-45a1-b3bd-e54b93b6e7b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_192e64d6-ef4c-43bb-be34-e1233ba33079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6178a660-9246-4139-8669-da0e6b411206" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_192e64d6-ef4c-43bb-be34-e1233ba33079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsStockOptionGrantsAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b9d39d1-5ad6-4c31-ac00-c88192675ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b9d39d1-5ad6-4c31-ac00-c88192675ab5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:to="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6bdf6b27-c66c-4c3f-a120-f206f7ee623b" xlink:to="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eddea9c-1bbd-49f6-a683-3e1eb70d7db5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:to="loc_srt_MinimumMember_7eddea9c-1bbd-49f6-a683-3e1eb70d7db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78b51f7e-3e74-4044-965c-7327a866c11c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f78e0be-8693-4196-b5e3-3c999c7a3bef" xlink:to="loc_srt_MaximumMember_78b51f7e-3e74-4044-965c-7327a866c11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d8508ee-6999-42ca-97e3-a50b6b76d9e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ab96009-fad4-4005-a701-78ad5c647977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ab96009-fad4-4005-a701-78ad5c647977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9557d828-2e5f-4381-a660-ece9944da74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9557d828-2e5f-4381-a660-ece9944da74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c3b26804-aa55-4070-a0b2-585b5c9bda97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c3b26804-aa55-4070-a0b2-585b5c9bda97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3c95b346-cd22-45bb-9383-9c986a1d7119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3c95b346-cd22-45bb-9383-9c986a1d7119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a002a1d9-3d61-4e46-abdc-3793efb944c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a002a1d9-3d61-4e46-abdc-3793efb944c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b71c1f6-8fdf-4b9d-b79d-a985d07c93bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad8b3d1f-b02c-489c-9edd-e9d63d1e35a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b71c1f6-8fdf-4b9d-b79d-a985d07c93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#StockbasedPaymentsStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f85f155e-b782-4d2e-9dc2-c69a377bdd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f85f155e-b782-4d2e-9dc2-c69a377bdd64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:to="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_55ebda19-761b-4b8b-aa26-251238a7c082" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DirectorsAndEmployeesMember_4b8cee61-8fa3-4902-9926-bf31b619cb79" xlink:href="csbr-20220430.xsd#csbr_DirectorsAndEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:to="loc_csbr_DirectorsAndEmployeesMember_4b8cee61-8fa3-4902-9926-bf31b619cb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_NonEmployeesMember_936ede18-9904-42b9-b567-1a975d8dafba" xlink:href="csbr-20220430.xsd#csbr_NonEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_beb57b96-0944-4dcc-a15d-2aacacfda4d0" xlink:to="loc_csbr_NonEmployeesMember_936ede18-9904-42b9-b567-1a975d8dafba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63f92021-a511-452e-9429-134bfe7df701" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acfb2bce-a24f-4084-ab15-f7270b8cd397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acfb2bce-a24f-4084-ab15-f7270b8cd397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_265be27a-4a24-41a5-836e-a76c82fa0620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_265be27a-4a24-41a5-836e-a76c82fa0620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_219c18ca-c1c6-4102-8aad-f531cf7a401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_219c18ca-c1c6-4102-8aad-f531cf7a401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_2658f81f-f0c2-488e-bf7f-4a6e0f430bc3" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_2658f81f-f0c2-488e-bf7f-4a6e0f430bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e9a877b-73c7-4bce-b5d3-810f406bd127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e9a877b-73c7-4bce-b5d3-810f406bd127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b610bfe4-de97-44fa-a812-1cbe1c5f8235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b610bfe4-de97-44fa-a812-1cbe1c5f8235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6cd1984-d626-40c6-806e-9545e678be90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d4ee7fd8-4255-4dd1-a1e8-c50176aa54cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6cd1984-d626-40c6-806e-9545e678be90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0c226c82-15a1-4eb9-b455-8f36703414b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0c226c82-15a1-4eb9-b455-8f36703414b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5227e88-8e17-44f2-91d5-682a19440856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5227e88-8e17-44f2-91d5-682a19440856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5921a48a-4f5c-4fcb-a6ba-dbd94be06f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5921a48a-4f5c-4fcb-a6ba-dbd94be06f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8ecada82-3079-41b4-874a-d789a3aece84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8ecada82-3079-41b4-874a-d789a3aece84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc4c0063-e4a8-430d-ac33-fee9d92d019f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc4c0063-e4a8-430d-ac33-fee9d92d019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_575fd4fc-5f44-4c0f-b4cc-140681ad1cca" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_575fd4fc-5f44-4c0f-b4cc-140681ad1cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6000d9a0-234d-48e6-8022-f1a607bd9804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6000d9a0-234d-48e6-8022-f1a607bd9804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7c28961f-487b-44ed-b426-8159d28eec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7c28961f-487b-44ed-b426-8159d28eec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbd62fc0-8448-488a-a79b-3e19a662f131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_043c82d7-1a29-4206-8a11-0dcfc03d4b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbd62fc0-8448-488a-a79b-3e19a662f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_24935cba-0072-46dc-b82e-2ac743717aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_24935cba-0072-46dc-b82e-2ac743717aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f4155753-cbc4-42df-9c16-f3527bddecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f4155753-cbc4-42df-9c16-f3527bddecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72e96f3b-12b7-464d-97cd-f79a9e1c42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72e96f3b-12b7-464d-97cd-f79a9e1c42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_a42b4047-64e6-4b5a-882e-b43922925d56" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_a42b4047-64e6-4b5a-882e-b43922925d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_7d79d916-a69d-4e80-a435-2ef2aa6e9540" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_7d79d916-a69d-4e80-a435-2ef2aa6e9540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f8ac8a57-2eee-4212-8236-6a18559a7729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f8ac8a57-2eee-4212-8236-6a18559a7729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_843aeced-2be0-46ae-97b2-800857dfa379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_843aeced-2be0-46ae-97b2-800857dfa379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a5587e89-434a-4e84-83d8-56634624e9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a5587e89-434a-4e84-83d8-56634624e9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_ea35a163-8597-4548-8578-57fd4f760b15" xlink:href="csbr-20220430.xsd#csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted_ea35a163-8597-4548-8578-57fd4f760b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b40a98f-b333-4b66-83fc-5694338714e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b40a98f-b333-4b66-83fc-5694338714e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5249ba42-7957-4685-8935-704a418fd8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5249ba42-7957-4685-8935-704a418fd8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6223bab1-ef8c-4fca-878b-66b26cc60f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_736c103f-d47e-4906-b8f3-cafa9a08d9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6223bab1-ef8c-4fca-878b-66b26cc60f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxes" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxes"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_67bf1d28-9c64-4b74-a86b-1b141bc22f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a85f7350-dfa9-4099-b3ff-c2851960b7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67bf1d28-9c64-4b74-a86b-1b141bc22f38" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a85f7350-dfa9-4099-b3ff-c2851960b7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_879d02bb-ed21-484a-9cb0-b944a72fc6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6956b561-8310-42a4-8273-6b34a5030f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879d02bb-ed21-484a-9cb0-b944a72fc6e4" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6956b561-8310-42a4-8273-6b34a5030f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4606504c-101a-4bf0-9e11-76cf3d514ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879d02bb-ed21-484a-9cb0-b944a72fc6e4" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4606504c-101a-4bf0-9e11-76cf3d514ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_186688de-d98a-440a-8d51-5afde4ddd4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879d02bb-ed21-484a-9cb0-b944a72fc6e4" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_186688de-d98a-440a-8d51-5afde4ddd4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7e61ea71-8628-4c5f-96f1-f522b6b1beb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879d02bb-ed21-484a-9cb0-b944a72fc6e4" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7e61ea71-8628-4c5f-96f1-f522b6b1beb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d67afc7c-9d45-4df3-bedc-c4ef3113ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d67afc7c-9d45-4df3-bedc-c4ef3113ec3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_09174cd6-0b20-42a8-8157-04f29b332dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d67afc7c-9d45-4df3-bedc-c4ef3113ec3e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_09174cd6-0b20-42a8-8157-04f29b332dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fbe7b9af-eca2-4115-864b-9fb3ef4fd858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d67afc7c-9d45-4df3-bedc-c4ef3113ec3e" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fbe7b9af-eca2-4115-864b-9fb3ef4fd858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_65f84bc7-c717-4f49-91ad-c4b736a70845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_65f84bc7-c717-4f49-91ad-c4b736a70845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2494cba1-a9b1-40b9-ad84-2565d3aa8d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_65f84bc7-c717-4f49-91ad-c4b736a70845" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2494cba1-a9b1-40b9-ad84-2565d3aa8d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_2f4b5972-dab8-4d9b-84e1-e780424dda61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_65f84bc7-c717-4f49-91ad-c4b736a70845" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_2f4b5972-dab8-4d9b-84e1-e780424dda61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_0897e621-ad63-497d-b778-54b6f3eefd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_0897e621-ad63-497d-b778-54b6f3eefd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_39843cf0-880a-4b92-a083-b817bdee5bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_0897e621-ad63-497d-b778-54b6f3eefd29" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_39843cf0-880a-4b92-a083-b817bdee5bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_396d156c-69de-402a-bce9-91a004544f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_0897e621-ad63-497d-b778-54b6f3eefd29" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_396d156c-69de-402a-bce9-91a004544f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d7ba22e8-6cfd-490a-bedc-408f0be04e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d7ba22e8-6cfd-490a-bedc-408f0be04e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_483cead8-6eba-49a9-9356-6aea66e0a313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_317ac8c4-3fd7-4872-9dc5-7c0068de96cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_483cead8-6eba-49a9-9356-6aea66e0a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b75200a9-67dc-4850-b7fd-047c4413d553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b75200a9-67dc-4850-b7fd-047c4413d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5023459f-8280-4952-a34f-efc6a02a011b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5023459f-8280-4952-a34f-efc6a02a011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9a51d6dd-aaca-4603-be33-ea27137bbfff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9a51d6dd-aaca-4603-be33-ea27137bbfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_234bf896-4e77-4337-b6e0-1ac12db93c2c" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_234bf896-4e77-4337-b6e0-1ac12db93c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_26ad1492-0dbc-4d2e-aba0-de53684718f2" xlink:href="csbr-20220430.xsd#csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition_26ad1492-0dbc-4d2e-aba0-de53684718f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_92dc0e6c-2bc9-48de-aff6-b04fb0baa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_92dc0e6c-2bc9-48de-aff6-b04fb0baa1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_618ad19a-e542-4e29-b106-0b18dd514b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd932a9e-46b4-4b8d-9c74-2f65900e47f0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_618ad19a-e542-4e29-b106-0b18dd514b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_22acbb1c-87f5-499b-a308-e9384a186041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_22acbb1c-87f5-499b-a308-e9384a186041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_21813ac6-bce4-404c-bd7d-feb62a242e19" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability_21813ac6-bce4-404c-bd7d-feb62a242e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_3a70e5fe-ac67-4c18-bc7c-b0559fc98606" xlink:href="csbr-20220430.xsd#csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization_3a70e5fe-ac67-4c18-bc7c-b0559fc98606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_09b6b368-9394-416e-b248-2b6a3d7289c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_09b6b368-9394-416e-b248-2b6a3d7289c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_005fe74b-adbb-4b24-949b-291ec8687580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_005fe74b-adbb-4b24-949b-291ec8687580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4bace0cd-6915-4418-93ba-3d3be957b378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4bace0cd-6915-4418-93ba-3d3be957b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3b2fe236-dcc0-4e3d-882c-9b4a3262eda2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3b2fe236-dcc0-4e3d-882c-9b4a3262eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_619fa0eb-3a30-41c4-9259-3b956e3c3c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b140ae-1467-4051-a141-d63a0f823b68" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_619fa0eb-3a30-41c4-9259-3b956e3c3c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13c5d71e-15c0-485c-93a2-ac3821513764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_82ef3c7c-9bdc-4fa1-9cfd-48c69d8eb063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13c5d71e-15c0-485c-93a2-ac3821513764" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_82ef3c7c-9bdc-4fa1-9cfd-48c69d8eb063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4b6d87d1-5db7-4386-8b44-1a8c25a41700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13c5d71e-15c0-485c-93a2-ac3821513764" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4b6d87d1-5db7-4386-8b44-1a8c25a41700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount_ae0d4890-6bdf-4dc4-979b-e9bb194aec34" xlink:href="csbr-20220430.xsd#csbr_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13c5d71e-15c0-485c-93a2-ac3821513764" xlink:to="loc_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount_ae0d4890-6bdf-4dc4-979b-e9bb194aec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cef92648-40c8-4335-a1f7-b2b457ef3e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13c5d71e-15c0-485c-93a2-ac3821513764" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cef92648-40c8-4335-a1f7-b2b457ef3e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2af2549-bf80-4ca4-a300-d260392e40cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2af2549-bf80-4ca4-a300-d260392e40cd" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c6a3cd6c-875a-4c5f-bada-4039f6b30044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c6a3cd6c-875a-4c5f-bada-4039f6b30044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2247ebf4-86c3-43f5-b36e-2f139106632e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2247ebf4-86c3-43f5-b36e-2f139106632e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_431c5458-26e2-483c-aaca-5b7e44aadbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_431c5458-26e2-483c-aaca-5b7e44aadbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9db4e758-c392-45ba-b994-56760a5d885a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9db4e758-c392-45ba-b994-56760a5d885a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7a9c8001-b666-4119-a768-b4398fac642b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1c6b634-579c-42d2-98a5-2d2e99315eb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7a9c8001-b666-4119-a768-b4398fac642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShare" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70546c89-6b8d-47f1-b9cf-f8c4d052a0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5806f00b-8f10-4e11-9545-9be5ecfcf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70546c89-6b8d-47f1-b9cf-f8c4d052a0c6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5806f00b-8f10-4e11-9545-9be5ecfcf1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3901889b-428b-4a58-a262-0dbd26b3d837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_878884e8-f133-4bf9-98bb-8f2ee9cdf963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3901889b-428b-4a58-a262-0dbd26b3d837" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_878884e8-f133-4bf9-98bb-8f2ee9cdf963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4c75c877-cf98-4259-aee7-e346360817c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3901889b-428b-4a58-a262-0dbd26b3d837" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4c75c877-cf98-4259-aee7-e346360817c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0fd4b12-0de6-4ef6-a62c-5372ca49d839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_356426c1-9bd7-41d1-bd17-b278444013d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0fd4b12-0de6-4ef6-a62c-5372ca49d839" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_356426c1-9bd7-41d1-bd17-b278444013d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f717c66-67ad-4ad2-a0be-944654891e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_356426c1-9bd7-41d1-bd17-b278444013d6" xlink:to="loc_us-gaap_NetIncomeLoss_8f717c66-67ad-4ad2-a0be-944654891e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_61d79f67-39f4-461d-8f2a-f96d3a04de77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_356426c1-9bd7-41d1-bd17-b278444013d6" xlink:to="loc_us-gaap_EarningsPerShareBasic_61d79f67-39f4-461d-8f2a-f96d3a04de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0fd4b12-0de6-4ef6-a62c-5372ca49d839" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87ba645b-12ff-4831-8efb-3db193192a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87ba645b-12ff-4831-8efb-3db193192a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef29f8e7-759c-48f8-866a-bcbe6d881566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef29f8e7-759c-48f8-866a-bcbe6d881566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_b8c7b4f5-6079-4392-8e5f-f31ee4ed015e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_b8c7b4f5-6079-4392-8e5f-f31ee4ed015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ca1d579-911b-48b5-b0ab-7e443e6ca416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ca1d579-911b-48b5-b0ab-7e443e6ca416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2638a012-c489-4611-9115-34f76c9fd701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_94ff0774-056e-472a-9697-c2cc071e4aaa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2638a012-c489-4611-9115-34f76c9fd701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cf16a8c-1259-4535-8f77-9b5016437b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cf16a8c-1259-4535-8f77-9b5016437b0c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6068c378-af2d-4173-9677-b5cf27833519" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_02e744a6-01cd-47ea-9c6e-62231e1d0a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ec38d48-a145-4d2d-95a7-b6b4acea3329" xlink:to="loc_us-gaap_EmployeeStockOptionMember_02e744a6-01cd-47ea-9c6e-62231e1d0a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7710a800-f73b-47d4-9203-743e30ff98d5" xlink:to="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74d22d7e-6574-483b-aebb-80caa94f1244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_22853c51-9d96-40f5-b862-a24a9afcbc35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74d22d7e-6574-483b-aebb-80caa94f1244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="csbr-20220430.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f735821e-b56b-412d-9c48-bc9a3b6f6945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c8d729d0-1bc1-4047-913a-e263eacf56cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f735821e-b56b-412d-9c48-bc9a3b6f6945" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c8d729d0-1bc1-4047-913a-e263eacf56cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_82dc0e04-924d-4de4-b23f-d37a83769cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_82dc0e04-924d-4de4-b23f-d37a83769cfe" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:to="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a2f9b59f-2b0b-431b-bc8f-fc9ebebad77b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberOneMember_c11d5e4a-cd6d-471c-b455-f50fe06daea2" xlink:href="csbr-20220430.xsd#csbr_BoardMemberOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:to="loc_csbr_BoardMemberOneMember_c11d5e4a-cd6d-471c-b455-f50fe06daea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_BoardMemberTwoMember_fae1418f-ddc1-402d-9c91-4f6faf760805" xlink:href="csbr-20220430.xsd#csbr_BoardMemberTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32f0cfcc-d0b1-47bd-b497-4ffd290aa583" xlink:to="loc_csbr_BoardMemberTwoMember_fae1418f-ddc1-402d-9c91-4f6faf760805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:to="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0ca7015f-05fa-4880-aefa-8a3e242d0091" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_429a3ddd-d0ce-4de6-9779-2e0c444e41cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ef6c4ec-f8a6-4fb2-80f3-54232cfd0e15" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_429a3ddd-d0ce-4de6-9779-2e0c444e41cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_576f5ae2-c18f-4f2a-831f-ecf02e01ee06" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_01f87a86-4bd4-4af3-9a28-43b1adba4845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_49abfe1b-505e-4414-86f8-f16ac35ea9c4" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_01f87a86-4bd4-4af3-9a28-43b1adba4845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/Leases" xlink:type="simple" xlink:href="csbr-20220430.xsd#Leases"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_407aa09a-c76a-49f9-9f14-d2a406248d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_f27e7fa6-8a21-4a29-a822-7ba311289b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_407aa09a-c76a-49f9-9f14-d2a406248d71" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_f27e7fa6-8a21-4a29-a822-7ba311289b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_57e6fdaf-dde0-4d9b-a2d2-323727096caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_AssetsAndLiabilitiesLesseeTableTextBlock_a58b1df0-2239-42c4-a76c-7b7b663f0aaa" xlink:href="csbr-20220430.xsd#csbr_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57e6fdaf-dde0-4d9b-a2d2-323727096caa" xlink:to="loc_csbr_AssetsAndLiabilitiesLesseeTableTextBlock_a58b1df0-2239-42c4-a76c-7b7b663f0aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c0c0c8de-fe58-40ef-b355-7af9d3ab41a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57e6fdaf-dde0-4d9b-a2d2-323727096caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c0c0c8de-fe58-40ef-b355-7af9d3ab41a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cfcb61b0-cd4b-43b8-baea-d3ef9f7d198b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfcb61b0-cd4b-43b8-baea-d3ef9f7d198b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a6f6b1a-ade7-4b37-836f-064b94ddc71b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_CorporateHeadquartersMember_afb7d5a8-9e03-456f-8671-9f247e5af10d" xlink:href="csbr-20220430.xsd#csbr_CorporateHeadquartersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_CorporateHeadquartersMember_afb7d5a8-9e03-456f-8671-9f247e5af10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDMember_323d30e1-a677-4873-aa56-381686d42f07" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_RockvilleMDMember_323d30e1-a677-4873-aa56-381686d42f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_RockvilleMDNewLocationMember_c1e84433-72ab-4ac9-8d6f-4da64423ccd4" xlink:href="csbr-20220430.xsd#csbr_RockvilleMDNewLocationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_RockvilleMDNewLocationMember_c1e84433-72ab-4ac9-8d6f-4da64423ccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_MilanItalyMember_70b5606e-44ec-418b-b459-e37e971c782c" xlink:href="csbr-20220430.xsd#csbr_MilanItalyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0dde77f7-1259-49c3-9a08-01e53a390825" xlink:to="loc_csbr_MilanItalyMember_70b5606e-44ec-418b-b459-e37e971c782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_bc1bbcda-dbac-4d3d-9dde-d417a2e64a2b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_82a8cbab-1b9c-412d-9d91-44decd472f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseExpense_82a8cbab-1b9c-412d-9d91-44decd472f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_078d5f1b-f715-4efd-9084-eb79d92c649e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_078d5f1b-f715-4efd-9084-eb79d92c649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2bafe0c-0b70-4629-94ef-06f011403631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2bafe0c-0b70-4629-94ef-06f011403631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e9e025d4-9a5d-41fb-a596-e1dbaa4ef43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseLiability_e9e025d4-9a5d-41fb-a596-e1dbaa4ef43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_csbr_OperatingLeaseIncrementalRentExpense_f9025c30-0a1c-4136-a1ae-b957a1d1a70e" xlink:href="csbr-20220430.xsd#csbr_OperatingLeaseIncrementalRentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_csbr_OperatingLeaseIncrementalRentExpense_f9025c30-0a1c-4136-a1ae-b957a1d1a70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1c78538b-5923-4147-adf1-7f94947294e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1c78538b-5923-4147-adf1-7f94947294e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c611cf0-24d0-4851-9aaa-92f510f79e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c611cf0-24d0-4851-9aaa-92f510f79e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_402c257e-95ea-4456-879f-cb978dbf3eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_08d1d1d3-b8c2-49a4-a5b0-52351aa7d583" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_402c257e-95ea-4456-879f-cb978dbf3eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesROUAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e3490346-370e-4c0c-b1c1-ec83b1191af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2e4036c-f906-4049-a71e-1ebc14c19073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3490346-370e-4c0c-b1c1-ec83b1191af4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2e4036c-f906-4049-a71e-1ebc14c19073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a94adfed-1606-4426-9b8a-65f1e41a8191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3490346-370e-4c0c-b1c1-ec83b1191af4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a94adfed-1606-4426-9b8a-65f1e41a8191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6480f23-378b-4ed5-b65d-79dc98f9d442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3490346-370e-4c0c-b1c1-ec83b1191af4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6480f23-378b-4ed5-b65d-79dc98f9d442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aee15798-955a-467b-af8c-3b80e8f955ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aee15798-955a-467b-af8c-3b80e8f955ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2a22642d-a9f8-4dd5-b9f2-b8f71c2d429d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2a22642d-a9f8-4dd5-b9f2-b8f71c2d429d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_03408a86-5ea5-40fe-b7fc-b53fc4576b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_03408a86-5ea5-40fe-b7fc-b53fc4576b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_65058611-01a4-4b4b-bd04-f113303dffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_65058611-01a4-4b4b-bd04-f113303dffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ce7057c5-89ee-4735-b6eb-0d7ee78bf9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ce7057c5-89ee-4735-b6eb-0d7ee78bf9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0927063c-6b7d-407c-9189-1e82745bee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0927063c-6b7d-407c-9189-1e82745bee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_82b154fc-e67a-4724-8c78-3f8f23a9fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_82b154fc-e67a-4724-8c78-3f8f23a9fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f4301e6-2114-4cce-9670-aec39b2d8bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f4301e6-2114-4cce-9670-aec39b2d8bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c865ccb5-34d2-4ba3-a17f-db4cfd9fe662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c865ccb5-34d2-4ba3-a17f-db4cfd9fe662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_87f7222d-166e-4d04-9e00-5571b56ffbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97700808-059b-4eab-9ce8-6eb36b70d00c" xlink:to="loc_us-gaap_OperatingLeaseLiability_87f7222d-166e-4d04-9e00-5571b56ffbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="csbr-20220430.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947549648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jul. 20, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--04-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHAMPIONS ONCOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-1401755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One University Plaza, Suite 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">808-8400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CSBR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,522,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, are incorporated by reference into Part III of this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000771856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946737520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947700960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 9,007<span></span>
</td>
<td class="nump">$ 4,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,513<span></span>
</td>
<td class="nump">6,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,664<span></span>
</td>
<td class="nump">12,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">8,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">7,134<span></span>
</td>
<td class="nump">6,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long term assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">35,378<span></span>
</td>
<td class="nump">27,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,868<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,414<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">11,071<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,479<span></span>
</td>
<td class="nump">11,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion operating lease liabilities</a></td>
<td class="nump">8,412<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,282<span></span>
</td>
<td class="nump">20,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 200,000,000 shares authorized; 13,522,441 and 13,414,066 shares issued and outstanding at April 30, 2022 and 2021, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">81,064<span></span>
</td>
<td class="nump">79,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(71,982)<span></span>
</td>
<td class="num">(72,530)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">7,428<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 35,378<span></span>
</td>
<td class="nump">$ 27,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946772448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">13,522,441<span></span>
</td>
<td class="nump">13,414,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">13,522,441<span></span>
</td>
<td class="nump">13,414,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947628848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Oncology services revenue</a></td>
<td class="nump">$ 49,109<span></span>
</td>
<td class="nump">$ 41,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of oncology services</a></td>
<td class="nump">23,632<span></span>
</td>
<td class="nump">21,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,374<span></span>
</td>
<td class="nump">7,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">6,379<span></span>
</td>
<td class="nump">5,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,117<span></span>
</td>
<td class="nump">6,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">48,502<span></span>
</td>
<td class="nump">40,674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_BasicAndDilutedEarningsPerShareAbstract', window );"><strong>Net income per common share outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per common share outstanding, basic (in usd per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per common share outstanding, diluted (in usd per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic (in shares)</a></td>
<td class="nump">13,197,170<span></span>
</td>
<td class="nump">13,138,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted (in shares)</a></td>
<td class="nump">14,159,799<span></span>
</td>
<td class="nump">14,573,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_BasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted, Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_BasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted, Other Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947298192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Apr. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,726,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Apr. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2020</a></td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 77,978<span></span>
</td>
<td class="num">$ (72,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock on exercise of stock options</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Apr. 30, 2021</a></td>
<td class="nump">13,414,066<span></span>
</td>
<td class="nump">13,414,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Apr. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2021</a></td>
<td class="nump">$ 7,428<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">79,945<span></span>
</td>
<td class="num">(72,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock on exercise of stock options</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Apr. 30, 2022</a></td>
<td class="nump">13,522,441<span></span>
</td>
<td class="nump">13,522,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares) at Apr. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2022</a></td>
<td class="nump">$ 9,096<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81,064<span></span>
</td>
<td class="num">$ (71,982)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947164336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by&#160;(used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net gain on disposal of equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,818)<span></span>
</td>
<td class="num">(2,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">974<span></span>
</td>
<td class="num">(1,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">183<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(631)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">4,815<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="num">(1,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,384)<span></span>
</td>
<td class="num">(3,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ProceedsFromRefundOfSecurityDeposit', window );">Refund of security deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,384)<span></span>
</td>
<td class="num">(3,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ProceedsFromExerciseOfOptionsAndWarrants', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="num">(3,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">8,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">9,007<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 6,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ProceedsFromExerciseOfOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ProceedsFromExerciseOfOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ProceedsFromRefundOfSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Refund Of Security Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ProceedsFromRefundOfSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949508208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Champions Oncology, Inc. (the &#8220;Company&#8221;), is engaged in drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms.  The Company&#8217;s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. Utilizing the TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, the Company offers multiple services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform is designed to facilitate drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited, and Champions Oncology S.R.L. For the years ended April&#160;30, 2022 and 2021, there were no revenues earned by these subsidiaries.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company operates in one reportable business segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949499248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations. Foreign currency balances are translated at each month end to US dollars, and any resulting gain or loss is recognized in our results of operations, as the amounts are not material.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.   Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions.&#160; We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents. As of&#160;April 30, 2022&#160;and 2021 the Company had cash balances of $9.0&#160;million and $4.7&#160;million, respectively, and no cash equivalents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash on hand, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services.  For the year ended April&#160;30, 2022, the Company had net income of approximately $548,000, an accumulated deficit of approximately $72.0 million, working capital of $2.2 million and cash of $9.0 million. We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least August 2023. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, accounts receivable, prepaid expenses, and other current assets, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted market prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than level one inputs that are either directly or indirectly observable; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has no assets or liabilities that are measured at fair value on a recurring and/or non-recurring  during the years ended April&#160;30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, computer hardware and software, and internally developed software. Assets in progress include equipment or software not yet placed in service. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870">three</span> to seven years. Refer to Footnote 4, "Property and Equipment" for a detailed discussion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for its leases under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.&#160;&#160;The Company has not recognized any impairment losses for the Company&#8217;s long-lived assets for the years ending April&#160;30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors, market conditions, or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit&#8217;s carrying amount exceeds its fair value, referred to as a &#8220;step zero&#8221; approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. Under FASB's Accounting Standards Update ("ASU") 2014-02, Topic 350, "Intangibles&#8212;Goodwill and Other" goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairment evaluation test involves comparing the current fair value of each business unit to its carrying value, including goodwill. Fair value is typically estimated using a discounted cash flow analysis, which requires the Company to estimate the future cash flows anticipated to be generated by the business unit being tested for impairment as well as to select a risk-adjusted discount rate to measure the present value of the anticipated cash flows. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. The Company estimates cash flows for the business unit over a discrete period (typically four or five years) and the terminal period (considering expected long term growth rates and trends). Estimating future cash flows requires significant judgment by management in such areas as future economic conditions, industry-specific conditions, product pricing, and necessary capital expenditures. The use of different assumptions or estimates for future cash flows or significant changes in risk-adjusted discount rates due to changes in market conditions could produce substantially different estimates of the fair value of the business unit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reportable segment. The Company assesses goodwill impairment by business unit.  Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the businesses.&#160;&#160;Future events, including but not limited to continued declines in economic activity, loss of contracts or a significant number of customers, or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment indicators exist and that goodwill is impaired.&#160;For the year ended April 30, 2022, the Company's annual assessment did not result in any impairment indicators. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received in advance of products to be delivered or services to be performed.&#160;&#160;When products are delivered and/or services are performed, deferred revenue is recognized as earned.  Deferred revenue is expected to be recognized within one year.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities represent amounts for uncertain tax positions relating to one of our foreign entities and a financing lease of laboratory equipment in exchange for a lab supplies purchasing commitment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Oncology Services</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of oncology services relates primarily to our Translational Oncology Solutions ("TOS") business unit. TOS costs consist of direct costs related to laboratory supplies, mice purchases, and maintenance costs for studies completed internally as well as charges from Contract Research Organization's for studies handled externally. Indirect costs include salaries and other payroll related costs of compensation for personnel directly engaged in providing TOS products and services. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, are expensed when incurred.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs represent both costs incurred internally for research and development activities, including personnel costs, mice purchases, and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses represent costs incurred to promote the Company&#8217;s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company&#8217;s common stock purchase warrants and stock options. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payments</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically recognizes expense for stock-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of stock-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved &#8220;simplified method&#8221; noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. &#160;Estimated volatility is based upon the historical volatility of the Company's common stock.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based payments over the period that the awards are expected to vest.&#160;&#160;In the event of forfeitures, compensation expense is adjusted.&#160;&#160;The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of April&#160;30, 2022 and 2021, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;As of April&#160;30, 2022 and 2021 the Company has recorded $181,000 of liabilities related to uncertain tax positions relative to one of its foreign operations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company accrued $0 and $3,000, for interest and penalties on the Company&#8217;s statement of operations for the years ended April&#160;30, 2022 and 2021, respectively. The Company does not anticipate any significant unrecognized tax benefits to be recorded during the next 12 months.&#160;&#160;For the year ended April 30, 2022 and 2021, the Company recognized a provision for income taxes of $35,000 and $75,000, respectively.  These amounts are mainly attributable to taxable income earned in Israel relating to transfer pricing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers.  The objective of the standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under this standard, companies recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue is generated from contracts with customers. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacology Study and Other Services</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incremental Costs of Obtaining a Contract (Sales Commissions)</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the costs of obtaining a contract can be expensed immediately, rather than capitalized and amortized, if the amortization period is one year or shorter.  Sales commissions for the Company represent contract costs with a term of one year or less.  Therefore, under ASC 606, the Company elected the practical expedient to expense these costs as incurred.&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, Unbilled Services and Deferred Revenue</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise when the revenue recognized exceeds the amount billed to the customer.  Such situations occur due to divergences between revenue recognition and the invoicing milestones which are based on predetermined payment terms.   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Being Evaluated</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses".  This update requires immediate recognition of management&#8217;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#8212; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. We adopted this guidance on May 1, 2021. The adoption of this ASU did not have a material impact is reflected in the Company's current year consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949471968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock', window );">Accounts Receivable, Unbilled Services and Deferred Revenue</a></td>
<td class="text">Accounts Receivable, Unbilled Services and Deferred Revenue<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable and unbilled services were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:71.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and unbilled services</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:71.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,071&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,256&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is shown as a current liability on the Company's balance sheet.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 30, 2020 unbilled services was $2.4&#160;million and deferred revenue was $5.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Unbilled Services And Deferred Revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949578400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb">Property and equipment, net</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense was $1.6&#160;million and $1.2 million for the years ended April&#160;30, 2022 and 2021, respectively.  Depreciation and amortization expense, excluding expense recorded under finance leases, was&#160;$1.5 million and $925,000&#160;for the years ended&#160;April 30, 2022&#160;and&#160;2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of&#160;April 30, 2022&#160;and&#160;2021, property, plant and equipment included gross assets held under finance leases of&#160;$713,000 and $343,000, respectively. Related depreciation expense for these assets was $87,000 and $124,000 for the years ended&#160;April&#160;30, 2022&#160;and&#160;2021.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized software development costs under a hosting arrangement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the cost of computer software obtained or developed for internal use as well as the software development and implementation costs associated with a hosting arrangement ("internal-use software") that is a service contract in accordance and with ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC-350"). We capitalize certain costs in the development of our internal-use software when the preliminary project stage is completed and it is probable that the project itself will be completed and the software will perform as intended. These capitalized costs include personnel and related expenses for employees and costs of third-party consultants who are directly associated with and who devote time to these internal-use software projects. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs incurred for significant upgrades, increased functionality, and enhancements to the Company's internal-use software solutions are also capitalized. Costs incurred for training, maintenance, and minor modifications are expensed as incurred.  Capitalized software development costs are amortized using the straight-line method over an estimated useful economic life of three years.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has capitalized development and implementation costs in accordance with accounting guidance for its Lumin Bioinformatics platform ("Lumin").  Lumin is the Company's new oncology data-driven software program and data tool which is operates as Software as a Service (SaaS).  These capitalized costs represent salaries, including direct payroll-related costs, certain software development consultant expenses and molecular sequencing programming costs incurred in the engineering and coding of the software development.  Capitalized costs are classified as assets in progress during the development process until development is complete and the asset is available for sale. The initial version of the Lumin platform was launched during fiscal year 2021, at which time initial capitalization ceased and amortization commenced. The total Lumin assest placed into service and available for sale as of July 31, 2020 was $484,000.   </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continued to develop increased functionality, expand product design and usability, and add enhancements to the Lumin platform.  In accordance with accounting guidance, these costs were capitalized. This developmental work did not render the initial released version to be obsolete or diminished in value but, rather, added to the base functionality of the existing platform.  During the third quarter of fiscal year 2022, these capitalized costs were placed into </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service as the enhanced version was launched and made available for sale. The total cost of the enhanced Lumin asset placed into service and available for sale as of January 31, 2022 was $1.4&#160;million, bringing the total capitalized gross asset investment to $1.9&#160;million. Amortization expense related to this asset addition was $317,000 and $134,000 for the years ended April 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During fiscal 2020, the Company entered into a finance lease for laboratory equipment. The lease had costs of approximately&#160;$231,000, at inception, through November 2020. This lease expired December 2020. Prior to expiration, the  monthly finance lease payment was approximately&#160;$19,000. The future minimum lease payments remaining under this finance lease at April 30, 2021 and 2020 were zero and&#160;$135,000, respectively. The present value of minimum future obligations was calculated based on interest rate of&#160;4.75%. Depreciation and amortization expense related to this finance lease was zero and $124,000 &#160;for the years ended April 30, 2022 and 2021, respectively.</span></div>During fiscal 2022, the Company recognized a finance lease for laboratory equipment.  This equipment was obtained as the result of a laboratory supplies purchase commitment with costs of approximately $370,000 at inception through December 2025. Cash payments for this lease are in the form of consideration for purchasing lab supplies under a purchase commitment agreement. The present value of the minimum future obligations of $370,000 was calculated based on an interest rate of 3.25%. Depreciation and amortization expense related to this finance lease was $87,000 and zero for the years ended April 30, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949566384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contracts with Customers</a></td>
<td class="text">Revenue from Contracts with Customers<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology Services Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The following table represents disaggregated revenue for the twelve months ended April&#160;30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacology services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other TOS revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personalized oncology services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology services revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers,  specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software. </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div>Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.  Refer to Note 3 for related balances.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949594368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Significant Customers</a></td>
<td class="text">Significant Customers<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended April&#160;30, 2022 and 2021, one and none of our customers accounted for more than 10% of our total revenue, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>As of April&#160;30, 2022, one customer accounted for 17% of our total accounts receivable balance.  As of April 30, 2021, no customers accounted for 10% or more of our total accounts receivable balance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949540624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company&#8217;s financial position or results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Payment Arrangements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company&#8217;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company has not accrued any liquidated damages associated with the Amended and Restated Registration Right Agreement as the Company has filed the required registration statement and anticipates continued compliance with the agreement.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div>The Company contracts with third-party vendors to license tumor samples for development into PDX models and use in our TOS business. These types of arrangements have an upfront fee ranging from approximately nil&#160;to $30,000 per tumor sample depending on the successful growth of the tumor model and ability to develop them into a sellable product. The upfront costs are expensed as incurred. In addition, under certain agreements, for a limited period of time, the Company is subject to royalty payments if the licensed tumor models are used for sale in&#160;our TOS business,&#160;ranging from 2% to 20% of the contract price&#160;after recouping certain initiation costs.  Some of these arrangements also set forth an annual minimum royalty due regardless of tumor models used for sale.   For the years ended April&#160;30, 2022 and 2021, we have recognized approximately $401,000 and  $127,000 in expense related to these royalty arrangements, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949715344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Payments</a></td>
<td class="text">Stock-based Payments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation in the amount of $912,000 and $598,000 was recognized for years ended April&#160;30, 2022 and 2021, respectively.&#160;Stock-based compensation costs were recorded as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOS cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan ("the Plans"). In general, these plans provide for stock-based compensation to the Company&#8217;s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (&#8220;2021 Equity Plan&#8221;). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed 2&#160;million shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair market value of the common stock subject to the option or right at the date of grant.  As of April 30, 2022, approximately 1.8&#160;million shares were left to issue under this plan. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2010 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant.  After February 2021, no more shares were available to be issued from this plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Equity Incentive Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &#8220;2008 Equity Plan&#8221;).&#160;&#160;Such awards may be granted by the Company&#8217;s Board of Directors.&#160;&#160;Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock-based payments to non-employee consultants under the Plans, the fair value of the stock-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.&#160;&#160;The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company&#8217;s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award. After 2018, no more shares were available to be issued from this plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2013, the Compensation Committee of the Board of Directors of the Company adopted changes to the Director Compensation Plan of 2010 (the &#8220;Director Plan&#8221;) effective December 1, 2013.&#160;&#160;Under the Director Plan, independent directors of the Company are entitled to an annual award of a five-year option to purchase 8,333 shares of the Company&#8217;s common stock, and the Chairman of the Board of the Company is entitled to an annual award of a five-year option to purchase 16,667 shares of the Company&#8217;s common stock.&#160;&#160;Independent directors who serve as chairperson of a committee will also receive an annual grant of a five-year option to purchase 1,667 shares of the Company&#8217;s common stock. All options issued under the Director Plan vest quarterly at a rate of 25%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in October of each year. New directors will receive a grant upon joining the Board equal to the pro-rata annual grant for the remainder of the year.&#160;Options issued under the Director Plan are now issued pursuant to the 2021 Equity Plan.&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April&#160;30, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.2%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 0.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64% - 66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted during the years ending April&#160;30, 2022 and 2021, was $5.56 and $5.11, respectively. The Company&#8217;s stock options activity and related information as of and for the years ended April&#160;30, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,778,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,663,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,000&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,995,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949572544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text">Provision for Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the Company&#8217;s effective tax rate and the United States statutory tax rate for the years ended April&#160;30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US vs. foreign tax rate difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&#160;&#160;Significant components of the Company&#8217;s deferred tax assets and liabilities as of April&#160;30, 2022 and 2021 consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use, net asset/liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.730%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense; class life changes to qualified improvements (in general, from 39 years to 15 years); and the ability to carry back net operating losses incurred from tax years 2018 through 2020 up to the five preceding tax years. The Company has evaluated the new tax provisions of the CARES Act and determined the impact to be either immaterial or not applicable. </span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the available evidence about future tax planning strategies, taxable income, and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of&#160;April&#160;30, 2022&#160;and&#160;2021.&#160;&#160;For the years ended&#160;April&#160;30, 2022&#160;and&#160;2021, the Company recorded a valuation allowance of&#160;$15.5&#160;million and $15.3&#160;million, respectively.&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;April&#160;30, 2022&#160;and&#160;2021, the Company&#8217;s estimated U.S. net operating loss carry-forwards were approximately $48.0&#160;million and&#160;$46.9&#160;million, respectively. Net operating losses generated prior to May 1, 2018 have a 20-year carryforward and will begin expiring in&#160;2025&#160;for federal and&#160;2031&#160;for state purposes. Losses generated in the fiscal years since the year ended April 30, 2019 may be carried forward indefinitely.&#160;&#160;A valuation allowance has been recorded against all of these loss carryforwards.</span></div><div style="text-align:justify;text-indent:33.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership may result in a limitation on the amount of net operating losses that may be utilized in future years. During the fiscal year ended April 30, 2013, approximately&#160;$12.0 million&#160;of the Company&#8217;s net operating losses became subject to limitation under Internal Revenue Code Section 382 in connection with an ownership change on January 28, 2013. As a result of the ownership change, the Company&#8217;s annual limitation on its use of net operating loss carry-forwards is approximately&#160;$432,000.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company files income tax returns in various jurisdictions with varying statutes of limitations.&#160;&#160;As of&#160;April&#160;30, 2022, the earliest tax year still subject to examination for state purposes is fiscal 2018.&#160;&#160;The Company&#8217;s tax years for periods ending April 30, 2002 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the changes to the Company&#8217;s uncertain tax positions for the period and years ended April&#160;30, 2022 and 2021 in thousands:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment made on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;30, 2022 and 2021, the above amounts of $181,000  for each fiscal year were included in other long-term liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949570112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per ShareA reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net income per share computation (dollars in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,138,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per share computation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,138,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental shares from assumed exercise of warrants and stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average share &#8211; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,159,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,573,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total potential stock-based instruments outstanding at April&#160;30, 2022 and 2021 that could have an effect on the future computation of dilution per common share.  These figures were not included in the above calculation as, to do so, would be antidilutive:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949598848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions include transactions between the Company and its shareholders, management, or affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both years ended April&#160;30, 2022 and 2021, the Company paid a member of its Board of Directors $36,000 and $54,000 for consulting services unrelated to his duties as a board member.  During the years ended April&#160;30, 2022 and 2021, the Company paid another board member $17,000 and $5,500, respectively, for consulting services unrelated to his duties as a board member.  All of the amounts paid to these related parties have been recognized in expense in the period the services were performed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949570112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company accounts for its leases under ASC 842.&#160;Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both an operating lease ROU asset and operating lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company has elected to apply the short-term lease exemption practical expedient for each class of underlying assets and excludes short-term leases having initial terms of 12 months or less. The Company recognizes rent <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense on a straight-line basis over the lease term for these short-term leases. The Company has determined that no material embedded leases exist. Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.9 million and $1.3 million for the years ended April&#160;30, 2022 and 2021, respectively. </span></div><div style="text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases the following facilities:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company&#8217;s corporate headquarters. The lease was renewed during fiscal 2022 and expires in November 2026. The Company recognized $88,000 and $91,000 of rent expense relative to this lease for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease (the "Original Premises") on January 11, 2017. The operating commencement date was August 11, 2017. This lease originally expired in August 2028.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by six months. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In accordance with ASC 842, the Company evaluated the first amendment and also performed a reassessment of the existing lease for Suite 025 to determine the impact of the six-month term extension. As a result of this assessment, the Company recognized an additional operating ROU asset and related operating lease liability for Suite 025 of $118,000 and $125,000, respectively, as well as an incremental net rent expense of $8,000 during the three months ended July 31, 2020. The Company did not recognize the incremental rental expense under this amendment during fiscal 2020 as the Expansion Premises lease commencement date was during fiscal 2021.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $3.8&#160;million, each, respectively.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">On December 22, 2020, the Company executed the second amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suites 025, 050, and 104 ("Additional Expansion Premises") and add on Suite 201. The Additional Expansion Premises operating lease commencement date was April 1, 2021 and, under the second amendment, reaffirms that all three leases expire February 28, 2029. Upon the Additional Expansion Premises operating lease commencement date (April 1, 2021), the Company also recognized an operating ROU asset and related operating lease liability for Suite 201 of $3.3&#160;million, each, respectively. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">For the leases related to the premises at Piccard Drive, the Company recognized $1.7&#160;million and $1.2&#160;million of rental expense for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1405 Research Boulevard, Suite 125, Rockville, Maryland 20850 (&#8220;New Location&#8221;), which consisted of laboratory and office space where the Company conducted operations related to its primary service offerings. The Company executed this lease on November&#160;1, 2018. The operating commencement date was January&#160;17, 2019. This lease was set to expire in&#160;April 2024. The Company terminated this lease on June 30, 2020 and transitioned its activities from this location to the Expansion Premises, as defined above, during the first quarter of fiscal 2021. Upon lease termination, the Company recognized a decrease in the related operating ROU asset and operating lease liability of approximately $850,000 and $926,000, respectively, as well as a gain on lease termination of $76,000.  The Company recognized zero&#160;and&#160;$43,000&#160;of rental expense for fiscal 2022 and 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed the lease for its laboratory space in June 2021, and commenced occupancy during the three months ended October 31, 2021. This lease expires May 2023. The Company executed the lease for its office space on October 1, 2021. This lease expires September 2027. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Company recognized an operating ROU asset and related operating lease liability for the lab and office space of $205,000 each, respectively.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Company recognized rental costs associated with these leases of $81,000 and zero for fiscal 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:48.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net<br/></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities<br/></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 30, 2022, the weighted average remaining operating lease term and the weighted average discount rate were&#160;6.7 years and&#160;5.73%, respectively.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments due each fiscal year as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:74.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total undiscounted liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, Property and Equipment, for more information on financing leases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947417536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company operates in one reportable business segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#8217;s international operations. Foreign currency balances are translated at each month end to US dollars, and any resulting gain or loss is recognized in our results of operations, as the amounts are not material.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.   Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions.&#160; We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></div>The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, accounts receivable, prepaid expenses, and other current assets, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted market prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than level one inputs that are either directly or indirectly observable; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</span></div>Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, computer hardware and software, and internally developed software. Assets in progress include equipment or software not yet placed in service. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870">three</span> to seven years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases The Company accounts for its leases under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors, market conditions, or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit&#8217;s carrying amount exceeds its fair value, referred to as a &#8220;step zero&#8221; approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. Under FASB's Accounting Standards Update ("ASU") 2014-02, Topic 350, "Intangibles&#8212;Goodwill and Other" goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairment evaluation test involves comparing the current fair value of each business unit to its carrying value, including goodwill. Fair value is typically estimated using a discounted cash flow analysis, which requires the Company to estimate the future cash flows anticipated to be generated by the business unit being tested for impairment as well as to select a risk-adjusted discount rate to measure the present value of the anticipated cash flows. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. The Company estimates cash flows for the business unit over a discrete period (typically four or five years) and the terminal period (considering expected long term growth rates and trends). Estimating future cash flows requires significant judgment by management in such areas as future economic conditions, industry-specific conditions, product pricing, and necessary capital expenditures. The use of different assumptions or estimates for future cash flows or significant changes in risk-adjusted discount rates due to changes in market conditions could produce substantially different estimates of the fair value of the business unit.</span></div>The Company has one reportable segment. The Company assesses goodwill impairment by business unit.  Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the businesses.&#160;&#160;Future events, including but not limited to continued declines in economic activity, loss of contracts or a significant number of customers, or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment indicators exist and that goodwill is impaired.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue and Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received in advance of products to be delivered or services to be performed.&#160;&#160;When products are delivered and/or services are performed, deferred revenue is recognized as earned.  Deferred revenue is expected to be recognized within one year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers.  The objective of the standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under this standard, companies recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue is generated from contracts with customers. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacology Study and Other Services</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incremental Costs of Obtaining a Contract (Sales Commissions)</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the costs of obtaining a contract can be expensed immediately, rather than capitalized and amortized, if the amortization period is one year or shorter.  Sales commissions for the Company represent contract costs with a term of one year or less.  Therefore, under ASC 606, the Company elected the practical expedient to expense these costs as incurred.&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, Unbilled Services and Deferred Revenue</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise when the revenue recognized exceeds the amount billed to the customer.  Such situations occur due to divergences between revenue recognition and the invoicing milestones which are based on predetermined payment terms.   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock', window );">Other Non-Current Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities represent amounts for uncertain tax positions relating to one of our foreign entities and a financing lease of laboratory equipment in exchange for a lab supplies purchasing commitment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Oncology Services</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Oncology Services</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of oncology services relates primarily to our Translational Oncology Solutions ("TOS") business unit. TOS costs consist of direct costs related to laboratory supplies, mice purchases, and maintenance costs for studies completed internally as well as charges from Contract Research Organization's for studies handled externally. Indirect costs include salaries and other payroll related costs of compensation for personnel directly engaged in providing TOS products and services. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, are expensed when incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Research and development costs represent both costs incurred internally for research and development activities, including personnel costs, mice purchases, and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock', window );">Sales and Marketing</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses represent costs incurred to promote the Company&#8217;s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company&#8217;s common stock purchase warrants and stock options.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payments</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically recognizes expense for stock-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of stock-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved &#8220;simplified method&#8221; noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. &#160;Estimated volatility is based upon the historical volatility of the Company's common stock.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based payments over the period that the awards are expected to vest.&#160;&#160;In the event of forfeitures, compensation expense is adjusted.&#160;&#160;The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of April&#160;30, 2022 and 2021, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;As of April&#160;30, 2022 and 2021 the Company has recorded $181,000 of liabilities related to uncertain tax positions relative to one of its foreign operations.</span></div>The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Being Evaluated and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Being Evaluated</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses".  This update requires immediate recognition of management&#8217;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#8212; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. We adopted this guidance on May 1, 2021. The adoption of this ASU did not have a material impact is reflected in the Company's current year consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_OtherNoncurrentLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Non-current Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_OtherNoncurrentLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_SalesAndMarketingExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales And Marketing Expense, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_SalesAndMarketingExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946769664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of accounts receivable, unbilled services, and advanced billings</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable and unbilled services were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:71.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and unbilled services</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of advanced billings</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:71.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,071&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,256&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949598848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb">Property and equipment, net</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949790480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table represents disaggregated revenue for the twelve months ended April&#160;30, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacology services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other TOS revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personalized oncology services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology services revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table> Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers,  specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949245952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Stock-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text">Stock-based compensation costs were recorded as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOS cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan ("the Plans"). In general, these plans provide for stock-based compensation to the Company&#8217;s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April&#160;30, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.2%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 0.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64% - 66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock-based Compensation, Stock Options, Activity</a></td>
<td class="text">The Company&#8217;s stock options activity and related information as of and for the years ended April&#160;30, 2022 and 2021 is as follows:<div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,778,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors<br/>and<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-<br/>Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, May 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,663,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,000&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of April 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,995,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946749360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text">The components of the provision for income taxes are as follows (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the Company&#8217;s effective tax rate and the United States statutory tax rate for the years ended April&#160;30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US vs. foreign tax rate difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in uncertain tax position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities as of April&#160;30, 2022 and 2021 consist of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use, net asset/liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the changes to the Company&#8217;s uncertain tax positions for the period and years ended April&#160;30, 2022 and 2021 in thousands:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment made on tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949591856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">A reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net income per share computation (dollars in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,138,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per share computation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,138,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental shares from assumed exercise of warrants and stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average share &#8211; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,159,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,573,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total potential stock-based instruments outstanding at April&#160;30, 2022 and 2021 that could have an effect on the future computation of dilution per common share.  These figures were not included in the above calculation as, to do so, would be antidilutive:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended April 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947653840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets and Liabilities</a></td>
<td class="text">ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):<div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:48.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net<br/></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities<br/></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Operating Lease Payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments due each fiscal year as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:74.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total undiscounted liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949563152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>segment </div>
<div>subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_NumberofOperatingSubsidiaries', window );">Number of operating subsidiaries | subsidiary</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_NumberofOperatingSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_NumberofOperatingSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010942747024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 9,007,000<span></span>
</td>
<td class="nump">$ 4,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">548,000<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">71,982,000<span></span>
</td>
<td class="nump">72,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_WorkingCapital', window );">Working capital</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit) from income tax</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947577792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details) - Few Contracts - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-05-01<br></strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=csbr_FewContractsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue arrangements by service contract period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=csbr_FewContractsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue arrangements by service contract period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=csbr_FewContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=csbr_FewContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-05-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-05-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946197776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_TradeAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="nump">$ 4,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled services</a></td>
<td class="nump">4,106<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Total accounts receivable and unbilled services</a></td>
<td class="nump">10,143<span></span>
</td>
<td class="nump">7,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 9,513<span></span>
</td>
<td class="nump">$ 6,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_TradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_TradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949749552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 11,071<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946180800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled services</a></td>
<td class="nump">$ 4,106<span></span>
</td>
<td class="nump">$ 3,020<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 11,071<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010943575184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 12,711<span></span>
</td>
<td class="nump">$ 10,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(5,577)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 7,134<span></span>
</td>
<td class="nump">$ 6,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">8,618<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010943243296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Finance lease, depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets under finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713,000<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,711,000<span></span>
</td>
<td class="nump">10,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmount', window );">Servicing asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAsset', window );">Servicing asset at gross capitalized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization', window );">Hosting arrangement, amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_FinanceLeaseAxis=csbr_A2020FinanceLeaseMember', window );">2020 Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_FinanceLeaseCost', window );">Finance lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_FinanceLeaseMonthlyPayment', window );">Finance leases monthly payments</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance lease, payment, due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_PresentValueMinimumFutureObligationsInterestRate', window );">Present value of minimum future obligations interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease, depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_FinanceLeaseAxis=csbr_A2022FinanceLeaseMember', window );">2022 Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_FinanceLeaseCost', window );">Finance lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_PresentValueMinimumFutureObligationsInterestRate', window );">Present value of minimum future obligations interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease, depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=csbr_FinanceLeasedAssetsMember', window );">Finance Leased Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,888,000<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="nump">$ 1,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_FinanceLeaseMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Monthly Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_FinanceLeaseMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_PresentValueMinimumFutureObligationsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present Value Minimum Future Obligations Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_PresentValueMinimumFutureObligationsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for capitalized implementation cost from hosting arrangement that is service contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=118198657&amp;loc=SL118198666-228104<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of servicing assets that are subsequently measured at fair value and servicing assets that are subsequently measured using the amortization method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6469459&amp;loc=d3e122501-111745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of an asset representing net future revenue from contractually specified servicing fees, late charges, and other ancillary revenues, in excess of future costs related to servicing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6469459&amp;loc=d3e122501-111745<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6469459&amp;loc=d3e122492-111745<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128311188&amp;loc=d3e122625-111746<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6469459&amp;loc=d3e122501-111745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_FinanceLeaseAxis=csbr_A2020FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_FinanceLeaseAxis=csbr_A2020FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_FinanceLeaseAxis=csbr_A2022FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_FinanceLeaseAxis=csbr_A2022FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=csbr_FinanceLeasedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=csbr_FinanceLeasedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947613264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total oncology services revenue</a></td>
<td class="nump">$ 49,109<span></span>
</td>
<td class="nump">$ 41,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=csbr_PharmacologyServicesMember', window );">Pharmacology services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total oncology services revenue</a></td>
<td class="nump">46,833<span></span>
</td>
<td class="nump">39,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=csbr_OtherServicesMember', window );">Other TOS revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total oncology services revenue</a></td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=csbr_PersonalizedOncologyServicesMember', window );">Personalized oncology services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total oncology services revenue</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=csbr_PharmacologyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=csbr_PharmacologyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=csbr_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=csbr_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=csbr_PersonalizedOncologyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=csbr_PersonalizedOncologyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949650208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=csbr_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=csbr_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947200688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CollaborationArrangementRoyaltyFee', window );">Royalty fee per tumor sample</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice', window );">Royalty payment, as percent of contract price</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CollaborationArrangementRoyaltyFee', window );">Royalty fee per tumor sample</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice', window );">Royalty payment, as percent of contract price</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CollaborationArrangementRoyaltyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement Royalty Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_CollaborationArrangementRoyaltyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Royalty Fee, Percent Of Contract Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947881968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2013</div></th>
<th class="th"><div>Feb. 18, 2011</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 912<span></span>
</td>
<td class="nump">$ 598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockOptionsAwardSharesToPurchaseCommonStock', window );">Stock options award shares to purchase common stock (in shares)</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="nump">$ 5.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2021Member', window );">Equity Incentive Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Strike price as percent of market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2010Member', window );">Equity Incentive Plan 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Strike price as percent of market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2010Member', window );">Equity Incentive Plan 2010 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_DirectorCompensationPlanMember', window );">Director Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockOptionsAwardSharesToPurchaseCommonStock', window );">Stock options award shares to purchase common stock (in shares)</a></td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock', window );">Stock option award shares to purchase unregistered common stock (in shares)</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Vested percent</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=csbr_DirectorCompensationPlanMember', window );">Director Compensation Plan | Board of Directors Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase', window );">Term of option to purchase</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock vested for share based compensation arrangement by share based payment award options during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Term of Option to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_StockOptionsAwardSharesToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares to purchase common stock option awards during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_StockOptionsAwardSharesToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares to purchase of unregistered common stock option awards during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=csbr_EquityIncentivePlan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=csbr_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=csbr_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=csbr_DirectorCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=csbr_DirectorCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947493312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments - Allocation of Stock-based Compensation Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 912<span></span>
</td>
<td class="nump">$ 598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=csbr_TranslationalOncologySolutionsCostOfSalesMember', window );">TOS cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=csbr_TranslationalOncologySolutionsCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=csbr_TranslationalOncologySolutionsCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947495792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments - Stock Option Grants Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rates Minimum</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rates Maximum</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility Minimum</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility Maximum</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010943294976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Payments - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">1,653,646<span></span>
</td>
<td class="nump">2,271,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">166,052<span></span>
</td>
<td class="nump">135,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(108,375)<span></span>
</td>
<td class="num">(687,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(11,209)<span></span>
</td>
<td class="num">(48,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(36,875)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(5,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">1,658,239<span></span>
</td>
<td class="nump">1,653,646<span></span>
</td>
<td class="nump">2,271,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">1,658,239<span></span>
</td>
<td class="nump">1,653,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested (in shares)</a></td>
<td class="nump">1,354,479<span></span>
</td>
<td class="nump">1,332,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in usd per share)</a></td>
<td class="nump">9.44<span></span>
</td>
<td class="nump">9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised (in usd per share)</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="nump">2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Canceled (in usd per share)</a></td>
<td class="nump">4.71<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited (in usd per share)</a></td>
<td class="nump">7.45<span></span>
</td>
<td class="nump">7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired (in usd per share)</a></td>
<td class="nump">9.60<span></span>
</td>
<td class="nump">10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">4.51<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest (in usd per share)</a></td>
<td class="nump">4.51<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested (in usd per share)</a></td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Granted</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Vested</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 11,384<span></span>
</td>
<td class="nump">$ 10,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">11,384<span></span>
</td>
<td class="nump">$ 10,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">11,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="nump">$ 5,778<span></span>
</td>
<td class="nump">$ 9,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=csbr_DirectorsAndEmployeesMember', window );">Directors and Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">1,618,231<span></span>
</td>
<td class="nump">2,228,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">155,552<span></span>
</td>
<td class="nump">135,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(108,375)<span></span>
</td>
<td class="num">(686,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(11,209)<span></span>
</td>
<td class="num">(47,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(36,875)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">1,617,324<span></span>
</td>
<td class="nump">1,618,231<span></span>
</td>
<td class="nump">2,228,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">1,617,324<span></span>
</td>
<td class="nump">1,618,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested (in shares)</a></td>
<td class="nump">1,349,895<span></span>
</td>
<td class="nump">1,323,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=csbr_NonEmployeesMember', window );">Non- Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">35,415<span></span>
</td>
<td class="nump">43,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(5,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">40,915<span></span>
</td>
<td class="nump">35,415<span></span>
</td>
<td class="nump">43,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">40,915<span></span>
</td>
<td class="nump">35,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested (in shares)</a></td>
<td class="nump">4,584<span></span>
</td>
<td class="nump">9,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=csbr_DirectorsAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=csbr_DirectorsAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=csbr_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=csbr_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947497952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current, total</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947498736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">US vs. foreign tax rate difference</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">80.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(47.30%)<span></span>
</td>
<td class="num">(61.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition', window );">Increase in uncertain tax position</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">27.70%<span></span>
</td>
<td class="num">(24.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Increase in uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947174208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability', window );">Right of use, net asset/liability</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">3,874<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forward</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="nump">11,404<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">15,502<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(15,502)<span></span>
</td>
<td class="num">(15,341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Right Of Use Asset (Liability)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax liability attributable to deductible temporary differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010946157296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision for Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Operating loss, limitations on use</a></td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Limitations On Use, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947506752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes - Change in Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition based on tax positions related to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Payment made on tax positions related to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition based on tax positions related to current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947216912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Basic and diluted net income per share computation (dollars in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to common stockholders</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in usd per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted income per share computation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to common stockholders</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average common shares (in shares)</a></td>
<td class="nump">13,197,170<span></span>
</td>
<td class="nump">13,138,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental shares from assumed exercise of warrants and stock options (in shares)</a></td>
<td class="nump">962,629<span></span>
</td>
<td class="nump">1,434,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Adjusted weighted average share - diluted (in shares)</a></td>
<td class="nump">14,159,799<span></span>
</td>
<td class="nump">14,573,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in usd per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947511632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">1,332,854<span></span>
</td>
<td class="nump">1,653,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">1,332,854<span></span>
</td>
<td class="nump">1,653,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010949135152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details) - Board of Directors - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=csbr_BoardMemberOneMember', window );">Board Member One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related related party transaction, amounts of transaction</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=csbr_BoardMemberTwoMember', window );">Board Member Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related related party transaction, amounts of transaction</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=csbr_BoardMemberOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=csbr_BoardMemberOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=csbr_BoardMemberTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=csbr_BoardMemberTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010943417792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">8,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_CorporateHeadquartersMember', window );">Corporate Headquarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDMember', window );">Rockville, MD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_csbr_OperatingLeaseIncrementalRentExpense', window );">Operating lease incremental rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDNewLocationMember', window );">Rockville, MD New Location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_MilanItalyMember', window );">Milan Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_csbr_OperatingLeaseIncrementalRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Incremental Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">csbr_OperatingLeaseIncrementalRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>csbr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_CorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_CorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDNewLocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_RockvilleMDNewLocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_MilanItalyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=csbr_MilanItalyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010947511760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - ROU Assets and Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">$ 8,230<span></span>
</td>
<td class="nump">$ 8,521<span></span>
</td>
<td class="nump">$ 8,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">$ 8,412<span></span>
</td>
<td class="nump">$ 8,783<span></span>
</td>
<td class="nump">$ 8,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140010943551648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">&#160;Total undiscounted liabilities</a></td>
<td class="nump">19,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(9,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 9,466<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>csbr-20220430_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:csbr="http://championsoncology.com/20220430"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="csbr-20220430.xsd" xlink:type="simple"/>
    <context id="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i579e3079125343b4ac0c1233280dec0b_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i848cb9d7336747e68cfca92323b68acd_I20220720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="ied6c8b18575745c19253a47ee2b946cd_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i6ca155caea5f443da349ba10a3f84e1c_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ieaa0daba14924b7d8838223b79f88c5b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="if02f3872d53a43f0a007156fe38211da_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i2374b15e0606422f934d250e545fd7fd_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ia75e18175028428b92779412b437c5ac_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib54a1d7487da488cbb84e20d7806250c_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i9fbb1281510d4a9893e74a6b8dad4aa2_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ide558d40319b4db7bc7ac08294103641_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i003c4a752f33480a906e9a3da5091e95_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i1bc700e99e614f63be6283f7eea85ac1_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="iad133947d589468393bb167e733a7f9e_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i6f8236966dfe48fdbde9087ecc55f047_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i2f31a264cd4f4bd691dfd8d18e642222_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="id431aa7354ed4c17822b0e24b7a2d5f8_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i99f25fb6e99f4ed98158edec2f27704a_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i21e22e4b5df54df1862ddd1cc4b4935a_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:FewContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i8bd7cd0ec9ba489bbd06b6da6761fbcc_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:FewContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ia1df8ed1c598465da670d79e3593edc3_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i48e36386ee4d4a73a89948ef648fc5c7_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ie0b6dabdf94b404eb4437550f85937c4_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i2b035faecffc4387a2253d46e038e904_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="id8b1597843e04e4d850927f9e6336bec_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i568b515a477e47eab0c4e0a329fa4bb3_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ia0ad5abd59b8400788b5b367632d5473_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ic35ac20f4a06475fa1113e6fe75b4f85_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i70b0060bd8694b6fb702f24b7e796e2b_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ifb1aaf64c59043568e7d5f17d579c269_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i748895a7edfe4b3297a3b13b1255c579_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i5e5aecbec4114718bfe16c50c87355f3_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i0f37c8ede37d417ea5b2dcff2fe06109_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">csbr:FinanceLeasedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i1c343591f7aa43e9bbf094ff48848b15_D20190501-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">csbr:FinanceLeasedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i75381282e8854f8aa4162452573b81af_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i37caf4f2f3b94b46a64f2e1ccc27d921_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i603726853868452081ffb4f2ddec75af_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i8779c4cdedb2440f85a3c8ca3a5b66f1_D20191201-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ic0b7070af4eb4a99ab731259dead4896_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia82b4636bcec43a581c7c41150e8c863_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ieb85b2ee4da64c099fc6a0fbbd34f4d4_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i19fa58ff128b48d4a12d943d7cb17020_D20190501-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i22b89d0c347047c4a863838d447fe6b2_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i7944dc3e37d5471fac3e5aa26a76720a_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2020FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2022FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i11b3c65241cc4e8181694452a5e4d0eb_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="csbr:FinanceLeaseAxis">csbr:A2022FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iccbb55bcd7d8409f95ab07871b4f00eb_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PharmacologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ic5ae863a047f404ebf60eb56f8352be7_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PharmacologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iad9d5b70c71944c3b1537441f0cba8e8_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i22e613c7ed7e462d8916e09de7dfd9b6_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie75ddc90488642fe9524dca29561cb31_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PersonalizedOncologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i3ace46fb73764dc580412ddfa1073ea4_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">csbr:PersonalizedOncologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">csbr:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ia8c0dcae4e7d40d4b0fb1669660fdd03_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i2997e8d60bcf46f9ba6c1f4ca4110249_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ia55eff6dffbf4ce19f35251ba3c322f6_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ic23746d0989e4145af18c84580ca48f6_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i49c8d68a641f4e3b847ea1ccfcd8e347_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i43786c34b50d435293e7048f0d6fb091_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i24b63951e3c94191b0de18e0a98025b5_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">csbr:TranslationalOncologySolutionsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i541e144c82554a4e88aec80277e945e8_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">csbr:TranslationalOncologySolutionsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i72c10eebe3ea442a931103ac31ce4af1_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ice1add8ac2df4b9ebbefa41994d6bc10_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i94a9f833a47649688056938280a6100a_D20110218-20110218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-02-18</startDate>
            <endDate>2011-02-18</endDate>
        </period>
    </context>
    <context id="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:EquityIncentivePlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ic8f8fd968db64d9aab0a9c7ba34faf09_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:DirectorCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-12</startDate>
            <endDate>2013-12-12</endDate>
        </period>
    </context>
    <context id="ibd0fa135aa62446eb639c81206006175_D20131212-20131212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">csbr:DirectorCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-12</startDate>
            <endDate>2013-12-12</endDate>
        </period>
    </context>
    <context id="i2499764558fa4746ac056a1fff5047ae_D20131212-20131212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <startDate>2013-12-12</startDate>
            <endDate>2013-12-12</endDate>
        </period>
    </context>
    <context id="i98768c91edc344c293525a163b2ebfb6_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i5f86018505f24f40a948b8a3bda2f392_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6a5a1fb68099489386e300756890aabb_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i7c0d1264a9d342c3a89311559d727593_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="id74600c6b29b46c4882983e3cc60d3ed_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="if5e6f0d067d84392bf315f54788e6654_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i8126402c4f4240ec950ef891d3d9bad6_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i494cc1892ba8486dadda4d692b680743_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="idabe360fb07c401a827aa2b65746f3bb_D20190501-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:DirectorsAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">csbr:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i69a6fd87cc4541c9b8207826c0d2619a_I20130430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2013-04-30</instant>
        </period>
    </context>
    <context id="i7a9df412082144bbb11d4d6da935fb41_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i2ee677f4c8194c56a69b04f0e5332d03_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="id4d88492120f4baca21ed89485bb0844_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i25d9cbec92d244c1bbb79ddf79455794_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ifb4a80baff484f72aa17c4f7022a0626_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">csbr:BoardMemberTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="if06e952147154d71b46d16b5e28a9fbe_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:CorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i80a586d6407045b5b2f71a3e6734cb67_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:CorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i85ae521181894cad8b64e2c702464cd0_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="ic847c89affc44622b37366e5f79fce04_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia727ea5ecb214935b2eeee869e2b3b96_D20200501-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ie013b3012171467f93337908fb07dbff_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i0c2df47285234084835a949fca5c80c3_I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="i29d1b96629e44d2bb9a499800cbc3b4c_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i690a0daa1ab0464ba51eacbabf4ce92b_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8aea2d8b8182467a8e0b368c96d67fa9_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2ef7fbd4bc8c4f4aab264f5fd41fec64_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i99c506566730476cb94f0263057c0930_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:RockvilleMDNewLocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="i8f1c7838e6524ef6b1bb93bf4114d1ba_D20210501-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ib43d4a95e25b464dacea18dbf70da83b_D20200501-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">csbr:MilanItalyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i96bb2ef9275f46ac8d01edb098d08a40_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771856</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>csbr:subsidiary</measure>
    </unit>
    <unit id="segment">
        <measure>csbr:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV8yLTEtMS0xLTE0Mzky_f112a631-988e-4870-a340-4726d31ff2ff">0000771856</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV83LTEtMS0xLTE0Mzky_2e60382e-6889-487c-85b4-c8dbcead7b77">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV85LTEtMS0xLTE0Mzky_299884bf-a246-4353-8124-f9b867fde213">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV80L2ZyYWc6NGI1OTc2YTlkODA4NGMyODgwNWI1ZTcyMjhhZWRiNGYvdGFibGU6MTI5ZDE4ZTMyMGM0NDU5NDliMjA0YmFkNzQ3MTQxYTUvdGFibGVyYW5nZToxMjlkMThlMzIwYzQ0NTk0OWIyMDRiYWQ3NDcxNDFhNV8xMC0xLTEtMS0xNDM5Mg_03154902-c643-4bce-8ed3-a1c5a7254321">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_4f9d5fac-8fa3-4bdf-b216-6f35e4ad8cd6">http://fasb.org/us-gaap/2022#ServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMC0xLTEtMTQzOTI_83245714-dbce-4c16-95f3-18378f367455">http://fasb.org/us-gaap/2022#ServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_4bd9ec76-9111-4d75-a50f-d39d93fb58f3">http://fasb.org/us-gaap/2022#ServiceMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMC0xLTEtMTQzOTI_f5fd1e33-d369-4f1c-8371-9f7463dbc1e1">http://fasb.org/us-gaap/2022#ServiceMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE5_1f0a56c5-228a-46bb-9941-e144d25aa94a">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8wLTEtMS0xLTE0Mzky_9398304f-48b6-4e91-b1f5-de708f9d94a0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8xLTItMS0xLTE0Mzky_ccf954ef-22ca-46ef-b328-13f5fd4583d1">2022-04-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NTM2NDMxZmQ5MTU5NDExZWJlNjFkOGFkMTk1ZWU1MTkvdGFibGVyYW5nZTo1MzY0MzFmZDkxNTk0MTFlYmU2MWQ4YWQxOTVlZTUxOV8xLTItMS0xLTE0Mzky_217066fe-8c6b-40e6-85ba-6cd6cfa2c74c">--04-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NmQyMzY5YzAyNjQ1NDZmNWIyYzEzNDc2ZDljOTMyMjIvdGFibGVyYW5nZTo2ZDIzNjljMDI2NDU0NmY1YjJjMTM0NzZkOWM5MzIyMl8wLTEtMS0xLTE0Mzky_ac738822-327a-44c8-8d0f-13d0427e2844">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjIw_dc695d46-ff1c-4de5-80e4-e3fb477b76e4">001-11504</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE1_24443dc0-8006-4972-b47f-b1e1afb85c75">CHAMPIONS ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF8wLTAtMS0xLTE0Mzky_4f264ee7-a439-4208-858c-e94ce0b6e393">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF8wLTEtMS0xLTE0Mzky_cf322bfd-7de0-4578-bda4-7ddc1765cd65">52-1401755</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF80LTAtMS0xLTE0Mzky_efc59d8e-4b65-443b-b010-11506dc0d3ec">One University Plaza, Suite 307</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF80LTEtMS0xLTE0Mzky_1f375ab8-790d-4e2e-ba14-a275abb1eefe">07601</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF81LTAtMS0xLTE0MzkyL3RleHRyZWdpb246ZmJkODk4ZmY1YTdiNDZjM2IzNjg5Y2VhYWRhMDY0ODRfNA_caaf0634-e681-4ce5-a45d-ab5fe6cd91ba">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZmQ0Nzk2NDEyMjg2NDMyODkwYTY3OTY4NmY5Zjg2MzAvdGFibGVyYW5nZTpmZDQ3OTY0MTIyODY0MzI4OTBhNjc5Njg2ZjlmODYzMF81LTAtMS0xLTE0MzkyL3RleHRyZWdpb246ZmJkODk4ZmY1YTdiNDZjM2IzNjg5Y2VhYWRhMDY0ODRfOA_fa4f145e-7e83-4a8a-b8e5-8b556c1db061">NJ</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE2_dac4ce2a-2170-49e0-bbf4-badcf131b615">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE3_513720f6-20fa-402f-a5ec-ce06d8092f36">808-8400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTAtMS0xLTE0Mzky_ad1b369c-716d-41e4-afd3-cde40e2031d7">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTItMS0xLTE0Mzky_e52f043c-5add-469e-bc01-d036b6d2612e">CSBR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6NDU2MzE4NDU5MTY1NDNmZWEzMWVkYTYwOGU3NDI0ZjYvdGFibGVyYW5nZTo0NTYzMTg0NTkxNjU0M2ZlYTMxZWRhNjA4ZTc0MjRmNl8xLTQtMS0xLTE0MzkyL3RleHRyZWdpb246MjljNjc1ZGNmM2NiNDFlMGI5Y2FkZWE1MGZjNWY1Y2NfNA_b5f13ec0-72e9-4fd4-868d-40025c77ecb0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjA4_fcef21a0-908a-4e91-b8e6-ce64d649b902">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjA5_42e320f1-4e25-466d-8f81-b41f01301ec5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEw_ef97cc43-7559-4a01-8898-ce06cf212ce6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEx_a532048a-0501-4478-8577-6a59c694f01f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8yLTAtMS0xLTE0Mzky_d087f40c-1a9d-40e1-babe-72da03705d4d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8yLTYtMS0xLTE0Mzky_68f13ebb-0e63-473b-8a22-07c8a276cdaa">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGFibGU6ZGZiNzMxMzBjOTUwNDZkYzgwMTBlMzExNDhiNWZlM2QvdGFibGVyYW5nZTpkZmI3MzEzMGM5NTA0NmRjODAxMGUzMTE0OGI1ZmUzZF8zLTYtMS0xLTE0Mzky_cf766b18-6cb1-4cb8-bc6a-6ed9c232be3c">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEy_45e57d83-889c-4863-b15e-8293611a6bf2">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjEz_50564527-be3f-4068-afcd-bd557f2bd8ed">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i579e3079125343b4ac0c1233280dec0b_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8yNzQ4Nzc5MDcyNzk1_cbb117d5-eede-4221-9b0a-e52e884014bc"
      unitRef="usd">44000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i848cb9d7336747e68cfca92323b68acd_I20220720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8yMTk5MDIzMjU4OTIz_a2608d10-3bd5-41dd-9d49-b482087c6223"
      unitRef="shares">13522441</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xL2ZyYWc6NmUzZDQ3MzYyMWJkNDVhMzg5MmYzZTc5OTkxMzQ0NjAvdGV4dHJlZ2lvbjo2ZTNkNDczNjIxYmQ0NWEzODkyZjNlNzk5OTEzNDQ2MF8zMjE4_b97ec693-b2e5-4b97-99c9-1063450e4462">Portions of the Registrant&#x2019;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, are incorporated by reference into Part III of this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDMvZnJhZzo3YmQ1MmZhNGNlYWQ0NTI4YWVhYjI5ZWUwNWNlZWNhYy90YWJsZToyN2FkNDFhMmFlY2U0ZTlhYWUzNjVkOTY3MWYyNDhjOC90YWJsZXJhbmdlOjI3YWQ0MWEyYWVjZTRlOWFhZTM2NWQ5NjcxZjI0OGM4XzAtMC0xLTEtMTc2NTYvdGV4dHJlZ2lvbjo5MWI1ODk5ZTE1OTU0YWU2YmQ2ZmZjODgxYzlkY2Q5Zl8yNzQ4Nzc5MDY5NjA0_be179926-e205-4bd2-94d9-a48e32002ff8">274</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDYvZnJhZzo2YzYyN2FhOWY0OTg0MjliOTdjMWE1MjJjY2RmMTlkNy90ZXh0cmVnaW9uOjZjNjI3YWE5ZjQ5ODQyOWI5N2MxYTUyMmNjZGYxOWQ3XzIxOTkwMjMyNjEzNjE_dc1b83bb-5e18-4830-95cd-e41f29888fce">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDYvZnJhZzo2YzYyN2FhOWY0OTg0MjliOTdjMWE1MjJjY2RmMTlkNy90ZXh0cmVnaW9uOjZjNjI3YWE5ZjQ5ODQyOWI5N2MxYTUyMmNjZGYxOWQ3XzIxOTkwMjMyNjEzNjI_25a71d1b-3587-453b-8691-05a78160b7bd">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMtMS0xLTEtMTQzOTI_36938a8a-b5f7-491d-8629-7677cb73e3bd"
      unitRef="usd">9007000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMtMy0xLTEtMTQzOTI_1202badd-7ec0-471f-be9a-835473b94608"
      unitRef="usd">4687000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQtMS0xLTEtMTQzOTI_578a74e9-f0dd-4014-a76d-481d9094801a"
      unitRef="usd">9513000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQtMy0xLTEtMTQzOTI_2feb43f1-c3b3-4371-88e2-8fdbc0f5ac26"
      unitRef="usd">6986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzUtMS0xLTEtMTQzOTI_ae921059-73e3-4e4d-aaa5-f5de0537d8cd"
      unitRef="usd">1144000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzUtMy0xLTEtMTQzOTI_e71ec72c-f401-4101-b5bf-b31610d6f4f0"
      unitRef="usd">957000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzctMS0xLTEtMTQzOTI_b3c5d763-729a-4a63-aeb5-8cc556957164"
      unitRef="usd">19664000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzctMy0xLTEtMTQzOTI_b9877828-5c51-4eed-a566-050c45bf6381"
      unitRef="usd">12630000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzktMS0xLTEtMTQzOTI_7b235032-919e-4103-b79d-caa63d211fe6"
      unitRef="usd">8230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzktMy0xLTEtMTQzOTI_37a873e9-fa36-40d3-bb42-573a7c55e4fd"
      unitRef="usd">8521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEwLTEtMS0xLTE0Mzky_dc10a248-6aa9-48f6-a35a-ba1fd99be1dc"
      unitRef="usd">7134000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEwLTMtMS0xLTE0Mzky_7b70c048-d2ae-4092-8417-9db0aee53c4a"
      unitRef="usd">6090000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzExLTEtMS0xLTE0Mzky_91b95727-7cac-4152-a9ce-78fcb2f5b5e1"
      unitRef="usd">15000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzExLTMtMS0xLTE0Mzky_edabbab8-60ae-4178-998c-60d4464d8f80"
      unitRef="usd">15000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEyLTEtMS0xLTE0Mzky_2f799c6e-c68e-47d9-821c-eb3dae36f9e7"
      unitRef="usd">335000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzEyLTMtMS0xLTE0Mzky_7f22e920-adc1-4ef5-b240-d7048668036b"
      unitRef="usd">335000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE0LTEtMS0xLTE0Mzky_38d80e73-04a9-40a4-9d8a-4fdc1a05e61d"
      unitRef="usd">35378000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE0LTMtMS0xLTE0Mzky_eac64ebd-56d5-40d5-b5da-59c7bafad1ff"
      unitRef="usd">27591000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE4LTEtMS0xLTE0Mzky_0315a1ef-6146-497f-8d08-f24f09dece83"
      unitRef="usd">2868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE4LTMtMS0xLTE0Mzky_9da2f92c-13b8-483b-8a02-7452df9507bd"
      unitRef="usd">1894000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE5LTEtMS0xLTE0Mzky_f063f250-da6b-4202-b008-ebb0e8c26232"
      unitRef="usd">2414000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzE5LTMtMS0xLTE0Mzky_a583fa6e-f9a7-47bf-b635-f3d54990dd37"
      unitRef="usd">2231000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIwLTEtMS0xLTE0Mzky_405995fb-89b7-4411-b815-0d8df1560400"
      unitRef="usd">1054000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIwLTMtMS0xLTE0Mzky_fbe1bb70-8322-48bd-b0fa-5cecad315a81"
      unitRef="usd">818000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIxLTEtMS0xLTE0Mzky_778f7cc8-00f8-43a4-a59c-b46a3863a6c8"
      unitRef="usd">72000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIxLTMtMS0xLTE0Mzky_5b278403-e275-4de8-b6d2-ddbfeb085e33"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIyLTEtMS0xLTE0Mzky_2d9f9353-dc94-45e6-8f5c-13a39006c295"
      unitRef="usd">11071000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzIyLTMtMS0xLTE0Mzky_6a031407-c29d-46c0-ad06-63f6a0f7a48d"
      unitRef="usd">6256000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI0LTEtMS0xLTE0Mzky_6150bf62-026e-47de-a574-00f5ce3e34ad"
      unitRef="usd">17479000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI0LTMtMS0xLTE0Mzky_26571182-c402-4e30-9fd9-90480c9dde1f"
      unitRef="usd">11199000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI3LTEtMS0xLTE0Mzky_76709711-023a-42fe-9c39-ae61080bdeb9"
      unitRef="usd">8412000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI3LTMtMS0xLTE0Mzky_9eb3ec37-c989-4711-811b-bca957ac2226"
      unitRef="usd">8783000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI5LTEtMS0xLTE0Mzky_e853a4cd-8dcc-4925-9e82-fd7179f4ea64"
      unitRef="usd">391000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzI5LTMtMS0xLTE0Mzky_bee8f3f9-e94f-4269-bbe1-34fc4768c4fa"
      unitRef="usd">181000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMxLTEtMS0xLTE0Mzky_df6fee05-776f-4656-8ce9-41556e5c786f"
      unitRef="usd">26282000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzMxLTMtMS0xLTE0Mzky_08cc8d85-6243-4dae-a646-f3882a7ae1e1"
      unitRef="usd">20163000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMTg_1dfd5822-fca5-4fb3-bea0-a4ab251bb3be"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMTg_ff1b95da-2613-4e33-b163-277e1f306e95"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMzI_38dd9d4e-497b-4343-a3e9-4b00174e82fb"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfMzI_55a84de0-dc24-4f7c-bc28-3426c46d23f2"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNTQ_23ced4c6-c5a3-4591-b145-6fc5b973c9b0"
      unitRef="shares">13522441</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNTQ_8c3e9b70-6707-4cc7-881a-78dfb674c242"
      unitRef="shares">13522441</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNjE_4fe54d5e-f4a8-4ea4-a757-ac71a1aa7c22"
      unitRef="shares">13414066</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTAtMS0xLTE0MzkyL3RleHRyZWdpb246YTczM2Y2OTUxOTZhNDg5MDk2NDdiMWE4YTJkNjRiZDlfNjE_ec9c2a7c-8809-424f-b327-00374f2ba9ef"
      unitRef="shares">13414066</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTEtMS0xLTE0Mzky_6e0fcfe4-c7a6-412f-af15-1a08efba0dde"
      unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM0LTMtMS0xLTE0Mzky_82355084-896d-40fc-ad43-7c69856ae13b"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM1LTEtMS0xLTE0Mzky_8523a3a5-8827-43fe-8e58-d05e0d906efd"
      unitRef="usd">81064000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM1LTMtMS0xLTE0Mzky_c4553774-5e77-4081-b5c5-e1036427f271"
      unitRef="usd">79945000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM2LTEtMS0xLTE0Mzky_ff157e07-fd4f-44d1-8c69-c00f21652eda"
      unitRef="usd">-71982000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM2LTMtMS0xLTE0Mzky_e504ff9b-c358-41ef-86f4-59dae936c42b"
      unitRef="usd">-72530000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM4LTEtMS0xLTE0Mzky_3373fa73-02b8-4c76-b006-bfa37f470b56"
      unitRef="usd">9096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzM4LTMtMS0xLTE0Mzky_bbb353e2-b893-466f-8269-0fc31aa0c896"
      unitRef="usd">7428000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQwLTEtMS0xLTE0Mzky_4c5f9f77-1f73-4174-b949-3c3262fb9aae"
      unitRef="usd">35378000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMDkvZnJhZzowMzhhNmY5YWUwNzc0N2NmYmFkNGNkYmNkZTgzOGQzOC90YWJsZTo4ZWFiYWE3YzVlYzU0YjUyODQ1NjRlNjRkN2E5YjgyYy90YWJsZXJhbmdlOjhlYWJhYTdjNWVjNTRiNTI4NDU2NGU2NGQ3YTliODJjXzQwLTMtMS0xLTE0Mzky_05422523-80ac-4246-9368-65b0faee0049"
      unitRef="usd">27591000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMS0xLTEtMTQzOTI_b73448b3-0775-42ce-9aba-c46434278de8"
      unitRef="usd">49109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzQtMy0xLTEtMTQzOTI_8a8cd345-7ad0-463f-a70e-368422e60bb1"
      unitRef="usd">41040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMS0xLTEtMTQzOTI_b5141ca8-bd31-43ed-9581-8eda85fa6888"
      unitRef="usd">23632000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzctMy0xLTEtMTQzOTI_77f810b8-12d9-4537-9847-e82218b3a4b8"
      unitRef="usd">21446000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzktMS0xLTEtMTQzOTI_1d744928-a81c-4237-8793-8066be01eb1c"
      unitRef="usd">9374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzktMy0xLTEtMTQzOTI_60ebe0f5-8d25-4fff-a640-d6362c91c909"
      unitRef="usd">7196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzEwLTEtMS0xLTE0Mzky_a2886761-2eeb-46a6-9a2a-cea59fc75267"
      unitRef="usd">6379000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzEwLTMtMS0xLTE0Mzky_6c79a509-e92f-494f-aa26-f1303647753c"
      unitRef="usd">5520000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzExLTEtMS0xLTE0Mzky_a2ed3730-3a85-44e9-8e9b-aa7ab5098925"
      unitRef="usd">9117000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzExLTMtMS0xLTE0Mzky_de816ba0-2c57-4d46-9f6c-8ed723a550cb"
      unitRef="usd">6512000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE0LTEtMS0xLTE0Mzky_85a702aa-966b-4e8b-9fbe-bb0775e4f428"
      unitRef="usd">48502000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE0LTMtMS0xLTE0Mzky_d7195193-e04d-4502-a3ad-029054fa2ae5"
      unitRef="usd">40674000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE2LTEtMS0xLTE0Mzky_22acd847-0172-4f64-a3c3-2128bfbb9e23"
      unitRef="usd">607000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzE2LTMtMS0xLTE0Mzky_79746e90-7cbd-4a4e-b3c7-3d62b01ad7c7"
      unitRef="usd">366000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzIxLTEtMS0xLTE0Mzky_d1121bd2-969f-435d-83de-74702d3b68c8"
      unitRef="usd">-24000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzIxLTMtMS0xLTE0Mzky_8e6cfcc5-d432-4c6b-86a8-98b21c90d683"
      unitRef="usd">71000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI1LTEtMS0xLTE0Mzky_c7ebf73e-b4d8-47d7-b868-f5d950ba998c"
      unitRef="usd">583000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI1LTMtMS0xLTE0Mzky_35457165-2d4d-46fa-87b7-b8008c58b1e5"
      unitRef="usd">437000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI2LTEtMS0xLTE0Mzky_b378eced-533b-438e-93f7-6b9ebc82d926"
      unitRef="usd">35000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI2LTMtMS0xLTE0Mzky_c1ecf6cb-4e4e-4676-b9c8-b4a761bd69b7"
      unitRef="usd">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI4LTEtMS0xLTE0Mzky_3e1bb81b-f103-4cf6-87f7-131470487017"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzI4LTMtMS0xLTE0Mzky_1d7b9136-cd5b-49f6-97da-a4dfc30a0b46"
      unitRef="usd">362000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMxLTEtMS0xLTE0Mzky_840f8ca1-a7af-409e-a969-2b6695ed2106"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMxLTMtMS0xLTE0Mzky_89c5f030-5129-4224-9053-05ccfd418962"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMyLTEtMS0xLTE0Mzky_5b6cc0e7-dab6-42bb-b8f5-11bbf15702fb"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzMyLTMtMS0xLTE0Mzky_5a5d87aa-4afb-436b-b48f-cfa910718dad"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM1LTEtMS0xLTE0Mzky_a7693543-8a2d-4d32-8e59-a771eb3e3680"
      unitRef="shares">13197170</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM1LTMtMS0xLTE0Mzky_91c8ffd1-00e6-48a8-8127-d3431ff1824d"
      unitRef="shares">13138995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM2LTEtMS0xLTE0Mzky_bacdf407-bec9-48ea-beec-413a224b9211"
      unitRef="shares">14159799</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTUvZnJhZzo3NDFlNzNlMGZjMDM0YTJjYjRlOTVmZTBhNTA5NTkxMS90YWJsZTo4ZDIyOTg3ZmI5ZGU0MTMxYjE5MThiNTA3NTFkNzQ5MC90YWJsZXJhbmdlOjhkMjI5ODdmYjlkZTQxMzFiMTkxOGI1MDc1MWQ3NDkwXzM2LTMtMS0xLTE0Mzky_0b28a0d6-9b1d-46f8-a22e-cfda811a3d51"
      unitRef="shares">14573561</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieaa0daba14924b7d8838223b79f88c5b_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMS0xLTEtMTQzOTI_caca578f-d6b1-470e-bde2-abab802d3a50"
      unitRef="shares">12726728</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieaa0daba14924b7d8838223b79f88c5b_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMy0xLTEtMTQzOTI_8a8160ea-ca00-4600-8fab-97f6d63ac638"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzItNS0xLTEtMTY3Mjc_3deff684-1da5-48a3-9eb3-93db847fbae5"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="if28cfb84fd6b4cc794bd9f9ee62a0bd2_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzItNy0xLTEtMTY3Mjk_bfb349d3-7554-433b-a65c-b978e88d3e86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="if02f3872d53a43f0a007156fe38211da_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtOS0xLTEtMTQzOTI_deafc48b-77a6-4cce-b7dc-4b03ee17528f"
      unitRef="usd">77978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2374b15e0606422f934d250e545fd7fd_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMTEtMS0xLTE0Mzky_35a609a4-1ea4-4b16-a9b3-ddd9b48b02db"
      unitRef="usd">-72892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzQtMTUtMS0xLTE0Mzky_12ad006a-b1d7-4a00-b91a-e0ee3373f3fd"
      unitRef="usd">5099000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzUtOS0xLTEtMTQzOTI_5b9665e7-7de2-40e3-8875-c3864c74b7f7"
      unitRef="usd">598000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzUtMTUtMS0xLTE0Mzky_69727759-7e95-4a79-b275-88c6987abe14"
      unitRef="usd">598000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ib54a1d7487da488cbb84e20d7806250c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTEtMS0xLTE0Mzky_fe72c419-15e2-4013-8a4c-c37e99f9f7b9"
      unitRef="shares">687338</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i1a6f0c5e4283425bb2f8cf97a26242b8_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTktMS0xLTE0Mzky_3a55ac35-df45-4723-b539-b25677169753"
      unitRef="usd">1369000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEwLTE1LTEtMS0xNDM5Mg_da1ce86b-64c5-4b8f-9f3a-27ff03e75a87"
      unitRef="usd">1369000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="i9fbb1281510d4a9893e74a6b8dad4aa2_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEyLTExLTEtMS0xNDM5Mg_afb83b3c-5f4f-4ca3-ba94-342845165dc3"
      unitRef="usd">362000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzEyLTE1LTEtMS0xNDM5Mg_849c6fbf-32cf-472b-8908-034d3ad5954a"
      unitRef="usd">362000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide558d40319b4db7bc7ac08294103641_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTEtMS0xLTE0Mzky_68d71c9e-1529-4ced-b4f2-aa788228750d"
      unitRef="shares">13414066</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ide558d40319b4db7bc7ac08294103641_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTMtMS0xLTE0Mzky_05f1898d-e2db-4851-8937-0dde75861120"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i003c4a752f33480a906e9a3da5091e95_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTUtMS0xLTE0Mzky_3753e97a-c187-4341-9fef-22e223cbaf0d"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i003c4a752f33480a906e9a3da5091e95_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTctMS0xLTE0Mzky_b75de040-2ef3-4967-a2cd-5dd6df61ad2b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bc700e99e614f63be6283f7eea85ac1_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTktMS0xLTE0Mzky_9b79ac35-e838-4539-80b1-36c123df19c9"
      unitRef="usd">79945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad133947d589468393bb167e733a7f9e_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTExLTEtMS0xNDM5Mg_21f824f4-b0e9-476b-8553-8626965089c4"
      unitRef="usd">-72530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE0LTE1LTEtMS0xNDM5Mg_9570ec40-91e1-4b41-9a20-d7dd7ae7d993"
      unitRef="usd">7428000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE1LTktMS0xLTE0Mzky_b08b0bc1-c720-4f45-a514-102ce9cee50f"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE1LTE1LTEtMS0xNDM5Mg_eb243045-73be-4444-a562-2901b0aa4eab"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTEtMS0xLTE0Mzky_c8f9dacc-c815-4038-b204-dd34f926c42b"
      unitRef="shares">108375</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i982d80cfb5b84801858e1ebf20e9c1fe_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTMtMS0xLTE0Mzky_a8b8e446-7116-4a66-97f0-43ea3415d41c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i3d4fe59ddac84c3b9df8c0fed8705ffe_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTktMS0xLTE0Mzky_613b4759-6526-4c16-8350-751ab0659ca2"
      unitRef="usd">207000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE2LTE1LTEtMS0xNDM5Mg_ffb416a7-46f9-4bef-be55-03fcf1e3a117"
      unitRef="usd">208000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="i6f8236966dfe48fdbde9087ecc55f047_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE4LTExLTEtMS0xNDM5Mg_52ce5476-6ee3-4d2e-84bc-b480f88c5249"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzE4LTE1LTEtMS0xNDM5Mg_0ad16013-bd0e-466d-8153-8925a049ed51"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTEtMS0xLTE0Mzky_54787cd8-5ec8-4d73-94d7-e5d5b0315784"
      unitRef="shares">13522441</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaf19ac5dcc08486aaa9a0de72ec24874_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTMtMS0xLTE0Mzky_83dfb10a-66fc-45bc-aff7-0a260076c8bb"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2f31a264cd4f4bd691dfd8d18e642222_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTUtMS0xLTE0Mzky_ac852d59-a4d2-4845-8ffe-b587e026773e"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i2f31a264cd4f4bd691dfd8d18e642222_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTctMS0xLTE0Mzky_1bdf1583-441a-4920-8885-5bfa0a56c677"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id431aa7354ed4c17822b0e24b7a2d5f8_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTktMS0xLTE0Mzky_516627a9-c0c0-49bf-a8bb-22d6b73c7926"
      unitRef="usd">81064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99f25fb6e99f4ed98158edec2f27704a_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTExLTEtMS0xNDM5Mg_f9aa0c9d-e888-4076-ac9a-a028f8eff3b7"
      unitRef="usd">-71982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMTgvZnJhZzphYzg3YzE1NWJlMzA0ZjkyYTc1MmM4N2Y0ZDQyZTViNC90YWJsZTo5MDNjY2Y1YjAwZTg0ZTkyYmU1MDU1ZGE5YTc4OGEyNC90YWJsZXJhbmdlOjkwM2NjZjViMDBlODRlOTJiZTUwNTVkYTlhNzg4YTI0XzIwLTE1LTEtMS0xNDM5Mg_cd3212ad-c2f3-4871-94d7-433a987e0245"
      unitRef="usd">9096000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMtMS0xLTEtMTQzOTI_3e1bb81b-f103-4cf6-87f7-131470487017"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMtMy0xLTEtMTQzOTI_13b04685-c83a-4e88-ab36-a2aea127c4a4"
      unitRef="usd">362000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzYtMS0xLTEtMTQzOTI_265f90bb-920d-43df-be58-3e2717af7166"
      unitRef="usd">912000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzYtMy0xLTEtMTQzOTI_c0ff4af4-4acb-4603-a678-3784fbc92ae9"
      unitRef="usd">598000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzctMS0xLTEtMTQzOTI_3814fbb7-f390-449e-b9c7-0ffb3d8cbad9"
      unitRef="usd">1627000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzctMy0xLTEtMTQzOTI_998c68f1-a524-4d00-8367-dda81a7961c6"
      unitRef="usd">1184000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzEwLTEtMS0xLTE0Mzky_56db8d73-7b85-4a76-b947-08e44f3a63f4"
      unitRef="usd">4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzEwLTMtMS0xLTE0Mzky_636a9d02-727d-40e4-b466-d7705935856e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzExLTEtMS0xLTE0Mzky_ac099198-5c20-4211-a2b4-18b098062d09"
      unitRef="usd">786000</csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzExLTMtMS0xLTE0Mzky_dc8e0780-14b7-446b-a80b-59a67a1823f2"
      unitRef="usd">398000</csbr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE0LTEtMS0xLTE0Mzky_ddb4f27e-3bd3-434d-a71e-01193980c2d3"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE0LTMtMS0xLTE0Mzky_5a3affcb-3479-4785-b36c-d52e90b1d7cf"
      unitRef="usd">75000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE1LTEtMS0xLTE0Mzky_90b61f44-1680-459a-9e36-b1cec979d5dd"
      unitRef="usd">292000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE1LTMtMS0xLTE0Mzky_84fea443-8ed3-470f-8246-3183606d5b65"
      unitRef="usd">49000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE5LTEtMS0xLTE0Mzky_aa921b29-d00b-4950-901f-cbc83d7bb54c"
      unitRef="usd">2818000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzE5LTMtMS0xLTE0Mzky_adf89cb8-e8cf-45d3-b831-92231a101222"
      unitRef="usd">2265000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIwLTEtMS0xLTE0Mzky_f510d5b2-4986-4e35-ad87-b0e6b6fa28e5"
      unitRef="usd">187000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIwLTMtMS0xLTE0Mzky_065ebb79-f55a-4470-ba68-6f3b6f12fb25"
      unitRef="usd">572000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIzLTEtMS0xLTE0Mzky_e7bf831b-6bce-4957-9ce9-1ec2a2962651"
      unitRef="usd">974000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzIzLTMtMS0xLTE0Mzky_9b579139-936f-41e3-8fb2-80e01fa3a220"
      unitRef="usd">-1246000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI0LTEtMS0xLTE0Mzky_e20314e7-7815-4a49-b8f8-bbc9f5abc346"
      unitRef="usd">183000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI0LTMtMS0xLTE0Mzky_3b745c7c-d758-42e9-acb2-635f310a15b7"
      unitRef="usd">-316000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI1LTEtMS0xLTE0Mzky_87703635-9697-47a9-aa70-0db62ebcf350"
      unitRef="usd">-631000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI1LTMtMS0xLTE0Mzky_3871f033-ae23-401f-9602-564818f9f994"
      unitRef="usd">-242000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI2LTEtMS0xLTE0Mzky_7ae7cb8e-562e-4017-a110-f9312240f6eb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI2LTMtMS0xLTE0Mzky_97d97491-7b17-4308-b631-7c51211b3084"
      unitRef="usd">3000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI3LTEtMS0xLTE0Mzky_23d0536b-c0ec-43b0-950a-774a64e65581"
      unitRef="usd">4815000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI3LTMtMS0xLTE0Mzky_9ea7576b-8c7a-443f-8df5-b440f38b7bcb"
      unitRef="usd">441000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI5LTEtMS0xLTE0Mzky_d38f9d89-6154-4bf0-acea-c66a4ed8f141"
      unitRef="usd">6497000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzI5LTMtMS0xLTE0Mzky_c19f5c39-c8d2-432d-897d-0fa2eb01d53f"
      unitRef="usd">-1681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMyLTEtMS0xLTE0Mzky_a0e826fd-6ecc-4fe3-aa4d-ab5bf370adb0"
      unitRef="usd">2384000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMyLTMtMS0xLTE0Mzky_8be9c912-ab93-45d0-baa3-df56e7ba1e09"
      unitRef="usd">3281000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <csbr:ProceedsFromRefundOfSecurityDeposit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMzLTEtMS0xLTE0Mzky_119521bf-53b1-4e28-89fb-69ed521393c5"
      unitRef="usd">0</csbr:ProceedsFromRefundOfSecurityDeposit>
    <csbr:ProceedsFromRefundOfSecurityDeposit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzMzLTMtMS0xLTE0Mzky_02a3cf5e-24d0-49ce-8919-8062288a72cc"
      unitRef="usd">112000</csbr:ProceedsFromRefundOfSecurityDeposit>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzM2LTEtMS0xLTE0Mzky_de5f37e5-e4a4-441d-bb84-1cc42276259b"
      unitRef="usd">-2384000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzM2LTMtMS0xLTE0Mzky_f569dfdf-9a40-4ae1-ba92-3412d04d444d"
      unitRef="usd">-3169000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <csbr:ProceedsFromExerciseOfOptionsAndWarrants
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQxLTEtMS0xLTE0Mzky_844ba755-150f-4f85-809d-e855b54604c0"
      unitRef="usd">207000</csbr:ProceedsFromExerciseOfOptionsAndWarrants>
    <csbr:ProceedsFromExerciseOfOptionsAndWarrants
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQxLTMtMS0xLTE0Mzky_f3d4b9f0-206d-499d-a9df-57ab84664332"
      unitRef="usd">1369000</csbr:ProceedsFromExerciseOfOptionsAndWarrants>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQzLTEtMS0xLTE0Mzky_5a1915f8-e44b-4d93-abf4-49b69a5c6a53"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQzLTMtMS0xLTE0Mzky_f7976a9e-d770-4764-bc9f-72567dd854be"
      unitRef="usd">174000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQ3LTEtMS0xLTE0Mzky_81e70c10-01d0-4ef5-ab32-9c52dfe53105"
      unitRef="usd">207000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzQ3LTMtMS0xLTE0Mzky_f5dd99d1-522c-4b7a-a1a1-c8dc01306e75"
      unitRef="usd">1195000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUxLTEtMS0xLTE0Mzky_5b05605e-653e-4a26-ac2f-d6872e31756d"
      unitRef="usd">4320000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUxLTMtMS0xLTE0Mzky_bd523da7-1d4a-46df-98a9-8723b7cdeeab"
      unitRef="usd">-3655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUyLTEtMS0xLTE0Mzky_eff60053-56af-457b-b6cf-1d6d69ec7f43"
      unitRef="usd">4687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzUyLTMtMS0xLTE0Mzky_88d80998-6b00-4279-a8e4-8e7e531aeacb"
      unitRef="usd">8342000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU0LTEtMS0xLTE0Mzky_3f7fc325-f772-4202-b936-dab317a5ded6"
      unitRef="usd">9007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU0LTMtMS0xLTE0Mzky_14574fee-e4c4-4770-9a40-8700953256bc"
      unitRef="usd">4687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU4LTEtMS0xLTE0Mzky_0cb4489e-1149-4351-beb5-4101e6ed564e"
      unitRef="usd">205000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjEvZnJhZzplMDYxNWIxMTA1ODQ0NjFhODc5NDM5ZmNmYzYwYjg1Ny90YWJsZTpmY2UzYjBkNzdkNWU0YjEzYjkwNDJiN2EwNzJkM2NmZS90YWJsZXJhbmdlOmZjZTNiMGQ3N2Q1ZTRiMTNiOTA0MmI3YTA3MmQzY2ZlXzU4LTMtMS0xLTE0Mzky_c733905a-70e4-4197-8f42-29c69335d430"
      unitRef="usd">6121000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE2MTk_ff2106b9-040b-425a-a23f-51d8872aa305">Organization and Basis of Presentation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Background&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Champions Oncology, Inc. (the &#x201c;Company&#x201d;), is engaged in drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms.  The Company&#x2019;s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. Utilizing the TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, the Company offers multiple services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform is designed to facilitate drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited, and Champions Oncology S.R.L. For the years ended April&#160;30, 2022 and 2021, there were no revenues earned by these subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The Company operates in one reportable business segment.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <csbr:NumberofOperatingSubsidiaries
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzExNzI_aa562848-82a1-4aa2-b310-dee2454f794e"
      unitRef="subsidiary">3</csbr:NumberofOperatingSubsidiaries>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE2MTc_59b1907d-8700-49e3-a0c0-9cbd25929b0e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The Company operates in one reportable business segment.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMjcvZnJhZzo4YjE0ZTk5MzVlODI0MjUxODFiM2M5N2EzOWVlYTk3MC90ZXh0cmVnaW9uOjhiMTRlOTkzNWU4MjQyNTE4MWIzYzk3YTM5ZWVhOTcwXzE1ODQ_6cbc86ee-85e0-44f7-b220-ea7628963475"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjk4_d2541ac9-04c1-48f7-b849-5f07e05a4185">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#x2019;s international operations. Foreign currency balances are translated at each month end to US dollars, and any resulting gain or loss is recognized in our results of operations, as the amounts are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.   Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions.&#160; We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents. As of&#160;April 30, 2022&#160;and 2021 the Company had cash balances of $9.0&#160;million and $4.7&#160;million, respectively, and no cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash on hand, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services.  For the year ended April&#160;30, 2022, the Company had net income of approximately $548,000, an accumulated deficit of approximately $72.0 million, working capital of $2.2 million and cash of $9.0 million. We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least August 2023. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash, accounts receivable, prepaid expenses, and other current assets, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted market prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level two&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than level one inputs that are either directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has no assets or liabilities that are measured at fair value on a recurring and/or non-recurring  during the years ended April&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, computer hardware and software, and internally developed software. Assets in progress include equipment or software not yet placed in service. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870"&gt;three&lt;/span&gt; to seven years. Refer to Footnote 4, "Property and Equipment" for a detailed discussion. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for its leases under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.&#160;&#160;The Company has not recognized any impairment losses for the Company&#x2019;s long-lived assets for the years ending April&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors, market conditions, or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit&#x2019;s carrying amount exceeds its fair value, referred to as a &#x201c;step zero&#x201d; approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. Under FASB's Accounting Standards Update ("ASU") 2014-02, Topic 350, "Intangibles&#x2014;Goodwill and Other" goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impairment evaluation test involves comparing the current fair value of each business unit to its carrying value, including goodwill. Fair value is typically estimated using a discounted cash flow analysis, which requires the Company to estimate the future cash flows anticipated to be generated by the business unit being tested for impairment as well as to select a risk-adjusted discount rate to measure the present value of the anticipated cash flows. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. The Company estimates cash flows for the business unit over a discrete period (typically four or five years) and the terminal period (considering expected long term growth rates and trends). Estimating future cash flows requires significant judgment by management in such areas as future economic conditions, industry-specific conditions, product pricing, and necessary capital expenditures. The use of different assumptions or estimates for future cash flows or significant changes in risk-adjusted discount rates due to changes in market conditions could produce substantially different estimates of the fair value of the business unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reportable segment. The Company assesses goodwill impairment by business unit.  Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the businesses.&#160;&#160;Future events, including but not limited to continued declines in economic activity, loss of contracts or a significant number of customers, or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment indicators exist and that goodwill is impaired.&#160;For the year ended April 30, 2022, the Company's annual assessment did not result in any impairment indicators. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue represents payments received in advance of products to be delivered or services to be performed.&#160;&#160;When products are delivered and/or services are performed, deferred revenue is recognized as earned.  Deferred revenue is expected to be recognized within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Non-Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities represent amounts for uncertain tax positions relating to one of our foreign entities and a financing lease of laboratory equipment in exchange for a lab supplies purchasing commitment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Oncology Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of oncology services relates primarily to our Translational Oncology Solutions ("TOS") business unit. TOS costs consist of direct costs related to laboratory supplies, mice purchases, and maintenance costs for studies completed internally as well as charges from Contract Research Organization's for studies handled externally. Indirect costs include salaries and other payroll related costs of compensation for personnel directly engaged in providing TOS products and services. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs represent both costs incurred internally for research and development activities, including personnel costs, mice purchases, and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales and Marketing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses represent costs incurred to promote the Company&#x2019;s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company&#x2019;s common stock purchase warrants and stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically recognizes expense for stock-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of stock-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved &#x201c;simplified method&#x201d; noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. &#160;Estimated volatility is based upon the historical volatility of the Company's common stock.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses stock-based payments over the period that the awards are expected to vest.&#160;&#160;In the event of forfeitures, compensation expense is adjusted.&#160;&#160;The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of April&#160;30, 2022 and 2021, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;As of April&#160;30, 2022 and 2021 the Company has recorded $181,000 of liabilities related to uncertain tax positions relative to one of its foreign operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company accrued $0 and $3,000, for interest and penalties on the Company&#x2019;s statement of operations for the years ended April&#160;30, 2022 and 2021, respectively. The Company does not anticipate any significant unrecognized tax benefits to be recorded during the next 12 months.&#160;&#160;For the year ended April 30, 2022 and 2021, the Company recognized a provision for income taxes of $35,000 and $75,000, respectively.  These amounts are mainly attributable to taxable income earned in Israel relating to transfer pricing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers.  The objective of the standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under this standard, companies recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All revenue is generated from contracts with customers. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;      The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmacology Study and Other Services&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incremental Costs of Obtaining a Contract (Sales Commissions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the costs of obtaining a contract can be expensed immediately, rather than capitalized and amortized, if the amortization period is one year or shorter.  Sales commissions for the Company represent contract costs with a term of one year or less.  Therefore, under ASC 606, the Company elected the practical expedient to expense these costs as incurred.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables, Unbilled Services and Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise when the revenue recognized exceeds the amount billed to the customer.  Such situations occur due to divergences between revenue recognition and the invoicing milestones which are based on predetermined payment terms.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Being Evaluated&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses".  This update requires immediate recognition of management&#x2019;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#x2014; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. We adopted this guidance on May 1, 2021. The adoption of this ASU did not have a material impact is reflected in the Company's current year consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzI3_638018e5-7342-4f00-a848-a654ce6d8c13">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjcz_30ffef43-aac8-462f-8eeb-7b5f498de987">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company&#x2019;s international operations. Foreign currency balances are translated at each month end to US dollars, and any resulting gain or loss is recognized in our results of operations, as the amounts are not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY4_2f40bf97-4d87-4f25-a930-96cd888cf91e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.   Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions.&#160; We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.&#160;&#160;Actual amounts could differ significantly from amounts previously estimated.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzE0_5ca4a38a-45ac-4d4d-a6c6-0d6e1cbe2782">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:Cash
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzM4NDgyOTA3MzUyODY_6ea7f44b-c4bd-4fa8-a4b7-74de2415656a"
      unitRef="usd">9000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzM4NDgyOTA3MzUzMDA_7547f912-7b00-4ddf-a4b6-8bdb5c6e748f"
      unitRef="usd">4700000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQwNjI_acadbc8f-22e9-40ef-bbac-f9e85da4d14d"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQwNjI_f34ad310-30f1-42d3-b9dd-6f739d557cef"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ1Nzg_15dbaa6f-4d30-48a4-a514-b85e207d34d2"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2MjI_17d164de-f3cd-4e76-bf8d-6509722507c2"
      unitRef="usd">-72000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <csbr:WorkingCapital
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2NDU_8adc4c4d-fb19-4c6f-9520-2584b5a6818e"
      unitRef="usd">2200000</csbr:WorkingCapital>
    <us-gaap:Cash
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ2NjA_700e4eed-aeee-436f-92df-00574925d4cf"
      unitRef="usd">9000000</us-gaap:Cash>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjU0_88808c5e-f541-4961-b862-4d1dd13296d9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash, accounts receivable, prepaid expenses, and other current assets, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted market prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level two&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than level one inputs that are either directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.&lt;/span&gt;&lt;/div&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjQz_2277304d-ec89-4eba-96a2-9a8911959848">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, computer hardware and software, and internally developed software. Assets in progress include equipment or software not yet placed in service. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzY0NDg_489a1117-214a-43b8-9e75-8a8ec84f1870"&gt;three&lt;/span&gt; to seven years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjQ0_a73b6207-3226-407a-8fb2-2a7e3f49c506">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzI2_383bde18-92df-4aea-a192-20a285f0b063">Leases The Company accounts for its leases under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjc0_3b89e0c0-363c-4929-85ba-b97d8ba52d16">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.&#160;&#160;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.&#160;&#160;The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.&#160;&#160;These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzgyOTQ_c47f4c34-4196-42fb-ac57-d832501a0963"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzgyOTQ_ff329aa6-2149-41c4-8c34-5a15d5b15b9e"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzAx_3e36c3b7-9a8c-45cd-a171-bb2767c42c6d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors, market conditions, or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit&#x2019;s carrying amount exceeds its fair value, referred to as a &#x201c;step zero&#x201d; approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. Under FASB's Accounting Standards Update ("ASU") 2014-02, Topic 350, "Intangibles&#x2014;Goodwill and Other" goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impairment evaluation test involves comparing the current fair value of each business unit to its carrying value, including goodwill. Fair value is typically estimated using a discounted cash flow analysis, which requires the Company to estimate the future cash flows anticipated to be generated by the business unit being tested for impairment as well as to select a risk-adjusted discount rate to measure the present value of the anticipated cash flows. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. The Company estimates cash flows for the business unit over a discrete period (typically four or five years) and the terminal period (considering expected long term growth rates and trends). Estimating future cash flows requires significant judgment by management in such areas as future economic conditions, industry-specific conditions, product pricing, and necessary capital expenditures. The use of different assumptions or estimates for future cash flows or significant changes in risk-adjusted discount rates due to changes in market conditions could produce substantially different estimates of the fair value of the business unit.&lt;/span&gt;&lt;/div&gt;The Company has one reportable segment. The Company assesses goodwill impairment by business unit.  Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and operational performance of the businesses.&#160;&#160;Future events, including but not limited to continued declines in economic activity, loss of contracts or a significant number of customers, or a rapid increase in costs or capital expenditures, could cause us to conclude that impairment indicators exist and that goodwill is impaired.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzExMTk2_58721803-65b4-4c80-aa05-aa53632b9abe"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjcw_cf9d5ffb-7114-4ce1-b7e0-9406587b13a8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue represents payments received in advance of products to be delivered or services to be performed.&#160;&#160;When products are delivered and/or services are performed, deferred revenue is recognized as earned.  Deferred revenue is expected to be recognized within one year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers.  The objective of the standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under this standard, companies recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All revenue is generated from contracts with customers. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;      The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmacology Study and Other Services&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incremental Costs of Obtaining a Contract (Sales Commissions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the costs of obtaining a contract can be expensed immediately, rather than capitalized and amortized, if the amortization period is one year or shorter.  Sales commissions for the Company represent contract costs with a term of one year or less.  Therefore, under ASC 606, the Company elected the practical expedient to expense these costs as incurred.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables, Unbilled Services and Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise when the revenue recognized exceeds the amount billed to the customer.  Such situations occur due to divergences between revenue recognition and the invoicing milestones which are based on predetermined payment terms.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <csbr:OtherNoncurrentLiabilitiesPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjkw_7a8dcbc2-4267-4bd3-8eae-aa876c34c08e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Non-Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities represent amounts for uncertain tax positions relating to one of our foreign entities and a financing lease of laboratory equipment in exchange for a lab supplies purchasing commitment.&lt;/span&gt;&lt;/div&gt;</csbr:OtherNoncurrentLiabilitiesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjk2_cdac3949-ba91-4cf0-be17-554702b06c14">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Oncology Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of oncology services relates primarily to our Translational Oncology Solutions ("TOS") business unit. TOS costs consist of direct costs related to laboratory supplies, mice purchases, and maintenance costs for studies completed internally as well as charges from Contract Research Organization's for studies handled externally. Indirect costs include salaries and other payroll related costs of compensation for personnel directly engaged in providing TOS products and services. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, are expensed when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY0_05723aba-5bfd-420b-ba4a-44cad142379c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Research and development costs represent both costs incurred internally for research and development activities, including personnel costs, mice purchases, and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.&#160;&#160;All research and development costs are expensed as incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <csbr:SalesAndMarketingExpensePolicyPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzA4_168fcdef-78f8-425a-865b-0dfd484e48f9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales and Marketing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses represent costs incurred to promote the Company&#x2019;s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</csbr:SalesAndMarketingExpensePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMzA5_13c1e20e-2efc-4b31-ab69-2de5178cfe40">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company&#x2019;s common stock purchase warrants and stock options.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjg0_b6ee916c-80ec-49e6-b8bb-7622d9cde2fa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically recognizes expense for stock-based payments based on the fair value of awards on the date of grant.&#160;&#160;The Company uses the Black-Scholes option pricing model to estimate fair value.&#160;&#160;The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable.&#160;&#160;The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of stock-based awards.&#160;&#160;These assumptions are based on historical information and management judgment.&#160;&#160;The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant.&#160;Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved &#x201c;simplified method&#x201d; noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. &#160;Estimated volatility is based upon the historical volatility of the Company's common stock.&#160;&#160;The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses stock-based payments over the period that the awards are expected to vest.&#160;&#160;In the event of forfeitures, compensation expense is adjusted.&#160;&#160;The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjY2_c93355f0-0c1a-49e2-9865-b162f2019574">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.&#160;&#160;In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.&#160;&#160;The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.&#160;&#160;Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of April&#160;30, 2022 and 2021, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits.&#160;&#160;If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.&#160;&#160;As of April&#160;30, 2022 and 2021 the Company has recorded $181,000 of liabilities related to uncertain tax positions relative to one of its foreign operations.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4MzA3_047c5512-63f0-4c4c-8839-feecc87e4924"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4MzA3_a845f159-7e5b-4a9f-8e7b-a6ff7569f1eb"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4NTY0_a0f1cddb-5c28-4fa8-bdda-890a9e58de2b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzE4NTcx_a6b53cd0-7c23-4e0f-8b81-732792280b3a"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ5NDc4MDIzNjMwOTE_3620ef18-9cde-406b-9d62-8a57be272716"
      unitRef="usd">35000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzQ5NDc4MDIzNjMxMDA_4e7f9a27-7ed0-44fb-90e0-16cefdb942f5"
      unitRef="usd">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i21e22e4b5df54df1862ddd1cc4b4935a_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzU0OTc1NTg1MzIxMA_7df82ab4-ff54-4a74-b995-3c9d0dd68996">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i8bd7cd0ec9ba489bbd06b6da6761fbcc_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzU0OTc1NTg1MzIxOA_ed6444d1-ee53-4ab9-a19f-3b2fa83fe708">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzAvZnJhZzowMWFlNTIwMDliOGY0ODFiODg1NmQyMjllMzUzMzUyOC90ZXh0cmVnaW9uOjAxYWU1MjAwOWI4ZjQ4MWI4ODU2ZDIyOWUzNTMzNTI4XzMwMjc1_4e314a9a-55d3-46dd-87f1-02b87e0a8712">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Being Evaluated&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses".  This update requires immediate recognition of management&#x2019;s estimates of current expected credit losses ("CECL").  Under the prior model, losses were recognized only as they were incurred.  The new model is applicable to all financial instruments that are not accounted for at fair value through net income.  The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements and have not yet determined the impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740) &#x2014; Simplifying the Accounting for Income Taxes. ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. We adopted this guidance on May 1, 2021. The adoption of this ASU did not have a material impact is reflected in the Company's current year consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <csbr:AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4Ng_60e80525-eda8-4dae-83f4-a2e323c30234">Accounts Receivable, Unbilled Services and Deferred Revenue&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable and unbilled services were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable and unbilled services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue is shown as a current liability on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 30, 2020 unbilled services was $2.4&#160;million and deferred revenue was $5.8&#160;million.&lt;/span&gt;&lt;/div&gt;</csbr:AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4OQ_0369a031-6239-496d-ab14-4df5a62fc083">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable and unbilled services were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable and unbilled services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <csbr:TradeAccountsReceivable
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzItMS0xLTEtMTQzOTI_0671c949-29a3-4fb0-9ce6-7961b2e58068"
      unitRef="usd">6037000</csbr:TradeAccountsReceivable>
    <csbr:TradeAccountsReceivable
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzItMy0xLTEtMTQzOTI_1fce1761-88a8-4d8c-b5a5-3600fcb296d7"
      unitRef="usd">4304000</csbr:TradeAccountsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzMtMS0xLTEtMTQzOTI_712978ef-3849-4f41-b0f0-f08ceb2ddb12"
      unitRef="usd">4106000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzMtMy0xLTEtMTQzOTI_b7877830-bca9-4358-8d46-72df06277372"
      unitRef="usd">3020000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableGross
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzQtMS0xLTEtMTQzOTI_e3fa09c1-fca0-4ebf-975d-c46efe7d34cf"
      unitRef="usd">10143000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzQtMy0xLTEtMTQzOTI_6b3858cf-4175-4576-98d2-c283c21cd57c"
      unitRef="usd">7324000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzUtMS0xLTEtMTQzOTI_58db6c23-f85a-4bea-831c-b58f9fab2fae"
      unitRef="usd">630000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzUtMy0xLTEtMTQzOTI_1b655ec1-0898-4e23-bbd9-d3170bda941d"
      unitRef="usd">338000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzYtMS0xLTEtMTQzOTI_51f83738-0975-4b4e-9d43-72fa545c124d"
      unitRef="usd">9513000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZToyZWU1YjZlYTE1NWQ0ZjY0Yjg1MTdhZjI1NWM2ZjNmMS90YWJsZXJhbmdlOjJlZTViNmVhMTU1ZDRmNjRiODUxN2FmMjU1YzZmM2YxXzYtMy0xLTEtMTQzOTI_cfeee966-93ba-446b-b2e6-f069d8f9f8f1"
      unitRef="usd">6986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzI4Mw_12fe5b2e-edc5-4b0e-82b3-f6704945eb5d">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZTo2MTBiNWQwNDI5YzM0NzEyOTBjOTA1ZjkzMThhY2NiZS90YWJsZXJhbmdlOjYxMGI1ZDA0MjljMzQ3MTI5MGM5MDVmOTMxOGFjY2JlXzItMS0xLTEtMTQzOTI_c7a00054-aee9-4338-bea3-f7a2f4c19faa"
      unitRef="usd">11071000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90YWJsZTo2MTBiNWQwNDI5YzM0NzEyOTBjOTA1ZjkzMThhY2NiZS90YWJsZXJhbmdlOjYxMGI1ZDA0MjljMzQ3MTI5MGM5MDVmOTMxOGFjY2JlXzItMy0xLTEtMTQzOTI_a8e975a6-6f0a-4b7a-a13c-24cebca6a3cf"
      unitRef="usd">6256000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:UnbilledContractsReceivable
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzIxOTkwMjMyNTU5NjI_d3f34f3b-12d5-4f47-bf9f-31241423d3fc"
      unitRef="usd">2400000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzMvZnJhZzo3ZTU5YmE0YzQ2Yzg0NDI3YWU0OTcxYjdiMjM4ZGI4Ni90ZXh0cmVnaW9uOjdlNTliYTRjNDZjODQ0MjdhZTQ5NzFiN2IyMzhkYjg2XzIxOTkwMjMyNTU5NzY_05c2d21e-a048-4b5f-8bf7-a0d90a57ca0a"
      unitRef="usd">5800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxODY_7da2f199-f416-4363-bada-78e85c260368">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense was $1.6&#160;million and $1.2 million for the years ended April&#160;30, 2022 and 2021, respectively.  Depreciation and amortization expense, excluding expense recorded under finance leases, was&#160;$1.5 million and $925,000&#160;for the years ended&#160;April 30, 2022&#160;and&#160;2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of&#160;April 30, 2022&#160;and&#160;2021, property, plant and equipment included gross assets held under finance leases of&#160;$713,000 and $343,000, respectively. Related depreciation expense for these assets was $87,000 and $124,000 for the years ended&#160;April&#160;30, 2022&#160;and&#160;2021.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized software development costs under a hosting arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the cost of computer software obtained or developed for internal use as well as the software development and implementation costs associated with a hosting arrangement ("internal-use software") that is a service contract in accordance and with ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC-350"). We capitalize certain costs in the development of our internal-use software when the preliminary project stage is completed and it is probable that the project itself will be completed and the software will perform as intended. These capitalized costs include personnel and related expenses for employees and costs of third-party consultants who are directly associated with and who devote time to these internal-use software projects. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs incurred for significant upgrades, increased functionality, and enhancements to the Company's internal-use software solutions are also capitalized. Costs incurred for training, maintenance, and minor modifications are expensed as incurred.  Capitalized software development costs are amortized using the straight-line method over an estimated useful economic life of three years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has capitalized development and implementation costs in accordance with accounting guidance for its Lumin Bioinformatics platform ("Lumin").  Lumin is the Company's new oncology data-driven software program and data tool which is operates as Software as a Service (SaaS).  These capitalized costs represent salaries, including direct payroll-related costs, certain software development consultant expenses and molecular sequencing programming costs incurred in the engineering and coding of the software development.  Capitalized costs are classified as assets in progress during the development process until development is complete and the asset is available for sale. The initial version of the Lumin platform was launched during fiscal year 2021, at which time initial capitalization ceased and amortization commenced. The total Lumin assest placed into service and available for sale as of July 31, 2020 was $484,000.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continued to develop increased functionality, expand product design and usability, and add enhancements to the Lumin platform.  In accordance with accounting guidance, these costs were capitalized. This developmental work did not render the initial released version to be obsolete or diminished in value but, rather, added to the base functionality of the existing platform.  During the third quarter of fiscal year 2022, these capitalized costs were placed into &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;service as the enhanced version was launched and made available for sale. The total cost of the enhanced Lumin asset placed into service and available for sale as of January 31, 2022 was $1.4&#160;million, bringing the total capitalized gross asset investment to $1.9&#160;million. Amortization expense related to this asset addition was $317,000 and $134,000 for the years ended April 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During fiscal 2020, the Company entered into a finance lease for laboratory equipment. The lease had costs of approximately&#160;$231,000, at inception, through November 2020. This lease expired December 2020. Prior to expiration, the  monthly finance lease payment was approximately&#160;$19,000. The future minimum lease payments remaining under this finance lease at April 30, 2021 and 2020 were zero and&#160;$135,000, respectively. The present value of minimum future obligations was calculated based on interest rate of&#160;4.75%. Depreciation and amortization expense related to this finance lease was zero and $124,000 &#160;for the years ended April 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;During fiscal 2022, the Company recognized a finance lease for laboratory equipment.  This equipment was obtained as the result of a laboratory supplies purchase commitment with costs of approximately $370,000 at inception through December 2025. Cash payments for this lease are in the form of consideration for purchasing lab supplies under a purchase commitment agreement. The present value of the minimum future obligations of $370,000 was calculated based on an interest rate of 3.25%. Depreciation and amortization expense related to this finance lease was $87,000 and zero for the years ended April 30, 2022 and 2021, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxODg_5370f90a-fb98-43c5-bc8a-ee760826a916">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_d0e54618-5027-402e-97b5-cbf85b7f6442"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTAtMS0xLTE0Mzky_f966c824-065f-42b9-b717-91f06b782abb"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia1df8ed1c598465da670d79e3593edc3_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzItMS0xLTEtMTQzOTI_b4eae45f-1ea0-4229-9ad4-26adf7aeea62"
      unitRef="usd">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i48e36386ee4d4a73a89948ef648fc5c7_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzItMy0xLTEtMTQzOTI_77c992ac-5da7-446d-a0a9-67e62968ba08"
      unitRef="usd">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie0b6dabdf94b404eb4437550f85937c4_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzMtMS0xLTEtMTQzOTI_3e50f270-3060-47b6-bb78-a352f476d171"
      unitRef="usd">1667000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b035faecffc4387a2253d46e038e904_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzMtMy0xLTEtMTQzOTI_b50b58b7-0cac-400a-bf04-eadba11e7dad"
      unitRef="usd">1461000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8b1597843e04e4d850927f9e6336bec_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzQtMS0xLTEtMTQzOTI_70650f41-8e14-43e2-8a41-58bb8184359e"
      unitRef="usd">8618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i568b515a477e47eab0c4e0a329fa4bb3_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzQtMy0xLTEtMTQzOTI_a177dafe-816f-4198-8650-44f5e4835d1b"
      unitRef="usd">6640000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia0ad5abd59b8400788b5b367632d5473_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzUtMS0xLTEtMTQzOTI_887f455a-63d6-43bf-be82-7f7b00e01437"
      unitRef="usd">1888000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic35ac20f4a06475fa1113e6fe75b4f85_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzUtMy0xLTEtMTQzOTI_70319f30-0ac9-4afc-8745-e09e5db4ef5e"
      unitRef="usd">484000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i70b0060bd8694b6fb702f24b7e796e2b_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzYtMS0xLTEtMTQzOTI_44eba336-18cb-4562-8e2b-c3abba7306ec"
      unitRef="usd">181000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb1aaf64c59043568e7d5f17d579c269_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzYtMy0xLTEtMTQzOTI_ff342d2b-9026-4383-870d-d663ccd1b152"
      unitRef="usd">1211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i748895a7edfe4b3297a3b13b1255c579_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzctMS0xLTEtMTQzOTI_356f6fb9-687d-4400-b61a-c3c02ecea309"
      unitRef="usd">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e5aecbec4114718bfe16c50c87355f3_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzctMy0xLTEtMTQzOTI_f7d5a538-31b7-4bcc-8277-7671ad7a63f4"
      unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzktMS0xLTEtMTQzOTI_2d4ec75c-653d-4ebd-8a44-6bb26bc4259f"
      unitRef="usd">12711000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzktMy0xLTEtMTQzOTI_a2fbd872-d5a8-413c-9246-9fc8c0818475"
      unitRef="usd">10046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEwLTEtMS0xLTE0Mzky_c6b033fa-e554-4c92-b635-0b740e5f72ad"
      unitRef="usd">5577000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEwLTMtMS0xLTE0Mzky_e82ed26f-73a5-4050-bc9b-731b8d192a0d"
      unitRef="usd">3956000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTEtMS0xLTE0Mzky_08d13fb7-001b-45ee-8cee-3c1cf51daeb5"
      unitRef="usd">7134000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90YWJsZTo5OGFmYzliZGUzNWI0YjU5OGIyY2ZhNDY4OGM5NzkzMi90YWJsZXJhbmdlOjk4YWZjOWJkZTM1YjRiNTk4YjJjZmE0Njg4Yzk3OTMyXzEyLTMtMS0xLTE0Mzky_d38eea01-adf8-4cee-a415-05fe64381620"
      unitRef="usd">6090000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3NTk_d8c7fb21-8443-46d1-9e47-a2120d220a0d"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzE1Nw_565186e4-bd0f-49c8-8abd-0765853dac87"
      unitRef="usd">1200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzI5OQ_28464dea-6ecf-40d2-b45c-51e18942b999"
      unitRef="usd">1500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzMwNw_c5d291d9-4d67-48fc-98ac-dbf152b07c5c"
      unitRef="usd">925000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3NzM_521826e9-d7ef-41fb-9dc6-78850e615e94"
      unitRef="usd">713000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzIxOTkwMjMyNjY0Mzc_e51d8808-2710-4b86-b0db-1202b9dc2ed7"
      unitRef="usd">343000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Depreciation
      contextRef="i0f37c8ede37d417ea5b2dcff2fe06109_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzUzMg_c7b2b5f4-781e-4778-8a8c-8823bc631a3e"
      unitRef="usd">87000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1c343591f7aa43e9bbf094ff48848b15_D20190501-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzUzOQ_30a9d995-11c8-4153-b1dc-6f7e1cec54a3"
      unitRef="usd">124000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i75381282e8854f8aa4162452573b81af_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzI0NjE_27e76dc8-4c2e-42b9-b819-b7165290a3ee">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i37caf4f2f3b94b46a64f2e1ccc27d921_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzM1Njk_70f7d88b-ad95-4ced-b607-e972f6057123"
      unitRef="usd">484000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ServicingAssetAtFairValueAmount
      contextRef="i603726853868452081ffb4f2ddec75af_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3ODQ_327e0791-efc4-4d89-a7e4-18562d929640"
      unitRef="usd">1400000</us-gaap:ServicingAssetAtFairValueAmount>
    <us-gaap:ServicingAsset
      contextRef="i603726853868452081ffb4f2ddec75af_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU3OTg_2b888d38-9025-4bfb-ab40-744175240e18"
      unitRef="usd">1900000</us-gaap:ServicingAsset>
    <us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MTI_352b2077-4d1c-41f5-a1ca-720b759ee84a"
      unitRef="usd">317000</us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization>
    <us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MjI_42a8daab-da8c-4664-ba4e-e7dc82666e60"
      unitRef="usd">134000</us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization>
    <csbr:FinanceLeaseCost
      contextRef="i8779c4cdedb2440f85a3c8ca3a5b66f1_D20191201-20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU2NzI_cbafb765-4071-4fa2-9e18-6f757fb8f025"
      unitRef="usd">231000</csbr:FinanceLeaseCost>
    <csbr:FinanceLeaseMonthlyPayment
      contextRef="ic0b7070af4eb4a99ab731259dead4896_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU4MjE_22bff57d-c7ef-44a2-b76d-54b92c49737d"
      unitRef="usd">19000</csbr:FinanceLeaseMonthlyPayment>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ia82b4636bcec43a581c7c41150e8c863_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU5MjY_e4a7d3d0-a3ce-4f5a-905f-301a9cd2a1f3"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ieb85b2ee4da64c099fc6a0fbbd34f4d4_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzU5MzM_a10027f8-4f64-4e45-a3de-9aea875cf006"
      unitRef="usd">135000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <csbr:PresentValueMinimumFutureObligationsInterestRate
      contextRef="i19fa58ff128b48d4a12d943d7cb17020_D20190501-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYwNDA_c6253661-9cb6-430a-a0e2-281c22ffe498"
      unitRef="number">0.0475</csbr:PresentValueMinimumFutureObligationsInterestRate>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i22b89d0c347047c4a863838d447fe6b2_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4MzE_9dd68d41-081b-405d-971b-82cf714a7617"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i7944dc3e37d5471fac3e5aa26a76720a_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzYxMTY_ad01c50b-45c9-45be-8b7f-6fdbad99b0e2"
      unitRef="usd">124000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <csbr:FinanceLeaseCost
      contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NDE_cc20b9df-de7c-4cab-9034-7b4b8e6ee565"
      unitRef="usd">370000</csbr:FinanceLeaseCost>
    <csbr:FinanceLeaseCost
      contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzIxOTkwMjMyNjc2MTM_8f03a127-91d7-4fe7-8b58-9204b8031679"
      unitRef="usd">370000</csbr:FinanceLeaseCost>
    <csbr:PresentValueMinimumFutureObligationsInterestRate
      contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NTE_aca7cbfb-9bb9-4384-8fc8-69e730a7026e"
      unitRef="number">0.0325</csbr:PresentValueMinimumFutureObligationsInterestRate>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie8d827ab38ba4b2a96e8368d7280b31b_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NTg_a716b649-5749-467b-8527-7cc76b0eb107"
      unitRef="usd">87000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i11b3c65241cc4e8181694452a5e4d0eb_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzYvZnJhZzphYjExM2YzODk3Y2I0ZWJlYTYzNjEzZjUwMzU0NGQ2OS90ZXh0cmVnaW9uOmFiMTEzZjM4OTdjYjRlYmVhNjM2MTNmNTAzNTQ0ZDY5XzQ5NDc4MDIzMzU4NjY_7f54f734-da73-4b21-bc7f-7f41126f35d3"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90ZXh0cmVnaW9uOjIzNDA5NDViMDM0YTQ2MmRiN2UzZTM5NDA5M2M1OTFlXzQwNTk_a73331df-e731-41b1-8b25-b973aa452e3c">Revenue from Contracts with Customers&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Oncology Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The following table represents disaggregated revenue for the twelve months ended April&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacology services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other TOS revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personalized oncology services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology services revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers,  specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.  Refer to Note 3 for related balances.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90ZXh0cmVnaW9uOjIzNDA5NDViMDM0YTQ2MmRiN2UzZTM5NDA5M2M1OTFlXzQwNjA_231a2289-0fe2-4080-86a4-2a3519cdb58f">The following table represents disaggregated revenue for the twelve months ended April&#160;30, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacology services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other TOS revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personalized oncology services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology services revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt; Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers,  specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccbb55bcd7d8409f95ab07871b4f00eb_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzItMS0xLTEtMTQzOTI_b72d47c1-e65e-4b95-a38a-12fec2d56ca4"
      unitRef="usd">46833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5ae863a047f404ebf60eb56f8352be7_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzItMy0xLTEtMTQzOTI_98991520-cf68-414f-8bf7-130c462044b7"
      unitRef="usd">39473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad9d5b70c71944c3b1537441f0cba8e8_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMS0xLTEtMTU1MDc_f6e1d08c-905e-4357-86bb-f5bc391ee889"
      unitRef="usd">2227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e613c7ed7e462d8916e09de7dfd9b6_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMy0xLTEtMTU1MDc_b83b8176-9352-481f-9492-cf22faf4e075"
      unitRef="usd">1401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie75ddc90488642fe9524dca29561cb31_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMS0xLTEtMTQzOTI_742e0d22-8fa6-4224-86bb-2f3f53d87986"
      unitRef="usd">49000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ace46fb73764dc580412ddfa1073ea4_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzMtMy0xLTEtMTQzOTI_4ac21d76-91d6-4485-92da-0e2ec24735ee"
      unitRef="usd">166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzUtMS0xLTEtMTQzOTI_9c127d5d-dd33-4e32-a67f-5c29feaf561c"
      unitRef="usd">49109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xMzkvZnJhZzoyMzQwOTQ1YjAzNGE0NjJkYjdlM2UzOTQwOTNjNTkxZS90YWJsZTo0MzMwNmNhN2QyM2U0OTUwYjI2ZmFmMzY2N2FjMmUzOC90YWJsZXJhbmdlOjQzMzA2Y2E3ZDIzZTQ5NTBiMjZmYWYzNjY3YWMyZTM4XzUtMy0xLTEtMTQzOTI_5d148589-4e2a-4a8a-be28-d96bf08b59d4"
      unitRef="usd">41040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDIvZnJhZzo1Yjk1ZGE0ODY2MTY0ZWNhOTZiYWFlYzlkMjg2OThhYi90ZXh0cmVnaW9uOjViOTVkYTQ4NjYxNjRlY2E5NmJhYWVjOWQyODY5OGFiXzI1OQ_49c372d9-1c52-45f7-a50b-dd31ad1c233c">Significant Customers&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended April&#160;30, 2022 and 2021, one and none of our customers accounted for more than 10% of our total revenue, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;As of April&#160;30, 2022, one customer accounted for 17% of our total accounts receivable balance.  As of April 30, 2021, no customers accounted for 10% or more of our total accounts receivable balance.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDIvZnJhZzo1Yjk1ZGE0ODY2MTY0ZWNhOTZiYWFlYzlkMjg2OThhYi90ZXh0cmVnaW9uOjViOTVkYTQ4NjYxNjRlY2E5NmJhYWVjOWQyODY5OGFiXzIxOTkwMjMyNTY0MzE_2b2f2aae-2213-4f03-af35-a5038485dfdc"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzIwNjM_b9b51b27-d711-43aa-9f79-8e3b64fcceea">Commitments and Contingencies&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company&#x2019;s financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Registration Payment Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company&#x2019;s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company has not accrued any liquidated damages associated with the Amended and Restated Registration Right Agreement as the Company has filed the required registration statement and anticipates continued compliance with the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;The Company contracts with third-party vendors to license tumor samples for development into PDX models and use in our TOS business. These types of arrangements have an upfront fee ranging from approximately nil&#160;to $30,000 per tumor sample depending on the successful growth of the tumor model and ability to develop them into a sellable product. The upfront costs are expensed as incurred. In addition, under certain agreements, for a limited period of time, the Company is subject to royalty payments if the licensed tumor models are used for sale in&#160;our TOS business,&#160;ranging from 2% to 20% of the contract price&#160;after recouping certain initiation costs.  Some of these arrangements also set forth an annual minimum royalty due regardless of tumor models used for sale.   For the years ended April&#160;30, 2022 and 2021, we have recognized approximately $401,000 and  $127,000 in expense related to these royalty arrangements, respectively.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <csbr:CollaborationArrangementRoyaltyFee
      contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzEzNjc_7b7e818a-3434-427a-a018-a061b6b4df44"
      unitRef="usd">0</csbr:CollaborationArrangementRoyaltyFee>
    <csbr:CollaborationArrangementRoyaltyFee
      contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5MTM_349047d4-a292-48d6-938d-357d5607ca36"
      unitRef="usd">30000</csbr:CollaborationArrangementRoyaltyFee>
    <csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice
      contextRef="i09828ea7d129413093b3a3fbae595b40_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzE3Mzc_e60e187d-0822-4641-bf61-a6428d001b35"
      unitRef="number">0.02</csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice>
    <csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice
      contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5MjI_3e910b73-b97c-4a01-8c44-0de84540ce40"
      unitRef="number">0.20</csbr:CollaborationArrangementRoyaltyFeePercentOfContractPrice>
    <us-gaap:RoyaltyExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzIxOTkwMjMyNTc3Mjk_b1aa13c3-dd91-419e-b735-47e8f05846c5"
      unitRef="usd">401000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDUvZnJhZzo3NDVkN2QwMTkyMTc0MDU1YmQyZmU5OWEzOTAwNjYwZi90ZXh0cmVnaW9uOjc0NWQ3ZDAxOTIxNzQwNTViZDJmZTk5YTM5MDA2NjBmXzYwNDczMTM5NTQ5Mjg_ddeb0548-5acd-4036-8bf4-94d0853dceb8"
      unitRef="usd">127000</us-gaap:RoyaltyExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNjU_b396c0f4-706e-4d16-84c6-bb5361bd1efa">Stock-based Payments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation in the amount of $912,000 and $598,000 was recognized for years ended April&#160;30, 2022 and 2021, respectively.&#160;Stock-based compensation costs were recorded as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TOS cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan ("the Plans"). In general, these plans provide for stock-based compensation to the Company&#x2019;s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (&#x201c;2021 Equity Plan&#x201d;). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed 2&#160;million shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair market value of the common stock subject to the option or right at the date of grant.  As of April 30, 2022, approximately 1.8&#160;million shares were left to issue under this plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2010 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (&#x201c;2010 Equity Plan&#x201d;). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant.  After February 2021, no more shares were available to be issued from this plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2008 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the &#x201c;2008 Equity Plan&#x201d;).&#160;&#160;Such awards may be granted by the Company&#x2019;s Board of Directors.&#160;&#160;Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock-based payments to non-employee consultants under the Plans, the fair value of the stock-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.&#160;&#160;The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company&#x2019;s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award. After 2018, no more shares were available to be issued from this plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Director Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2013, the Compensation Committee of the Board of Directors of the Company adopted changes to the Director Compensation Plan of 2010 (the &#x201c;Director Plan&#x201d;) effective December 1, 2013.&#160;&#160;Under the Director Plan, independent directors of the Company are entitled to an annual award of a five-year option to purchase 8,333 shares of the Company&#x2019;s common stock, and the Chairman of the Board of the Company is entitled to an annual award of a five-year option to purchase 16,667 shares of the Company&#x2019;s common stock.&#160;&#160;Independent directors who serve as chairperson of a committee will also receive an annual grant of a five-year option to purchase 1,667 shares of the Company&#x2019;s common stock. All options issued under the Director Plan vest quarterly at a rate of 25%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in October of each year. New directors will receive a grant upon joining the Board equal to the pro-rata annual grant for the remainder of the year.&#160;Options issued under the Director Plan are now issued pursuant to the 2021 Equity Plan.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April&#160;30, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8% - 1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1% - 0.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64% - 66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of stock options granted during the years ending April&#160;30, 2022 and 2021, was $5.56 and $5.11, respectively. The Company&#x2019;s stock options activity and related information as of and for the years ended April&#160;30, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Directors&lt;br/&gt;and&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, May 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,778,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Directors&lt;br/&gt;and&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, May 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,663,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(686,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(687,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,995,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzc4_1a0d76b2-d0c5-4758-8ee1-7d6eeb4c8a23"
      unitRef="usd">912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzg1_8a12cfda-df64-44ed-8fac-1e44285f01cf"
      unitRef="usd">598000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzg_f81227eb-d75c-4d8e-8325-14a165cf7324">Stock-based compensation costs were recorded as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TOS cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan ("the Plans"). In general, these plans provide for stock-based compensation to the Company&#x2019;s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8c0dcae4e7d40d4b0fb1669660fdd03_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzItMS0xLTEtMTQzOTI_2f16afb0-4b36-4c9e-b88d-f89fb97762f6"
      unitRef="usd">563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2997e8d60bcf46f9ba6c1f4ca4110249_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzItMy0xLTEtMTQzOTI_f85b18fb-6b0c-4b0c-b9cd-106803550ae0"
      unitRef="usd">292000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia55eff6dffbf4ce19f35251ba3c322f6_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzMtMS0xLTEtMTQzOTI_9e5a3e16-a8e0-4dad-b1b0-276a3ef2e005"
      unitRef="usd">189000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic23746d0989e4145af18c84580ca48f6_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzMtMy0xLTEtMTQzOTI_739701b4-9895-4dbe-b0cc-fdf250bd1b4c"
      unitRef="usd">199000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49c8d68a641f4e3b847ea1ccfcd8e347_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzQtMS0xLTEtMTQzOTI_a41f5e71-4b1b-492c-9ea2-3f1a546be0ca"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i43786c34b50d435293e7048f0d6fb091_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzQtMy0xLTEtMTQzOTI_609bedf0-c1ea-4174-9123-d02a3654cfad"
      unitRef="usd">23000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24b63951e3c94191b0de18e0a98025b5_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzUtMS0xLTEtMTQzOTI_180d6a8d-2251-40ad-874a-8b8d4a76104c"
      unitRef="usd">142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i541e144c82554a4e88aec80277e945e8_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzUtMy0xLTEtMTQzOTI_4d1150fa-d9af-4297-8283-bd8daa8ce157"
      unitRef="usd">84000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzgtMS0xLTEtMTQzOTI_0dd6e012-f3a3-47dc-bbfe-f877d8a8b548"
      unitRef="usd">912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo1NjM5MjQxODAzN2Q0NTkyYTYzZTdiNjJlMDI2YWVmZC90YWJsZXJhbmdlOjU2MzkyNDE4MDM3ZDQ1OTJhNjNlN2I2MmUwMjZhZWZkXzgtMy0xLTEtMTQzOTI_e6b86154-94e6-4054-b047-9d4db5c0723e"
      unitRef="usd">598000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i72c10eebe3ea442a931103ac31ce4af1_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzEwMTY_c086f19b-72e7-43eb-aa06-4716590851a0"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzA0Njc_c0738754-1e02-442e-b742-d194441df409">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i00e645f5a9674c9a95427a3f039083c8_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzA0ODc_7fdc2693-e06d-4d8d-bda9-3dfbc18c1efe"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ice1add8ac2df4b9ebbefa41994d6bc10_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzIxOTkwMjMyNzEwMjc_bc235863-37ef-412a-84d5-2b890dba9e8c"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i94a9f833a47649688056938280a6100a_D20110218-20110218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzcyNw_ce69302b-64fb-4c1e-b93f-ea7745b708bc"
      unitRef="shares">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzgxMw_5ed02c4f-7781-42c5-8529-7f1b02f448fe">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia3c94b5b633840379480c469a78ed5bf_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzk3Mg_ab1487df-86ef-409b-b006-921785fe8b3b"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic8f8fd968db64d9aab0a9c7ba34faf09_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzE1MTY_7af34e76-5f0c-47f4-928e-76f5166497a5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase
      contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzM_b288f478-9cdd-45b4-909e-c38a940927cc">P5Y</csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase>
    <csbr:StockOptionsAwardSharesToPurchaseCommonStock
      contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI2NTI_0d624ea7-7b9f-452d-8be3-168434fed5f9"
      unitRef="shares">8333</csbr:StockOptionsAwardSharesToPurchaseCommonStock>
    <csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase
      contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI3NDg3NzkwODQ0NDA_19f34667-4fdf-4d6b-8f80-cb91dab7c334">P5Y</csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase>
    <csbr:StockOptionsAwardSharesToPurchaseCommonStock
      contextRef="i2499764558fa4746ac056a1fff5047ae_D20131212-20131212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI3OTY_7a5eba26-413d-465c-90f2-f7a0e30d7ced"
      unitRef="shares">16667</csbr:StockOptionsAwardSharesToPurchaseCommonStock>
    <csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase
      contextRef="i27dda0340a2541cdbfa3006b67c7f596_D20131212-20131212"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzOTA_a1197ec3-ece4-461d-94fe-db19b5b66f6f">P5Y</csbr:SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase>
    <csbr:StockOptionsAwardSharesToPurchaseUnregisteredCommonStock
      contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzI5NjY_ef66f921-3577-41ef-866f-e5dc3893217e"
      unitRef="shares">1667</csbr:StockOptionsAwardSharesToPurchaseUnregisteredCommonStock>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="ibd0fa135aa62446eb639c81206006175_D20131212-20131212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzMwNzg_e3c79d48-84ae-4bfe-a473-73d63e40d175"
      unitRef="number">0.25</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNzA_828780ac-8a0b-4cba-b02d-c1f68b5d1152">&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April&#160;30, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8% - 1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1% - 0.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64% - 66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if0ddfa245fb243609ba9ca071f1c7aef_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjozYWZlZDM0YjNiZjQ0ZGJhYmVlYmRlYWNkNzA3NjhkNF83_e71164db-7be6-4651-ab4d-511fbdb93d25">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i98768c91edc344c293525a163b2ebfb6_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxOGZmYWI5M2U1YTU0ZDhkOGJhNDg3ZDQ5NWFhNmQzYl80_b5cf204e-1f38-4328-9af3-7e7b59f206be">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5f86018505f24f40a948b8a3bda2f392_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzItMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxOGZmYWI5M2U1YTU0ZDhkOGJhNDg3ZDQ5NWFhNmQzYl85_7de1bb72-8966-46f4-a781-88b29ea7a6e2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4MmE1NWI1MmUxODU0MWRkODc0NDQyNjg1MGRjYTkzNF80_d145cdfa-c205-44b4-b4df-350506f39b9d"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4MmE1NWI1MmUxODU0MWRkODc0NDQyNjg1MGRjYTkzNF85_f2f96b6e-d6e6-4b8f-afc5-17836f3e88a0"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4NWY4MjgxYmMwNGE0YjJhYTAxZmFjN2MxNTJhYmM4Nl80_9cf6f864-535d-418a-ac66-a111419bd4e2"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzMtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4NWY4MjgxYmMwNGE0YjJhYTAxZmFjN2MxNTJhYmM4Nl85_525dabd2-f0dd-4b5c-ac7d-9a2acda24ea8"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo0NTQ0NmU5NDg1MDU0NjIyYTE1OGM3YjAxNDM3MWNjZl80_06b8a958-a22d-4a08-bb6d-c30b0c4be8a8"
      unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo0NTQ0NmU5NDg1MDU0NjIyYTE1OGM3YjAxNDM3MWNjZl85_5279c083-f3c3-42d0-9b4a-521b7fe6c4e1"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4OGM3NWNiY2VjOGM0NjQ2YWYxNGNmYzYzMjE1YjljOV80_cade790b-0915-4585-8462-5ac2dfc7095e"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzQtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjo4OGM3NWNiY2VjOGM0NjQ2YWYxNGNmYzYzMjE1YjljOV85_0a984fa9-851b-4049-b95d-c2abab03a446"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzUtMS0xLTEtMTQzOTIvdGV4dHJlZ2lvbjoxNTU4NTRhMzZkNTg0ZjFiOWEzYzk4NDNiYmU5ODY5Ml80_366ac487-8454-4a1e-bf71-3b8251969708"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo2NTA5NTY0YzViMmE0NTY4OGZkYjFjMjY2MDBmMDYzYi90YWJsZXJhbmdlOjY1MDk1NjRjNWIyYTQ1Njg4ZmRiMWMyNjYwMGYwNjNiXzUtMy0xLTEtMTQzOTIvdGV4dHJlZ2lvbjplMTU2YmMwZmI0ODI0NTNmYmI3Mzk2NGM2NTJiNzJlMF80_49d5c643-cd26-4727-b85f-6ff4b7563dc8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzM2NzI_8af8fe08-4e0f-4817-97e2-387701b7873e"
      unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzM2Nzk_d508d9eb-2ac9-4f2d-abad-18b12e367d6a"
      unitRef="usdPerShare">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90ZXh0cmVnaW9uOmMyZjNlZDFmMTE0ZDQzN2Q4NmRkNjg0NmE1OGM5OWFkXzQzNjk_f289196d-f508-4245-9967-c2eba67d1e3f">The Company&#x2019;s stock options activity and related information as of and for the years ended April&#160;30, 2022 and 2021 is as follows:&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Directors&lt;br/&gt;and&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, May 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,778,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Directors&lt;br/&gt;and&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, May 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,663,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(686,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(687,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,995,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a5a1fb68099489386e300756890aabb_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMS0xLTEtMTQzOTI_c57c2542-2dac-4a2e-9896-74d4cfb884d2"
      unitRef="shares">1618231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMy0xLTEtMTQzOTI_8e7ff568-7f06-4b69-a0c1-1e8884f305b7"
      unitRef="shares">35415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtNS0xLTEtMTQzOTI_2929cb73-48c4-4f1f-b079-eeb39ba8f866"
      unitRef="shares">1653646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtNy0xLTEtMTQzOTI_28a686a2-32de-4e6d-9c9a-34cafcc23993"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtOS0xLTEtMTQzOTI_cec3c2fa-ce68-4a4f-8bdd-38f8e80e6c67">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEtMTEtMS0xLTE0Mzky_fe823878-1c23-453e-a8a3-385173c9c97a"
      unitRef="usd">11384000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMS0xLTEtMTQzOTI_6195a6c5-6a19-4a17-89ab-0602592b3246"
      unitRef="shares">155552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMy0xLTEtMTQzOTI_23f18af5-5e48-4891-989a-35d51c9e87c7"
      unitRef="shares">10500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItNS0xLTEtMTQzOTI_1bead16a-da1c-4cb0-98f8-2641bd93d088"
      unitRef="shares">166052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItNy0xLTEtMTQzOTI_d59025a0-7377-4c7d-a66d-dd945b138dc9"
      unitRef="usdPerShare">9.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItOS0xLTEtMTQzOTI_6776fb2f-fa7e-4b11-8dd2-69b23774b739">P9Y3M18D</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzItMTEtMS0xLTE0Mzky_e009e3dd-1434-4cee-94a5-e49bf7acd692"
      unitRef="usd">0</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtMS0xLTEtMTQzOTI_22f4093a-1620-4038-aa49-5efd9de989f1"
      unitRef="shares">108375</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtMy0xLTEtMTQzOTI_a8b1eb71-6354-4de2-a0d8-b2399d64d307"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtNS0xLTEtMTQzOTI_2ca1898e-5bb0-42cc-afc0-850efbbf344a"
      unitRef="shares">108375</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzMtNy0xLTEtMTQzOTI_7a95cf2a-3fb8-4034-ac84-5aca6323a67c"
      unitRef="usdPerShare">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtMS0xLTEtMTQzOTI_b8d57de2-81a7-461a-96bb-d98f512202b7"
      unitRef="shares">11209</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtMy0xLTEtMTQzOTI_6f3430cf-c8e1-4d4e-a282-0f1e5893fbc9"
      unitRef="shares">0</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtNS0xLTEtMTQzOTI_06825931-460f-4746-a8bb-ea6a7d069cf5"
      unitRef="shares">11209</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzQtNy0xLTEtMTQzOTI_0f2ed7d3-2de7-4096-91e6-4ed3cb50514b"
      unitRef="usdPerShare">4.71</csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtMS0xLTEtMTQzOTI_25215710-22e9-4b99-a806-7d277569c398"
      unitRef="shares">36875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtMy0xLTEtMTQzOTI_08dde4b8-4d6a-4b36-9727-55085c07308c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtNS0xLTEtMTQzOTI_ff0f469e-d956-412a-9119-521d4dfd020b"
      unitRef="shares">36875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzUtNy0xLTEtMTQzOTI_3117469c-b137-4ab6-af7f-999a96bc1cf6"
      unitRef="usdPerShare">7.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ib30cc84217ef4219bc5a5b4410f9c075_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtMS0xLTEtMTQzOTI_fd081bd7-f845-4a48-8069-760d10558714"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i2397541b56f6425f90433d4f228fe5e9_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtMy0xLTEtMTQzOTI_cf685b44-e447-487a-b810-e98c9f6d62d9"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtNS0xLTEtMTQzOTI_feb31345-5672-40a3-b6b9-7395def2020c"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzYtNy0xLTEtMTQzOTI_3c43cb91-ba18-42dd-8c1a-30abaee6c944"
      unitRef="usdPerShare">9.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMS0xLTEtMTQzOTI_111d3699-03a2-4805-b301-e9c28a0f82f0"
      unitRef="shares">1617324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMy0xLTEtMTQzOTI_551f1142-4b8f-4e8c-a270-07d558e28104"
      unitRef="shares">40915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtNS0xLTEtMTQzOTI_b17ebfb8-f13e-40b0-9672-5a9033e4b367"
      unitRef="shares">1658239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtNy0xLTEtMTQzOTI_9a533378-6aba-4b39-a07d-a4f19a2106fd"
      unitRef="usdPerShare">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtOS0xLTEtMTQzOTI_20adfb8e-3fae-4b65-84b9-04f0504d20b3">P4Y10M24D</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzgtMTEtMS0xLTE0Mzky_b252c5ce-9fa8-407d-961e-8b21281b09b5"
      unitRef="usd">6131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTEtMS0xLTE0Mzky_54c002d5-4aae-4cc4-8f68-6f84dfcd6330"
      unitRef="shares">1617324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTMtMS0xLTE0Mzky_19d3ca21-30f2-468e-99f2-54074c8a9585"
      unitRef="shares">40915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTUtMS0xLTE0Mzky_ee94b29d-895f-42b8-8fe0-bcdab6662761"
      unitRef="shares">1658239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTctMS0xLTE0Mzky_63cf99ba-e103-42e7-88d3-8dd23ce397e8"
      unitRef="usdPerShare">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTktMS0xLTE0Mzky_f9d5f22e-2d67-46f3-825d-34b6c88c8a31">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEwLTExLTEtMS0xNDM5Mg_cb7a1d52-7c02-47e6-8386-9ad3de2ba83b"
      unitRef="usd">6131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id74600c6b29b46c4882983e3cc60d3ed_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTEtMS0xLTE0Mzky_e8a4dbc7-2f23-466a-8057-6af60b12ab99"
      unitRef="shares">1349895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if5e6f0d067d84392bf315f54788e6654_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTMtMS0xLTE0Mzky_2d67853f-5595-41fc-af26-0ad7ca15b3f7"
      unitRef="shares">4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTUtMS0xLTE0Mzky_d3081440-21a7-4dc7-88aa-9487868e465a"
      unitRef="shares">1354479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTctMS0xLTE0Mzky_f653ebf8-9835-4a63-bb57-a36a193ee271"
      unitRef="usdPerShare">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTktMS0xLTE0Mzky_a18f6e28-20cd-4111-9d5b-989b54f2d099">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTpkNTRiMDEyMDk1ODg0ODY5OTkyYTQ3NDVhYmVlNTgzMy90YWJsZXJhbmdlOmQ1NGIwMTIwOTU4ODQ4Njk5OTJhNDc0NWFiZWU1ODMzXzEyLTExLTEtMS0xNDM5Mg_d3540097-a1f5-4a62-8807-fa0ccce575d5"
      unitRef="usd">5778000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8126402c4f4240ec950ef891d3d9bad6_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMS0xLTEtMTQzOTI_03071b1b-f142-48fa-885a-6889e11081e8"
      unitRef="shares">2228326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i494cc1892ba8486dadda4d692b680743_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMy0xLTEtMTQzOTI_a6744b7a-1c29-4d98-9cb5-8803b8acd88c"
      unitRef="shares">43332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtNS0xLTEtMTQzOTI_64973144-f343-42d2-8be0-2ae40121ae18"
      unitRef="shares">2271658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtNy0xLTEtMTQzOTI_444d6b53-251d-4189-be72-f512b01ab1a2"
      unitRef="usdPerShare">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idabe360fb07c401a827aa2b65746f3bb_D20190501-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtOS0xLTEtMTQzOTI_301506d8-cf43-420a-8d35-fad75e134abd">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEtMTEtMS0xLTE0Mzky_6e79d1d9-b9d6-45d8-a244-576add36efd8"
      unitRef="usd">10663000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMS0xLTEtMTQzOTI_056b7e96-1cba-4508-aaa3-dd88db9614ca"
      unitRef="shares">135834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMy0xLTEtMTQzOTI_550cd9df-b924-4f98-9661-86b0240dffe4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItNS0xLTEtMTQzOTI_f92e80c2-39cb-46bc-876e-ce30e6866bdb"
      unitRef="shares">135834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItNy0xLTEtMTQzOTI_7ef06f09-b2d9-46b3-8c5f-3af02fed5376"
      unitRef="usdPerShare">9.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItOS0xLTEtMTQzOTI_5aba6a70-f083-4d42-b053-9b2911d1c882">P7Y3M18D</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzItMTEtMS0xLTE0Mzky_bfbb2d7c-b0fe-4d3e-a8de-08787f5b383a"
      unitRef="usd">259000</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtMS0xLTEtMTQzOTI_ec507dc1-abe2-416d-aadd-1bbcb8f7bb38"
      unitRef="shares">686178</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtMy0xLTEtMTQzOTI_0bad998b-e8ef-45a4-926a-d9821ae4bd60"
      unitRef="shares">1160</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtNS0xLTEtMTQzOTI_4ce07c30-a09f-44e2-a628-f8deaf041142"
      unitRef="shares">687338</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzMtNy0xLTEtMTQzOTI_3cb3a167-f2ba-4ab4-aa8a-4a14b2617dc5"
      unitRef="usdPerShare">2.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtMS0xLTEtMTQzOTI_9d92cdaa-7ca9-47dd-9c7e-db0696a4a344"
      unitRef="shares">47751</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtMy0xLTEtMTQzOTI_0aa2d49c-a06c-4bf4-80c3-7cfe10a2be74"
      unitRef="shares">923</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtNS0xLTEtMTQzOTI_7b2b4b36-107a-438a-9de5-f0886e1e3bf8"
      unitRef="shares">48674</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod>
    <csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzQtNy0xLTEtMTQzOTI_f7a2b717-018e-4e59-9bbe-620fc76a107d"
      unitRef="usdPerShare">6.03</csbr:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtMS0xLTEtMTQzOTI_e47267ee-24e8-4b5a-886f-b7ab8ce68702"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtMy0xLTEtMTQzOTI_720e9d52-0139-426c-aead-05fcfae019cb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtNS0xLTEtMTQzOTI_f253882d-04f7-460f-85a0-37fd5d94e396"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzUtNy0xLTEtMTQzOTI_2d4b4526-ec6f-4732-9c2f-277a885f7dae"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i78b932b7fbce4752a68a21cc3422366f_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtMS0xLTEtMTQzOTI_f101f2c9-b247-4701-876f-fbb44af970fb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iacfc4894f2eb417ca75b26df827c69e5_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtMy0xLTEtMTQzOTI_6c09fabb-b13d-43d7-88ce-5b662e893fc0"
      unitRef="shares">5834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtNS0xLTEtMTQzOTI_9f1876cc-4940-4629-829f-dfab8838e68e"
      unitRef="shares">5834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzYtNy0xLTEtMTQzOTI_276a5259-99cc-4778-a819-132a358adbc5"
      unitRef="usdPerShare">10.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a5a1fb68099489386e300756890aabb_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMS0xLTEtMTQzOTI_a74e1388-d589-417e-881f-4e2943374ac1"
      unitRef="shares">1618231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMy0xLTEtMTQzOTI_11cb6de8-9153-4fda-906e-2f0ab9520301"
      unitRef="shares">35415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtNS0xLTEtMTQzOTI_98b35815-b47d-4ccb-aafa-a421da71fac9"
      unitRef="shares">1653646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtNy0xLTEtMTQzOTI_b7e313c7-b2c3-4883-84ca-a77d2404eace"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtOS0xLTEtMTQzOTI_d525927c-d33f-4c8e-91fe-5dd85724d5d8">P5Y4M24D</csbr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzgtMTEtMS0xLTE0Mzky_8a70154b-14d7-420a-92be-5afa671cf282"
      unitRef="usd">11384000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i6a5a1fb68099489386e300756890aabb_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTEtMS0xLTE0Mzky_ed5f85c0-591f-41b0-8cd1-8c7ac6f2abc6"
      unitRef="shares">1618231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTMtMS0xLTE0Mzky_d4b223a3-07a6-4db9-9d45-b05c0294f241"
      unitRef="shares">35415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTUtMS0xLTE0Mzky_0ec6eb2d-a1ac-482c-ae57-1145c411e513"
      unitRef="shares">1653646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTctMS0xLTE0Mzky_c39e9034-b7db-4740-af53-f41963f9c969"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTktMS0xLTE0Mzky_00e938ad-f58e-4ef1-9d10-96204b084dee">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEwLTExLTEtMS0xNDM5Mg_0c9d6888-8a9b-404c-9eb8-ec6bb091cdea"
      unitRef="usd">11384000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6a5a1fb68099489386e300756890aabb_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTEtMS0xLTE0Mzky_7fe3e1a9-a75b-4485-a017-be1ac0428459"
      unitRef="shares">1323270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7c0d1264a9d342c3a89311559d727593_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTMtMS0xLTE0Mzky_c29c2213-cedc-47c2-8e67-fa1bf5b2fa14"
      unitRef="shares">9584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTUtMS0xLTE0Mzky_32e999f0-8f6f-4474-922d-bd4bc14b564b"
      unitRef="shares">1332854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTctMS0xLTE0Mzky_8007d0ff-613c-4fdd-b823-7989d1b7166f"
      unitRef="usdPerShare">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTktMS0xLTE0Mzky_79a6a43a-4939-4618-bd4e-2014808959a1">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNDgvZnJhZzpjMmYzZWQxZjExNGQ0MzdkODZkZDY4NDZhNThjOTlhZC90YWJsZTo0OTA0YjZhMDc3YTA0YzA4YWJmNDUwNWU1ZTU3OTUwMC90YWJsZXJhbmdlOjQ5MDRiNmEwNzdhMDRjMDhhYmY0NTA1ZTVlNTc5NTAwXzEyLTExLTEtMS0xNDM5Mg_b7839d9d-fd77-47b2-9f66-c6d36f5f497c"
      unitRef="usd">9995000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMTc_721bcafc-2bbc-4cab-a4c8-32144ae65f90">Provision for Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the provision for income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the United States statutory tax rate for the years ended April&#160;30, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US vs. foreign tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&#160;&#160;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of April&#160;30, 2022 and 2021 consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use, net asset/liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.730%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense; class life changes to qualified improvements (in general, from 39 years to 15 years); and the ability to carry back net operating losses incurred from tax years 2018 through 2020 up to the five preceding tax years. The Company has evaluated the new tax provisions of the CARES Act and determined the impact to be either immaterial or not applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated the available evidence about future tax planning strategies, taxable income, and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of&#160;April&#160;30, 2022&#160;and&#160;2021.&#160;&#160;For the years ended&#160;April&#160;30, 2022&#160;and&#160;2021, the Company recorded a valuation allowance of&#160;$15.5&#160;million and $15.3&#160;million, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;April&#160;30, 2022&#160;and&#160;2021, the Company&#x2019;s estimated U.S. net operating loss carry-forwards were approximately $48.0&#160;million and&#160;$46.9&#160;million, respectively. Net operating losses generated prior to May 1, 2018 have a 20-year carryforward and will begin expiring in&#160;2025&#160;for federal and&#160;2031&#160;for state purposes. Losses generated in the fiscal years since the year ended April 30, 2019 may be carried forward indefinitely.&#160;&#160;A valuation allowance has been recorded against all of these loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:33.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#x2019;s ownership may result in a limitation on the amount of net operating losses that may be utilized in future years. During the fiscal year ended April 30, 2013, approximately&#160;$12.0 million&#160;of the Company&#x2019;s net operating losses became subject to limitation under Internal Revenue Code Section 382 in connection with an ownership change on January 28, 2013. As a result of the ownership change, the Company&#x2019;s annual limitation on its use of net operating loss carry-forwards is approximately&#160;$432,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company files income tax returns in various jurisdictions with varying statutes of limitations.&#160;&#160;As of&#160;April&#160;30, 2022, the earliest tax year still subject to examination for state purposes is fiscal 2018.&#160;&#160;The Company&#x2019;s tax years for periods ending April 30, 2002 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table indicates the changes to the Company&#x2019;s uncertain tax positions for the period and years ended April&#160;30, 2022 and 2021 in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment made on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;30, 2022 and 2021, the above amounts of $181,000  for each fiscal year were included in other long-term liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMDA_bbeb7da4-bd70-471b-aba9-30ff89e4ab36">The components of the provision for income taxes are as follows (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItMS0xLTEtMTQzOTI_a7b12bb6-69fb-4a7d-8fb3-afdd665f0a48"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItMy0xLTEtMTQzOTI_41785e85-65ed-4d73-bd39-71c4006366db"
      unitRef="usd">10000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItNS0xLTEtMTQzOTI_49358809-a1b0-45fa-afe8-cc83b3938186"
      unitRef="usd">25000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzItNy0xLTEtMTQzOTI_68dc4af7-5572-4716-aed4-51c5e0285697"
      unitRef="usd">35000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtMS0xLTEtMTQzOTI_0047d9ce-e2ca-4e75-82d1-26c372f8c3b3"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtMy0xLTEtMTQzOTI_a7d5339a-badb-4b32-9125-6db8d2b08740"
      unitRef="usd">10000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtNS0xLTEtMTQzOTI_1c86d8d1-e4f1-47df-bc7d-3e26b7eac1cb"
      unitRef="usd">25000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo0MWFlNzY3YjllNzI0ZWIxOWJjN2JkNjJhZmFlZmY1YS90YWJsZXJhbmdlOjQxYWU3NjdiOWU3MjRlYjE5YmM3YmQ2MmFmYWVmZjVhXzYtNy0xLTEtMTQzOTI_0c420a93-016e-417d-8cf0-67ea29b072dc"
      unitRef="usd">35000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItMS0xLTEtMTQzOTI_847402bf-71ad-4c0b-a7aa-3ce724a27405"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItMy0xLTEtMTQzOTI_34a50949-ce99-4442-81d7-6a637afcc20f"
      unitRef="usd">13000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItNS0xLTEtMTQzOTI_197d9a75-d7e6-428f-b183-f1be7b748950"
      unitRef="usd">62000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzItNy0xLTEtMTQzOTI_ac0a25c0-7871-47d4-bd08-1c37c7fd896d"
      unitRef="usd">75000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtMS0xLTEtMTQzOTI_4110cc2b-53b3-4c3b-bcc2-3e739a7f881a"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtMy0xLTEtMTQzOTI_daa7e3bd-6506-4f7a-a159-6e71124b2577"
      unitRef="usd">13000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtNS0xLTEtMTQzOTI_6b3c84b8-52df-44ba-8695-45010dcbc29a"
      unitRef="usd">62000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZToyZDgyYjAzNzc3MmQ0NDEzYmQ1NzAyMzVkMzBiNzc1Zi90YWJsZXJhbmdlOjJkODJiMDM3NzcyZDQ0MTNiZDU3MDIzNWQzMGI3NzVmXzYtNy0xLTEtMTQzOTI_e2e13f42-f26a-4bf2-8ca8-9caad73eca19"
      unitRef="usd">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMDg_9ae53cd3-0675-457f-a3e8-18295b61a1d4">&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the United States statutory tax rate for the years ended April&#160;30, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US vs. foreign tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzItMS0xLTEtMTQzOTI_33f5bd5c-8211-491f-ba21-cf4939f6f5d6"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzItMy0xLTEtMTQzOTI_9d012278-c307-40e3-82c7-ae1e88428cec"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzMtMS0xLTEtMTQzOTI_ac001ffb-93c5-40c2-a085-c80a2d3e4655"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzMtMy0xLTEtMTQzOTI_4ef88ea2-c783-4c5d-a3b2-438a63815087"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzQtMS0xLTEtMTQzOTI_dffc60ad-475b-44c2-8850-7530f8d92687"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzQtMy0xLTEtMTQzOTI_9d5337c1-94fb-4b33-88b0-b528fbc9139d"
      unitRef="number">0.808</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzUtMS0xLTEtMTQzOTI_cde7e92e-a090-46b2-953c-fde10c843fb9"
      unitRef="number">0.473</csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzUtMy0xLTEtMTQzOTI_5e981d3b-ad31-40c3-b00f-7ff8f0fc10f6"
      unitRef="number">0.615</csbr:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzYtMS0xLTEtMTQzOTI_b50e5dff-6b2a-4192-8ca4-e8c0634ecbe6"
      unitRef="number">0</csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition>
    <csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzYtMy0xLTEtMTQzOTI_122c76bf-7bde-40c3-b8d6-1ddf2f0d6757"
      unitRef="number">-0.007</csbr:EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzktMS0xLTEtMTQzOTI_8af0dbe1-eaec-4bcc-9458-e0cec786aec4"
      unitRef="number">0.277</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzktMy0xLTEtMTQzOTI_bfc15079-2821-4148-8723-2bedef86437b"
      unitRef="number">-0.243</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzEyLTEtMS0xLTE0Mzky_b846d564-c285-415d-b03b-f6ab2a454bff"
      unitRef="number">0.060</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTo5ZTI4MjcwZDg1MGI0OWJjYjkyNzdiZTI2OTU1ZjAxMy90YWJsZXJhbmdlOjllMjgyNzBkODUwYjQ5YmNiOTI3N2JlMjY5NTVmMDEzXzEyLTMtMS0xLTE0Mzky_286890bd-c1cb-4e21-bfae-35808c0c4a1f"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyOTc_f6db584a-e441-4576-b1bd-da01c766bc18">Significant components of the Company&#x2019;s deferred tax assets and liabilities as of April&#160;30, 2022 and 2021 consist of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use, net asset/liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzItMS0xLTEtMTQzOTI_f362c055-1cbb-41a2-91c5-434f1d1669a4"
      unitRef="usd">162000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzItMy0xLTEtMTQzOTI_fab70c8f-6945-41f5-b152-d2da4b4c70ab"
      unitRef="usd">232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzMtMS0xLTEtMTQzOTI_98a61b8c-a8eb-45ed-95a4-4699086fff92"
      unitRef="usd">316000</csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability>
    <csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzMtMy0xLTEtMTQzOTI_a6ca8ca5-5a71-4cc7-95c3-04fd20ab2158"
      unitRef="usd">271000</csbr:DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability>
    <csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzQtMS0xLTEtMTQzOTI_db720f30-ecf9-4e48-bda3-87f7db2cee68"
      unitRef="usd">396000</csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization>
    <csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzQtMy0xLTEtMTQzOTI_031409d5-cde3-4a32-9ae7-ee7b6b81efa6"
      unitRef="usd">206000</csbr:DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzYtMS0xLTEtMTQzOTI_b5413a9f-fa37-4c15-8d5b-622c916c459f"
      unitRef="usd">3874000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzYtMy0xLTEtMTQzOTI_20374af0-4b52-4f3f-b5b8-d49d83bc49d6"
      unitRef="usd">3640000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzktMS0xLTEtMTQzOTI_c85078ab-b6c8-40b0-9e3b-5ee0b1ab2995"
      unitRef="usd">11546000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzktMy0xLTEtMTQzOTI_faf53332-0c37-4f62-9922-61e3b560e4a5"
      unitRef="usd">11404000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzExLTEtMS0xLTE0Mzky_c94933de-bd3f-4563-9858-17b28e07747b"
      unitRef="usd">15502000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzExLTMtMS0xLTE0Mzky_96745b75-6454-4ca7-b7a8-9d247eae8e8b"
      unitRef="usd">15341000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzEyLTEtMS0xLTE0Mzky_5543820b-3c3e-431a-bb21-6cd9d0152dd6"
      unitRef="usd">15502000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzEyLTMtMS0xLTE0Mzky_2fd57a73-db60-4686-95d7-d0cd87914270"
      unitRef="usd">15341000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzE0LTEtMS0xLTE0Mzky_67462a09-f858-427b-99ac-ec95790a6256"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjNzI4Mzk4NjlmNjc0ZjJhYmM2NGQ5NDhkYzA2ZjM3Zi90YWJsZXJhbmdlOmM3MjgzOTg2OWY2NzRmMmFiYzY0ZDk0OGRjMDZmMzdmXzE0LTMtMS0xLTE0Mzky_4d4f0c2d-f934-4077-8f7d-03a339d771c4"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzYwNDczMTM5NTYzNTI_0c70d770-1343-4456-97dd-ea9cca824b0b"
      unitRef="usd">15500000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzE2MzQ_7437a908-0695-46e6-a563-d4700cbeaf41"
      unitRef="usd">15300000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzYwNDczMTM5NTYzNjc_b990d1cf-6f40-4d31-b412-a2416bf70425"
      unitRef="usd">48000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzE3NTM_79b86755-3731-4508-9e35-fdcd894b50e4"
      unitRef="usd">46900000</us-gaap:OperatingLossCarryforwards>
    <csbr:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="i69a6fd87cc4541c9b8207826c0d2619a_I20130430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzIzODc_470bda35-7d37-4564-8d77-58a4caf403ab"
      unitRef="usd">12000000</csbr:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <csbr:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzI2NDM_7440d984-b17d-4c0e-a021-ec81ed2a54e8"
      unitRef="usd">432000</csbr:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMzMjA_8419ec3f-a728-46a8-8506-ebfeaa7723b0">&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table indicates the changes to the Company&#x2019;s uncertain tax positions for the period and years ended April&#160;30, 2022 and 2021 in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment made on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzItMS0xLTEtMTQzOTI_e8553d57-0357-4b3b-9c82-7142c48a5979"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia75e18175028428b92779412b437c5ac_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzItMy0xLTEtMTQzOTI_60acc6b0-9c5b-41b5-a1e0-7960e7376203"
      unitRef="usd">178000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzMtMS0xLTEtMTQzOTI_bd2ee991-9405-40de-b786-06c05307df5f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzMtMy0xLTEtMTQzOTI_92d96220-1b53-4164-964c-e2b9ae4136fc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzQtMS0xLTEtMTQzOTI_4c453b53-b642-4dcc-9394-fdda45aed46e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzQtMy0xLTEtMTQzOTI_3439a649-16f8-44df-a3e2-fe9fb3ccde1c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzUtMS0xLTEtMTQzOTI_874ae9c2-9e1f-4be1-a607-ce1b82293e32"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzUtMy0xLTEtMTQzOTI_28c6c9fc-b13a-44ed-8317-7741a6f1f1bb"
      unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMS0xLTEtMTQzOTI_4fc183ea-4154-42d9-8ecc-3c5a8750dee8"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMS0xLTEtMTQzOTI_82a07bf0-7a59-41c1-8964-55fc4e867370"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90YWJsZTpjMWYzMmRkMmU3N2Q0MjM2ODYzY2I1YTFiNjE3YWNjNS90YWJsZXJhbmdlOmMxZjMyZGQyZTc3ZDQyMzY4NjNjYjVhMWI2MTdhY2M1XzctMy0xLTEtMTQzOTI_bfdcc759-eb1d-45a0-be39-f0853c198d5d"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyNDA_4fc183ea-4154-42d9-8ecc-3c5a8750dee8"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ca155caea5f443da349ba10a3f84e1c_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTQvZnJhZzphZDg3YTYxYWQ5MTQ0YTQ1YjJkOTBlNzkzZTFmMWM3NC90ZXh0cmVnaW9uOmFkODdhNjFhZDkxNDRhNDViMmQ5MGU3OTNlMWYxYzc0XzMyNDA_82a07bf0-7a59-41c1-8964-55fc4e867370"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1Mg_cd9c3bac-8b95-48b1-98f5-d9171f68d830">Earnings Per ShareA reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net income per share computation (dollars in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average common shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,138,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted income per share computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,138,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental shares from assumed exercise of warrants and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted weighted average share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,159,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,573,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the total potential stock-based instruments outstanding at April&#160;30, 2022 and 2021 that could have an effect on the future computation of dilution per common share.  These figures were not included in the above calculation as, to do so, would be antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1NA_2d731b77-8872-4357-ba7b-885be60c8961">A reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net income per share computation (dollars in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average common shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,138,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted income per share computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,138,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental shares from assumed exercise of warrants and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted weighted average share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,159,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,573,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzMtMS0xLTEtMTQzOTI_34719ea6-f5b3-42a0-b00c-f2c563965cfe"
      unitRef="usd">548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzMtMy0xLTEtMTQzOTI_32297808-c2a4-4601-a897-e42383aff7d7"
      unitRef="usd">362000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzQtMS0xLTEtMTQzOTI_ee0275f2-1f37-464c-9925-561d06716bdf"
      unitRef="shares">13197170</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzQtMy0xLTEtMTQzOTI_653e1f67-5fad-41ee-89d1-409a4dbbd94b"
      unitRef="shares">13138995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzUtMS0xLTEtMTQzOTI_34d0cbe4-e60c-411b-916f-4285d46dcd46"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzUtMy0xLTEtMTQzOTI_e7853e11-27c9-4914-a3dc-9afaaef648cb"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzgtMS0xLTEtMTQzOTI_53c792b9-d685-4e1f-b74d-56dad7834ada"
      unitRef="usd">548000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzgtMy0xLTEtMTQzOTI_34b06d3f-459c-47da-9928-09668db03acf"
      unitRef="usd">362000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEwLTEtMS0xLTE0Mzky_178f4009-4106-477e-945f-75b5e7ea3579"
      unitRef="usd">548000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEwLTMtMS0xLTE0Mzky_3d3ff591-130e-4a96-9428-ff8404592e00"
      unitRef="usd">362000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEyLTEtMS0xLTE0Mzky_121127e3-d777-414d-85c6-f76d3b48ead0"
      unitRef="shares">13197170</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEyLTMtMS0xLTE0Mzky_4d394b36-819f-4896-a781-ce4b762d84d3"
      unitRef="shares">13138995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEzLTEtMS0xLTE0Mzky_3cc9c8dd-f454-4a2d-9cd7-64339ec8d7e4"
      unitRef="shares">962629</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzEzLTMtMS0xLTE0Mzky_6a3e2020-5008-4577-8f13-bc3362a6b504"
      unitRef="shares">1434566</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE0LTEtMS0xLTE0Mzky_ef049a85-a4a3-4e79-bada-d530d60c6b0f"
      unitRef="shares">14159799</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE0LTMtMS0xLTE0Mzky_82c91c04-8232-4620-a064-cec861d5300c"
      unitRef="shares">14573561</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE2LTEtMS0xLTE0Mzky_87a014dc-cc33-4481-a86a-916add3ece98"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo0NWIzNWQzN2U1YWQ0Y2RiYWQyMDg0MjQ4YmI2MWE2OS90YWJsZXJhbmdlOjQ1YjM1ZDM3ZTVhZDRjZGJhZDIwODQyNDhiYjYxYTY5XzE2LTMtMS0xLTE0Mzky_b9cab68a-ee44-48eb-9027-3a35c8e353cc"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90ZXh0cmVnaW9uOjRlOTQ4Mjc2MmIxYTQzNzZhNDFiNjMwMGQ2YmMxZGRhXzQ1Ng_7a57eb3b-b0b5-4d86-a938-a2c77c44b6d8">&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the total potential stock-based instruments outstanding at April&#160;30, 2022 and 2021 that could have an effect on the future computation of dilution per common share.  These figures were not included in the above calculation as, to do so, would be antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended April 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a9df412082144bbb11d4d6da935fb41_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzItMS0xLTEtMTQzOTI_2d275c3c-4ee0-41f2-8828-59e7b9d13539"
      unitRef="shares">1332854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ee677f4c8194c56a69b04f0e5332d03_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzItMy0xLTEtMTQzOTI_bbe3f28d-7e17-4f3f-9605-d0011db32df4"
      unitRef="shares">1653646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzUtMS0xLTEtMTQzOTI_560b7ccc-bce7-4e7b-9c72-3ee6abce4eb2"
      unitRef="shares">1332854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNTcvZnJhZzo0ZTk0ODI3NjJiMWE0Mzc2YTQxYjYzMDBkNmJjMWRkYS90YWJsZTo3MDc0ZmJmYjk3ZWY0ZjY2OWRiNTU2MTM2YWEzYmI5MC90YWJsZXJhbmdlOjcwNzRmYmZiOTdlZjRmNjY5ZGI1NTYxMzZhYTNiYjkwXzUtMy0xLTEtMTQzOTI_fa826ca4-28bb-499b-a0f2-7ab5113ba8c5"
      unitRef="shares">1653646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzgyNg_81e65756-d0c2-4580-8d3f-84fe4300e81f">Related Party Transactions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party transactions include transactions between the Company and its shareholders, management, or affiliates.&#160;&#160;The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consulting Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both years ended April&#160;30, 2022 and 2021, the Company paid a member of its Board of Directors $36,000 and $54,000 for consulting services unrelated to his duties as a board member.  During the years ended April&#160;30, 2022 and 2021, the Company paid another board member $17,000 and $5,500, respectively, for consulting services unrelated to his duties as a board member.  All of the amounts paid to these related parties have been recognized in expense in the period the services were performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2NjM_02a7a78a-bdc8-4199-a6f5-cb11a300a648"
      unitRef="usd">36000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="id4d88492120f4baca21ed89485bb0844_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2NzI_8c4d3302-fc42-4ea8-8da0-00bfb19ebc12"
      unitRef="usd">54000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i25d9cbec92d244c1bbb79ddf79455794_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM2ODE_4e90ae8b-b447-4835-be30-4e7a1a3e88ac"
      unitRef="usd">17000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ifb4a80baff484f72aa17c4f7022a0626_D20200501-20210430"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjAvZnJhZzphYjk5NDQ3OTUxN2M0MDk4YmJmMGQzMGFlZTQ5MGIxZi90ZXh0cmVnaW9uOmFiOTk0NDc5NTE3YzQwOThiYmYwZDMwYWVlNDkwYjFmXzYwNDczMTM5NTM3MTk_bf2ddcab-0622-419c-934d-86fee1d1c496"
      unitRef="usd">5500</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzY_a07747be-48bd-426b-acde-e59ecd1ad13f">LeasesThe Company accounts for its leases under ASC 842.&#160;Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both an operating lease ROU asset and operating lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company has elected to apply the short-term lease exemption practical expedient for each class of underlying assets and excludes short-term leases having initial terms of 12 months or less. The Company recognizes rent &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expense on a straight-line basis over the lease term for these short-term leases. The Company has determined that no material embedded leases exist. Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.9 million and $1.3 million for the years ended April&#160;30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:15.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases the following facilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company&#x2019;s corporate headquarters. The lease was renewed during fiscal 2022 and expires in November 2026. The Company recognized $88,000 and $91,000 of rent expense relative to this lease for fiscal 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease (the "Original Premises") on January 11, 2017. The operating commencement date was August 11, 2017. This lease originally expired in August 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by six months. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;In accordance with ASC 842, the Company evaluated the first amendment and also performed a reassessment of the existing lease for Suite 025 to determine the impact of the six-month term extension. As a result of this assessment, the Company recognized an additional operating ROU asset and related operating lease liability for Suite 025 of $118,000 and $125,000, respectively, as well as an incremental net rent expense of $8,000 during the three months ended July 31, 2020. The Company did not recognize the incremental rental expense under this amendment during fiscal 2020 as the Expansion Premises lease commencement date was during fiscal 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $3.8&#160;million, each, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;On December 22, 2020, the Company executed the second amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suites 025, 050, and 104 ("Additional Expansion Premises") and add on Suite 201. The Additional Expansion Premises operating lease commencement date was April 1, 2021 and, under the second amendment, reaffirms that all three leases expire February 28, 2029. Upon the Additional Expansion Premises operating lease commencement date (April 1, 2021), the Company also recognized an operating ROU asset and related operating lease liability for Suite 201 of $3.3&#160;million, each, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;For the leases related to the premises at Piccard Drive, the Company recognized $1.7&#160;million and $1.2&#160;million of rental expense for fiscal 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;1405 Research Boulevard, Suite 125, Rockville, Maryland 20850 (&#x201c;New Location&#x201d;), which consisted of laboratory and office space where the Company conducted operations related to its primary service offerings. The Company executed this lease on November&#160;1, 2018. The operating commencement date was January&#160;17, 2019. This lease was set to expire in&#160;April 2024. The Company terminated this lease on June 30, 2020 and transitioned its activities from this location to the Expansion Premises, as defined above, during the first quarter of fiscal 2021. Upon lease termination, the Company recognized a decrease in the related operating ROU asset and operating lease liability of approximately $850,000 and $926,000, respectively, as well as a gain on lease termination of $76,000.  The Company recognized zero&#160;and&#160;$43,000&#160;of rental expense for fiscal 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed the lease for its laboratory space in June 2021, and commenced occupancy during the three months ended October 31, 2021. This lease expires May 2023. The Company executed the lease for its office space on October 1, 2021. This lease expires September 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;The Company recognized an operating ROU asset and related operating lease liability for the lab and office space of $205,000 each, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;The Company recognized rental costs associated with these leases of $81,000 and zero for fiscal 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets, net&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 30, 2022, the weighted average remaining operating lease term and the weighted average discount rate were&#160;6.7 years and&#160;5.73%, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments due each fiscal year as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total undiscounted liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4, Property and Equipment, for more information on financing leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMDE4OQ_df401ebd-ed64-4c3b-95ec-efca69fd702b"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9356490417104a61b9e4f780d34d7f1c_D20200501-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzIwODM_5b451219-d229-4ce4-9710-5ddc7114f797"
      unitRef="usd">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="if06e952147154d71b46d16b5e28a9fbe_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzI0NDg_1324c636-6157-4f86-af9e-fd1009eda226"
      unitRef="usd">88000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i80a586d6407045b5b2f71a3e6734cb67_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzI0NTU_d12b1e1e-9f29-45a3-92d7-afd387a2ed26"
      unitRef="usd">91000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i85ae521181894cad8b64e2c702464cd0_I20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjExOTQ_27ebb077-bb04-48f6-8245-bb2380aeb309">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i85ae521181894cad8b64e2c702464cd0_I20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzM_e6b6c7cd-8690-4aa9-84f2-0a606691271f">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic847c89affc44622b37366e5f79fce04_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2MjY_633cff9c-db35-44c7-93b9-603ce06f1519"
      unitRef="usd">118000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic847c89affc44622b37366e5f79fce04_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2MzM_e9f30ad1-f157-4e3f-b517-f2ee50403842"
      unitRef="usd">125000</us-gaap:OperatingLeaseLiability>
    <csbr:OperatingLeaseIncrementalRentExpense
      contextRef="ia727ea5ecb214935b2eeee869e2b3b96_D20200501-20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzM2OTc_bd8e2a05-c048-48bc-8628-2a8c3c1dc1ef"
      unitRef="usd">8000</csbr:OperatingLeaseIncrementalRentExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie013b3012171467f93337908fb07dbff_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzQxMDg_05e15ed3-4a0b-4de0-9a96-eed2ed0f836a"
      unitRef="usd">3800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0c2df47285234084835a949fca5c80c3_I20210401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMDcwMg_17afcd00-c2e5-4af2-8c96-89d38d587796"
      unitRef="usd">3300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i29d1b96629e44d2bb9a499800cbc3b4c_D20210501-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMjAyNw_e37f8539-cc26-4793-8ff3-79d50e748aa2"
      unitRef="usd">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i690a0daa1ab0464ba51eacbabf4ce92b_D20200501-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU0OTc1NTgyMjAzNQ_02298f8b-42de-442c-b1a3-4b86e06c6c20"
      unitRef="usd">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU2NDM_6d217f9f-22b0-479a-8810-14b588ac9b90"
      unitRef="usd">850000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="iaa645732a77f4bb9bb16ddf5a16c7a41_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU2NTA_f39fd0df-6842-4ddf-9250-bbb692beb830"
      unitRef="usd">926000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i8aea2d8b8182467a8e0b368c96d67fa9_D20200630-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3MTA_501547b9-c750-41ab-9760-70c0c405d167"
      unitRef="usd">76000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2ef7fbd4bc8c4f4aab264f5fd41fec64_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3NDM_5f5c6bfb-16a8-42a3-8cae-67687c0b8d47"
      unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i99c506566730476cb94f0263057c0930_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzU3NTA_ec151935-cffe-44b7-8c8f-7b32fc1b8604"
      unitRef="usd">43000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMjQ_a035e70b-4fbe-48b9-a5b0-534877a700e8"
      unitRef="usd">205000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibfb03f6e415b41ebbbafb256ac77b32b_I20200330"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMjQ_b155ae00-da2b-4df6-93bd-8c07f9dc1cba"
      unitRef="usd">205000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8f1c7838e6524ef6b1bb93bf4114d1ba_D20210501-20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMzQ_36161eee-9b2f-4a56-b6ca-2e840d12a94e"
      unitRef="usd">81000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ib43d4a95e25b464dacea18dbf70da83b_D20200501-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyNDI_b902bf24-75ab-44dc-aa4c-aa25ceb8261a"
      unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <csbr:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzQ_2420d765-b22f-4b8e-8e32-15c778fde7ef">ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):&lt;div style="text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets, net&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</csbr:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzEtMS0xLTEtMTQzOTI_7b235032-919e-4103-b79d-caa63d211fe6"
      unitRef="usd">8230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzEtMi0xLTEtMTQzOTI_aff07cdd-42f1-4ec8-ac24-a06d1a26bb10"
      unitRef="usd">8521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzItMS0xLTEtMTQzOTI_405995fb-89b7-4411-b815-0d8df1560400"
      unitRef="usd">1054000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzItMi0xLTEtMTQzOTI_54968638-7798-4eae-95c1-75d7d97e8fad"
      unitRef="usd">818000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzMtMS0xLTEtMTQzOTI_76709711-023a-42fe-9c39-ae61080bdeb9"
      unitRef="usd">8412000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i96bb2ef9275f46ac8d01edb098d08a40_I20200501"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZToxYTA5OTZkMWFlNmI0ZjMyYmIxZDQ2YmQxZDViMDQwZC90YWJsZXJhbmdlOjFhMDk5NmQxYWU2YjRmMzJiYjFkNDZiZDFkNWIwNDBkXzMtMi0xLTEtMTQzOTI_6b7c5502-df86-4cfc-9eaa-719efee6b078"
      unitRef="usd">8783000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMTU_dd0023e8-a4bc-4c27-87de-a67b4a72abf1">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYwNDczMTM5NjEyMTc_b56ddc53-3962-4da8-866b-006e1d192bae"
      unitRef="number">0.0573</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90ZXh0cmVnaW9uOmJmZjM3ZDA1NDIwMzRhOTg4MTAyMjIxMmZiMmMwNWQ4XzYyMzU_6c40d289-315e-475a-abdd-742ecd85e801">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments due each fiscal year as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total undiscounted liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzAtMS0xLTEtMTQzOTI_b5aaed20-780d-462c-9bfd-396f7222f096"
      unitRef="usd">2735000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzEtMS0xLTEtMTQzOTI_60ceda94-693d-41bf-8fa1-94c4fce250ba"
      unitRef="usd">2809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzItMS0xLTEtMTQzOTI_976580c1-91d6-469c-b76d-209277fff326"
      unitRef="usd">2848000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzMtMS0xLTEtMTQzOTI_920c21c0-bdfd-4e76-a916-0599751ac7fd"
      unitRef="usd">2895000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzQtMS0xLTEtMTQzOTI_d67bdeb0-eb28-4edb-8d91-90a4e6eb0e14"
      unitRef="usd">2860000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzUtMS0xLTEtMTQzOTI_cfdc5f71-f936-4995-a33a-ff818929a8a7"
      unitRef="usd">5164000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzYtMS0xLTEtMTQzOTI_6e7ae5ba-b3c8-4e6f-bf6f-eeaca6338c1e"
      unitRef="usd">19311000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzctMS0xLTEtMTg2Nzk_58f4fc3a-7504-4080-b4b7-6bdc35b5ef0a"
      unitRef="usd">9845000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ied6c8b18575745c19253a47ee2b946cd_I20220430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NmNmMGI4NWZkYjQ0YTE5M2M4OGY0ZmM3MDYzMTgxL3NlYzo3NzZjZjBiODVmZGI0NGExOTNjODhmNGZjNzA2MzE4MV8xNjMvZnJhZzpiZmYzN2QwNTQyMDM0YTk4ODEwMjIyMTJmYjJjMDVkOC90YWJsZTo2MzliODQwZDlkNTU0ZmFlYTQyMzRjMzM5NzcxNzBhYS90YWJsZXJhbmdlOjYzOWI4NDBkOWQ1NTRmYWVhNDIzNGMzMzk3NzE3MGFhXzgtMS0xLTEtMTg2ODM_f1880fc0-021f-4d28-b1ff-0c9020ccef2d"
      unitRef="usd">9466000</us-gaap:OperatingLeaseLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ("#]E0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " " @_94R>:(Z>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OI\V*BZ&;B^))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS
M#4RG@] ^XG/T 2-93%>3ZX<D=-BP U$0 $D?T*E4Y\20FSL?G:+\C'L(2G^H
M/0)OFAMP2,HH4C #J[ 0F>R,%CJB(A]/>*,7?/B,?8$9#=BCPX$2M'4+3,X3
MPW'J.[@ 9AAA=.F[@&8AENJ?V-(!=DI.R2ZI<1SK<55R>8<6WIX>7\JZE1T2
MJ4%C_I6LH&/ #3M/?EW=W6\?F.0-YU6SKCC?\D;PM;B^?9]=?_A=A)TW=F?_
ML?%94';PZR[D%U!+ P04    " " @_94F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ("#]E28V^NQV@<  )4O   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK<^(V%(;_BH;N='9G0O"-P&X39@A)NK0;0L-N.]M./PA;@">V124YE_[Z
M'ME@XXPL[(Z2#\$&G]?68TD^KW7.GRA[X!M"!'J.HX1?=#9";#_U>MS?D!CS
M4[HE"?RRHBS& G;9NL>WC. @"XJCGF-99[T8ATEG=)Y]-V>C<YJ**$S(G"&>
MQC%F+Y<DHD\7';NS_^(^7&^$_*(W.M_B-5D0\6T[9[#7*U2","8)#VF"&%E=
M=,;VIRMW( .R(WX/R1,_V$:R*4M*'^3.-+CH6/**2$1\(24P?#R2"8DBJ037
M\<].M%.<4P8>;N_5;[+&0V.6F),)C?X( [&YZ P[*" KG$;BGCY])KL&]:6>
M3R.>_4=/^;'>QP[R4RYHO N&*XC#)/_$SSL0!P%#JR; V04XKP)LKR; W06X
M30.\78"7D<F;DG&XP@*/SAE]0DP>#6IR(X.914/SPT3>]X5@\&L(<6(TH8^$
MH2[ZMKA"[]]]0.]0F*#;,(K@IO#SGH!3R -[_D[N,I=S:N1L!]W21&PXNDX"
M$E0%>G!MQ04Z^PN\=+2*XRT[1:YU@AS+<107--&'_Y)&IQ!:&WZE#[_S!9S=
MSL)M36O< K>;Z;E:W'^-EUPPZ/)_JPCG"IY:0<X#G_@6^^2B P.=$_9(.J,?
M?[#/K)]4=$R*71D2JY#S"G*>3GUT1?T4YAN!OKYLB0J;/MRVNK^J^&BCVO(Q
M)%;ATR_X])OQ&2=)BB-T3[:4"14HO8Y@J0KO1!O5%I0AL0JHLP+463-0<\)"
M&LB)"L'4J>Q3>J5B:JJ=F[3Q;:$9$JM &Q30!MJF3E+&)+.;D/O0N;X3S+3@
M]&K=KN5U74M%3!O8EI@AL0JQ84%LV'"^8ABRI"S)J1^3>JT5CKAR4&K#VM(R
M)%:A];&@]5';PNM$A.(%NE=$T"R-EX2I*.DU+,ONVG;?\E2DM*%M21D2JY"R
MK3)CLYJPNB?K4&81T,5F.%:.PB-"D\_CV_GT;K9 =[/)W9>[G[^?H.EL<JKB
MIY=J"]"46I7@0<YK-R$X37S*8$1B.3A/T$+ 9(8H0Q.:)H*]P&>@QJI7O[I6
M M0&M09H2*T*T"D!.DT ?L7/:!K )!>N0C^CJ!F\1R3[3M?V+'O0[ROI:8-;
MTS.D5J57>@!;FRCOZ8V# -3YR7X#?8'CT%VB[G-Z28A"WQ)PT(Q+Z7F$_\70
MH],0>K1K#91(C5H#4VI5I*4YL/7I_6ND<\H%Y"E_AMOZ4:Q7M 9GEJWD9M0R
MF%*K<BM-@ZW/]E]SF\@]F *_TJ=$"4TO]QG[#R3A\%])SJB',*56)5>Z"%N?
M_+\F5SP]YHP^AHFO[G-ZS=DO2FQ&780IM2JVTD?81XQ$!HT17#\N]0).S:@T
M:AQ,J54AE=;!UN?[7Z@T6?,-3739\!&1H37L#CU+Z;+TH:UIO85SL$OK8.OS
M_J^A -= 5\AVWB\_H 7Q4P:]3(E,KS2A<0PYS$)0_^$$;<'C/N(H)>B==0KF
M FT)0WR#F=**Z:5;(WT+B^&4%L/1.P/PK$&8K-'B)5[22$7RB,!D<7FO?%EK
MU$:84JM2*FV$HT_T]ST-73_[&YRL2:T1.R(T&R^NQK\I>1EU#:;4JKQ*U^ T
M<@U_D"CJ/B208<!8Q1PFN0!-.4_5L]P1S1E58C-J%TRI5;&5=L%I9!=^IQ'8
M4LSRMR1,N3AS1*D&EE$C8$JM"JLT DXC([!_7YF_<<NF,LC/4C4TO>)WHHJ:
MZ*-:4WL+&^"4-L!I9 .FB2 L7XF5;W;Q'J.2FEZQCII1"V!*K4JMM !.(PN0
M#4<T@?1_39DR[3BB,Z-)%_L^ 1D0"7)!)3VC3L"46I5>Z00<?2*_H[>(<12A
MRY3#SUP]/O4Z=0M6^K#6L-["$3BE(W#TR?P.UG5,V%K.9C^#@MB AXJW.%'W
MN?^YI*"/:XWM+:R!4UH#1Y_03R<W]VB<!J$ 8SX6@G"1OZ:\B?!:24VO5T_-
M:/9O2JU:HE!F_VZC!8;%!A(U71<[(E,+2Q_7NBCA+4R 6YH M]%:PCQ=1J$/
M_8IBY>-2K]*ZJL.H+=BI]3,U62CV./*\\]ZCBDN9[+N-DOVJI5Y(]\S172I@
M(":9Q7R?.6K^00G-9!H_V:F='333=ON.XWEVT=@=D+=(^-V#&B%]FKY?.N8'
M*U20%BSEFM^*0$*F?KEX1'4N$V&:</FF1&S(P?KACS\,'7OP$Y?U<F$29NG?
MG-'GE_RE9K:*O8()-(0KDG50^Q*36T*RU!H$LQN[H5$ Q@0)BI8$K2"+"=!3
M"(\I>;J=60[A]L.=+RVS[" AS\H(MRGCJ5S/! &XNC3*YVK;&Z,T >77.H7&
MV!?9^Y^/KG>",)P +CD@ 6PS@L)7#-F>(?P")YIC)M!T.LVQA!S)<D(DRX64
MZZ!ZR*U'WEN8);<T2VXSLP0WF,']G *T9_0K44_V1Y9+X&\PL(?],R4UHV;)
ME%J56FF67+VU&<O>E0V*NBSBB$#]@]&H.S*E5L54NB.W89W5KF9H5VYU U\K
MT_PC<C??E<2,.B)3:E5BI2-R]4[F-;&LRJJ>U[%U$G5)FCZL-3&CMJAW4,<L
MG4Y6#\Z1+^LQ\I+FXMNBYGR<55KWRL/S@O5;+(T21Q%90:AU.H#!P/(:\'Q'
MT&U6%;VD0M XV]P0#$\9>0#\OJ)4['?D"8I*_-%_4$L#!!0    ( ("#]E2@
MP/1/. (  +<%   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC93?;]HP
M$,?_%2N3]E21$"C=6!()^D-CHA5JM>UAVH-)#F(UMK.S:=K_?F<',B9!U)?8
M9]]]_3D[=TFC\=F4 ):]RDJ9-"BMK:=A:/(2)#<#78.BG8U&R2V9N U-C< +
M'R2K,(ZB22BY4$&6^+459HG>V4HH6"$S.RDYOLVATDT:#(/#PJ/8EM8MA%E2
M\RT\@?U>KY"LL%,IA 1EA%8,89,&L^%T/G'^WN&'@,8<S9G+9*WULS,611I$
M#@@JR*U3X#2\P#54E1,BC#][S: [T@4>SP_J=SYWRF7-#5SKZJ<H;)D&GP)6
MP(;O*ONHFZ^PS^?2Z>6Z,O[+FM9W1"?F.V.UW >3+85J1_ZZOX>C@.'G,P'Q
M/B#VW.U!GO*&6YXEJ!N&SIO4W,2GZJ,)3BCW*$\6:5=0G,UFNT)8ME#M\](]
M):$E6;<9YGN)>2L1GY$8QNQ>*UL:=JL**/X7"(FG@XH/4/.X5W%6XX"-H@L6
M1W'<HS?JDAQYO5%?DAJ/TV2_9FMCD7Z*WZ<R;O7&I_5<H4Q-S7-( ZH$ _@"
M0?;QPW 2?>FA'7>TXS[UCO9.H&2+FU-X_0+QU;@'X[+#N'P7Q@.7<(JA/_I6
M& 4XDS4@6RY7/3R3CF?R+IZESL_^J/T*"VH&0EVP!^H5WP -O)W""H^*20)N
M?<LP+-<[9=NZZE:[KC1KB_&?>]O2[CENA3*L@@V%1H,KNC-LVT1K6%W[TEQK
M2X7NIR5U5D#G0/L;K>W!< =TO3K["U!+ P04    " " @_94G=%I?%0%  #G
M%0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;+68;6_;-A#'OPKA%7L
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MWT#Z@Y#WG)28IH"\J/52$ %4W0,F5X2K2;E?/#9JWP""T/,ZU*91[/>,;-!
M!X/0#TSB[ 2^P.2+@Z +:+%"@>O8$<,&,1Q$O"L)QY(63R C:O$%7*^R9VQY
M5JF;+7%O,80&4(3V>+;4%B-?KQDVZ*B!CHX4@U)-+E_K(B _*EHJ'9.]G)&!
M$$*W.[JF4>#$/8,;-YSQ\.#6]9DQ-;J2\'R@ F+SW?H=P$&3 SSHM%KC# +^
MP5BZH5EF%1#'>*#K=J&.&!UB[4D@/&'>](_6SOW@J;X;1ETXTPR%?MQ3?+ 5
M*WB:6F44/]*,2DKLD@7?5;/>*]IATJUJP6'9:E2BQ*]:(JP)N^: 1X'Q6DPK
M&,5>SUMI50P>E3%>D73_K5@9375"'NRN!C8KY/953BMB<%C%WBJG9+S>,[,E
M8)T%^!B^1<L<W\ WK2(8]="W:@:'Y>SN0&Z/@9IR%:(NIFG3L^+"5L_@L*#=
MD"51@*G:S:Q)4=GKU!0E")T0=O%,LP#Y/1L9V(H7'%:OPUW!L6$T=0F&7AAW
M42UF$,9Q#VLK8'!8P;ZRXBSI%NU_K%A3N"(/&J5@L0HCU\Z/6H%#PP*W+=EB
M+XLCM,@B:'&W,"Q&,.I9'%"K>N@4U3O&9]&T $7=X;29.3#H&\^]/FU8^A:2
M)<\KEJ6$BU_JK9=\M;=K[]NO_1_:AUKM0T=:-I;GJO"%3GX,/IP[#E0RR,$:
M9Q6Y5$VP,W:V?T"L,-?=2257C--_2'H)H#OV$1I['JSWJ^I6Z<W8"8(W8RJ$
M%JZZHZFDD.I"SRXL@>JS:=;TZ;6%[KC':G$3):D/7+)7Z_!;-+8K$C:;O@)I
M51@=4>$TI7J54)6L^[4S6H $EU15MA73E-D(.D;G8S$+X]CKV6>B5H[1L!RK
M+4.55QF6:O13LJ0)M?8/R%33LQ#&YJ2SV2&_KT5#K?"B4_I(89E[5EQ356,G
M#KJP%GWV4,\> ;7RBX;EUUC$ZJ(]&3TTSC=L&WN+F6UC/]D[A=-'H']B_D0+
MH61KJ?R<\U %X-M3Q>V-9&5],/?(I&1Y?;DB6$%K _7[DC'Y=J//^IJSW=F_
M4$L#!!0    ( ("#]E0&#O.$I@(  &@'   8    >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&ULK55=3]LP%/TK5C9-(+'FLV%B;:02BD!B4%&V/4Q[<)/;QL*Q
M,]MI8;]^MA.BEH51I.4A\<<]Q^=<.]>C#1?WL@!0Z*&D3(Z=0JGJQ'5E5D")
MY8!7P/3,DHL2*]T5*U=6 G!N025U \^+W1(3YB0C.S83R8C7BA(&,X%D7998
M/)X"Y9NQXSM/ [=D52@SX":C"J]@#NIK-1.ZYW8L.2F!2<(9$K <.Q/_)(U-
MO WX1F CM]K(.%EP?F\ZE_G8\8P@H) IPX#U9PTI4&J(M(Q?+:?3+6F V^TG
M]G/K77M98 DII]])KHJQ\\E!.2QQ3=4MWUQ ZV=H^#).I7VC31,[/'905DO%
MRQ:L%92$-5_\T.9A"^!'+P""%A#L"PA;0&B--LJLK3.L<#(2?(.$B=9LIF%S
M8]':#6%F%^=*Z%FB<2I);Z[G-U>79Y.[Z1DZG5Q-KM,IFE],IW=S=### I@J
M0)$,TT/T$;U'+I*%'I4C5^G5#8>;M2N=-BL%+ZPTJ<0 A=X1"KP@Z(&G^\/]
M7;BK/7?&@\YX8/G"%_CF"BO0QU$AOD3GA&&6$4S1C$MBS]>/R4(JH4_9SSZK
M#7?4SVW^O!-9X0S&COZU)(@U.,F'=W[L?>XS_I_(=M(0=FD(_\6>I+PLM5M]
MSK+[(U1A@=:8UH ."$,YIQ0+B2H0S:X?]J6BX3^V_*9FK!-OX'EZB];;'E^+
MVA$?=>*C-XAO#B;"M2JX(+\AMR::T5[E#7F\I4G7ON9YIGZ?R!T'P\[!\.T.
MB)3UZ^J'?VGRPV$01-'SU/<%1G[DQ7&_]KC3'K]=N[XHI,(L)VSUFH%X7P-]
M@;T&W*TZ:.Z@+UBL").(PE)#O<&Q3H5HZGK34;RRI7'!E2ZTMEGHJQ"$"=#S
M2\[54\=4V^YR3?X 4$L#!!0    ( ("#]E0VEXTA) 4  ( 5   8    >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&ULK5A=;^(X%/TK%CM:M5*GB9TOT@4D2IG=
M2MM2%6;G8;0/(3$0-8G9V$#GWZ^=A"0DCH=J>(%\7%^?<^_-/;8'!Y*^T0W&
M#+S'44*'O0UCVSM-H_X&QQZ])5N<\#<KDL8>X[?I6J/;%'M!-BB.-*3KMA9[
M8=(;#;)G+^EH0'8L"A/\D@*ZBV,O_7&/(W(8]F#O^. U7&^8>*"-!EMOC>>8
M?=V^I/Q.*[T$88P3&I($I'@U[(WAW0298D!F\4^(#[1V#025)2%OXN8Q&/9T
M@0A'V&?"A<?_]GB"HTAXXCC^*YSVRCG%P/KUT?N7C#PGL_0HGI#H6QBPS;#7
M[X$ K[Q=Q%[)X2]<$+*$/Y]$-/L%A]S6YL;^CC(2%X,Y@CA,\G_OO0A$;0!T
M.@:@8@ Z=X!1## RHCFRC-:#Q[S1("4'D IK[DU<9+')1G,V82+2.&<I?QOR
M<6PTF3W/9W\_/HP7TP<P7_"_I^GS8@YF7\#L9?HZ7CQR _ 9?)T_@*M/U^ 3
M"!.PV) =]9* #C3&,0A/FE_,=Y_/ASKF@P@\D81M*)@F 0Y.'6@<?,D '1G<
M(Z7'\3:]!89^ Y".D 30Y/SA4 ''* -J9/Z,#G^/B4]B#.;,8YB7.P/?QTO*
M4EZN_\JBE3LSY<[$-WQ'MYZ/ASW^D5*<[G%O]/MOT-;_D#&]D+,3WF;)VU1Y
M'\TX[XBL?P#A./0QY1_Y'B<[+&.=N[(R5Z+1[$>F"W5WH.WK="164#?UTNH$
MIU7BM)3YF1#**.#%"W@K3#T6)FN WWE7I)C>R;!:E\S0A9R=,+=+YK8R0X(Y
M("M FIF2L<Y=V;78(\,V4"-#$BMHFK8\0TZ)TU'B?.7,O=3?9$D*>!%%9"N^
M)!E,IP7 -1RS@;)MY$"W V2_!-E7@IQ[$<[+B*O?&Q9E),/7;TUM&TZSSMM&
MEH4ZRMPM\;E*?'_BA%=WE"'T BX<H6A"0C)E,-UV&"%T&C#;1K8%D1PFU"O]
MT95 %X1QF+[BJY2*C-X"8_8MO5F?,C/=KA7(*>B::$(EZ*+)KU(2'P&31 X4
MMJ.F-R,K,3+LC@*%J *)E)UNQC8X/491VMH*!Q?J;9?R=DJWTEVHE+>";IAG
MYJJ@?7T#$BSM'(6W>LP_HV;GD!@YL",OE5!"M5(6Q;/$?!&.CX"9]WY,E12M
MV>X1?:.)MFUD&DX'W$HOH5*41B\IV8?9JIWCK<&5PK3:A6PU4;9M'*L#9"5M
M4*UMSWS#DT.3PK);*PG+[#=QM8T,NZN]55H&'>5'6 $#O$_P/A?'/))TX_'4
M\UT59;SG=6@'5,KDA[_."WD[C4,EEU"MEV?&X4;LR4(?7/%=QHX&F6UF="V-
M4#YGOY8R_59O?<12*Z,CLY7 0K7"GLTH"*,=P\&YG-RS.$FM.JH556*,=&6U
M?LMVO1RKM^>BML8GK.C/"A8IE?ZC!7LI;Z>AJ"0>J27^_%#42C9_*<TK:FL\
M-*#K0$=OY%9N:?1=MZ--HFI)@)0:_!%2]:I5T4)ML":T7,=MKG*EEI9C6':'
MHJ)*^I%:^E_SG>8-X%H5['R6+23G^>X&?)^^,W'LM(PPF":[N%BM27?C/YFG
M=/F$XR5.92XFO^3BE'^UHD#J%878V5V O'J2L\C_BHN<O%8[R^)PU]D1'^6%
MNDM8?BA4/BV/$<?9X5GC^3V\F^2'@96;_&SRR4O784)!A%?<I7[K<,U/\^.^
M_(:1;79BMB2,D3B[W& OP*DPX.]7A+#CC9B@/'0=_0]02P,$%     @ @(/V
M5$UP[]]^!0   "0  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R]6FU3
MXS80_BN:W,WUF"G$\FO,A<Q ;!>F=T )M-/I](.P%>+!MG*60N#?5W*,X[?X
M'"KN"_'+[J/5/EII=_%X3=)'NL"8@><X2NC)8,'8\G@XI/X"QX@>D25.^)LY
M26/$^&WZ,*3+%*,@4XJCH:HHYC!&83*8C+-GU^ED3%8L"A-\G0*ZBF.4OISA
MB*Q/!G#P^N F?%@P\6 X&2_1 YYA=K>\3OG=L$ )PA@G-"0)2/'\9' *CSU5
M$0J9Q)\A7M/2-1!3N2?D4=Q<!"<#15B$(^PS 8'XSQ.>XB@22-R.[SGHH!A3
M*):O7]&];/)\,O>(XBF)_@H#MC@9C 8@P'.TBM@-69_C?$*&P/-)1+._8)W+
M*@/@KR@C<:[,+8C#9/.+GG-'E!2@MD-!S174O@I:KJ#5%8P="GJNH-<45&N'
M@I$K&'6%79,V<P4S\_W&69FG'<309)R2-4B%-$<3%QE=F39W<)B(E35C*7\;
M<CTVF5Y=SJZ^7CBGMZX#9K?\YYM[>0NN/# ]/[W\S9V!BTO^_&KZ^_G55\>]
MF7WZ,%*A]06X?]Q=W/X-#L'=S &?/QZ CR!,P.V"K"A* CH>,FZ=&&/HYY:<
M;2Q1=UAR2QB*6M2FW6I3$L=\A<X8\1];M)T?#,JCD:[2EYWZ;K?^:1"$(D)0
M!*Y1&!QR%TS1,FR?B?<#+-]?Q:L(,1P !\]#/V15D"'GMB!8+0A6,U1]!^H9
MBE#B8_"9FT87*,7T " &3I?I$="47X&JJ$H;69VH8K\[IDODXY,!W] H3I_P
M8/+I S25+VT4;L#,#$SL=4\3J%JJ::FC\?"IS);,45V98)XDL J'6L&A]BX<
M=J+NRZ%,,.<-8*"-8IE&>9+ *A3K!<5Z+XK[T+I!,DK19"BV78VD:5,(:K5@
MZ[1H#Q*:0UF6;=5"VVM*'?+XM]5"K.(WH_";D>EI._QVD?AB"^>QX>#-U8$X
MA[+M?$&B *?T%^!^7X7L!?QS0Z((\(1DC=+@WS;/&C(#1B:8(Q/,E0GF20*K
ML&\6[)N=49/1?"@RRP#X).;I-D59PHJ?Q35NX]ALG$6&75NKT\Y1]Z5.)IC;
MPWI/TH 51JR"$:N3D0M*5]E&1N:"$9&:44$2R$C!J1_2[%W^<"G8HH!GC( '
M98H21LNG7!M_G>/O&Z-6PYWFR-*T>EHB<TQ7)I@G":S"]:C@>B2?ZS9*1\WT
M4#/K!UJG+?O&I$PPMX_YGJ01*T39!5%V)U&7F/%#D5/4NB':C8-9,]6:\SOQ
M]W6^3#!7)IAG-Y@LNZ+B>ZAL*VSE_V;OL+5<5EK6E0YUQ31K[/26=+I-W=?W
M4M$\66A5FDJ-$/@^-'7"[GL@245S<K3RPE"J*\*5.J G"ZW*X;;7 ?LU.WKQ
MIC;+%KW>D)BV2#7JJ!:9AI>;'1#+MG6C=DBTB/$BR="4'7O0MH$ M9]8)D&I
MC06I:(Y4-%<JFB<+K;H(MBT&V-UC>$NUE$.65Z0-Z]E!][A[,R@3S>TS 4_6
MD%5BMCT,V%DD_X2BJ=N O2/6:.8;RDBSC/K&*+5K(17-DX56I7S;N(#=G0MI
MM1-L=@14I7&*F<U3K,Z5U#9%JU56/>K>HU$!MYT*V-VJZ*Z*<N5*EU5O^%5F
M+>](17.EHGFPV2DINZ-*P;:! +L["#UR;K65G+:2VU!578=UAOI*.MVF[NU]
MF6B>++0J3=OV >SN'[R9)IG%^50JF@.;M7XC:9?:6Y"%5OTO\+8+H?;K0O3A
M+8<J[WVV8M>[#BU24*__/[<I4_=RB\@(*F8-R6L1.[2@/:JW9X:E;R'$MS'?
M4/H0\FPIPG.NJ!Q9'"'=?&ZRN6%DF7T><4\8(W%VN<"(5T1"@+^?$\)>;\07
M%\5'/Y/_ %!+ P04    " " @_94BXH&,%X&  !(&P  &    'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;*U9_V^;.!3_5ZS<=-JD98E-0DBOC92EZZW2UE9+
M=_O9 2?A!CBSG;2]O_Z>@4+ QNVD2-,*Y/GQ>5\_S_C\@8N?<LN80H]IDLF+
MWE:IW=E@(,,M2ZG\P'<L@U_67*14P:W8#.1.,!KEB])D0(9#?Y#2..O-SO-G
M=V)VSO<JB3-V)Y#<IRD53Q]9PA\N>KCW_.!;O-DJ_6 P.]_1#5LR]7UW)^!N
M4&F)XI1E,N89$FQ]T9OCLX7GZ06YQ#\Q>Y!'UTB;LN+\I[ZYCBYZ0XV()2Q4
M6@6%/P>V8$FB-0&.7Z727O5.O?#X^EG[56X\&+.BDBUX\B..U/:B%_10Q-9T
MGZAO_.$S*PT::WTA3V3^/WHH98<]%.ZEXFFY&!"D<5;\I8^E(XX68+]C 2D7
MD/:"4<<"KUR0>VY0(,O-NJ2*SLX%?T!"2X,V?9'[)E\-UL29#N-2"?@UAG5J
MMKB]6=Y^N;Z<WW^Z1,M[^//UT\W]$MU>H<5\^1E=?;G]L41]]'UYB=Z^>8?>
MH#A#]UN^ES2+Y/E  0:M:1"6[_M8O(]TO \3])5G:BO1IRQB45/! ,!7%I!G
M"SX2I\;Y3GQ WO ](D-"+( 6KU^.'7"\RJ%>KL_KT'>[8X*J.-L4&1JKF,DS
MFY\*-2.[&EV]9W)'0W;1@_*43!Q8;_;G']@?_F6S\43*&A:/*HM'+NVS&V@V
M<1;RE-G,+-:.\[6ZIQQFXU%P/C@<HS=E/)]4,@U0XPK4V!F&>?0O% _T&R61
MXM!P0IZ%<<)05J'5S_5=2.46[00_Q)"0:/54..;M7L)=G+U#_+41'9\RHB=2
MUG">7SG/=T9TJ7CXLZ^[8X3 4T 9DN9-ESWJ:VN<"XW^40RGF+3B;,J,IX$]
MSI,*ZL0)]9*!_6%<P(.6A&C*A8K_>Q'OQ,""?3)I ;8(X6!D1QQ4B(,7RV4#
M_(H 7Q3+'9<T07R-V*]]O-,):T,;&$#ZHQ964V1H!SJM@$Z=0.M.EC!(!20T
M(_;YN@^5@:B43%G[_]3 ,0G\%E93QNM*!#RLF6SHQ/MWZ53%!!!ED0#@5]XT
MPTI90X?O"L06D?YDW 'YB'RQ$_(\@3&*9B%#,)"AB.]7:KU/H,^$?)_9W5MJ
M/ 9"INU"LPB-IAU@20V6.%OJ8DNS#9-Z #AJB7D>Y)67Q'05)]WML51_HOYX
M*FU-9]0LCYV4.IN7(=+,PN(#727VS/+,M"$!;A.@58SX7?E5,S-V4_.=8#L:
M1\]]L(@35ULF8+84 IJ-HY!+W0U0.&BW2)O4>-+!WKBF;^PDN-J_._K4Z=RQ
MR3F3=ENT"/4Q&?D= &N*Q&Z.!(!BSQI9;\5H<AX.O#9&4ZCOX2Z(-35B-S>V
M&_A+4$VVZ_L>;F.U2)%15[QK4L1N5KS-DS+C6?\Y,9_1/EFQNMBN!&J*>!TH
M:T;$;DJ\9&L&Z"*H^@/+]O:L-,EM%.!Q&YU%:H3M^$A-@<1-@3>6<1:Y)UF;
M"<0D.W\T;5>^1:J/_:#+B)H4"7;RS'5V8/(U\S9QDNOO$LJIM#6MKMF5. EK
M=K<7X597*8PL$#V(E'K*V[5S+BR5-JO1"]I-T";FD<Y0U2Q(W"SXC:WWFE'6
M2#*H6RA6%#&8:&,[6)/EVD5K$<&XH[F0F@;)RSO4O"S*2H!_9HI9$5O(S>9>
MBQCT[XZ)B]0D2-R;V"L88V'7^HI*..G6\U3:FE;7S$K<S'HG>,A8)-%:\!1&
M%R;"N*@+OM-#?3'%/% A:,>,3$P^)4.C?5F8V>N,64VZQ$VZ1<Q82;DPO>3?
M(*PH328URL%"MGC2L0$E-=F2E[>@!DVL+<EFA6WRJL6YIA#&TXYYEM3\2]S\
M>YV%(O?KVX@55^]T.6M;K% M).L1P\FF5-_SQQU@O9J,/3<9+P#5>[1BFSC+
MM%LA@9\8%=9O@2:5CGQCU+9(!5[7Z.75?.NY-Z$%3E;T\4Z$YHYR.C3";I%J
MV-%$6'.CY]YYWNBQ4.?K48YFD;6+VS^UGG3G>2IM36<<?5]^@7/-SS"(KQ0%
ML9S;V&.8;]3S3PK\][8 Y:O'C=INCZX6(1^3]BPQ.#J32)G8Y$<U$N6[NN+C
M?O6T.@Z:YX<@K><?\=FB.-2IU11G3%^I@-J28-H:5 X_3 "2*(YMBAO%=_G)
MQXHKQ=/\<LMHQ(06@-_7G*OG&_V"ZO!L]C]02P,$%     @ @(/V5).(V ">
M!   D0H  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RE5MMNVT80_94!
M P0.H.AFYP)?!%A.TQI-$,&7-D#1AQ4Y(A<F=YG=I67YZWMF*=&2X;@N^B)Q
MR9DS9\[,SN[QTKH;7S 'NJM*XT^2(H3Z<##P:<&5\GU;L\&7A765"EBZ?.!K
MQRJ+3E4Y& ^'[P>5TB:9',=W,S<YMDTHM>&9(]]4E7*K*9=V>9*,DLV+"YT7
M05X,)L>UROF2PW4]<U@-.I1,5VR\MH8<+TZ2T]'A]$#LH\$?FI=^ZYDDD[FU
M-[(XSTZ2H1#BDM,@" I_MWS&92E H/%CC9ET(<5Q^WF#_CGFCESFRO.9+?_4
M62A.DH\)9;Q031DN[/(W7N?S3O!26_KX2\NU[3"AM/'!5FMG,*BT:?_5W5J'
MESB,UP[CR+L-%%E^4D%-CIU=DA-KH,E#3#5Z@YPV4I3+X/!5PR],OKE<&7VO
M6HE,1E/EM2>[H)ECSR;$+\>#@%CB,4C7N-,6=_P3W-&8OEH3"D^_F(RS78 !
M2'9,QQNFT_&SB*>UZ]/^L$?CX7C\#-Y^E_E^Q-M_0>8].K/&VU)G#T)LYR]Z
M?-9&F52KDB[QDM&8P=-?IW,?'%KK[Z<D:@D</$U MMNAKU7*)TDML=PM)Y/7
MKT;OAT?/I'?0I7?P'/K_*.RSN$^S?EDPO$UO<F<;&)P5JJKQSM,W@QZV^:I'
MYR;MTUXHF%Z_^C@>#X_.;%4KLXJKT=&;'@&338YAD9$VE+DFITS[U-ZR6\6X
M&=]BSM12' H%0N4%H:;J;>:P^66,>%8N+4BJ%CC7[*.?-L;>*AD05!<*NWW#
M::XMAM4-NQ8>4%27*L@T]'VZ M<MDJ,/1YZNFLJZ7YU:!+KBM# 1B&9K)TE!
M0:.Z=E:!1[!4L_/6J%+?:Y-3BB9#M%0YCN,FHZ:&=***KA!ZJR.+I@)4D'A>
M]-!5U1A^BYFD4RT*5#KE'9*$J+<ZDZ0I/)#;9!39M.ES$W2*7I>LH<&6<1JA
M1+C&"V% UDYSP$C?SMV')H-1CY:%ECRW2,RYU*B3QQR3!1 XTW$ZQZS0YU+9
M]C/$:64SE*(5(R?/(2 R]+\.>BV;X/^+\K&SDLTR03NIF(SC0@X91)\J<R,4
M&J-_- SJ."PHA2#8X.ST/8J1S""_:/N)I:,R^L[&QI@^H;W9I^]OJ+(9ETA\
M.V6[6*#*5.&LT'7))/L&Q?'_47'/?!,U[UH&##:]U**UF^)A&_1IVJDHKNNZ
MQ,"M[I$H+] T*A6F9-<[LBU#CVSC=OH7_:-S@\C 6*@4)9"!^'@[+G4H"&>^
M-+/U8;//4EP=I*M]S?A%M,>$2?E6>.6WS%5FZTW?\YWVT@ MO]T&+^"%C<]H
M)22MHIEOYEYG6J%+_>$3DX?VSKU37*(CONA*!PFW,Z*F.^6X[O_>[RQ[CTP[
MS,O^1?]+GW!UB/JN,'9D>.$L))QDNNR.L@B AU'L&.SZI?P8BUF%B=6@5' 5
MM><K,?"\DT__)Z/VJ1-DL'5-J-CE\3+D49W&A/;&T+WM[ENG[37CP;R]K'U5
M+M=(M^0%7(?]#^\2<NT%J%T$6\=+Q]P&7&'B8X$[(SLQP/>%A:3KA03H;J&3
M?P!02P,$%     @ @(/V5!MIOK[_(   Q&0  !@   !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6RM/=MRW#:6O\+29"=254N69#O.Q(FK;"4SZREG[+7LY&%K
M']@DV(V8370(4NW.U^^YX0!@LR5G=UYLB22 @W._ ?I^Y_I/?FW,4'S>M)W_
MX60]#-OO'CWRU=IL2G_AMJ:#-XWK-^4 O_:K1W[;F[*F09OVT?7EY3>/-J7M
M3EY\3\_>]2^^=^/0VLZ\ZPL_;C9EOW]E6K?[X>3J)#QX;U?K 1\\>O']MER9
M6S-\W+[KX;='.DMM-Z;SUG5%;YH?3EY>???J"7Y/'_QBS<XG/Q>XDZ5SG_"7
MU_4/)Y<(D&E--> ,)?QW9VY,V^)$ ,;O,N>)+HD#TY_#['^GO<->EJ4W-Z[]
MU=;#^H>3;T^*VC3EV [OW>X_C>SG*<Y7N=;3O\6.OWWR^*2H1C^XC0P&"#:V
MX__+SX*'9,"WET<&7,N :X*;%R(H?RR'\L7WO=L5/7X-L^$/M%4:#<#9#HER
M._3PUL*XX<4M$Z-P37%K5YUM;%5V0_&RJMS8#;9;%>]<:RMK_/>/!E@/1SVJ
M9.Y7//?UD;FOKHN?73>L??%35YLZG^ 1 *K07@=H7UW?.^/+;7]1/+Y<%->7
MU]?WS/=8=_^8YGM\;+[#;1;__7+IAQZXY7_F=LSS/9F?#R7H.[\M*_/#"8B(
M-_V=.7GQU[]<?7/Y_!YHGRBT3^Z;_?])JW_7W,6[WG:5W;;P(WQ]XSH/;^J2
MA.S#VA25/C%UT=BNA*_+MO #/ !Q'GP!X]NQ-L4 7Y>\ LV%O]^XS;;L]D79
MU86%Q[NU:]O]N=MU,)L?E][6MNP!CHOB9=N"* RFQ^EM!S]4,GA9MK J (BS
M #$[7Y(2\,6ZO#/%TIBN,*T%>2(@;9< #9]=%"#Q(,]=<3/VO>FJ/6U,0/OK
M7[Z]OGKVW!>-?)1"531C1TL!2%48;#UM[>/%[451PW9*X.(/$:IB!<J386V=
M]PAV;T#C50X(\0?#9\J^ RK KA-(<&)8_#?0<,7@%![SN5J7W0JF@-T533M6
MPUCR]GFGG:C$G1W6*=)U9X3,KI1]@ 7H>7Q$C.XMHAI@)E2WA--R )BK=;%!
M#5 8I(,K/M[*_OV"MHM[ #D!#8H<AF@H7$](P*WE&'!C+]\2KT2@8"K&;[EA
M3D)(.C<H;UP4'[W!,3_YP>)#3T@$"=V6/ >^_!*VQ8_0$-IAS\C[Q\N7[P"J
MWT<+H,&"'1@R_!@WNRD_F<+HDK1?#\9ORZ08UH"BLFF(>&ND]];UA+F-"@1\
M;P;A#%LN;6L'*U/5UE> J+%G,03 $(>X]+%!O SN+\C:PULF^3D"7&_N3#<*
M..8SN G(NO78(RWC(/P-:&5=?9&IEH@940<+G!P^=C"VAPF0W1=1/P W&'M7
M+EN<N&SM'T2Y10 C< L_O"M;9OFB;,'O0 Y%\4![;8!Q85/E9T'4@D;> 3<1
MJD@%5N76#K@&ZAS7##MDJ1H6:MV6R%LY/P@/@XFN/IVC9U 7J'\ #;(RO(2!
M?<DT"82_*'XUY$@01T<LP(BUA<EZ0$]+^ 1] G OZ#NW1&M"^T#B@>S5Q)#
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M$Q?%NQZ5H5 $O2:VS-ECHX\EZ.MKA@V];#9F/3!%+^Z1RE0+CB3H6:2(3K$
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M8]P87JQ]/;"OV(N*F!< :)+HBFJD,8*64P"2ILK;3?32858@8C'-AKBA=;*
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M?HR^"=]@=^+A2_;/W*"H"4\K+!TC#@-FPM?A<.-TZ;_(+K5S.O>7&09^84@
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M-P^M-^#]TA@Z*#[ \(IF;U!+ P04    " " @_94 1._R,D#  !%"0  &0
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M7 J.+9T&H'\N9=.]T +]?PA<_0-02P,$%     @ @(/V5,GDJ+O-"   +Q<
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MPP"1>;R<P8[II)!<#D7OR*+#2,FE<SMM5D)6MFZ24'JO\$2H(K@6B+"@E>=
M6&H#S36\YQ0D!UJYJ1UL5[X+J594[:'N<0YWDT?B'@#JI<XE_/TE"3R-X*(U
MGZ.D7T')JY^+322+USZT&\0@)?V?LLA-GQ@6<9/GKE;'FR(M.273+!7<6M!B
M6![#C34=M_-W(DO.@'H"-,':>9.YI")\!F_^$0=.LE=GB+AT@NM]L/GGE]0
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M02NN*!FA147(2V_A<(R&X7Y4X'['=ES[@?@3/[DJT %W"CA87\,1!3G 4 ?
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M/)F1@@++2VO]:1,<3+-^^Q]02P,$%     @ @(/V5#Y _J8P"P  A"$  !D
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M5S0IO3NCYSYAW;;=;MM?F:+7$$C!1BT4!GT'CTAKM;Q26=:4$7Q[IUW5 $S
MFZA;&VMIS@>OBSN<J V^4**DBD,P7)>[=^MFV;1.R6A>:I:0EGJ1A"O<KEO
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MO:KU/\V:]7I;NX[S%L#'3>/8D=7[<GE+4+).R2]E($U_JE(.NF7R>%_L_X:
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M']8*U*ZTM5WMB[NNK_8Q15/<>2D<%B^-Y0CJA;,GD0;2UHL^V#Y>)T@W/1N
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MM5AWSJI]@#R<QEL-Q?MVI1H)@[[)9P:1J&HR^GY>]-W9<3R: W2J0NF-KQR
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M.KNA/]=:@;? !^#WI;6=_X +A+=PO_I?4$L#!!0    ( ("#]E1_=:1_Z0(
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MHRRUKFY9T;\"M7.@\U(I>]BX ,/?9_$74$L#!!0    ( ("#]E1>W?WAK0(
M   &   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)54;6_:0 S^*U8V
M39N$FM="81 )VDW;AZJH99NF:1^.Q"11+W?L[H!VOWZ^2TAI19'V)?&=[<>/
M?;;'.ZGN=8EHX*'F0D^\TICUR/=U5F+-])E<HR#-2JJ:&3JJPM=KA2QW3C7W
MHR#H^S6KA)>.W=U<I6.Y,;P2.%>@-W7-U.,,N=Q-O-#;7]Q616GLA9^.UZS
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M<XSH2:CC1!<E549RFMU*%&!L&] L.KV@/LF?PF-.BK:44H$A1[-#OD6HFP9
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M*KD88_Y-W4/JA=-E>+?7VF$7"-,-METPW@#/<ZW=?N%;0=O(Y[\!4$L#!!0
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M:;#6W;#$]@W* G"_D-*\3&S!]S^$Y"]02P,$%     @ @(/V5)3A44]W @
MS08  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULK55=3]LP%/TK5H8F
MD!C.5POJTDA -(V'354[MH=I#VYRVU@X=F8[+?OWLYT0"DU1'WA)_''/\3W'
M]G6R%?)!E0 :/5:,JZE7:EU/,%9Y"151%Z(&;F960E9$FZY<8U5+((4#50R'
MOC_&%:'<2Q,W-I-I(AK-*(>91*JI*B+_W0 3VZD7>$\#<[HNM1W :5*3-2Q
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M;(MGV]&B=N5D*;0I3JY9FO<&I TP\RLA]%/'5JC^!4O_ U!+ P04    " "
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M+W-H965T,S4N>&ULM9QK;]LV%(;_"N$-0P=DL47YFB4&VNC6H2V"!MT^#/O
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MO6D)K**V7ZKMOU%Y]MNTH"6PB@6VM?M 6VT7:(&X7WN.XW0/"K0FRO8LN[Y
M[;V&PFY^B\J&@1*<)G\@?$F[EFXCX&OO5EMH5?G.3K[S1C5; +=E0TMH51MV
MO8_=V%?\5]6Z-9_^PYI]&6/[_D')FGOML&Q?(WU*X&A.5T3DW62Y6IY$+G7_
M?; ^4B<4W6;O8/+CS35F44(X2F$A(:WSKF3$\A-#/A%TJ9ON!RID#ZV'L3QE
M 5,!\OJ"4K&=J W*<UOP%U!+ P04    " " @_946:6H]4\"  !S!0  &0
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M9&G291%#N=C-8COG/'G..4^]8T]W7%S+#$"AFYPR.7,RI8H3UY5)!CF61[P
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M=W2L"8GR#J"<*%[88_055_I0;H<9X!2$,=#O5YRKNXGY0'T3,_\#4$L#!!0
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MF J0UV>4BOU$;5 VD>%_4$L#!!0    ( (&#]E1<"1FAUP@  /4]   9
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MSQ@W;\IL6S]U^R4KRVQ3OWSDT8KG58#X^T.6E:]OJB_8/^E]\R=02P,$%
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M+A>J7P:N ]3]&6-R.] /*#OP\!]02P,$%     @ @8/V5,+#LM]C P  (@H
M !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULK59-C]LV$/TKA(H46R"Q
MOFS+N[4%['H3)(< QF[3'HH>:&ED$Y%(E:3LS;_OD)*UMDIK>Z@/EDC-/+XW
M' YG>13RN]H#:/)2E5RMO+W6]9WOJVP/%54340/'+X60%=4XE#M?U1)H;IVJ
MTH^"8.Y7E'$O7=JYC4R7HM$EX["11#551>6/!RC%<>6%WFGBB>WVVDSXZ;*F
M.W@&_:W>2!SY/4K.*N"*"4XD%"OO/KQ;AX%QL!:_,SBJLW=BI&R%^&X&7_*5
M%QA&4$*F#03%QP'64)8&"7G\W8%Z_9K&\?S]A/[)BD<Q6ZI@+<H_6*[W*V_A
MD1P*VI3Z21P_0R=H9O R42K[3XZM;3+W2-8H+:K.&1E4C+=/^M(%XLPAO.80
M=0[1T&%ZQ2'N'&(KM&5F93U23=.E%$<BC36BF1<;&^N-:A@WV_BL)7YEZ*?3
MC10'9O<$4X)\X9FH@/Q&7T"1#^0),L$S5C)J0RX*\K$HP ;>V) GJH'</(*F
MK%2_+'V-A RLGW6+/[2+1U<6#R/R57"]5^0CSR&_!/!122\G.LEYB$81[VLY
M(7'PGD1!%#D(K?^[>SA")^ZC&UN\^ K>:SS)(U-9*50C@?QYOU5:8@+_Y0I9
MBSAU(YI3?:=JFL'*PV.K0![ 2W_^*9P'O[KD_D]@%^*GO?CI&'KZ"7*0M"2L
M#8+&(%!-E*:ZT4+^(!*SQQ6 %A4K@X$U9>B0!A.S'8=S96]975">]91GHY2_
M/9.#FIBC@,>?6\J&)<D9YKT$GCD)MYBW%TR",!X0=EH%,S?A>4]X/DKX61MZ
MKQ%^3SB6?CRH11?\+7 HF';1GKL(Q4/:+JM%L C.?E>"GO0:DE$-&\!RS('K
MLS K%^%QF)MI,HF#=ZXRM'[#<QY.9O_RO-"RZ+4L1J'PP.-EJLR6D 9U2"R-
M;1[50C%315W"%HY<'FS#PID]B3ORMSW;VU&VZSWE.\OU0,NF+?*TQ)N=7LGT
M6P>+*$D&7,<7O8FFCGVZX!\&K[=7\%:\3[4%7K"U44[:'<B@6 3S >_.[%)>
MF$2#(/MGMVT%<F>;$$4RT7#=WE3];-_HW-OK?3#_8!H@>XN_PK3=TU<J=XPK
M4D*!D,$DP>(AVX:D'6A1VSM]*S1V"/9UCTT<2&. WPLA]&E@%NC;PO0?4$L#
M!!0    ( (&#]E0505-T4@,  -\)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;*V636_;.!"&_PJA+8H6:"+JP[*3V@)<&XL6:(N@2;N'10^T-+:)
M4*)*4G:ROWZ'DJ(X%NWM82\V2<T[>H8<SFBZE^I>;P$,>2A$J6?>UICJVO=U
MMH6"Z4M908E/UE(5S.!4;7Q=*6!Y(RJ$'U*:^ 7CI9=.F[4;E4YE;00OX481
M71<%4X\?0,C]S N\IX5O?+,U=L%/IQ7;P"V8[]6-PIG?>\EY :7FLB0*UC-O
M'EPO FH%C<4/#GM],"8VE)64]W;R*9]YU!*!@,Q8%PS_=K  (:PGY/C5.?7Z
M=UKAX?C)^Y]-\!C,BFE82/$7S\UVYDT\DL.:U<)\D_N/T 4TLOXR*73S2_:=
M+?5(5FLCBTZ,! 4OVW_VT&W$@2"(3PC"3A#^KB#J!%$3:$O6A+5DAJ53)?=$
M66OT9@?-WC1JC(:7]AAOC<*G''4FO5%RQYLSP90@G\I,%D#NV -H<D$6LJAD
M":711*[)$M:@%.3V,9EK#;C,RIQ\YFS%!3<<-6^68!@7^BVJO]\NR9M7;\DK
MPDMRMY6U1FL]]0UBVY?[68?XH44,3R#.*W5)(OJ.A#0,'?+%[\N#EW(?-ZO?
ML;#?L;#Q%YWP][Q'9,EU)J2N%9"_YRMM%";E3U> K<?8[='>U&M=L0QF'EY%
M#6H'7OKZCR"A[UWA_D_.7@0?]<%'Y[RG\RQ3-:: >#YS5[RMDU'CQ!:271HD
M>'2[PS"&-F'T;/."+N[IXK-T31&RJ5IK>$=*+(+,IJG_1/OH8FU=)@<<49 <
ML0YMPG'@9AWUK*.SK$O X\DX:XL97B-62&7X/\V"BW,T8+B(KHY!'48A3=RD
M24^:G"6]-3*[O["U,B>8^MA =$L-#W8,+MADN*F3<7P$ZS!*8NJ&'?>PX[.P
M7_'0L<<I)"PW!"^G)AE3ZO$"R]N>J=P%.QYP!,$H/MY:EU5,8S?NI,>=G,6]
MDX8)VW;:RFJPJ#0IZ[Q5DR'!:$2/[Y7+*HI/9.M5SWEUEO,S:'U-?C!1=PDK
ML/^S,G,>_M4P"5V@3K.3I %][FCT/U-@N*/.OD,'-8@>09XU:0']@^YK/WV^
M,+7AI28"UJBAEV,4J_9KHIT8634->24-MO=FN,4O,%#6 )^OI31/$]OC^V^Z
M]%]02P,$%     @ @8/V5!6\1TSQ @  S H  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&ULK5;);MLP$/T50@V*%$BCS5+<U!:01"Z:0ULC6P]%#[0\
MMHE0I$I25M*O+TDIJATKA@WX(G&9]SA\,QS,H.+B42X %'K**9-#9Z%4<>ZZ
M,EM CN4I+X#IG1D7.59Z*N:N+ 3@J07EU T\+W9S3)B3#.S:6"0#7BI*&(P%
MDF6>8_%\"9170\=W7A9NR'RAS(*;# H\AUM0]\58Z)G;LDQ)#DP2SI" V="Y
M\,]'L;&W!@\$*KDR1N8F$\X?S>1Z.G0\XQ!0R)1AP/JWA"N@U!!I-_XTG$Y[
MI &NCE_8O]B[Z[M,L(0K3G^2J5H,G;Z#IC##)54WO/H*S7TBPY=Q*NT75;7M
M6<]!62D5SQNP]B GK/[CIT:'%8#_%B!H ,&N@+ !A+L">@V@MRL@:@#VZFY]
M=RM<BA5.!H)72!AKS68&5GV+UGH19O+D5@F]2S1.)6/!E\0&7><<NF89SP'=
MX2>0Z"/ZCH7 )I#H. 6%"94?].K];8J.CSZ@(T08NEOP4F(VE0-7:7<,J9LU
M1U_61P=O''U1B%,4>B<H\(*@ WZU.]SO@*>[P[T.^&AGN!^NPUT=@C8.01N'
MP/*%;_#]5QZE1&:4RU( ^G4QD4KHQ_2[2]Z:L=?-: K,N2QP!D-'5Q )8@E.
M\OZ='WN?N\0^)%EZ2++1@<C6PA*V80FWL2</F):XKFA4EU3,,NB*1$T261)3
MF9>)'T6>3JOEJL1=5N%KJW2K0_MJ=R"R->UZK7:]K=K]*,!4#S9'.ILERG0Q
M>=9%IL*BNUK4;/&*/+V^MR%BAU7\:4/$K9[M*^*!R-9$C%H1HSU$/$&4Y$39
MC)1(9V4I._,QVA0I#%X)N?7<?1_\(<E&T>8["58384W(N!4RWBKD/1.0\3DC
M?V&*E"ZS$V P(ZHS%>--#_K^*_UVL$D[;,[ZZS:CK6[OFUWN2B=@^KQO6,R)
M3A4*,TWOG9YI7T3=.]43Q0O;'$RXTJV&'2YTNPG"&.C]&>?J96+ZC;:!3?X!
M4$L#!!0    ( (&#]E1K)TY&)0,  /X(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;*U6;6_:,!#^*U963:W4-2&\JH-(0#NM'RHAVFX?IGUPDX-8
M=>S,=H#NU^_LA RZ0"NM7\ ^WSU^[L5W&:ZE>M(I@"&;C L]\E)C\DO?UW$*
M&=47,@>!)PNI,FIPJY:^SA70Q!EEW ^#H.=GE DO&CK93$5#61C.!,P4T466
M4?4\ 2[7(Z_E;05SMDR-%?C1,*=+N /SD,\4[OP:)6$9",VD( H6(V_<NIP.
MK+Y3^,9@K7?6Q'KR*.63W=PD(R^PA(!#;"P"Q;\53(%S"X0T?E687GVE-=Q=
M;]&_.-_1ET>J82KY=Y:8=.0-/)+ @A;<S.7Z*U3^="U>++EVOV1=Z08>B0MM
M9%89(X.,B?*?;JHX[!BT>@<,PLH@?&G0.6#0K@S:SM&2F7/KBAH:#95<$V6U
M$<TN7&R<-7K#A,WBG5%XRM#.1#,E5\RE!"N"W(A89D#NZ08T^42F*15+($R0
M!Q&#,E@4]HS,I&8V"9J<7@%*N3Y#[8>[*W)Z<D9.K,%]*@M-1:*'OD&:]C(_
MKBA-2DKA 4JMD-Q*85)-KD4"R3Z C_[53H9;)R?A4<1QKBY(.S@G81"&#82F
M;S=O':'3KF/>=GCM WASB*6(&6?45;)<8'@5RI:"_8;$17@" A;,Z'-RO8EY
MD3"Q).-,%L)H,BLS845&XCG%LJC,YF *A6GY,9><$ZSS-57)SZ84E P[S0QM
MZ[C4.8UAY&%OT*!6X$4?/[1ZP>>F\+T3V%XP.W4P.\?0HPGE%(OSG#S"D@D7
M%0RH28$\ U5-KI=X78=GF]PJ:@TPK:M=CQIT^H-:9X]HMR;:/4ITG"3NT;BN
MDQ!<&,Q87C\E!9P:/,"<YHKA8[3\&Y]/>4]OAUSP@OXQC3WRO9I\[RCY&7W&
MUFVP\R3P/]1[KU(_IK%'O5]3[[]7W.-"*>OEH<KIO\K^7XUV,_M!S7[PMO(&
MD=C"/D1M\(:B/JY3TO-W1DD&:NDFK":Q;3UEPZVE]1 ?N]GU0C[!X5[.XK\P
MY9?!+57X4C7AL$#(X**/C%0Y;<N-D;D;6(_2X/ASRQ0_4$!9!3Q?2&FV&WM!
M_<D3_0%02P,$%     @ @8/V5! :9KRH P  QPL  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&ULM5;;<MLV$/T5#)/IV#.I>1,IT9$XHTLZS4,ZGKAN
MGB$2$E&#  . DOOW78 4+<D4[0?G10+ W8-S=A? 3O="/JJ"$(V>2L;5S"FT
MKFY=5V4%*;&Z$17A\&4C9(DU3.76594D.+=.)7,#SXO=$E/NI%.[=B?3J:@U
MHYS<2:3JLL3ROP5A8C]S?.>P\)UN"VT6W'1:X2VY)_JANI,P<SN4G):$*RHX
MDF0S<^;^[=*W#M;B'TKVZFB,C)2U$(]F\C6?.9YA1!C)M(' \+<C2\*800(>
M/UM0I]O3.!Z/#^A_6/$@9HT560KV@^:ZF#D3!^5D@VNFOXO]GZ05%!F\3#!E
M?]&^M?4<E-5*B[)U!@8EY<T_?FH#<>3@QQ<<@M8A.'<877 (6X?0"FV865DK
MK'$ZE6*/I+$&-#.PL;'>H(9RD\9[+>$K!3^=?L&24[Y5Z(Y(=%]@2=#O:(E9
M5C-LXJR0V* >HZL5T9@R=0WF#_<K=/7Q&GU$+E+FJT*4HP=.M?H$BS#^NQ"U
MPCQ74U<#:;.UF[4$%PW!X )!/T#?!->%0E]X3O)3 !?4=I*#@^1%,(@XK^0-
M"KU/*/""H(?0\NWN_@"=L,M :/'""W@+K&B&(#@HIZS6)$<<3B_EF2@)JB#@
M-J0(IE6M;4[052X8P]*&61]">WW;%]QF[U'_WN:.N%45SLC,@4M $;DC3OK;
M!S_V/O<%YIW 3L(TZL(T&D)/_WH."M9:TC4$8\T(TL*$IH2HP%G)'@O!<B)[
MZZS!CRR^N=UV:32:3-W=L<*7-F$<=#8GQ*..>#1(O,EO;TZO('^URI]7KOMX
M-_"3(T[>C3<Z(]YK%/8SCSOF\6!EKMIZ'*K%/L+Q>];<.X&=!&#<!6#\BVMN
M_(::>VESL>8F'?')(/$?]O6"U,UW1,)KW-%M;F=3=\VPM^ :[/B(D!_ZR=@?
M>V?,>PW#29)$_?23CGXR2/\KSR2!7D%C=J"\D:)$6$&W :K($Y$95<2\37LL
M)>9:V1O4I@.)JGFY7I&9O&"?Q$$<)&<B7YKYHW 4Q7&_1M][?GF]097S_%]X
MWT'._I MW&9+M>_PX4%X14B[SRE%/TK&R;F67LMH'$:Q?T'-41_A#ZI9#3U>
M;[OHVAU>N>GZK<X/C'O4$I5$;FVGJ. <U%PWK4*WVG6C<]N#G:TO3)=J6ZUG
MF*;%_8;EED*9,;(!2.]F#$=8-EUC,]&BLHW76FAHX^RP@$Z;2&, WS="Z,/$
M;-#U[NG_4$L#!!0    ( (&#]E01W&GYLP(  &T(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0Y+GAM;*U6:VO;,!3]*\*#L<%:OQ*G9(ZA23L66"$T>WP8
M^Z#8-[&H'JXD)^V_GR2[7E*<T$&^V'K<<WS.U>,ZW0GYH$H C9X8Y6KBE5I7
M8]]7>0D,JTM1 3<S:R$9UJ8K-[ZJ).#"@1CUHR!(?(8)][+4C2UDEHI:4\)A
M(9&J&</R>0I4["9>Z+T,W)--J>V GZ45WL 2](]J(4W/[U@*PH K(CB2L)YX
MU^%X-K+Q+N G@9W::R/K9"7$@^W,BXD76$% (=>6 9O7%F9 J24R,AY;3J_[
MI 7NMU_8OSCOQLL**Y@)^HL4NIQX5QXJ8(UKJN_%[BNT?H:6+Q=4N2?:M;&!
MA_)::<%:L%' "&_>^*G-PQX@3(X HA80O08,C@#B%A [HXTR9^L&:YRE4NR0
MM-&&S39<;AS:N"'<KN)22S-+#$YGMUARPC<*+4"B98DEH NT;)84B35:" U<
M$TSI,[HAM+9)1TLM\H<+F[T"S;G2LC;KJA7Z< ,:$ZH^&@YEN53J:R/2?LK/
M6T'31E!T1% 8H3O!=:G0+2^@."3PC;O.8O1B<1J=9+RNY"6*@T\H"J*H1]#L
M[?#PA)RXRWCL^.(C?#.*E;*I=5E$O[^9>337P-2?OFPU9(-^,GO&QZK".4P\
M<X@5R"UXV?MW81)\[G-Z)K(#WX/.]^ 4>_9=:$Q1+A@SIU<Y[_!8DRVF=N_T
M66_X$L=G;Z-M%L9Q=#4<I/YVWU5/7#*,DT'2Q1T('G:"AR<%-^LC*GO=].H[
M"?_?I3D3V8'3I'.:G'-+)N?T?2:R ]^CSO?HS%MR],8MV1/7NR7]O9N;@=RX
M@J:,I)KKYH;K1KN:>>U*Q:OQJ:FE3>G[1],4XCLL-X0K1&%M*(/+D=EILBEN
M34>+RM6'E="FVKAF:?X'0-H ,[\6I@:T'?N![@\C^PM02P,$%     @ @8/V
M5.B9$NS" @  D D  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULO59M
M;]HP$/XK5C9-G=0U+Q! 78A48-,JK1OJR_9AV@>3'"1J'&=G0]I_/]L):2@O
M:B6V+]B^W#V^Y_&9<U!RO!<)@"0/+,O%T$JD+,YM6T0),"K.> &Y^C+GR*A4
M2US8HD"@L0EBF>TY3L]F-,VM,#"V*88!7\HLS6&*1"P9H_@X@HR70\NUUH;K
M=)%(;;##H* +N %Y5TQ1K>P&)4X9Y"+E.4&8#ZT+]WP\T/[&X4<*I6C-B68R
MX_Q>+R[CH>7HA""#2&H$JH85C"'+-)!*XT^-:35;ZL#V?(W^V7!77&94P)AG
M/]-8)D-K8)$8YG29R6M>?H&:CZ_Q(IX)\TO*VM>Q2+04DK,Z6&7 TKP:Z4.M
M0RO [>T)\.H [WE =T] IP[H&*)59H;6A$H:!LA+@MI;H>F)T<9$*S9IKD_Q
M1J+ZFJHX&5Y#1B7$9$I1/I);I+F@1F!!/I!O%)%JF<G)!"1-,_%>64><8DSX
MG$Q25(?!4;O>W4S(R=OW@2U54AK:CNH$1E4"WIX$7(]<\5PF@GS*8X@W 6S%
MIJ'DK2F-O(.(%P6>D8YS2CS'\W8D-'YYN'L@G4ZC<,?@=??@57)= 9L!DN\Y
M[)+H((*^R.>BH!$,+753!> *K/#=&[?G?-Q%[TA@&V2[#=FN0>^\MIS(KZ_*
ME5Q*8.+W+@FZQY3@2& ;$OB-!/[!\UY+@/58&"GDDQ2GA#*^S*70=ZAEWZ5*
MM95OMM)_R*NPTW,<)[!7;;K;7GZW[;7!H]?PZ+V\;F]+OBN]@PBO/;0C@6V0
M[3=D^_^H;OO'E.!(8!L2#!H)!O^O;@=;%>GVM^MVV\OWM\K6;C4W!K@P/5^0
M2*=2-87&VCPK+DPW?68?J>=&]3IX@JG>*E<4%ZGJ>!G,%:1SUE<I8=7_JX7D
MA6FA,RY50S;31#V9 +6#^C[G7*X7>H/F$1;^!5!+ P04    " "!@_94D9O_
M=6\'  !C40  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RUG%MOVS88
MAO\*X15#!Z2Q1/F4+#'01B<.S5:DZWHQ[(*QF42H#JXDQ\V_'R4KEBG)C%6\
MN4DL1]]#RGY"47QM76R2]%OV($1.?D1AG%T.'O)\=3X<9HL'$?'L-%F)6/[E
M+DDCGLO-]'Z8K5+!EV51% ZI84R&$0_BP?RB?.Y3.K](UGD8Q.)32K)U%/'T
MZ8,(D\WEP!P\/W$3W#_DQ1/#^<6*WXO/(O^R^I3*K>&.L@PB$6=!$I-4W%T.
MWIOGS#**@G*/?P*QR?8>D^)0;I/D6['!EI<#H^B1",4B+Q!<_GH45R(,"Y+L
MQ_<*.MBU613N/WZFN^7!RX.YY9FX2L*OP3)_N!S,!F0I[O@ZS&^2C2^J QH7
MO$429N5/LMGN.Z(#LEAG>1)5Q;('41!O?_,?U0NQ5V".#A30JH V"\8'"JRJ
MP&H4T$,%HZI@=&R7QE7!^-B"254P.;9@6A5,FP76@8)953 [MH6SJN"LU&'[
M_I5OOLUS/K](DPU)B[TEK7A0&E16R_<\B O9/^>I_&L@Z_+Y1R%-R<A;6^0\
M"+/?R#ORY;--WK[YC;PA04S^?DC6&8^7V<4PE\T51<-%A;[:HND!M$6NDSA_
MR(@3+\6RH][6UYM4 QC*X]P=+'T^V ]42_QC'9\2RS@AU*!&UP&]5![*<O-@
MN:TO?[]*=ZW3CG+G^'*SH]P]HMPP#Y9[1[QTQN%C]_7EU_Q)5\U>JDX/O6^*
M!]9.>JOD60>ESS(A3D@I_PFQ1;9(@U4Y^/[[4>Y+6"ZB[+^.CG[8@D?=X.+,
M=)ZM^$)<#N2I)Q/IHQC,?_W%G!B_=^F&A-E(F(.$N4B8AX3Y2!@#P12C1SNC
M1SKZ_*^52'D>Q/<D+ ?T$SD1B7,B?LA)42:Z1-;R^HJ,A-E;V+B$%7.UQ[EY
M9LA_^\=]03MVLIH[N<AN>4B8CX0Q$$P1;[P3;ZP5[T;$8L-#DHLTZM),6]U7
M,R3,1L(<),Q%PCPDS$?"F%ZL"8G*R9_&T<G.T4F?P9&DQ070N^3NW5IN<#D5
MR.5X&8N\RU\MN:^_2)B]A4WV1L 9M9K#9,=.XV+ZIPR3R&YY2)@_:8WR[>XS
M4(N*6M.=6M,^:IV0,."W01CD3UTR:5E]94+"[&G+D[/19-*0"=FB.VV]M5;K
M!.XA6_21, :"*=+-=M+-M-)Y7%Z8RVN5XIP;Q+R\;DGN2**ZV"6@EMM70"3,
MGK5T: YELY:BTW%C($/VR$/"?"2,@6"*>V<[]\ZT[GTM5P_%DO!':=N]/)F*
M8DFU/KD>F@AJL7W50\)L_0%/R)/@:49FU7R$F)0L^5/7>IB#[):+A'E(F(^$
M,1!,D=DTZM5/HY_.RR!;)&MYZ2R'TLXA5 _L*S*49E>TL_U1]-083ZW&4 IM
MU872/"C-A](8BJ;*NK=4;VIEO4K255)X27S!E]_7/)6#;== ]$$/ZBTIDF9#
M:0Z4YD)I'I3F0VD,15-5IK7*]+56X"LRRFTDS8;2'"C-A=(\*,V'TAB*IKI=
MATNF=J7_)];B]<#>2D-CI8JFK,',FO,)J[U\T%QD@O;*@])\*(VA:*I^=1)D
MZJ.@FV3Q[3$(0SFL7MN=MD&C'RC-AM(<*,V%TCPHS8?2&(JF&EQ'2N;XU28'
MT+P)2K.A- =*<Z$T#TKSH32&HJENUU&4V2N+.F9R (V@H#3;;.=+YK25U7?M
M15MA/;1G'I3F0VD,15,5K",KLU=FU2L.U:-[R]@.@4RS,;FTH4TZ4)H+I7D=
M+X<U:_Z?^- V&8JFNE@G6:8^RNJ7G^IAO>UK)THF'3?M0S;I0&DNE.9!:3Z4
MQE TU=(Z\S+U&5!SQ SB12HB>=[FX<NG;VCP5=&4J_&FL<@&'2C-A=(\*,V'
MTAB*IG[.O<ZUJ#[74A8!R)]B0SXFB_*3 EV.ZF%]'872;"C-@=)<*,V#TGPH
MC:%HJLYU\D7-UUH1H- H#$JSH30'2G.A- ]*\Z$TAJ*I;M=1&-7&$3^Q(J '
M]E8:FH!5M/U)=7,YH&.74>,3"BZT4QZ4YD-I#$53[:O#*MHKK.JU&$ [HJ%Q
MX]V^TK??6R_HMYR@-!=*\Z T'TIC*)KJ;)UP47W"U6_1H((IX22=-"V%IEA0
MF@.EN5":!Z7Y4!I#T51+ZQ2+ZK_ \O.?TJ[ ^^/JM"4L-)J"TAPHS872/"C-
MA](8BJ8*6T=35!]-70<AC^65% ^[QU%H#@6EV5": Z6Y4)H'I?E0&D/15'_K
M7(M.7VV1 !IK06DVE.9 :2Z4YD%I/I3&4#35[3HGH[URLF,6":!9&91FT_:W
MO69F<Y7@Q6^$N=!.>5":#Z4Q%$VUK\Z_:+_\J]<B 33_@M)L*,V!TEPHS8/2
M?"B-T7:F28TZAU?O\%,G8)8^ >NW2*"'];442K.A- =*<Z$T#TKSH316T?26
M#O=NQ!:)]+Z\BU]&RF\4;F]3MGMV=Z? ]^7]\1K/V^:YL[W?7XW9WG[PFJ?W
M09Q)J^\DTCB=RAZEVSOZ;3?R9%7>[NTVR?,D*A\^"+X4:;&#_/M=DN3/&T4#
MN_LJSO\'4$L#!!0    ( (&#]E2> IU_H0(  +\'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;*U56T_;,!C]*U:&)I HN=.*M9%*JVF38" 8V\.T
M!S?]TE@X=F8[+?S[V4[(TA(*TGA);.><X^^<^#+><'$O<P"%'@K*Y,3)E2K/
M7%>F.118GO 2F/Z2<5%@I;MBY<I2 %Y:4D'=P/-.W0(3YB1C.W8MDC&O%"4,
MK@6255%@\7@.E&\FCN\\#=R05:[,@)N,2[R"6U!WY;70/;=569("F"2<(0'9
MQ)GZ9_/8X"W@!X&-[+21<;+@_-YTOBXGCF<* @JI,@I8O]8P TJ-D"[C3Z/I
MM%,:8K?]I/[9>M=>%EC"C-.?9*GRB3-RT!(R7%%UPS=?H/%C"TPYE?:)-C5V
M.'106DG%BX:L*R@(J]_XH<FA0_"C%PA!0PC>2@@;0KA+"%\@1 TALLG45FP.
M<ZQP,A9\@X1!:S73L&%:MK9/F/GMMTKHKT3S5'(!.C2)!NCFZ@Y-I00E$69+
M9,?1!<$+0HDB&G(X!X4)E4<:?'<[1X<'1^@ $8:^Y[R2FB/'KM(5&5TW;68_
MKV</7IA]6HH3%'K'*/""H(<^>SO=[Z'/]],O\2/R?,OVMMFN3K&-,FBC#*Q<
MN#_*7].%5$*OY]]]>=024;^$V>-GLL0I3!R]B26(-3C)QP_^J?>I+YWW%)N_
MD]A6=&$;7;A//;DJ06!%V I1N^Z$V:T#G@TJW<%V51XC!JHOT5HYMLKFD%LG
MHR#4_W/=3:H'%)LETP7-7P%M.8M:9]%>9[-*"& *E5S8<XYGB.^8I?\V69^_
M6O^T4Y7OQ=&.O^>@D3_:L;<?L^4N;MW%>]U]XVR0_K?#^'GND1_L..P!#4?A
MCL570+5'MW-:FJOM$HL585+7FFF:=S+4?%%?%W5'\=(>H NN]'%LF[F^84$8
M@/Z><:Z>.N9,;N_LY"]02P,$%     @ @8/V5$C/3HH? P  50L  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&ULK99=;YLP%(;_BL6JJ972\AD2L@2I
M356M4JM%_=@NIETXX218!<QLDS3_?C80FA)**K2;8(/?<Y[W.. SWE#VPD,
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M54N3DO,N%+C'URPE_?@C"9S<1&4L)7<G[W_5RER^"]SSZ,/14>_N]'(_?M(
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M/%E,9B2]F\TVJ0,8 H#AQ0#)U8HZD!$ &?U!R'1C-U]F"PNXO"7+U6SM0,8
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M/O\_J2[G>]/U\9?E]\G1JW+!.<!O^\<O4$L#!!0    ( (&#]E0J9-*FR@$
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M7=VWL1"Y4)[_Q&-B+'WU]U%[V@45O\R.V_MAW+([#\^ZV_5[_/6,C_4O[$.
M]"%!^E @?60@?0Q!^K@%Z>,.I(][D#[X *41%%$Y"JD<Q52.@BI'496CL,I1
M7.4HL'(4606*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56B2*K1)%5HL@J
M4625*+)*%%DEBJP215:)(JM$D56AR*I09%4HLBH4616*K I%5H4BJT*15:'(
MJE!DS5!DS5!DS5!DS?Y3UG=CEG_]N[B]I[4NFT,^Z_[)3SX!4$L! A0#%
M  @ @(/V5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " " @_94R>:(Z>X    K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " " @_94F5R<
M(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    ( ("#]E28V^NQV@<  )4O   8              " @0T(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " " @_94H,#T
M3S@"  "W!0  &               @($=$   >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L! A0#%     @ @(/V5)W1:7Q4!0  YQ4  !@
M ("!BQ(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ("#
M]E0&#O.$I@(  &@'   8              " @148  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " " @_94-I>-(20%  " %0  &
M        @('Q&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ @(/V5$UP[]]^!0   "0  !@              ("!2R   'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ("#]E2+B@8P7@8  $@;   8
M              " @?\E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " " @_94DXC8 )X$  "1"@  &               @(&3+   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ @(/V5!MIOK[_(
MQ&0  !@              ("!9S$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( ("#]E2^3!"G_@(  'X'   9              " @9Q2
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ @(/V5"M&
MSR?R"   KA<  !D              ("!T54  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " " @_94(C9&L1 #   4!P  &0
M    @('Z7@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M ("#]E3/V9.U40(  %$%   9              " @4%B  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ @(/V5 $3O\C) P  10D  !D
M             ("!R60  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " " @_94>>8WUY$*   M(   &0              @('):   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ("#]E3)Y*B[S0@
M "\7   9              " @9%S  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ @(/V5)JT05_D P  8PD  !D              ("!
ME7P  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " " @_94
M"\ZJ4UH#  #W!P  &0              @(&P@   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( ("#]E0^0/ZF, L  (0A   9
M      " @4&$  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ @(/V5&E@&#6J'   D5L  !D              ("!J(\  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " " @_94?W6D?^D"  !D!P
M&0              @(&)K   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( ("#]E1$\H 6_0(  (D&   9              " @:FO  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ @(/V5%[=_>&M
M @    8  !D              ("!W;(  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " " @_94+GF2IH8%  #W#0  &0
M@('!M0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ("#
M]E1Y5C&=)04  /4-   9              " @7Z[  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ @(/V5-K@Z&<H!   5@H  !D
M         ("!VL   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " " @_944&9L)"H#  "#!P  &0              @($YQ0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ("#]E1./Q&]< (  )8%
M   9              " @9K(  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ @(/V5*7]"1JD!   'A<  !D              ("!0<L
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " " @_94MXE6
M+)<"  #4!P  &0              @($<T   >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( ("#]E1=27D"^P(  ",*   9
M  " @>K2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M@(/V5(@N)Z!4 @  ' 8  !D              ("!'-8  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " " @_94E.%13W<"  #-!@  &0
M            @(&GV   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( ("#]E08B&6C[P0  #4?   9              " @57;  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ @(/V5 -45&J>!P
MMDT  !D              ("!>^   'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " " @_94^ZNJYT(#  ###0  &0              @(%0
MZ   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ("#]E19
MI:CU3P(  ',%   9              " @<GK  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ @(/V5$H%9"H@ P  _@P  !D
M     ("!3^X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (&#]E3V3^O4#@,  (T+   9              "
M@;,( 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ @8/V
M5,+#LM]C P  (@H  !D              ("!^ L! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " "!@_94%4%3=%(#  #?"0  &0
M        @(&2#P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( (&#]E05O$=,\0(  ,P*   9              " @1L3 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ @8/V5&LG3D8E P  _@@
M !D              ("!0Q8! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " "!@_94$!IFO*@#  #'"P  &0              @(&?&0$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (&#]E01W&GY
MLP(  &T(   9              " @7X= 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ @8/V5.B9$NS" @  D D  !D
M ("!:" ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "!
M@_94D9O_=6\'  !C40  &0              @(%A(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( (&#]E2> IU_H0(  +\'   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "!@_94?'[I&]0!  #&'P
M&@              @ $:.@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "!@_94*F32ILH!  ";'P  $P              @ $F/ $
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ] *(0   A/@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>116</ContextCount>
  <ElementCount>273</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue</Role>
      <ShortName>Accounts Receivable, Unbilled Services and Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Revenue from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RevenuefromContractswithCustomers</Role>
      <ShortName>Revenue from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Significant Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SignificantCustomers</Role>
      <ShortName>Significant Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - Stock-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPayments</Role>
      <ShortName>Stock-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Provision for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxes</Role>
      <ShortName>Provision for Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://championsoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables</Role>
      <ShortName>Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/PropertyandEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Revenue from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RevenuefromContractswithCustomersTables</Role>
      <ShortName>Revenue from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/RevenuefromContractswithCustomers</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Stock-based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPaymentsTables</Role>
      <ShortName>Stock-based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/StockbasedPayments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Provision for Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesTables</Role>
      <ShortName>Provision for Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/ProvisionforIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/EarningsPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://championsoncology.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails</Role>
      <ShortName>Organization and Basis of Presentation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails</Role>
      <ShortName>Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails</Role>
      <ShortName>Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails</Role>
      <ShortName>Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Revenue from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RevenuefromContractswithCustomersDetails</Role>
      <ShortName>Revenue from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://championsoncology.com/role/RevenuefromContractswithCustomersTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Significant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/SignificantCustomersDetails</Role>
      <ShortName>Significant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://championsoncology.com/role/SignificantCustomers</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock-based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails</Role>
      <ShortName>Stock-based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Payments - Allocation of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails</Role>
      <ShortName>Stock-based Payments - Allocation of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Stock-based Payments - Stock Option Grants Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails</Role>
      <ShortName>Stock-based Payments - Stock Option Grants Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stock-based Payments - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails</Role>
      <ShortName>Stock-based Payments - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails</Role>
      <ShortName>Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails</Role>
      <ShortName>Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Provision for Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails</Role>
      <ShortName>Provision for Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Provision for Income Taxes - Change in Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails</Role>
      <ShortName>Provision for Income Taxes - Change in Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails</Role>
      <ShortName>Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://championsoncology.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Leases - ROU Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - ROU Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="csbr-20220430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="csbr-20220430.htm">csbr-20220430.htm</File>
    <File>csbr-20220430.xsd</File>
    <File>csbr-20220430_cal.xml</File>
    <File>csbr-20220430_def.xml</File>
    <File>csbr-20220430_lab.xml</File>
    <File>csbr-20220430_pre.xml</File>
    <File>csbrex2314302022.htm</File>
    <File>csbrex3114302022.htm</File>
    <File>csbrex3124302022.htm</File>
    <File>csbrex3214302022.htm</File>
    <File>csbrex414302022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="526">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "csbr-20220430.htm": {
   "axisCustom": 1,
   "axisStandard": 14,
   "contextCount": 116,
   "dts": {
    "calculationLink": {
     "local": [
      "csbr-20220430_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "csbr-20220430_def.xml"
     ]
    },
    "inline": {
     "local": [
      "csbr-20220430.htm"
     ]
    },
    "labelLink": {
     "local": [
      "csbr-20220430_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "csbr-20220430_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "csbr-20220430.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 407,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 30,
   "keyStandard": 243,
   "memberCustom": 21,
   "memberStandard": 20,
   "nsprefix": "csbr",
   "nsuri": "http://championsoncology.com/20220430",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://championsoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "csbr:AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue",
     "role": "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue",
     "shortName": "Accounts Receivable, Unbilled Services and Deferred Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "csbr:AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Property and Equipment",
     "role": "http://championsoncology.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Revenue from Contracts with Customers",
     "role": "http://championsoncology.com/role/RevenuefromContractswithCustomers",
     "shortName": "Revenue from Contracts with Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Significant Customers",
     "role": "http://championsoncology.com/role/SignificantCustomers",
     "shortName": "Significant Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Commitments and Contingencies",
     "role": "http://championsoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - Stock-based Payments",
     "role": "http://championsoncology.com/role/StockbasedPayments",
     "shortName": "Stock-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Provision for Income Taxes",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxes",
     "shortName": "Provision for Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Earnings Per Share",
     "role": "http://championsoncology.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Related Party Transactions",
     "role": "http://championsoncology.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Leases",
     "role": "http://championsoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://championsoncology.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)",
     "role": "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables",
     "shortName": "Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Property and Equipment (Tables)",
     "role": "http://championsoncology.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Revenue from Contracts with Customers (Tables)",
     "role": "http://championsoncology.com/role/RevenuefromContractswithCustomersTables",
     "shortName": "Revenue from Contracts with Customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Stock-based Payments (Tables)",
     "role": "http://championsoncology.com/role/StockbasedPaymentsTables",
     "shortName": "Stock-based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Provision for Income Taxes (Tables)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesTables",
     "shortName": "Provision for Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://championsoncology.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "csbr:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Leases (Tables)",
     "role": "http://championsoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "csbr:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "csbr:NumberofOperatingSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details)",
     "role": "http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails",
     "shortName": "Organization and Basis of Presentation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "csbr:NumberofOperatingSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i21e22e4b5df54df1862ddd1cc4b4935a_I20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i21e22e4b5df54df1862ddd1cc4b4935a_I20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "csbr:TradeAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details)",
     "role": "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails",
     "shortName": "Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "csbr:TradeAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details)",
     "role": "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails",
     "shortName": "Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnbilledContractsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details)",
     "role": "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails",
     "shortName": "Accounts Receivable, Unbilled Services and Deferred Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)",
     "role": "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Revenue from Contracts with Customers (Details)",
     "role": "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails",
     "shortName": "Revenue from Contracts with Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "iccbb55bcd7d8409f95ab07871b4f00eb_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Significant Customers (Details)",
     "role": "http://championsoncology.com/role/SignificantCustomersDetails",
     "shortName": "Significant Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "if7fe1cfb1ae7430f80f0555ef7bdd4f1_D20210501-20220430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock-based Payments - Narrative (Details)",
     "role": "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
     "shortName": "Stock-based Payments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i2499764558fa4746ac056a1fff5047ae_D20131212-20131212",
      "decimals": "INF",
      "lang": "en-US",
      "name": "csbr:StockOptionsAwardSharesToPurchaseCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Payments - Allocation of Stock-based Compensation Costs (Details)",
     "role": "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails",
     "shortName": "Stock-based Payments - Allocation of Stock-based Compensation Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ia8c0dcae4e7d40d4b0fb1669660fdd03_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Stock-based Payments - Stock Option Grants Assumptions (Details)",
     "role": "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails",
     "shortName": "Stock-based Payments - Stock Option Grants Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i6ca155caea5f443da349ba10a3f84e1c_I20210430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stock-based Payments - Stock Option Activity (Details)",
     "role": "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails",
     "shortName": "Stock-based Payments - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails",
     "shortName": "Provision for Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails",
     "shortName": "Provision for Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Provision for Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Provision for Income Taxes - Narrative (Details)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails",
     "shortName": "Provision for Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i6ca155caea5f443da349ba10a3f84e1c_I20210430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Provision for Income Taxes - Change in Uncertain Tax Positions (Details)",
     "role": "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails",
     "shortName": "Provision for Income Taxes - Change in Uncertain Tax Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "role": "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details)",
     "role": "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails",
     "shortName": "Earnings Per Share - Summary of Potentially Dilutive Stock-based Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "idafe82a06fb74e8b9595de8286cc6788_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Leases (Details)",
     "role": "http://championsoncology.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Leases - ROU Assets and Lease Liabilities (Details)",
     "role": "http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails",
     "shortName": "Leases - ROU Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i96bb2ef9275f46ac8d01edb098d08a40_I20200501",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ied6c8b18575745c19253a47ee2b946cd_I20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ieaa0daba14924b7d8838223b79f88c5b_I20200430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "role": "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "ieaa0daba14924b7d8838223b79f88c5b_I20200430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://championsoncology.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://championsoncology.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "csbr-20220430.htm",
      "contextRef": "i3b57121ffa6342bfba86b9b60c8fa579_D20210501-20220430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "csbr_A2020FinanceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Finance Lease",
        "label": "2020 Finance Lease [Member]",
        "terseLabel": "2020 Finance Lease"
       }
      }
     },
     "localname": "A2020FinanceLeaseMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_A2022FinanceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Finance Lease",
        "label": "2022 Finance Lease [Member]",
        "terseLabel": "2022 Finance Lease"
       }
      }
     },
     "localname": "A2022FinanceLeaseMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Unbilled Services And Deferred Revenue [Text Block]",
        "label": "Accounts Receivable, Unbilled Services And Deferred Revenue [Text Block]",
        "terseLabel": "Accounts Receivable, Unbilled Services and Deferred Revenue"
       }
      }
     },
     "localname": "AccountsReceivableUnbilledServicesAndDeferredRevenueTextBlock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "csbr_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "csbr_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information [Abstract]",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://championsoncology.com/20220430",
     "xbrltype": "stringItemType"
    },
    "csbr_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted, Earnings Per Share",
        "label": "Basic and Diluted, Earnings Per Share [Abstract]",
        "terseLabel": "Net income per common share outstanding"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "csbr_BoardMemberOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Member One [Member]",
        "label": "Board Member One [Member]",
        "terseLabel": "Board Member One"
       }
      }
     },
     "localname": "BoardMemberOneMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_BoardMemberTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Member Two [Member]",
        "label": "Board Member Two [Member]",
        "terseLabel": "Board Member Two"
       }
      }
     },
     "localname": "BoardMemberTwoMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_CollaborationArrangementRoyaltyFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement Royalty Fee",
        "label": "Collaboration Arrangement Royalty Fee",
        "terseLabel": "Royalty fee per tumor sample"
       }
      }
     },
     "localname": "CollaborationArrangementRoyaltyFee",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_CollaborationArrangementRoyaltyFeePercentOfContractPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Royalty Fee, Percent Of Contract Price",
        "label": "Collaboration Arrangement, Royalty Fee, Percent Of Contract Price",
        "terseLabel": "Royalty payment, as percent of contract price"
       }
      }
     },
     "localname": "CollaborationArrangementRoyaltyFeePercentOfContractPrice",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "csbr_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "verboseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "csbr_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "csbr_CorporateHeadquartersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Headquarters [Member]",
        "terseLabel": "Corporate Headquarters"
       }
      }
     },
     "localname": "CorporateHeadquartersMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Right Of Use Asset (Liability)",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Right Of Use Asset (Liability)",
        "terseLabel": "Right of use, net asset/liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax liability attributable to deductible temporary differences from depreciation and amortization.",
        "label": "Deferred Tax Liability Deferred Expense Depreciation And Amortization",
        "negatedTerseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_DirectorCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director Compensation Plan [Member]",
        "terseLabel": "Director Compensation Plan"
       }
      }
     },
     "localname": "DirectorCompensationPlanMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_DirectorsAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors and Employees [Member]",
        "terseLabel": "Directors and Employees"
       }
      }
     },
     "localname": "DirectorsAndEmployeesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted, Other Disclosure",
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosureAbstract",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "csbr_EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Increase in uncertain tax position.",
        "label": "Effective Income Tax Rate Reconciliation Increase in uncertain tax position",
        "negatedLabel": "Increase in uncertain tax position"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "csbr_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "negatedLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "csbr_EquityIncentivePlan2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2010 [Member]",
        "terseLabel": "Equity Incentive Plan 2010"
       }
      }
     },
     "localname": "EquityIncentivePlan2010Member",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2021",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "Equity Incentive Plan 2021"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_FewContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Few contracts.",
        "label": "Few Contracts [Member]",
        "terseLabel": "Few Contracts"
       }
      }
     },
     "localname": "FewContractsMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_FinanceLeaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease",
        "label": "Finance Lease [Axis]",
        "terseLabel": "Finance Lease [Axis]"
       }
      }
     },
     "localname": "FinanceLeaseAxis",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "csbr_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "terseLabel": "Finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_FinanceLeaseDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease [Domain]",
        "label": "Finance Lease [Domain]",
        "terseLabel": "Finance Lease [Domain]"
       }
      }
     },
     "localname": "FinanceLeaseDomain",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_FinanceLeaseMonthlyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Monthly Payment",
        "label": "Finance Lease, Monthly Payment",
        "terseLabel": "Finance leases monthly payments"
       }
      }
     },
     "localname": "FinanceLeaseMonthlyPayment",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_FinanceLeasedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Leased Assets [Member]",
        "label": "Finance Leased Assets [Member]",
        "terseLabel": "Finance Leased Assets"
       }
      }
     },
     "localname": "FinanceLeasedAssetsMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right Of Use Assets",
        "label": "Increase (Decrease) In Operating Lease, Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_MilanItalyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milan Italy",
        "label": "Milan Italy [Member]",
        "terseLabel": "Milan Italy"
       }
      }
     },
     "localname": "MilanItalyMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_NonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employees [Member]",
        "verboseLabel": "Non- Employees"
       }
      }
     },
     "localname": "NonEmployeesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_NumberofOperatingSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Operating Subsidiaries",
        "label": "Number of Operating Subsidiaries",
        "terseLabel": "Number of operating subsidiaries"
       }
      }
     },
     "localname": "NumberofOperatingSubsidiaries",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "csbr_OneCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Customer",
        "label": "One Customer [Member]",
        "terseLabel": "One Customer"
       }
      }
     },
     "localname": "OneCustomerMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_OperatingLeaseIncrementalRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Incremental Rent Expense",
        "label": "Operating Lease Incremental Rent Expense",
        "terseLabel": "Operating lease incremental rent expense"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalRentExpense",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_OperatingLossCarryforwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Limitations On Use, Amount",
        "label": "Operating Loss Carryforwards, Limitations On Use, Amount",
        "terseLabel": "Operating loss, limitations on use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUseAmount",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_OtherNoncurrentLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non-current Liabilities [Policy Text Block]",
        "label": "Other Non-current Liabilities [Policy Text Block]",
        "terseLabel": "Other Non-Current Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesPolicyTextBlock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "csbr_OtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Services [Member]",
        "label": "Other Services [Member]",
        "terseLabel": "Other TOS revenue"
       }
      }
     },
     "localname": "OtherServicesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_PersonalizedOncologyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized Oncology Services [Member]",
        "label": "Personalized Oncology Services [Member]",
        "terseLabel": "Personalized oncology services"
       }
      }
     },
     "localname": "PersonalizedOncologyServicesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_PharmacologyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacology Services [Member]",
        "label": "Pharmacology Services [Member]",
        "terseLabel": "Pharmacology services"
       }
      }
     },
     "localname": "PharmacologyServicesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_PresentValueMinimumFutureObligationsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present Value Minimum Future Obligations Interest Rate",
        "label": "Present Value Minimum Future Obligations Interest Rate",
        "terseLabel": "Present value of minimum future obligations interest rate"
       }
      }
     },
     "localname": "PresentValueMinimumFutureObligationsInterestRate",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "csbr_ProceedsFromExerciseOfOptionsAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock options and warrants.",
        "label": "Proceeds From Exercise Of Options And Warrants",
        "terseLabel": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptionsAndWarrants",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_ProceedsFromRefundOfSecurityDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Refund Of Security Deposit",
        "label": "Proceeds From Refund Of Security Deposit",
        "terseLabel": "Refund of security deposit"
       }
      }
     },
     "localname": "ProceedsFromRefundOfSecurityDeposit",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_RockvilleMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockville, MD [Member]",
        "label": "Rockville, MD [Member]",
        "terseLabel": "Rockville, MD"
       }
      }
     },
     "localname": "RockvilleMDMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_RockvilleMDNewLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockville, MD New Location [Member]",
        "label": "Rockville, MD New Location [Member]",
        "terseLabel": "Rockville, MD New Location"
       }
      }
     },
     "localname": "RockvilleMDNewLocationMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_SalesAndMarketingExpensePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales And Marketing Expense, Policy",
        "label": "Sales And Marketing Expense, Policy [Policy Text Block]",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "SalesAndMarketingExpensePolicyPolicyTextBlock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted",
        "terseLabel": "Aggregate Intrinsic Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant in Period Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock vested for share based compensation arrangement by share based payment award options during the period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested Percentage",
        "terseLabel": "Vested percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "csbr_SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Option to Purchase",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Option to Purchase",
        "terseLabel": "Term of option to purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardTermofOptiontoPurchase",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "csbr_StockOptionsAwardSharesToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares to purchase common stock option awards during the reporting period.",
        "label": "Stock options award Shares to purchase common Stock",
        "terseLabel": "Stock options award shares to purchase common stock (in shares)"
       }
      }
     },
     "localname": "StockOptionsAwardSharesToPurchaseCommonStock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "csbr_StockOptionsAwardSharesToPurchaseUnregisteredCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares to purchase of unregistered common stock option awards during the reporting period.",
        "label": "Stock Options Award Shares To Purchase Unregistered Common Stock",
        "terseLabel": "Stock option award shares to purchase unregistered common stock (in shares)"
       }
      }
     },
     "localname": "StockOptionsAwardSharesToPurchaseUnregisteredCommonStock",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "csbr_TradeAccountsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Accounts Receivable",
        "label": "Trade Accounts Receivable",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivable",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "csbr_TranslationalOncologySolutionsCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translational Oncology Solutions Cost Of Sales [Member]",
        "verboseLabel": "TOS cost of sales"
       }
      }
     },
     "localname": "TranslationalOncologySolutionsCostOfSalesMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_TwoThousandEightEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eight Equity Incentive Plan [Member]",
        "label": "Two Thousand Eight Equity Incentive Plan [Member]",
        "terseLabel": "2008 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEightEquityIncentivePlanMember",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "csbr_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://championsoncology.com/20220430",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://championsoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman",
        "verboseLabel": "Board of Directors"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r29",
      "r31",
      "r64",
      "r65",
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r133",
      "r224",
      "r229",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r183",
      "r190",
      "r237",
      "r238",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r409",
      "r412",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r183",
      "r190",
      "r237",
      "r238",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r409",
      "r412",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r133",
      "r224",
      "r229",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r131",
      "r168",
      "r169",
      "r224",
      "r227",
      "r391",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r131",
      "r168",
      "r169",
      "r224",
      "r227",
      "r391",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r162",
      "r167",
      "r168",
      "r169",
      "r170",
      "r183",
      "r190",
      "r236",
      "r237",
      "r238",
      "r271",
      "r272",
      "r273",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r409",
      "r412",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r162",
      "r167",
      "r168",
      "r169",
      "r170",
      "r183",
      "r190",
      "r236",
      "r237",
      "r238",
      "r271",
      "r272",
      "r273",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388",
      "r409",
      "r412",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r30",
      "r31",
      "r64",
      "r65",
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r134",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r22",
      "r377"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r14",
      "r135"
     ],
     "calculation": {
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "totalLabel": "Total accounts receivable and unbilled services"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "calculation": {
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails",
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r7",
      "r156"
     ],
     "calculation": {
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r281",
      "r282",
      "r283",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r240",
      "r286",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by\u00a0(used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails",
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r20",
      "r137",
      "r141",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedTerseLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Asset under Construction [Member]",
        "terseLabel": "Assets in progress"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r60",
      "r120",
      "r123",
      "r129",
      "r139",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r327",
      "r330",
      "r338",
      "r375",
      "r377",
      "r395",
      "r401"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r21",
      "r60",
      "r139",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r327",
      "r330",
      "r338",
      "r375",
      "r377"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r5",
      "r377",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r54",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r48",
      "r53",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of year",
        "periodStartLabel": "Cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r48",
      "r339"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r171",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r377"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $.001 par value; 200,000,000 shares authorized; 13,522,441 and 13,414,066 shares issued and outstanding at April 30, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r336",
      "r337",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r336",
      "r337",
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r336",
      "r337",
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Significant Customers"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r336",
      "r337",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of advanced billings"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r204",
      "r205",
      "r225"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails",
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofDeferredRevenueDetails",
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r43",
      "r391"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of oncology services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Oncology Services"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r61",
      "r312",
      "r319"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r61",
      "r312"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r61",
      "r312",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current, total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r61",
      "r312",
      "r319"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r108",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry-forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r51",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r51",
      "r154"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r51",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Finance lease, depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r277",
      "r278",
      "r279",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Stock-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r40",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r80",
      "r82",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r334",
      "r335",
      "r399",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "netLabel": "Basic net income per share (in usd per share)",
        "verboseLabel": "Net income per common share outstanding, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r40",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r82",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r334",
      "r335",
      "r399",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income per share (in usd per share)",
        "verboseLabel": "Net income per common share outstanding, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r62",
      "r294",
      "r321"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal income tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r294",
      "r321"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r294",
      "r321"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "US vs. foreign tax rate difference"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r294",
      "r321"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r35",
      "r36",
      "r37",
      "r67",
      "r68",
      "r69",
      "r71",
      "r77",
      "r79",
      "r101",
      "r140",
      "r195",
      "r202",
      "r281",
      "r282",
      "r283",
      "r315",
      "r316",
      "r333",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r365",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r61",
      "r293"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Finance lease, payment, due"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r353",
      "r358"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Finance lease payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets under finance lease"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r351",
      "r357",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease, depreciation and amortization expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Net gain on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedTerseLabel": "Gain on termination of operating lease",
        "terseLabel": "Gain on termination of operating lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r8",
      "r145",
      "r146",
      "r147",
      "r149",
      "r377",
      "r394"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization": {
     "auth_ref": [
      "r151",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for capitalized implementation cost from hosting arrangement that is service contract.",
        "label": "Hosting Arrangement, Service Contract, Implementation Cost, Expense, Amortization",
        "terseLabel": "Hosting arrangement, amortization expense"
       }
      }
     },
     "localname": "HostingArrangementServiceContractImplementationCostExpenseAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r51",
      "r153",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r152",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r38",
      "r120",
      "r122",
      "r125",
      "r128",
      "r130",
      "r392",
      "r397",
      "r400",
      "r406"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r159",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r295",
      "r302",
      "r308",
      "r317",
      "r322",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r63",
      "r78",
      "r79",
      "r119",
      "r293",
      "r318",
      "r323",
      "r407"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income tax",
        "totalLabel": "Provision for income tax",
        "verboseLabel": "Provision for (benefit) from income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r291",
      "r292",
      "r302",
      "r303",
      "r307",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r50",
      "r358"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r94"
     ],
     "calculation": {
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Incremental shares from assumed exercise of warrants and stock options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r60",
      "r124",
      "r139",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r328",
      "r330",
      "r331",
      "r338",
      "r375",
      "r376"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r60",
      "r139",
      "r338",
      "r377",
      "r396",
      "r403"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r60",
      "r139",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r328",
      "r330",
      "r331",
      "r338",
      "r375",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r49",
      "r52"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r32",
      "r33",
      "r37",
      "r39",
      "r52",
      "r60",
      "r70",
      "r72",
      "r73",
      "r74",
      "r75",
      "r78",
      "r79",
      "r90",
      "r120",
      "r122",
      "r125",
      "r128",
      "r130",
      "r139",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r335",
      "r338",
      "r398",
      "r404"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to common stockholders",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Basic and diluted net income per share computation (dollars in thousands):"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r81",
      "r86",
      "r87",
      "r88",
      "r89",
      "r91",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Diluted income per share computation"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Being Evaluated and Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash financing and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/OrganizationandBasisofPresentationNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r120",
      "r122",
      "r125",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating leases, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails",
      "http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion operating lease liabilities",
        "verboseLabel": "Non-current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net",
        "verboseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/LeasesDetails",
      "http://championsoncology.com/role/LeasesROUAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r360",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r156",
      "r351",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r157",
      "r357"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r6",
      "r155"
     ],
     "calculation": {
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r42",
      "r143"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r368",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Related related party transaction, amounts of transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r366",
      "r367",
      "r369",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r289",
      "r390",
      "r437"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r202",
      "r377",
      "r402",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r69",
      "r71",
      "r77",
      "r79",
      "r140",
      "r281",
      "r282",
      "r283",
      "r315",
      "r316",
      "r333",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r116",
      "r117",
      "r121",
      "r126",
      "r127",
      "r131",
      "r132",
      "r133",
      "r223",
      "r224",
      "r391"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total oncology services revenue",
        "verboseLabel": "Oncology services revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Deferred Revenue and Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r226",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RevenuefromContractswithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue arrangements by service contract period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r359",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of accounts receivable, unbilled services, and advanced billings"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r275",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Employee Service Stock-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r239",
      "r241",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r247",
      "r262",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Stock-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r59",
      "r102",
      "r103",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/EarningsPerShareSummaryofPotentiallyDilutiveStockbasedInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r301",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsAllocationofStockbasedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAsset": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of servicing assets that are subsequently measured at fair value and servicing assets that are subsequently measured using the amortization method.",
        "label": "Servicing Asset",
        "terseLabel": "Servicing asset at gross capitalized amount"
       }
      }
     },
     "localname": "ServicingAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServicingAssetAtFairValueAmount": {
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of an asset representing net future revenue from contractually specified servicing fees, late charges, and other ancillary revenues, in excess of future costs related to servicing arrangements.",
        "label": "Servicing Asset at Fair Value, Amount",
        "terseLabel": "Servicing asset"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Volatility Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Volatility Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk-free interest rates Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk-free interest rates Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails",
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares granted, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and Expected to Vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r246",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r284",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration term of awards"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionGrantsAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years), Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Strike price as percent of market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r56",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized software development costs"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/PropertyandEquipmentNarrativeDetails",
      "http://championsoncology.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r61",
      "r293",
      "r318"
     ],
     "calculation": {
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesComponentsofProvisionBenefitforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r27",
      "r35",
      "r36",
      "r37",
      "r67",
      "r68",
      "r69",
      "r71",
      "r77",
      "r79",
      "r101",
      "r140",
      "r195",
      "r202",
      "r281",
      "r282",
      "r283",
      "r315",
      "r316",
      "r333",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r365",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r101",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "verboseLabel": "Issuance of common stock on exercise of stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r195",
      "r202",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/StockbasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "verboseLabel": "Issuance of common stock on exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r60",
      "r138",
      "r139",
      "r338",
      "r377"
     ],
     "calculation": {
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled services"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueNarrativeDetails",
      "http://championsoncology.com/role/AccountsReceivableUnbilledServicesandDeferredRevenueSummaryofAccountsReceivableandUnbilledServicesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r290",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails",
      "http://championsoncology.com/role/ProvisionforIncomeTaxesNarrativeDetails",
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Payment made on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "verboseLabel": "Addition based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "verboseLabel": "Addition based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/ProvisionforIncomeTaxesChangeinUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r81",
      "r94"
     ],
     "calculation": {
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding diluted (in shares)",
        "totalLabel": "Adjusted weighted average share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r80",
      "r94"
     ],
     "calculation": {
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average common shares (in shares)",
        "verboseLabel": "Weighted average common shares outstanding basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://championsoncology.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://championsoncology.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=6469459&loc=d3e122492-111745"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "50",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=6469459&loc=d3e122501-111745"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=6469459&loc=d3e122501-111745"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r442": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r443": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r444": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r445": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r446": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r447": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001628280-22-019309-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-019309-xbrl.zip
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M(CF':;4?57*+E5G^D\1\[7V\N"V'V0#$ZPW#WA>E9X9X,SO[NS#_9YP(BT>
M&8EFW5^BD0>3:)(Q2S"@$!K:-/)%$#B!#0S8#^,@X*Z6:-93;%>U:GF"NIK^
M*>!CEZ,TX4FI?0>&2 :H96/24*VO-THY*GKE9"L;C+(A_"PV+Q-@K_5C<'V0
M#0_+C)_5?H@;/]'L6C.3'R-DZ\%866R#0(S $!=>1#GW0W32Q:&4GLVL2-C/
M!C2]7#&#B0*.AM.J@,BR8R?P;8%BUHDM!KM(7"^60$2$"/9L0+0IA+)RP=YE
MB=@;;K%14K)T1<!D.SZ-B"LMS_*H;<<A" 7;19>'&X-T$,\&3 >R9,E0BAV6
M#Y/A2;$B\&&^*TE ?->R VH'46C[P.V('5''YR[C3P>?1>T 85YL<5?"ZL$@
M=Z/(CH'YASZS/1L,]& !ZLMSX2B+U[$BES(B?!KX@E'0JB(0ZM*V!*BG'K"A
M1>BFJZQL+1Z@81Q%Q Z(2RQ!61B$CO3!Z(@"P> WLY\?0!]?L"P>JD*Z;B"H
MY9 PHB+R(^XS;@48>;0<CY*G<QVL,G4^E$]C!C26Y7 *6@)HVPX-+!9:G@R9
M(YAKA42&[K,!S5.;0@\'(@+D8EDR#*5':.PY$9BI@1/[4F*Q#7\^U+,(4^CA
MP,0$<9R0^L(-0NH%3NB */-\Z3L.\^-0/ALP/:DI]'#P<02-I1L*P7A N1.%
M @P!*Y8B\"TWCN4"(G//A9X6'SX, UL$%H\C%RR P((-#R2146P#W^3D.0+W
MZ0R!A0#4BP/;\4+/$[&D02PB(4,K\"7GKAM;U']^ 'UB0V A4&4Q"1EW!0?M
MGP8>8RQDEI"^+;D-1CQ]NBCJ*E/GHX1WP0 @S/8H!S%)(^&%1,0B$"20Z-BU
M[6<#FJ<V!!X.1(("B)CON%0*RHD?V'9D20PN,ENX<?!L0+0(0^#AP!2&L>W&
M$=C180R0"@,"RH@ #A?;OF]1]FS ]*2&P"_!9YH:-(Z*1"0LGUQ+#\)\P+?3
M^_5(W\L0F@ZKUW3+F/KF?0:<=<W\1(K^DB%4D9=O#]CP1&K$P9^=9)@,QH/G
MJ-W$EA QLRD0OTT=SPHC%G)F^20FW&<R7E& L<OG"C";2-N6-')%[%(1D\"S
MA1"$<QK1T'&7F%,C8#[EF1CSLJG)TB!3+&=77F!#D9SQ\BZN7%W&/&EQNT2H
MBD4/Y  X/O#Z3S)7752&7.Y':7+"=*+^2/)2BEXR@$?VXT.X6L0PAP15X0J@
M>I9_/L[ &R+#<2HLT0CUN%]J]K6U@4O&&!]%R0DBX7-A20Y,C@9A% G+BSS!
M/-\C<<3Y*^F\DL[3D<YCB:A'(1T&EC48!(2[84 ]%VG&$EC^X(:.%-Q97M*Y
ML_+S_03KA6>MA-TQ6 <E:+RJ2N@2_UIB2V$&4C20CN<$GI144#"\61"&<"WV
M:!!SE_O+'])9;D@]7'!'6BA\(A&'H+I95$:4.K[K6G$ 1.7S%7 L_A"DT"(?
MES)O'EH1@K(CRW%C)GD<<^H$/K-MUQ'4DY83R-"BSXR@GA9,#T=-(HB(&_H!
M=230$A6!:X4VQK ]Q_$BN<3*W4^!:;_LR[S#>#\9RGS2?GI%R,KU@L@E+J.^
M+ZDO661Q*BWFV&',:!0YSXRL%@2O!TP5L9AP05JY8110V,X P!<Y8#HYMG"I
M_]PTP,,L+B^84BOJ/[?!HD@S]0;VEED5A9 [+N.V%5-F>=0'248(<:072]^-
M*.@:SXS0%@VXAZ,XWXHLR[,B$7B@(7IQY%MVC)$SZ8>>M*-G1G&J[\*7H9#Y
M5@:;EH^5%;XB1!9'A#&PL< ^!H" ;).^<&,"__%#;GOA,R.R!<#J >F*!D'H
M,E]BFDX$"H?/G(C _]NNR['=Q?.B*]7>I)^E8F\PRK-S%2-=%=GE2A<,+]#>
M*2$4MC&*)?&X:_' =UPW?FY*XM.#Z@&3\F/'YY@SX/B"$E#HW<@6'!M\2\LC
M5KA"53#W@IEVO+<Z" G%%)]E+0SA#@BUD,0^8V!?AU$46R&-8V"D%,UNA"T)
M:]@N=>GL$L.6A/>'K?5@L/5=)R!V8,L@<,$<   3SZ:N[?I.%!"V"@D JV,G
M+#Y] )@TBREP92="M[/'//@A">?<]D5HDZJXVG_\GE7/%\JS->'^3[?:FDTN
MMQS?]@*@5B\ \K0"$L=@O]M"2.Z[0*=::R7+UFP,4)<\S X$/MA2E LI(IM2
M#),PAP><.:!J>%Y,M!0B=B6%"%D^3G5-L+3DS29.NGWOT:4-L>\M;0AY&/;#
MK<BW? M8D(PH"T,6 :>QW5!()F@0>C,PQ#^6CP^M)@SUHU,Z_)6"B, &P>%X
M$0>[#(@O(-Q' \VU9, #;XF-L@6#[G&BR%$ EA9&^T&4<RL,8^XQ*XXBX="8
M"KJ\W6R6!QH/V+DEC($@XA@TZH@&@C)BBY ZPN<1\>%#*V I+1=_>QJ+J$F*
M'XYQXK>TX1S!G_4 ]\Z(M^TH"(4%%K1O4>"3##ADX !J4#^67F2O@'VU1!BQ
M&*/)#RD5W$'7EDM]$C/XVV7,]ICO^;;%5L"WM4PP7$QKRT $ML\B)X@8C6P6
M>C)PO$#X=F!%#HF> 1W:SYT."8D<[KDVQ7('&9" >$"9KLU<4'\L&3T#.GQ*
M&"Z$#CF/(M>-N/!%0*TP#ET667[@DXC&5@W#Y:;#.[+Q/_59/F#ZE.;J[K-T
M)7*725!F&*@UL<I?C3V G^O%@>/:D?17@!J7#Y(+H4DF0N%&OL5] OR4.Q%Q
M'9]2$EL\8H$,5I\F5?K=<R9&VY8><;@OA2^I9XL@))ZT0B%]$8LP\E:?&)\2
MA(O14'U7"!Y:- @\:L<R!$5'<&:'KD<XJ*BK3X6?9%Y@AX3D2HK]X?.7D [C
M0(QQY#N^!Z!T XL2&^NMB>4[DM'5)\H%0G0A-!K[L20<L_VD#]"* RNV7->5
ML1\)0>-5H-%IH0>8&5@TBJE[!TEQ]G[R7@YY?\#RL[EL/\ZS\; L#B27R3F+
MTKL,DWMA58>=9OG6N"BS 2!1F]$/97WY5[_SG;7>4/E2??3:P\^1-;& 6R!<
M) 4%@5J"1A8@M8?-RZQ8",M9(43> [XSD$W_EX\9U\>TS0#W@QS*G*5X=IL8
M),.D4/ ]EU@!/'R>WA([#'T9",^*> Q2*(R8QTE,.:.$6#9=I8R\%0#Q8@PW
M%#VQ)^(X L!*$L9@>KLD8@YW;#OVGAL5'\HT388G .(.2"E9PM_/F( YGE3B
M"2L,0DD)=5E, AY04".!AH-X%6RZU8#N0FB7AAR8<\ \"DQ9.E& 59"$\YB+
M0#HKU2WT7M ]D(5D.>\#>%LI>,^8?*GC!QYW:.2"?@5\&<^% .,^M@28A%9(
MGAOY+A+ "Z%@FT:>$[I$.CRD)"21)20)I,7"P++=R'TN%*RLLE[.AD7*=(O+
MQM3/TC%>*3"3%MOGI,_3D>-2(@FE/+!=ES(J@X!)#D#V?1E25Z[2@4RK ^F%
MT+1O<V))&4GTSU&;A0X>X,RX0[BDH( M;W)CDQ^?LF&7#=I>.MT2=4^Y-< @
MPB=P%2N2X6A9TJ-N[++0\RD/6>A2VV=.;#FA%3A\%:)3RP";Q7-1,%"9$ 'C
MMHAI%,HHDC$#P1E2X45 =BM0>+L<M/6 ?9\I"^/ P6/!/1IZ06"Y7N@$=F Q
MCU@ZLPV]120PZS^6#38_W5OOP:%.K$=.AP6JM4T2W(-JYQ_]%1\3:K>1"ZJN
M$U#+\4,:6)QZ(?,#*=QHI0H$EP20"V*_01S$ HA<1!X5(6,16"K<CYA#8Q97
M%=HK"\C>1=;K9^."#<5.<M(O;P#L<P2J[0O!+(=:S 8CA8LH9HZ%;6U][L=N
M55#E$)O89OW'L@$5.78O*5.Y'^\-17*>B#%+I\S\?<9RL1]O)[GD99876WV6
M8!_71^3N];>P%QX\KDRAQT<@XF")%K'OP][G'OV5XVB%%3/BN(QY-J6>1)<&
M#XAM>8!&Q'=7 (%>(5FYH\(0M#C7#4"K]JG'."ASC,1Q[%K49W(!D%R)?0L#
MWPMX2+"/,:7<#C&&QHCG1+:,XI5)G5O(F14+\=&X<>#A<7F6&]LT!M$'*FD4
M,"<2S(Z=<!4.7%[8F14+ 9C'@)Z D@(+>U&'V)T:E!3?]8+0 C4T6EZGVG=T
MDQGY4F CBL$HS29R9?I/^]P2Q/8H"X5#;8Z=PAU"7#<4ONV[X1+7<=\%E6XV
M7#5@1([%>4!MXLL8_AM&W&5N1"FQXI!;_BK$DI:$5I; )G-"'XPQ+(7QJ.W&
MV!(23_*U[2"6KEP%0WNQ%+9X$ K0GRV+>Y$=1M3C- CL,'"DP[EG"4>*Y755
M+PD5/DZ755=ZL24L#VL'0=&+8H>XL4O]()">YR[QB0E+([$>\#0EU!TLFX,&
M;E,\5,FU9!R$1#@BC)CPEK?QR/*1R,,U(*$AY9P$0!L,3RL63 A&A0>_0?OV
MJ;.Z4'DR$GDX8 @62<>SXLCR.;4(PP8$#"#A@G2)G2A:0#>8'_7(+*8G91"%
MCAWY<<0E]5V;>0&S">=@IMB.Y\4K8N O 8]9O.W/> SJ4XA=)B-*?,Y\-[(]
M$0,M<"^4[C. Y1,JPXMQWX3,BT7@<TXQQA1&@6WY@>UQ2]@>"=61H\19$NXU
M9>3$>3A7"0M%3(EM!3:A-(HB0@1(5<%"QXT!K5? HFN*^6 $D6 RW[D\E'R<
M)V4BBYU+GHZ%%+MY-M G0*E0R7Y<GY/]2>:'?9;+]Y.;!YA-!:[)09U7OS]Z
MG,,!%F\EVE)ZOA]3'A!0NUR/>6%DT=B2KN/8=1'=<O.V9XX6"^&7@L4RL)F%
ME=]4@B[CAJZ *X''N0>VZ@IPBP7%Y''L+:PUEOD((#69B^:JS^JW]H?/LF8$
MI$H0T- F>&!3Q#BHO5* ]A2X460%=%4Z!KQPU%E,-8HK0CPJ);2%32DGH*7X
MH1"Q'U+7A?^L"->Y'PQ[%]E#(,S#X^E*<AU085E@10Q/]*"Q;S,&AAK\ =\
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M.LZ30B1<^1BR>!7I^$=W8&_C8.-PPZCZX^8O"?I)6ZPJ),A/V#"Y4K]_?P'
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M2&%ZZG61CT] ;RDX%H%.E QKZ;4;QCY(L&8.FD<;F>H,K5MV12#QX(&3<<I
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M![D5XN.$%%.?ZI3M^2';/T&//A"=+/LP+^6VJX;48D'_  $NX$>:\2D#53=
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M=U,5"9F!5Z*,.Z8/O<,3S)^A1/]N"XCEDO3E8L.%^W<WS&BR)D:I,N>TQLE
MB\W$M,8!&<U4.57XB*=!%SH%H& #V>[OJ>V'ZR??P+??9'/UB!A1O2G%]3JO
M4.RW>FSF;);:/DY4AP15]"6T9]7X1^"^WS",NTQT^#>KE.L[+?3J9)2V(35K
MF"OG"DH1_>9M]OFTK4-S0B&VS4 3M/+S_J2U_9W3[^YG=+=-[*J!"/:5T+V:
M=1UP7>3?LH^ON>,1^1KLFDN<5#E3NH_9[,'7-[0)K(_^K>),6..W8?Q+ZPU@
M;>&NJD75?I:I;%3F%I],"PQ;*],!;M5;WS@9,UA;*2ME0VUC4\"IAZYPI6X\
MH(@!%Z&"MLTQ.%5?0V-7-]Y;!S08S.ZG4C_TCE4F'B@[5=8WMJ:>/S2EV5R-
M7GC*7CT[&$A!YYSE$]W> ]>MT*LU8*$\ -]M(OG@WHQ;FA8N@1_#>+7GET[Z
M?S>L<]".+[?DUNJEC]\GQ+-D\U91GW8]=U$5=*MZ;J,NY5:PT>W++W2SC'*^
M6#O<H'6MMGKZ'_Z&/2W>QN.WI@<UH_58-RZM#F*::V\[9VM*+$H0<XF_YPFK
M6#=/Q\7,N>]E NQ-\\3J;#184I7R6+<7F)Y9-U>4H^BU.GRJGXRJ%.%^5JC6
M,I4PO8F1S+4YF<^7J%MD7" G;O=CF&V/, T3ZX.*IZO^D+.XK):Q7O7(: (Z
MU8%WE<M_'=>=Z[XA)]/BCFIWV)E49QI4/*Y1*FIVJR(237AZFLI8E%646L>O
M<1Y-;M5J9((]AS*>6YLUW9[BUB[X6VR*VVM>6TM@N,N:U[;::13+H-5\:%3*
M^O2>7TA;>55I?B:+NN;]ZVTIW ZW:_FJE]@.SVIW777(D+*1*BE<5ZGL'S8'
MI]8];*896XT]5[]550W5J9=X=F>NS^8<1Z?891/5(2GP(IB3:+"O&VFF4@.P
MPWN6P\+PW)*3I#I(>;W*#,#OI_!Q[,LTG>/4,,1!2NW,/<CXV3DH8S!T!\1O
MJOP@NC67<A'@V\V-YH#*-%&K5_K/C3.\98*H&\+$:O.NU<@I1='!E#=<V4DS
M?6#5CJ[/*E 2(**/KEH])%QEXMG=WE1EF#S5*EGK;"TV+OM5R@;&=5H(-\WO
M1&!BO1M"L9BGG2F=8:='=0170Q/H8Y"7F*F"VG%2:G]5/1MTYHS5N13M^51G
MR2A<!6T8_4R 9G5 +1NG30LR6:-Q_7Z+3&M'5J/17B?/:;.$X33\=M(<5%N=
M 7G"<N7H0^.A3D;MLRNXBD7#:"^IDY[;5*R"CQ(/^*U?4.>FJ\!MTZ4!']J;
M^?@F& #JP:0T-FNHU!Z0]LQR"?I?KAUH>47 "9Z(5_V-P]=T7$];'QB55H<1
MM"@: (Y=AH%2!1@QRFM25AVZ!#;DU(Z.ZI,ZJ>B9YFLN@Z+Q+W6*^%;5]_2@
MSFM:/:ZSJMQR4UG$?XV!4HA;=[Z[P(QW8=B.9<3C-#5+^&)U%HR4,Z3O!Y67
M/$,#58O4N3-X*K?OAK&O.94*YV) 8MT@ 9D.:U0'GH'!(+[7O$S];GND6QYH
MYSOCW=!Z5A,]"6Y_*4Z&K#Y;B F,A*M  4IT#?&'@ONJ-IU0YU"E"8"GBDV@
MRCC&HH2FRVJKH;4Z*A<%Q7K=$74FR7/J,F.E.O!TW>@G=0ZE]D*W?,^-4_F:
MPZV0\JQQW11U*9#2UBI83GW5($/B&+Z0@@"J^W;.!*ZR7&L"4Q]VY9:XLX-P
M%951<:TFS7;#V-1KTS*H<36U%ZE4\S-4>$4K,B(5.4U1M3IPH!TGY/E8%8M4
M*Y[-H%5>_B;2AR66^[//5&[_]FZKE4\_J:&H3TALY8,T[<FGC$$'-O)1I@))
M?)PJE*C3.6;/CIU]=M1/T@Q]/)/U6EN!!0'Q#LMK; !3=G$*(]0UQD-EIJPW
M!@!L]U3_B$!)BQ.,.+S,\XX5M7:S86-JS?*\YB18W?68:0Z+66%(J B?<W7F
M9S11'F>-0Y@4<E+A*T,NK_6E-F>LBZ>&*HNJC<A,8T)1 O3TH;6B826Z<F_J
MQ=9"9G;6@.Z8 _ @\%QZ;6&!14L8V_^72BS_D5Y*J[K12S+OKU('6H"AUHQ1
MZ+.U!U+5#.@PSM0OSBM(J?B+$D\I:S+FIEZ2;2 JE;D'K_R%!X=1T,+" #2_
MZ8M#S)91=:36'[,6VP<\4&4=S#B^49W3:\ /XU".2JED@1ZJ5<J@K3!U.ARK
MLCMUEF#3OAO,/M61'R/\RD.LEY7K7 OD$:DP=7J'=M57+IEIL9<R-%4RXT"Y
MS4J&N0%H.P.?&56"HH^Y(6B2%WI],$JUQ.E AVJ@Z^LC8>C/KDJ=&8QCM691
MG1>-RF4=Y5:?AR]U,'<N*\M9 UA_2#T[!MTE!>7;@MV[4&">QLCO-4"5L8$1
MN?;6Z!49[YG*=JHV!D_1-?YBPS%&LN";<VMK;]6T*7MSQBWZ$YK^IC/JC@+G
M."K =*YJ[V[8].G<WK=?KI:R/X2E@B42K-\PL08OX$V@@C/]SCK&VW2\1YDI
M%_7!J&J65?I+NVEZ?<30U&,"VZ$#QK9%R.V;<7T)=8^?:O9*A8K5T4.M,?YO
MH=I23'.2FNV;B3-6UM*U[A73GD+7*FH5YE0MYMOY9@]QGL#BLRA7149N-FG-
M>]-#R9<2 ,]24NXK$PBYHL3LK CDH3K))Z].G%I@TTZU04+R*CGCK1*Q^-3:
MNXN+BPU>\Y&:>#= 6"XR&W=&<6\A<\U!Z]V%745'-]KQ6L& "YOZM),#B1('
MG;@Z3:7UFG(K#3!YHRD$6)\K$%EO-:;#)J:YU/(K3IK#GZ]GAQY*X.Q5@$IU
M -4\&]GO(%$):"H2=;BS-6^?SLQ9<>1=[(=)+//?VBC]#"(2, M$V0W/?-;/
MU*<9S#\1U(-\RK/+B9YLE?8'&A/O2S%&?Q2AFUJ7@WM"WU<*3J9\X)5"PF:V
M0!^</*S:GVAM"%8'ZE5>C"N%X;"2UL3YC?V.;Q#W-_%[K0XV>[2)+A88O<C0
M2D9/.T-I$\&*1\I'H7WF6B\#\*ES]<!N1X<'/(.3TBZ".BZ@9KC>FB)(3G7Z
M537)&13; MFG\T%1U#:A!56DE%1E(C-CM092R: J720"!(K067&]WJA]%@N\
M@SH=\?\HIFRB-/IE.7K[Y@W28R'YQDEV?MMY)T\M5VYCR(GXYUKB^QZ/K2AP
M8Q%1RDCH\""(:<Q]RW-(0+Z1<&V9A>8>$(-!-C<>FSW?JG/<DLV9%&?&KO9F
MW:LIQ"J%>)9$8!]E_S][;]K<-G:M"_\5E&_GQCY%T1PT=K_GK9)E=Z*<;MO7
M<D[?\RD% IL48A!@,$AF?OU=TQX @A(E2R(HH2OIMB42V,.:AV>5Z/5A7A/#
M=YA@D+DCV@'-X!:HZX#F,%%4*+T&YI\IRBQP1B^.M33C?$/DZ"N!'@A-+T55
M.[DRZ*MY'_MA@<I0EI ZJ:] %]=SC1YU3RB65GZ@*D\]M66#_'#2EQQ@@^]A
M>QMK)1;TE:%+YBBH.$TW4_1HR"#7QX%;$665K*^3!-'1:0["WZ-DL&5T_!(K
MZPYWM++N*81*L^#&,#.#7[!E A( &2KTXA1;N*3#Q@!EH&ES)=D"Y"M=85#I
M7I*D-&<,EQ+!QH%JBH Y<K$Y%@+#3VF4W>>W%ESQ[7/;;JWS=V,XF,I&YQ!C
MJ?.&Z6L_'>P?]V#M7/@_/ASA7ZI%_U7A3B9KX\BXZFM1IZ!'4\ZQE(52X0CF
M5C0LX6C4'^A^@[YWPQLD-:];NS21PL=_&MF6!4F.@<F,OSAQG]V4L.5/)O!D
M3-%6%2WE; )</7V*&[%==J+$.Q5OA\!%&&>F!@EI>' 4D[;&X:4Q^!E8]#,#
M"L.-C5_P!$RT0/QY6G+E%&=TF5 S+;VHXB$"$15BIM:M32+)A UVM8Y0NB#D
ME+TBW:-)A_B,?[$_BS^3/UIT(C-QNH>K00^9:$!2NW<9_]:2<[W+M(6#_0?'
M\GS. V@T'C772N0"VTGU%U0/J*<3XMC16O_/Q$^^=9?R))="91R2]P-E,\LX
MLG:-!9XS9SZ&D\(QK2[=%6W]BHB%]!T91P^+7+K;>3*IMC+\N;DFL;N0I[H0
M0F*0VW"*0!G^F&"*=&^+V[B"_>C^DI*F6,_GYWD:,)Z#[H#I;O"Q;["(YKKH
M0U\FQ^WU3^<8=S-_1X<;<T%HV[KM$N@W7?EQ=V%/QG+<OJYOR5%+A7@K4^S$
M$"CR7_!#W=4\Q=68&%>48)ET$QLU%4N_7$_[3,?8JX$:;@G/S7##109Z)(NT
M%^TTX>MF20:ZH7PKGK*&1F@ AL"Z(8*3LH-O#-)5U:9K@"*P,+_.D\T,.>YG
M(."KN-X%)H]\V!:%ECGPK5WW5\Q)4P1'@L223]?36GL&1"A1G,'G!D+"Z2$2
MY):%Z317A1M$PW@?,/Y*G?V-G3+2G+C2P7*E*+*7Y#*9@D+<B!PE 6YJ>Z#E
MRSN8.1C+:(I!3.HO1,[I>^=3W!,))!VSJJ2A-++:-9-XF9@1+1-I,YAB9%0Y
M87<5<?RI&FED_"EN"L"RA9*!S7#:)H=2I<IDR57GV/A C9/V"2^BFZ\EG'".
MK0,A@T:2W-+TS;=4DA*C(2CZU@M*;\:*&TF-E*MVO6MY2XT\J>XSXD2RB\C3
M%-C@II<;GLIG;1,^AC?=W)!NR!6T+&':U*:'*DDA;KPE_+\%,$=$M%\#$Y.@
M+FTH\Z-<N= SSNF8-J=J<%VS()TIG$&*U2TN>KP38J8R67F-DT/HX1(E%!S#
M]FL-1$8NN&H&1\Q4@.CHV6 /SG4#\S6FS*\EB: 1"&M=S44E JXWB]\$^4CE
MN?HL>K7/<F,BBK&0>U-P=4"V_DPH**%,A-YI2+(OD&)QEBU4IIT4(E^ETLUL
M4.:NZN/5><*&NR'Y*@4"EB*)/N3M5%L/.Z)4BASY8PFK3FO?(X.,-\$Z3 ]:
M('7+\QF0C8)H@4&#*ADS2"YUF)J<,.O [O:>LE^FI(I)J5]4KE'NXV5(%(AQ
MQACT5,P?)]" !?=HU=?$G*[=5RZPI]%3*S%:^_%*<<$\S2I=U,;2@5\+NDM>
M(E !JQ+.O[%PB\B(B@HU%VIT9!SFF65;("WY B\B.&,_TYZ.S='HIL@JM)E]
M6L]M"ZQ"-=HUU<Q1VN1$]D>KNU8&Z'8=KZ3)+#4]0+O$-W<KUFS[NAW#WT$T
MK9I@371=T>.V'JVIF[O39MNPO/4--H+$5&[22?X#7_+(!R[M7^G0?QV]X0.1
M]OQ*O GM3<=$MMWA!GC[%WB ?H+3A^X1U&/(8R,6Y"*;6(ON9*\^0S]$&_M<
M'Q$0NC+V6E5'23D=5?CMJS=N6,2N?L$ CVCJF[9S^%&@0IZPN$CCR"+KYLL<
MI3$\4#^/D0H(0:8"6* ;^:N"U8I<?(3>D MBH$&80X70G<I-1055N' 7!8#B
MK_C$Z(T=B6!P!JH7AM^CIK9,!>DLH>>Q?X0Q"W/KXJ.GF7/5"2%!8^2)D:6E
M3.1&B7"[5'$]N:KB( /9-!GX(6C@7(,9Y)I29=8'4;N-&! Z$,%X1 0UGK#:
M>_:5>L,QQXNWHE<^N>DYC1WG0%(Y %:6><M,58J;+"J=,Z#-A;L0.&IYF I_
MT?X4%F17O%\0;_ $P[U5'\\4@VI+!NDW($,_FG)]=Q1K$(WX3C6>+5$'NZK&
M*HC$1B<@&0B^H1*EY5 :A1UJY$9 89L17=^[*&E(0N6SE9J[VL.YETI#,RX=
M(]<-$Y"E3"-38IPZA#@XI/8,Y*S6676-UQ  :62'Q(1Z&SACS6 %L/I2::IS
M0>+XN+J2?(<2CW:G)']+)X1#?P11F_"7V >@J0<5<1LE*^B<:$=4(/JN!5UQ
M3H;&U.)9,"]::,!%6B@]';,*VUDRGU[Y,\Y:E$D0@QS1^(*-3]/B'^D,7&K"
M4\CXN0*+DSCXD63RPOVZ2(W:UR^)CZG;E<6#@6NJ #4V^%YB;7'[ZVK9@XX@
M.@9BM1$(B!''1;@B14<OM1H+02"F/%^$%CVIBC-0AC*G(<.2#5=[4C,FODB*
MDR5VRT>BITI4PBE-BZP,M>" FR,I@3#TX ^.T!9@68?DDD22:[)4@4;@%0GE
M2S@BD'\A2<BE-AO+K$9]56M03X?;/<W8?HV^IO%S!>>W!C <^G,"WR-5B7./
MEGBGG#N483]AE"]*/;'$0;1"^%_819CWJG=^K:D\43,]><PGUT&%K;[Z78TU
MK8W1VB['LH@(TR2G47%8P#"-R&:/"@HO(?A1VN1$:%AH23KA]0L%+== 1?<]
ME!G4!VH^B2 [/(&KVC?13'U&4F*>&ILF*%"IR<X-94JZFRH]9$AY1=I59H#4
M+#MX2VSR895]DQCT'4&XU"(=>X'J#.%P@HG97D>YW@/J&WWZE&'%T46<_*/?
MTWP-G2.D,9D\4(,S5#X%6/0Y5IWT%?9:[Y5W;/=T^#38BT8. RKT')$HR;VU
M*(UQROK4$<IS9$8G].*;RY5OUS.E+[BLK-E)=2)0IK4*SY)G93J'CF=*QVU@
M4?I&7BW2A?9"J]")E0OM&:ARW[N*LM))U2Q\,,W +Y2/" $PHPN/TH0:@6K5
MT)#?H[RHB;2:\2;/T(GK3'''#^&BVD6S@;V@D8&"DR)2L1, 3]H;C=<4@S6/
MFM-2DE/]0FX_**EZ.$+B_:8'6BI4S.Q(QS1?J<61L9?ZT=4PAZU-<^K>NN*L
MK53#4F6+G0:JX;1ZV&8<HE"8IR5"\5"-BY?/T3GE$BH"\F97E^Z:# H1@>3A
MFLH6=\J@R*8*?G*O 4TPCJ;*P#;7D08%;]%.>;0(QAHV>C494R-XVH.#(VVS
M^[?,^VX8 VE*?I.]RQ2+$>CI<FCN-.7K1K_?\((>%2D\T=]5^FK_NM>*2[I:
M-Q<W4:+$48.5"^"3;VII,WK//I>T7>-*E$K/NH\]C''7;D3F&#,(V]0XEG:
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M94D+,/TNE;*>TCC8;!%U4NXII1S/!LIUHQ.FY1E!Q *AY#@J3ZTR)'.,SG^
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M7(^C<$<WUXL@I:9!F>ES2&$:IEI6_[(+^:3H0G>BK9:JS=.$R46?-PZCSF5
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MFD0826'36B4S?V8&K(M7;YI[@)0G:*M(?S)Z]Z([]$?UEG2Y*&]&?UAT"AU
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MV1:D-#/&ET>%RG4D"55  /$KG>#&VA<>%:;'QDWP^LPS<B0,D#U8VX\8U17
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M+5.=K<1>.%1PN1%I(/4PKD?IT^O+-"9._28 $13Q9CVW9T1E125RHP_AR&
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M!TL-504;UF:U+D%.Q@@'H;MGN;(K$3!DT2 8+3)\B*&Z@G:DAYD6:4_PV&T
M1<\P78(-HG@H.;XCT>Z)G1A+83<GDFMV1]9UKZ)<'6O<2@-*@RN?YQ??W37>
MX>PW!V7>8]%^I/N_'<!N!6>5HD%EV.P&6& VU^)E/=5CVP1 !"*%JE"D1<X
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MB"G4FS>% 7905+217#2,G:&=+V@HIO<'X2O2[/"\ ,D'U\T3;ZX)V#&"YY&
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M4BN/GG<7<W[GS7<79^"T&6>@$U\/'5Q9B^U0-]YK68'#AY1B-@#&MOMA)26
MC;1@O-^^5(FL67,:63F+D"_)3[9\W0.6S<L,O?$>&NA38%5. 4P51OC.O_;$
MCE^ CQ]94]R?IUD1_;LB'')V+&8;K.]FY\-&"-'M2).]P,\OS9=[JX[!^5?[
M:+R$T"]\H* T X.(/@ /1<<!UDP7A X*"#!X_#3S875E4)29C31,Z4,!ARUN
M\S">4=S@$VP[\Z3D]?4'/M$WN[B3'11#S@U4),YHOP?O9">;?AOQ_= OCX;T
MRQ\3/'VO^EKW:4VAP9&$^E18]]CAF[";Q O*+%-)L$3%#GQ*FMR+TYQDQ"=W
M%[>]:UB3$'X!EL&DI ('Y&H?SN" SF#F8](@<1I!8Y(PX >!#&)987,-&ZUT
M]^BG1544]^+/*/S/5]'1T6$P'4R.#Z;A9'_?'YZ,@^/CZ?XT.!H<CH?'PW\<
MC%ZU>7._1?\J(["2.01VYB]0;'E?%*>SNL3NTTE3<$!B<QF)4F'N78*GX17+
M!99OH3Q!LRBQ:<YIF5"! V96X=O9NHBN"6:2=4'YT3()R'; .*F46& Q29I]
MPP<&0@:9@O5DE%"1#"I+=;*1U"P*0#*"@T7V$HB@\X2>O@ K!9ZE>/ES168,
M!D[1,'(?"3_/TG+&91?T6Y!GE_":U97 \8)YA-\BTR^@X^' J\H*E*8@=J]@
M49C!#>3Q5#]23D +HS"%:TEFN3ZL7($TM2%ARL/@[_1A\$]U'M?[]<Y*RTDF
MP9Y"..E"ZQ%XC;^ %WT'15& 3O-^.M@_-HKSI_'A"/]2UWO>*2VPX:VK+P/R
M]8.@G)?LHX9J&@51T?#BHY%;)U0_]7I0GG+H=$]3]"[,-_O>'\J;J#A22*^7
M?M%PHT4Z4T0\%%%']1W@TNA#TSB]SNM]2T!P8.;Z(1 ,WBOH3Z1WYP.&?.!]
MJ#X+[[2< 4_CF8S[WL5E6L9AY6@F2M,?6=F9#_SDEA+)OND\,R38!+^2@.;.
MQ?'@W5EJA"/#E\"G\C( 2LFG94RE3_!H/$GXZ:4]SH04?(YWHQ;&+"AAJ]$4
M=P%<_GBYP+:8NV=XX[_BC=_15^DTR>:ALFD:PPDC!6*.JR1'64)6N4Z9S?U_
M@E0S:6DC&BU+_KR;-_3TE-Z\/$OI+-L^&6O_%*4Z:9_=(Z\=9 N*FGT$!4RD
MC44B$2IP<*U>EQAHBI(WCBOFF\O1R8"#B@9\_=.P?_3F@0)I#<5RE34VQYRH
MT(4U-7QX0E%LHQC)<$.?EXV86CT=V (JRRAP324KJPNH?Z*^!BQ(3O#PQ* +
M%%4HER!&O!SN'==%^?>B#",NO8/'AF#$%AAHYX 5F) JF=D 5KWNA@VR1;10
M>)-][PRLB!D'V5!&U2T5T*AIB3*,@HD1&Z)I!N:QGV%(L<PX3FE"_$W7_7"!
M^[9*H'.JDKB+!.K$S3W7;<2-2!BI4&D2,*-ZMG'\8$4VS-UV'?@^_41;,H/+
MPWH572-;%AAA T.9_4=RA=)I<8T&N>-8/J.@4UL9]E<08$GP@AAV."1L]6TS
MK6LC3,T=U!EW4/.-P3!X.,8]LY[Q1JL1VT!]5UD0Y1S-R(LT^ :ZCOUEC@N9
MK+<.(\&:8*D4U)9GP$M! %RE<<G1BLHSW:>!1 "WN+A_!6OUNM=EHS:,M!ZT
M.M+JG6&\*0!CY92-%;S#SRG(A1]P \:';>7S%UGY=MQ5OMUR1)ZW-CR!Z7[-
M(KYED86P"$@!N-MHBG]$L=7T$8K.28@/0YTQ.AWR;!NT,T[&'*OPPV@ZC0)P
MEWI>7D[^R0+8D\A(K+Y[_RS#F83 P0@"UP>$K>]T$.!B,%Z/DG/N?U,>FGES
MBK3XD[3D++Z:3K'O@-91P*7+6GWR5C#:F!3@6Y6)#F=S<1JX+N3WH($&B\MA
M9Q30A[-/0XRX%]@MFJ1HP16L8F 1$]@[EU&H2Y7DN)TXXGX#+"30$7!TU6#G
M/EIXJV>INU%QA?,TPVQ#3/VH.5S2A$W:CVFA6 R,S$&D3H0I #V!T%P4A!;%
M!9>;%_ #7:H=Q&7(3RLN82]A&I1L6YXG>&7D9>)J:E=>8"?H7+HI?&_A8Y-[
M&8,.<Y.C\$!4J;1-6GT4%+084*12^H%Y%0K'PD_=8\A@:1'</QX$1JR3E"\9
MU7H#*6DB$=\SRESR(RL<*1+_'^<I_L$G7Y;/F!QB%:M TRK&[Z_\**80L1\#
MO21<E$*WLY2H,]X[YROPPI'BLDBVB>D.7 U3Z38:3'9$3;6X+D1JIU["F;?$
M.<0<K*.0.'KFQ\L\,L%Q*\5 N''BB#ZG(VYD()L,%3*\1.<X;G6K1-1BEW*G
M$Z4PL:FX&S"BI%Z:A92((J'4*+":))M$Q/Z>1/BWBX*T$TBROYR>?N[S=7TE
M5P#?953F9C)<]&WNE7F3"H3#,1I4E![K0GPZO"_-2/3..7Z'PB_/%1Y$')FV
MG9[%2+"5=7SLDN&$6XO3O*0>75PSG@G%+NAAW)%CGR=;OG!4H%UQ-2*I550/
MEXC)=DIB@JY*9K@&'7?D,"C):Y#ML50;FG7C[]-9PO3R&G:ML]3X-A 'N"70
MW25HVOQ-S[ORXU(J!M%0H@NG6D$=FBW\[^:<\-%8(TB;6]+^.2H*E-\<N&$H
M>CY!<A'WF$A7:A7%OZ/\YYS]/L[U4MDGT+-S:HD'^KM(,[+?\):R2%&I)GXN
MG6 NG1LIIZB\DY#TGZ.W62?B6Z,$6["%"C-[&/S;*Q^,'R UO@AG94Q<UTXF
M.N6,KY^G"=U,"0*&G?(@RL#. "). J%19CO"G< /P ZC7)0]19HM#5NC+H#C
M6>(O<8G*TFZ=W'36>$DJF]<44H78 ED;#IASWUQ<P94W0J*G05&B/2SL$9#B
M9_WN6G"F>5X^!XQ\A:>$W6=R1?>I2]^^$MQ=]2W .MX7R_DO3I4/C[>:!=<B
MW$AIY&<MD:TP^-5H-2<R SHR"?T,Q-2[%/[SY]Q[_>OIQ;LWS9\Y2T/B1);O
MIQ=G;[S#P6%/HRLQ<Y[!HC,?BXM(>9_!@:5S< 7['CH[==T.#^%GZ 63IW>M
M-0G*]FMP[ZC:WD=A[@7R0)"VZ$/FI >S-):ZICD5U=N:)CPAEA?X@9JB^C?E
M_Z;HD^3&#@ /7(P#$*W6==''S$4]N<A==-:+6"IM.$F($E]]%Y=6XJ.Y<I:T
M)B[_8\['%HGP%%UU4F:D^2:P1E\[IKZ^$^\UWB JWXFM_=6_S-^0W<=7Z:/5
ME+*'BPH K!Z@0_CA+$U#LN<,L J5&QN"(*W*]U@F4@AFR9@Y0>C-Q*T79;9(
M)>;;8,7TO5.S*& .U^L&4S0@<D7C)2#[# /3/@%7D7VIUIT+VR&42N8L,3)8
MG";D'\=BYP9*;\@A5K^"H^7P!>UE[2V@L9-/(]".Q ]4$R-6E$/:?\[-7J4J
MT_>POBM>OQ$5^"56=)-5S??L7ATFQ*^B$'6[N3,)Y>@S MVM0UYDO3@V@B8.
M;=>;Q?5TC2?P;IK!4<@S-:7<8@.L<LS.LM[-MZD)FNS;F:X7S90%#3#7;>)T
M' ]$:D;Y3%Q)21.@,_"Z\DJ0QYO"+FK/R'0D+RPS323%-;IX0[JU,:>*^MY%
M.4'"+SB8(R&[ZOJ;J4ZN'XS0%/N?; D'UU)JXI/R1R(<HS((L00NH._]+M@D
MZ^A?RB)UKP)'TRH/P_-!&YE8P-0%XU+XP;;+H;?V+9+SXJ.K/'WA+RMJ9^K*
M/?0L%&U0BD,)0,9IJT!'EGE=?]^ZRZ*F\JHC9!QXE-@J5/PT<JJOTHA2<7EP
MJ<*2?+^8JTJPB4LBCY@1!",\393.O?N%V2B=CBY![5']CT2 08%K]\3NW:@!
M=";$,R6GA<0TND8D*JK*FHI0_2K1P'=1M%QQ&,!(E:LHMZY44.E4SFS#'YUI
M7>#CH8*T6;.&J!*6 +\RU'(>U )Z:]H9-O7<SF+G"EMLG3+L6W13[X95H(>6
MFPO5Y[DW6>Z9LV7?3Q?+BXFDG4DTTA0I'^-860JAS],+]':JY(U,'40+^I*[
M02Z\<%<JL7K7%:8[(:4G#NW2!HG[WG^OW7&CDJ2*XX1-2"^BYX8*+H$0%R=<
MFDR"KY(GP"]GN1]KO6/-1RDV1R.OP9*\CF OJ(?2(,#J+7PI&R-RW=A_8J66
M 5U9?XV9RM/XRD:VIB5V1=X_#_T,--XIT%PH8;;4D:2BN^:2A[#F.@=65,ZF
MF:^_+I;]7"EM^H,.Q=0"IUJL"')]GHH-V?<^X!,K'\!H2IEQ[YZ\F+20D:=(
M%1);4VM>DE_J:GNQ7B4?0PDY8UJ:[^K?<#BPK(0UP2Z815@JZ<\RI>Y<S=2^
M]ME;LJZ>5[G[BD?L6\)9<Y*:89=$%56BJ-S\WG"P-SK8&XYVN99R#4(+!4K?
MD:C_["_IO)Y?0.=%EFV<[$[91DLR97^X?8E&T5>ZLMW$PD+XI6HI3?TH<T+G
MUQ1)D]^AF8X_G6'^06+A\%+M4K^+?7CX17"94M_>PIBA:'N#SE QA1S$0G/>
MQ"JP\0NU/);YLK9(OZEE)=V@S6K3RQ9'4_"TKE+D%$S%]+PLRK^!WZX4U6<@
M5(R'@E7\-(H @.CUEI&*:\IP]7S<\^2SLHF[7%565DD[.ED9UYKD A/3QZ;3
M&_:H]5TVWJ,!N.12%.NER2WB"LRYP,:PTGC5$8353%6$AEL=*,. ],"C0B1]
M%=J5<=+0;1VL8P#[W^$HL8^3CH.CCE3U;]$RS*L(BM.Q5:4N,LV5*75\+5_'
MYT[ BYE&1?X&K]X68SJ+,=8M_<SYCACCU"[1CF3,,ZV<^+*2$3US,J(7.B/J
MX(QZB*N]JLYW&YMPK<''/) 7&F&'ZOU-HIBS!R@\,ITT%CN;A!@:S24)'.]:
M@5LGP+J->68*TV+4#/]FV2U?<?9\#QB.FR-L1,Y[_4J_<0_?J%_QZHWQA?V5
M@%TKZ/7&:ZG6<9 3KO,]XX-!#Z1D 2<035"S[7E_2=.0W&?\(,.1O'X%G]V#
MS[YZ0]EXF^XWNHI/67QC]T:DC*7Q7*WD6B#L\9R;IQ99BD61&(N?D4"V<5 =
M(C$/N*0 @X_1,'Y.&NF07W"9(/8[Z:$I BXS<_8M:[K^6:YD"P%C*Z7<>ZW,
M:C!T7PF3ZE6M+HI#)B$'"B,Z%JF5E# 2!TU-O1T9+S[&5"IB0P@WHW4D&E0*
MHU@&/!IQ$?"B]_#2,6IU":J15"50F0T7P9ECFS@(J22=1P'9#;QOM!0X"/P$
MOFA+I-391L4J')SGXDU@?<;V)AF&L?<*VH$+]]7W5G6!1J.H7RV%P$QP%UY"
M89&)'Q.?YI?H^9)9.ED*1+N^=TRU@+*G< 3%H70,++==%KI220 F>M9 :Z@F
MG:"E:&MKF,((N@%,5EQ"Q=KC,2G_5&+NB"6&P?R>B?/K2A4;L>,?;W+V8+A-
MJT]AH[1Z8!C>LT%2.G*=M*H="G>$P@%&&;T$(8QJ@4H$?8CUXF7-<.PVYUS?
M$%IHB EB8X'F=<#'&V6]'*>\17&=.YH^3G4"RC'!1_OJ?W^./2:ME6F.ITH5
M896"L*76#)BCY^L2ZXKNJL"[:BA0;'#6F&D$T(0ZMYD;M5PR"9V5Y_>:2@E7
MRM:X ';96(YH,B$^@IF!N$* FX:'RD[XW^>ZG%6O<)-Z6$ZINL MQC5WMT1N
MGA^8CO)_EN!]AY'U 5EX7"LIT%65E5'NBI"%4!8E5YA<,"D>O5J?B_$8AZV@
M3=I+K0+<<!:(OJCFX*ZB):7+\H/5J37\JY7&A@B^G/=,I*'>F=^K8EU21 ,W
MAZ&'1>R+ 6X:>7M4)V*,24:.8X< KRNI-D!(BJUV2J@Z5_=1@0UP:U-EHIDD
M*NG 2'&C]-Z#-U.TH%<G/+?WQ'2(2-)]A6HJ"KJRVC^TJ49WP<A7T3>P;"]3
M';)HX@(Z(*O&=$A M I\D!0;DUY/(W927.-[063!34@R64 *,.C%2X^=+S9*
M$<T46X\BNFR#1\#Q&D)8;>([3CS"$B+8L Z*?*TL8),O>BP0I!>4BADXE$,,
MIR_,MY$8Y_CQK*QH::H3=ZK#*P7QNJ@5?RQ_7.V(Y;_!N4IK$?7&:C@Q=PL^
M]22M+9;&_&F30.KTX-.E)&^\:&_UCMU<M2-;\3IM;QS1GV093,"X:J?K= 7!
MA@E\IM.744]?\RI^&AX31"DYU6%*?&LS]J0)W61XF3BK=4.#%0E".C(LC<9+
MX&*\X4BF&57DU2EU&TB<&'8,C.?'I(BU\X!H86O?6K6@J8)$:T<+B>[&A-!;
MIST&059218)^GX[UX$*<M5O@T[5W^D2M9D]!V?>WO#]GX-DCO;((?*?PAQ]T
MUONAHHQ;E46K_P;;[F]EHH *AH=<UH7UTD"5.=+6Z<7?O8]IGWZ[-QSWO%>V
MZOH\05AK/JL][PS$=51XOY%U\DJJBLH%>=XF11/-Y_ I_I%MK&GN\JUT]FC;
MS0(0\NO$&'K]ZNS#V6\85_/^;NK#&2"!DD0]_4'"&7+8+<5A!!P*76H0(GI7
MV.?,.R(B<9X)PY;<&ZIQ@4%:6-LW<D[#U!X*F[HU#X6;']+5;A9E4EZ;2XDZ
MJ7_JNT*IB ^81CG&XAB>8J)F44)^ ^4VO?<*B'>B<!J%R&K\BH!I4F4WB@ET
MTH$0Z6NYE\]A(RJ3] PE14C01.2"?_ S/*%04F\1E:/-HZ*@$_J#C7RY'3I*
M8S]?TF0W/Y"HA:6&37OJR$8CZP&/<4E^B@E;N(_?\'E;J3+:^<C$%Q7PU9XB
M#:!(6"<PGSKVN<6:+1":AM5 -)XT"T[\S=YPU*N$<ZC-Q#O:'[SQ2-2-?O$N
M,-<B#(G/N2$8U'<?K"N^J-8*GBP/IB)6>62]_WXE8$'2!I^9J7E*-;1BK6%D
M3B*5W'[#,I/ 'QSK7#Q19XY;3Y=(XD<CS.[L2;99^@HL)&T<E%)W6X\(D!D3
MS2UD@EXF]^&'8>[-RHA3,=2H0MWT OV IJ=3D4L=BCUQCGCJXXU[0<.K*[1Q
MJ'TTV)U"FRT=425"H^D<V9FH"MNK25CDIA;3JJH9F "+*E^O*'T_23"")=S@
MTG*-4:R_SPFRZM=N,Q<&54?#%XE/RMNP&W#O[_[2&\KL!,H58Z<*IQ*XRR9Q
M='-$_:^WZ>8':UC<74W[:3K=>R?N\ 6YPP9&KA7;>9:ACC^4-C$1;'ZOEC94
M$_+H09M&V.ONM.S4(Y;Z(4Y_!;=HV*]PA-DD%+&%7M5\!<%#4&&ORC+ Y:E'
M6IA:.SE.P,,#!(BA&<@B=9$OM.*I+UU")K/2QZ(]Q1$3X/DLW,-%+ND8'B!
MT!:2W!"6[OC5BJ__U-ASYR =O:/3_F//A+^CH/H_)8;7"H[4H?S_/^A0RM_?
M&T@/,$@)<H$G8WI?HOS;TU6)/U^L2PPIF#C$*EONXK"=PV%+>.VX;:QFHVT7
MU;C(!<ZHYOJ\;.F]]PN_XZT'J;S<&#B)ZM!R%(6<2,34(-)0)?L):AH)BP]E
M>&!"86*92TDT.0TT35'EBD*%UE+'[#!X5OR$7_>&+;_F#1E^OR4,?](VAG<
M\Y$J0)N:3K?<^X,*3CF:XU.6-G&#1?"%;<[Z;=E)6M%I39*6,\\NR,B/:;(%
MJ^-1A-#1JA"ZL9GQJ3L=-Q!?K?,-""PIC=E(^8R%62&Y BW."S^C-AJ:F/.[
MR:7^.?>^L(4!BL(1@][&M[2[*+)T%(@,ZLX@M.!A>;G #A0#&&JP"QC:$$M'
M)#6-89;/C-()NN3#=Q64Y.A^PB(P;.O #YQ=1FJZ^LLW<L#ZVU8G-7Q[Y9=O
M>E3KX?3=&T1JG.4CG7&IH)_*U0;NU2[LU?HWCR'$?D:#E6HRS)XNI2.HF+K=
MRM%B3,E2*FLT^.7V=?3HD\-?I"Y2 %F\+R6VS0S'_M[PX+7B8QL>A/(W>VT7
M=O[C!XU(=LHI9A#P^SWJA)]3K4M/JO8J'^QY<^5;B+7<F8[IG)4$Z3D*;@)T
MH<(R(BEE36B3W,_DM&>ZY:X39>-Y>(#VD5+'Q*<H(<"H@(./N8@G+R=S#)O;
M?5<V*Q5#&6U2BE_QCWDYQV%/_Y86'QT;[%6* (&]3+) H&XL',=%=;RF>>M9
M.I]'A*YKRC,RNC'\%.'8]%WQLHX&#2:K1AK";J5"$(76?:E-QU[I5^&I._,R
MB0Q8FNY2=4=BN?+'R=L05I*6"\H(#MZ\_KGU/U,6"7F/*\RR/$W</*N.4$_+
M)-"04GFE]80+5M)KH@!"A \$-"A3,S^3Q*@<H^7C)^]HVJ*VL(K3E@CI 'VR
MW$#(]C #P(,"O$LX:FJT-/3KFS&H%-_W$P.6155(#N"MG5M*B'\(M"2U 1%F
M%&38@11@.PT&B4)1(%/,,4:(/%=44>Y%F]A*_KS8TXW.G,0&FKB,%@1FF +/
M"XY/TW[[WCL7&$#9DMX'TDN,N$400EB@0+5CU&<^G1(+(_]A0;O!,C.IR]59
M#QIH'V[%_T;*$X<>5(H\5S&@5K2M\Q+#X::_UNR1F@<M\]K2*MZM2,U:<69M
M*CTC,*\Q+'CL=[/9P+DH6(O$H/ 8>S>=\Z8WE3GGL<X%W,GT:XW[S<6>LK5C
M;>AS?=-B0/-%VQOXHB_ZN1G2CFAD%*\%LJ5NNS75_1*% EX#GO"YH\F,@JZS
MR8U<LLXVG%9LP^F;-<I:ZD_12)%'K;+IC>_W35>1D=^3)2G?9A\BG?:,\'$D
M,FA=+>0;Y;O5O=)L&CD=KXU+DS;I&N1_8Z":KN:[;-I@[S7,(_A[_Z+/,P4\
MYZ+1]S"P>VM=C\U/U39<.\.+W<80L<_J3+:'/YB1VO1^S<"ZQRFBWNO18#A^
MH\OMK/BGVE12G!=(HRD)]T_9S$^DM]B(\:_87G[M+QWK]N&MG1=9+U9+4K2Y
M7JPM O;4RY<YAO2P?7!CEHH:!=5N")U-!SDA8O6J[4:QB"7)=NS$"U@VU\"X
MS6^I.5&7E6YRLM*\J?&1N///=X^3;6/I(67(3;-*E";Z1,QX]IK1*)$4W;(3
MS9N/TT!P3NCXKS@]2! O!5<"$2"J.'4$@?J27+9W+O!XE#LNR/W-YZKE?$<E
MAR,];>WF+4&WQA!;Q>B\HYG=%EOZB^.KP0%\IDZ<_\'=_JYYY _#R3]B5C]+
MRAX<8?KR=O\0.W[U<,70E3_7SMENU*[O4;A,:Y(^F$YV^AXS$D'B.?ZQ&RW%
MR]+%]D;:,:P3#<%QP=HYQ&20#AB8CO"@TZ5T,6K/F.<K40V$@T2TU-@LNCX1
MOZ*KC[6O83'XV2[$U><5N.9&1]XMUJQ 'M:ZU4! \%(<_'+J[.][WJF-/%10
MTL&<#DDQL'9CE1TC9DLM;,#ONXJ C,RQ+&N(]Z*/32C/14KGT&]EO;KFU!VE
MY<%28XS"SBXE:K6JNZ1?SB&R:.-Y:!H-BAG:U<1R.M+L.E_S9BQX+3-W(I*8
M^K<3LT:,H%A&EIF"V<U8H3K;4B%X^=P;#O;^BPBSGB!IXLS[#UC_$2R;%@@N
MDOWO.9[F'I+5>'6.<USE2IS4H,_AA8MHF8/Q10*GH Z@3(-#^!/@FST[X715
M#!*<1G+I:S2RVP-X>IJ?0P[R@-!D7(Q X:\87%',450#'\(_@<N@*PRNRWPH
MH2:)*;=XO#9?D)(?L8:'=Q R8Z79/J(D!\A)?1FPG QCTV2[TT^H]QME%DI2
M+;S=2*L^]+HLRPT\-UKP\Q2$34IP-H6=7Z22JRA+$P,I.*_&%FIV%LL]^V9$
M0B%SRJ$%6(7*Z;_&QNKI1(P&MUMG<CV%6=R:8*931E8WKIZ\3W.;^?^"D>G]
M9(6\A&.X29RDU(K<Z(GK1YH$&T3H:8$]VA],!C1"--R0"G%&!?,L3DER2U.[
M&2\AH#5%NOJ-C9:\=L4/%O2_&X3$+I:T'PW:4N'ZKFTE8LR4YS9]W_)JPMVM
MRMQ>8/A16&K\JL5[^WSZY:MW?G[><F+>\*@/6R*]AH.V2:_W$3J4*5;BK(05
MV6H_2S-$#@3#_R^H2%&+KA:>/WGYZWVH97M3;["PL+' 2T=)J=5& W:AW>+K
M=#%Z, 1]\SE+OR]MWQ2/S2X)U] ^F #] GUCH8<&'SQ$OR93 IFXV03&YVG*
MG&Q<)_^BLYZCMF4]MRFWAVV3VU98GSEC1#JYW,GE797+QZ.V&&FCMC&[U+$O
MO4_7"9AE4LYZ)H'D=U3NRCE?^CV1H*U\ZIHHS7+P8+Y(]H@FZ5VF,6;/?J<B
MYUM"B9WXK(O/79"?.RD*#]HB"L=M$X5:Z'UQ:OM9X&F^_NI %O6DZYQ]W$X0
MVML%6;;  'WGS'=&XRY+RK; 6@WWVR8I;9NN@ZGQJY(\_X64^K2$KSHF?R9,
M_ACA^Y-A^S,E__T\3GJ_Z:1A+<$>G#960/[,7=F/C\MYDZP]:)NL_?#],II$
M6"?8@'#F7> D2NSZ:C>-;.=&7_MOAOVF8WOZT[J;@:)CVWXVBY*](EW\S/GR
M@OHI3 (@"U6V!VN-_46N?M9_0&B)1>PO?XX2>B-]Z1=YEF0-,$Q^I1"^PX]%
MT)',XU]+!/WDI']\,,8@>I'!_T/]8HFO]RF^_K8(5W]W?-0?C\=K?SWH#]?^
M[J;'#@?]_<.CC1[[EI;,RX:#P0/^SU?C5^;L_. ;HDDGX9[<=1 H-9W^LO!#
M;/?Y>;3X[@WAD!Q-$*OIRJ'Q>6VA[IWG#7"S[=2S+E<!ONHLR@OJD_C,TRQ<
M&RW*YH;<Y P?Z'A84;;J@'[=&U4V>V>BF-(_.T449V[5=@4C.[_7Q=]^!*V\
M^/&/7?P.2H/*Q5]4QM-],C#7+XGW]U\V[U^X;95.D;.3F\C_['T U[-8OB3)
M<-!)!BL9SOS\TOLU3J]?E&0X?'&2X6-:<#=0A19N](Q>@"@X6J6#M^0MM=TQ
MW,(LD[4>]JC1P[XA,+'%33R_:O;3./9R?=1.SUO*@P?A+X$O@]J7=L[B%H<B
M[$;8:-SW=-RMCIB(&(@4JJ=XX>%@B'H4G.Z2D\;>Q=Y_W:-_KB4'WI;(TWY_
M?W__/I$GY,;C^T6>;O[=P='#Q[..#_I'O,T?C6?=UQ9IF4X9. %OIM"/Z98J
M*V@I-4:^P2;2%S# XW]U]X_*_=:JPL?,>\U6&#,ALB@\QR.KSM-'\J/+N?O*
M[T&96IO6Q4&ZV))%..X/-S!_[W%@&[(E[_R>/#F=/MK)\+I#!%(F'?<S ?OA
MIV Y?F,J3S$3_[+U!7J7F9H"0Q7%XN>W;Z^OK_NPS/XLO7I[F@67B W[5H4S
M/WL++I'_]NAH>'QP^!:7>W(P&([&P^%@-#HXWG\;#,='A\>AF@[W@_YE <+S
ME,&SI4",8#%"[Q0O-&9@['.3>T>[X'4E%3]9VO0[&A:G"XS?1]^]4PV.7&\]
M=KI W=A.8BQM;[A_)M;)[S[LS3O"ENCA\,W_]]:O]SW<3^1T4N6>4J63*YU<
M$;DR'.[OCP;[PX/!Z.!@</CV:G]P?#@<_>-X[QN+%:Q"9004@N8D*:,!4A]4
MY(B=Y8U?1V_6"9TS'E?OX/H2QL\Q0OR0I&$XG]$QB9J#3M1L6]2,.D'3"1H6
M-(>CX]'Q8 A.UL%H/'J+U@,(&1GY,5G&_O5WX-FC&XR9=_BAW)T4LJE(Z0_O
M+5%P8O8)B9.C!G&R"6TU=GIV8NCIQ-!^6^R=)Y<UPX.6RYJ;%RBR)L@GF?J^
M/]P?#P@.C"3$>T*-6VA$**?,R(["<?GUB0D/-G9[)\R6KGTSH;F_7FBN3%=P
MD!9):/ZMC)=BA8T&;]:+OG4,I@.W24ID>@,K_M@GNV5TR^B6L7O+:+')M)*Q
MKZWU29!5FMH85LL?M@6W,JXIA*W#K71IQF>79FR=$S(<M,4+Z8(AVP^&2-1U
M/#@<@%!\>S4^A!\>_.-8@JX?YHLX98#]4XTNW?.X2NYC>J7F$Y5Y!Q25&/>\
MB2JNL<BF,D8/ R=IDD3*^SW-LBCO>;_WW_<W#)@ L8[N'3$Q"QR.>(5=&';K
MHJ>+PW:BIY[P&1X=')Y@PN=@.#JV"9]*AN<F0<19W>$AYUHV%$.;"Z##'PC9
MXL)&@XV20"WQ:%JRC$X6/[XL'G>RN)/%-3-P/(;_@!FX?WA\-#)FX*<IB$8O
M5C26FH7NW\I$>6.VJ]9*W/?^501B,(IC^-[& O?^.3)W49VQMW4!L]\)F$[
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MES3]1SZ-'SJ?M_&GK^6P(-3/M/PF!8(>]6CZ'TXDG^-I?;&8P_JR3H?UDYS
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MKYPO\Y0O=,H5HUQ(PI&W+B#N8+:UB P1Q:2*K)1<B)6U9C?IT_YI 5KRM>U
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MK$ ?"2-<8JXD)K A":YJM",]4#FMC#EU&MMCTN&,.7?#G!D23+RTFK 2.2^
M"6O '"V]08;[Z!@VV/)DLI9UNB!:8Q;,8$B^-[*=4&<:?-->/B\>7)R$/@SS
M^!@0;7!@^J'HC8:#H>GZGZ7-?.#8WX6W\=Q"1JT9M-U=G/M/C7Y<-<3EI1_O
M0G\WZ>YB31\ZRT*V3+\+LS68/NY56E7G; 1G-G(#-K(S']^J.([*&8*,-!%Q
MK ,RNM2(VK+4(G@0$; 1_ +?^7I[_0[J,P8]<0RZHRF4,>B>,&@V9E<[$3'#
M2!"J$:>4(XT%0U@X%STG2I>TPJ Z!0L]MU2S51F==F<T#/X.%95_8@<]192]
M_00\.0R^;QZX.5Z3&85OA\*G<TQ0V-(Y'"3RQI: PM8BJZ) A%@;B9"81KL8
M)GAKK:BYJSSCVS/&M_OFF!G??A7?9EBF,,(K:0SB)J90L1+PC:N(7#2:8$F4
M-[["MT4YWN\?W[);/KOE%X9]GZI?@B\,],KLATN.^4'VS#\7S_QSO;XR7N>+
MM5[P[.X^5;+UL8XU1L<V])NQVND'S1\J-O$LW22W:R8$-R($\U?4C"R!O'&&
ME*$><<\H4D%H9*0DP;+ 2H57U@A;)5JN$EFG.D?YIMKB5?V.1#ZK>IU4?8;[
M:P)X'3U!&(<2<6444H1*!+)E .Y$4>['JL[4JM9W#D#/?N;[\#/?YLK+A.2/
MAW(5S[^CTV;9T>Z!B,W$>S$'>AGO%HAW5UR+,\Y'CB6RP6G NV#@I^ 0)\Q0
MRJVFA #>\54B]*K4=Z[)NGBE6Z+;=1EJ:D&L,M0\#-3,4"MLJ3+8ETA;4MWZ
M5P@@)B 7O5&$&.;%&&J$9*NBO'/BK?I 3<7,_C4TT"Y\]^VO:_^&+].>7VC+
MA91CXN%UE5Z1%;:NW6P=A,(XUSN&9Y^FJF'=WA!:3S'!T)DV]&P_%;H],?UA
MT8O%\" ,0K'1ZU9W"TUR6[YN=TW7M>%-NT/XPS&,9O#BVG%/'L[I"YD8\4EO
MT$ZK\64_=*HRCW]\:_OAP13O+GQPLN+PCX\8"YT Z+GV(W69X^+R;%S\FGI;
MX9^4I8O8*A&]Y=P0S9Q2D4<G<<F((E\(42O33QV<'SV< ! CVP_F")D((WQI
M.M_,Z6#E7Y<FXKC=13,3/SMGXYE9^[?MPT>OZ.ZC3NM<ANYJ6C?^L[[S;KO9
MV"V:C8WF6]@-5HOMQL;U:Z\V'8<^-]]N;ZZWMC:+W19\V]EJM(KFZP*&!)O5
M+@P#_M[<^-__--]N;GW8_7__I2B1?Q1;[S]NM_9J/[[?MKM%ZZ W@C;\H C?
M70"D3SE0QC3E]VL'<&SZ^[!4T]XAQF=I">1_($"UL\ H.N9D$%Y.?_ACFGJP
MW:WZ4GWHCTE;$]A(2WYF4ZEF:_SR1!N4?*&D2@HQL?LG#Y[HRHM*5V8VRO%K
M3+S0I;KV9?R"7/O:SYJ5+XBX_I,_:_7GKW$B<E]S7Y]Y7Y6^_M695J\P;>^<
M0[4&XY<W:O6:: ?YDVB'6IR_JT44O- W&=-XMWV<45U=O61C'$.P.^RYHQN$
M#?RC.V9)IZ$%S'@PZI\N;B+@K?W>MUD?U5)-RCKT-1E0IE.Q_7>F[5&[6_V\
M84[:0_A[GJAJHIP;'8\ZR<JM9F<SQ+9K7U]OXWX3;#^'&:^*F5=S72GL0:\#
MC'_P/]5?MOYOU!Z>7E5FYWGN3!>\[#=)^[04\A\[D1<UY)O$J3V9J5L_[HVZ
M-\&F9SD[>6'5:F'=XJUWW""7.H+X9@)Z93JFZ\)JL7[2;W<*AE>+=+"W@"B.
M^=5;JU/3FVVCMSLT#<9@;ZPA7%-NI5>**4J9E3HJY83]LET=FLZ<E6XW7L^>
MEHXML(K&+.W1Z/[D:/3D8.]LG^V=;9'&IS\[.V?K^//AT>E>RY&=XQW>H/"L
MS?>GGUM_M1L;YT>C8F>S<;A']\C>X?JWSZU]_+D%GSG^2'8V/Y+/;[8$?![Z
MN77:F#L:/?JV0QO0S[_:.YNO.LW-= 3[9_MSZ^.W1NNOH[U6YZ!QML_W6MOX
M[[/WTV/1X4[K_5FSM?W%&6>$5!'YTA+$)0[(^D 12-6J5#S,B!1?2E<E+>'?
MHG+,W4QG'BB^XI>VL84T6H/K=C?#A;O<MON'X2\G'LZGM/LU,)S/9'?1F!N;
M<35*9[<D('=Z&>2440!2P2!G,$:\A"\J&HNTC*4OF7$E4RFR]K[!;9GP[=X>
M<"N&$:ERT2H>87OBSDG-K==1AU!2@ZVG%Y7J^Z#]LMON_'\KP_XHS&K5U+E9
M:=>$;DP>F%7J'U5J>]@XYPTP.X?N"_,@^%)Q1+P1*5B=(1TL?&$>Q"6C-:F.
MRIQ"/=I5NH4LT7G07]CZO KU\\*\R<(\O;@PC[[8:!G7GB$I!$<\5=PPI7#(
M:JF"4IX%5=[WPLS<,'/#RS"!:61*4B^8X2QBH"&2B#(&H(@$$/0NW/ FUG$F
MCC<CCLT9Z]@'$QU7%DEI2@0 #]:Q] YQBUD(1 JJXLJ:E*L +ID\9@!\7@#X
MVRT0D#+)+1$!E[CDE$;-N*<"!\%%]#+ZZQ%P ,.$GS(4/K -/5>&0I@2:P.,
M/\ 7$&:)C ;&[[W7%C 24V\!"^FJTO/):7Y?$AB\CUB$3!\S>MZ-/AHI E%
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MP$@3]#E;)(7:^@6[QO>8V)\<BY$O2/M'?V2$,\::<#A%/RZVAN@MI\[9K\0
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M&0P*9--ZV^K36HP^=P9WEWZAD;T4@QH59H(P;FU,N<5O6$&5RP#/YX='<V\
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MLHZ//,YMG8^/1#')BS@*(Z'RD(E"A3QC26BBW"1:,@,JQ<8KQM>-);_O3;/
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M[G,2#0H"2PD/DXAFP$FH"?-,)J&2!4]D5J2,T?6>W^^>%WD*^CEE890F1<A
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MD%6L3E5RTDM+12:VYE@K$L[HWN6[(R5%(;,4T:\R$K)"T# 'M0DSSI*LD+P
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MP(]7SK(BO'MMN';!L4+[CA5$V3@>V2#3S=TJSD!N*\"1SS>%,SX&"T<W&]@
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MSF/(==X\(I%S"C0%$Y]6UH71=W?LOGE&#PRZQQMSM\A8'RFG2RL^^X,8SEI
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MCSQB]_#.<\,[[WT>;'5SK[+'K:T&".M_"V>=<Z#=W7BRU/MK ^?2X&#2,*W
MS"$14P1@D8LU<HI"+FK/24@<FY7UTWC2JP0S7'?CNH][;O!P1>BN^%P?ZGX
M*.=J'B%FW@<*+-3<177#'VVX(7]N<X">C]V5_2X9MQAC1LRJ6.G-+?K8XLG/
MV;0/H^=S]O _9QT/UD:L*NM6)?- 9JN9Z!??G:5JNV^[A[<W_9Y*P5-I&(I8
MAERW)B 7K$$L).>)]B0F,-K)F(I'5^5VG]#KHG1,+1U32\?4!SJFCG6W/%CU
M<:CXDG>$T"@$CMIQ;9P33B8J*./4$,5FM4IDLLU._]A?[8=MG<7KFM[7W.MF
M0X%\;6!V=6J50Z]F3T>UZOC&UW3UL2U:QMH*/A(;@K:>@JYW)CH7D^7$&!XD
MH">N;(5':[MB*[R5K0!<SH$D"2T98BHFQ FU2/,@$'7:X."LB3JGQJW=Y;P>
MLA:J6FPY E79NMTN;.2!R0I6>_8,KDVQP/(\^+[N<O(6W]>KC7O[I/8ANLZ9
M[5S4B*X\[V3(P=4^/\G=$G+_T,-V)Z]6'X^K/=UK.-<^.\U] :M>-M?&\LT>
M,/%G]&?9JV1KY_"0;!$!CG:K5G*5!RU_M.?,N=/W?^TRN[[E$2ZSVS<_PV5V
MGT^L[S:;.8_8T$N_T"-FN#5),V:YDMQ(K;$ @T%3C:T$XFFS<9?+8!"-!C],
M2]WUEZ;2;=VM<5Z*4M/VNJCQ1>-\ST=8*TP=DCPYQ,&>0\ZPA*)5B@NGL'9^
MT+5J?&';5_9_V7RF(+-5QC3'3!FNL>?26*5C$&Y\3Y[B_WJ%$LD_Z^=[(@9,
M/4](*4T0IUX@+:A!*A&':>)<9W?!,KB\GK5/B\OKU;?M$:OO[UE'N%8A(2TS
MN\?&(8>Q1(82I44"&YFY![Q<4[5,J^945URL5Q,<(/.X#=!YTZ*P P,O?X&[
M8F%]J7J.93$OE'F&+)>[\D^*Y?)FO=D![G\TVV?=UL4@4V9^V7V?R=M[,YTR
MBEP91->WW3*(>HO;^_?S6:Z*T=.NMU.*!IIU.--IC*:]^<"!TAT\Y:;Y<7L\
M3Z> 7B>= E@:P4D>C+4.6^.5LXPGF_"CVAL4"C@%7?J>Y+"ZLHGQJ"02*1?5
M4[E+&=41*9D$D6 B*BM>F0,6Z'VU<7\8RIJ\ZN0+('<3QRH/SUGKM$I1O$:'
M*CMS]9I1W:)2MQ'TI-N$3_5C(#VBT^RWSH3O.HXV-T7K)43"!NKV"-MJWC/P
MDK8GY@!TK6;\4653]GP_+EL!%;'JP*6*2PT>!:.X,:8*IJI1]1JC5.U=(D!P
MN 6$.V/?I-K$>;A779;;/_HST&^6W']JOJ>?'1J&DDY_KQVTSV'LG570'M6K
MMTX'<8K^D,. 45XE?8Z#\EL,M=]H]/:0^Y?ZF)Y[*O?\<7^T+"S(9W_0SB49
M\^V]Y>@UH^ZGL%9B7"6K#NAP\[2:^YSM"F]; 2CHKX'\WK%+*D7N(L!&)]K<
MG:8V]/%F]2;?6P (J[7S@R9H-/A3/\6WU7MV1HT\^ &T7*W%6I]D4YP]G4O
MK>>780]@O793=1>&_>JQ@4V NRHEG= J-L"N&[M?K<J[2MI/XY6PC2KGX6!
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MK\RA=P? U([MR0C WH2D3#0+(BWHOF/PG3#&H_/MS8^XL;FQEXM\<RD5XBG
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MW27^J@_>K4RB^_KB3:KC3^FO5_KKE?YZS^FO]])^>3-RR#17H^W=D*L- !>
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M!1W>!AWJM]&!F,"\I00QG"CB4H,Y9. G ?80]]H:H46)NBX%-,Q,U+5 P]M
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M)X=(%N= I9U@B J2\VVT02XJBI* )<?$.F)I3L2C+T[$FS.(?.9!SP??:2X
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MK9PV%!3C^85X,$28I<<F6>>0(RP@SH)"6ON(A).21FU8\GAE?7RYMI)^LBA
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M!A1@8I4342!@H2% >@L"[VVT(G'.@F7<.$NP94F#JO % A8# D;\W-HQH8E
MCJN N/<.69LLLIR28!5)UIN*" BV*KDL*+ H*'"WP_MY4/!T/_?C@:"XMR>)
M $,DP*G("/,*.6!^B&O-D.8>$$"I0#GFT<(DK[,UL\C"OVBNVIGL2'17"Y2J
MU\D=H:S2J&@Z*##<J"CD"!=5'@7&$O  '<$H2!&)$+10E >1N[2+-?Z,1D5/
M%LL7Z^&9\T_^STM \@G@.&L48R+4XKH%TQ2XQ>VV2\78F*B_8;C?DK8*$\$=
M(J!J$*?8(D,=H R8'%(1GVANAT;(*M/\&2V7ILDX9CC2>4]_J;<.2)51SD&
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M2[N$1[;OSN*?/JVX0IHA0+JY/MDPNK$Z!9.>A$ECBL\Y17%B&$6?#.*1:^1
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MWX,8M(^;OO8Y^K-.\_2B]LN[C4_O/_]:V_"GM7/;K;I1576R3]NUECU?J^W
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M&QYY"@CP<_<0GK_YQU'C^"_@F)^.=C\/2?_AI];VSD=>/_2T?KSU$SYS"6,
M!,B<LWY>__,CW<T<\\]/!_^]_$CJ^WL^&,] ))!VN0 RJ%1D=!(H&*)(DCKH
M/(5^4/!_(V.HA^T8%6=,&I8+K1DN8'-*&4 =<Z/D<*&4P9378,YKU:2/,+CQ
ME9)?NVG%^"8$#[_N[>D1TE!MC/$B6(Z9 PWF;$Q 5J3BP9J5UZO^,[S9_[#=
MIM\X"9O-W$1DUDK_O+X -#;V:%",N-P]3"N*>#Y!ZJQR\*MP,<^ZD61XA0.V
MCN?FBLX8[K@U7A-)<.+4*T^L&Q: C:J(ZHD']7;59R'7FNK7 ,NT&$B) ^F
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MX,TH%+P_^_ZC'G_?W2'[NWL7]>O/IP>')ZQ^N',%W[VLGWW/ZV?UB_UOGQA
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MUAK<Q4EK/7I60/GT^T8CG $83BIHAK3!P?3 Q6!!"2!@*G%&4\+2.-$P/N<
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MV0[1SDG;N6([R@9(W&_]<K[.6Y0$EA'7(NVZ%\XU!]&P($*M9C-W4;W5;N=
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M4%R!$_Y8JENYX94;7@VC"DK<XOH&)]0^AZ#$&G&XAYXQJ3C<JG5]@S.%/_9
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M)3PCSW$ 79+I",TPFO)\#[LMTR0>=A&>#8B-3+Z\SP5O1I9J/VWJ_G(O"FG
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MX9$K7JN8'!2K)"AT!4)0#J0V@E,<)2QK7;_= /:0/,">V'A=A>Y:V,UL]CK
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MGUSF.N2$NG5YY#KQX<!BFRW8<:^2W5P._:V"%3FI'%)6620(N410W",X4A*
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MC\0X&L IE2*5E>%R%SV[QT:ORFQZTL1-E+!M4?*I<'\^N6BI6Q#:TC@ $X*
M[)$FC5^"P*62T6%PS'@>90Q!T\H064G,<>.CC@YN@H-O"XZ;+ ]X3$PD:4C.
M"?GDR*)-QA )@*@-UCM3^YRY2<5QPV%+J=_$@=@6!R_B_SN?SLI).OW4O(BQ
M%3:,WL,POAV_A"_#&8Q:Q!9W-R*"OZ ST7K1'Q(R,!W.TL<T^3H,Z7V:#)OX
M(87F=*ZR?\#H/ V$4\&[:(@1/*"XN"$0C"(L,2>II1;8+>["5JCJFZ?CQNA!
M(>(FXF65G>_M='J>XJOS"9[3<S(7Q_?L<YH,@E*&1X@$2<6#VSB'>W-()&8C
M=02T)+/K8R>\DZKC1EUEK=S$C>H)-RVF%P0F&[)00"Q'=$MG.0&>'>%>9F]%
MP"/?[@8V/XAZE*C94"<W0:.W!<VO:8;R:,[2NV8Z'4CEC!1*$M#(KU3:X<YG
M,W$0-=4I9"UJ[RO7"#AN,&PNZYN*-[VZZ"FB;2=4(C1(I(TC**U'4@U%CU'I
MX+5A>W/1:SJ:"902VC@BHA>X^CANV<8DDJ4(*0IID]V3HUG%8Z*)1N-R)HR#
M1+0F32 R((+B;J,XF,CSCCVF+<*LG\"/TH!G(4V6B3 =.)&4>O1'5$DK!A,S
M!0?9]!5B;2FHN$E=R:;U'D+<0HRWQ7Z>S7,C?PZC!JWLO_PTFYRG'[]LQK/T
M;?9ZU+[P+S]-TVGYIAH2YL JIGTS+G[ BV_#Z8!#5(;91&36F<CHT%$-7!.%
MC 9JK-/>]P6,VPBJB),[,IQWX&8#1:_"S-8"[R%\N$33J_; [T348"GG6@D-
MMQ)4TZ19E3.^ P/;*Z[I2^H[@X0V60ETP4A@&2E$TP8/>8:&&R#\!6BFO7JX
M4+B6CM\_$M81=@\(N&)&_M*:_@.T<<#1@-Q9"FC+1EK.3$I,HBY'M/ALK.W3
MW"!B]WY-!>6LSB1M(-D>DHRW&-*7A$G**-I):.>BL2LML%(^1DGV$:3P$).H
MG85?2<PQJ+Z.I'M8[2NBOPOBE.:*)6Z),1R) QT(^N>,&$0JUSPH"[43S7<2
M= Q0J"?Q'G*&'](,^4OQ-4S&P_'I=$%5SE99Z1G)(!1Z38$1L""(<]H:&D#9
MJ"OCX'9*C@$ %62\,DOXG\^7!(.>[^];%=E]/#\[@\E%DS\.3\?#/ PPGKT(
MH3D?STHPMAD-PS!-?X7)!&;#K^E586XTW:30;L,WU2JVJ\'H4L$=)$E5"(QS
M@>XC4SZK*)41B4NA./#!AN_<;HV_GS3H"\\NWH_*V\:Q(/S+]2B)I3F@6:N)
M+:$O6>Q9GV*IA7:6\A0X4*B\WN^G:FO#%J:?!QZX5F ,85'C_LH\[J^@. $/
M*C%JI975;5E\[^[WK<I:OF'+KBO,/FKDD(;"UE<8M>[8["4NE M<./,D-'.4
M4IL#T<S@'HT[-7$Q4"*4,4S$#-+5CDS?3=%1@J"2 GHP;:\GBQS/(3LTK+V+
MD4A98&K $R.\#SP"\%#;H]ES8JYGY6\NWAW8K7B(GI^=C\JMJU<HZC"<#:3T
M69KL"4/SK.0=$8V9VE*/E2,PQ*2L[<O<3]71H:*R(BJ6PQ6#<]#>J1N?+GRN
M@>*&.A8<,3'S$H2)Q%H?"?56<1J82IS=9[;>\MRCT>JV,NNAMFLEI[]-4SX?
MO1OF-. F<X66"8DJE>0[2 +9 !$" D3.DQ"UEWH'LHX&%7VIHH>*KK=G7V X
M*32=Y'?-^/0=>E'QQ72:9M._IU%\TTR0UH'-FL:<+-&E@%\R/+PL,Y(D*9-0
MGF;):CL%G0@[.L345T<?!5WG148G^4/ZTDQF)0/\<9Y\GPZ"!>8930C?4FJF
MHB\WL!,!3I5C4J#/4[VZ:R4U1X>.2H+OH=3KM_%D7N+\[Q0_P;>?TQBEC62I
MD'URUI#@&9Z%Z/>6Y!\EX$0I@ [)Y=KW*5:0<G1@J"'RFTBP/2%A[@GA+]ZG
M,8QFPS1%B;P=S](D36>OOY7Z^33PRFL3$B<B<@1QH!E)UYHP"XXK9IQRM:/H
M6Y#[6!!5774W4><JW">>T[B@9T'[($DEC/<.S7"-7C?+I196H"W.O$E&4D-9
M[;J,%:0<'5IJB/R6H-;60<_2)R6>C]))7BF >=6:M (R!$6XC:5;3!#$"HH_
MIIR\2U9"$+6+^3K2MJOZSYXATHLJ]ETI.IW,!A]@?)K:ZB9&739"!$)5%"B>
MS(C5#,TPA9@/ %:(3C%T?.H5 .%//\!S[85[J_CL197-MB*M&!7_3L0BW=R%
MC'6J/+MHN'X.__YZSBV$OZR^+237HR(I_@DLDT09T$2:%(AG,1,5%7,VTIQ9
MIRMI^U;@BBK,^OI;1V"5]?8+2NKL_&Q!B+9&<I'0E<FQE(Y:/'MHN9H0HN$.
M6+2^T[WI>S1W[:6[L].V$GM30V854\XM(?#M"B&L4"RD)#2)8C@ )8YR1T#A
M"9!T1CH[7?"Z3WE77_H E;>QS%:NO'V5.'U(7]/X/%VYZ]Y[K=/J5^ZVZ*DC
MZTO53P%7IQ=@/"0F=3 N"9$M1!42,PR@8_73ZI=OFS)>/+<LA/F]XMQ,SDKS
MR1,_&IZV_0Z*\Q=F*7X:GN%'3O)'_.T4[;^%N!=.A!'60T13$#',B-32$*LD
M(XX'+SEN5R+6KC2I1_WVJ?<M*9E?Z&8# "&A=$C1JD3V<N3$H_]%/$>'S"C\
MOZQ]^ZP6[;N/?NP)O3?3_7M0?@^E9%OS,?<.A6 0<K8$-(]$XH9'@$E!=-0!
MC]#@1."'!N&=1F2.!;;KJ_L0XCKO)TT\#[.3R:)[3^M2F1BE*P:=<S00Z5PB
M7B5.0%*N(%G\3Z<<UCV&[&WOWE>T9Q_J;RJJH;)7NJ"GY#T6%$T7UQRZ$%4Q
M2+22D-V'C+;7T4V%5Q+PSK0?LZ+.IDQ8ZZYQK8FS ;=9R,I1DP17->(3.];Z
M'7&F'2E]';E65'9;S/<F_?$2#Y8)[F.7%X]<N9<2A$:."CGHSA,;<"/-5E$?
M98AHF74J@KSY[-T&+"I)O*DGKLH1J!]Q4$>%L28&M(]I:4FA1$E@<9)8L(DI
M*:7K5.%XZ'F9/9_4FPF\8GW[<ARN"QG'E[592_@KHOZ;2*['K$V2P4))-(,K
M 56;<3/22)B/"6B0+F77J7)CWPKLE+6IH;]U!-9KU@8,HQ2<P[-$4F0&ORL5
MB 29,(QYKT%T"E,]C*S-6F)?F;591V:]9FVBUYEF$XB1&@D)2(/C>"YP*E+
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MJ=6N_*S)P%+P35&G0LR2ALBD"LH5!\2&$'BY!)3TH,/SM[S@\!DFZ>?R C3
MBDNT["__?/'C(PL:7OP!DWC%9"\9V204"4F@P\RY0VQY2A(O8_PR0BM7'S>P
M-=5;5RR.VL^D>#LIE^XE-5[@T>A)R.C3R%!:: 1T-!.-25$/+-G:8SRZ4;;[
M$H(=(^U&O6-]A?5QWVA3(?UZ7J1_DMN_3E]\Q:VA>$UOFLG?\-_.!CD;;J)
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MIL*1::9<Y#:EP#O-D=VMQ;<6CT^+K'^;KS_0'7;J^6[CUD?-4?JE6[ M551
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MU;K%C(M?ER^EK^1?_^/_ U!+ P04    " "!@_94Y$;H;6>_  "U"P@ %0
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M]81%KEP>NFC80G94=+RWI3?W*F_NGX*:._?K<-K\60YAC$ LK#\^Y2E@ D%
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M!&#*92XIE3!V^L)[S3HU:FCEKG/?59O:9 R>92U[M<O^HY'>@RZ<E\&!.88
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M;H]/F]K>?*^/R>O'Y_,#5&\$Q$+3'.4@T;83(2<2<"DR$&N>*DBP%@S[T,Z
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M4'@=Q.\--HG?UURJ8O9FL2[6SQ_4Y\+&/2_6OYBW89:J'-,TA<#8(!E 1"G
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MOM]5=A#_G LDX8SPRU.-;7]?5?J,Z7W]GE!^O5U1\B;FKU#EMLMRHB7,8Z*
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MXYJ\=%G;:V+^.8K8.H(=K&2MZWPW%JBMV_WL[%I,I-8P24#"I UPQ1#PA$B
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MO0<?+Z_I5OT/4IYN'JQG3>UB88.?JY($#^:)$<43FS?.PW*FTS0C5,0 2L4
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MP^_')U:LK&OB_>IU43XM2S9_K]\MS63%5R7K+D+'':Q)RA-.( :8&6)'"5;
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MR).H ET7&6AA3R(+NU/C&!?ZW:R.P*3VK IWJL-^-;\O;+AYY2$*WJ7%@Y=
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MW.=?9>3RSO[\[0/NY:_*L+][OWYYEX_9D!/OEBMN4NE)@@GF>0:TDMCVAV:
M$R8!C1')$P3C./-PM9X>9&S[=HLRVBNG[?.EGR'2127>3D_/^O"8F2Z%',Y1
MY*,);Z=J(#7H\3)YJK[+%%S6>V?N'5#I74:_K_&N7-O1KR&^*;F>J8^Z"EMZ
M]?QZQLJR#GR!28[RG%*@(8D!8HP#2A4#!!+*"4**)4Z>2H>QQJ;\6J@V0*8"
M:S<P%=QN 4:7:';<088AK^^]8'?>_+=SUQD)M3&[,-*P6ZSK(A]MEAQNZ5I<
MTYYY+Y\6RVKQJ#K#5)[7Y?/KA513C63*8BT BG%JU4<&*+$1[IG 2)(8:>94
M.-EQO+&ID*9VY![F2=W6R- <-<@C"]VW[.9EWB_KDQ[8[%FGA""R0T%.)WIN
MJ,MY^?D#E^=T$O:X2J?;;?V%+E9#VB-<,Y^SS76JG$(I"*8)!#JFW.@>' ,B
MD%% $F80<P$EQN%C%L_!\?F8A@E6K+^>;:CB))JK*H-&-^%P7,V5+L['O(6?
M,C<S:*AIZ%NG.8<HUC-5Q3=9<7:NM[$C+Q*:>(W? 6,2ST(973#B-=*Z1"%>
M?68WS?N*E47Y43=)X<7\X72S6XXSABF!0(C,V'=9S@&#YC]9:OY/"1*GRJMN
MLMNP8S/S*M16<WXR3VT=*7YJTY%O-P49GL6>5>&&P"WD86KH^3$52*DY#CJH
M^O(CXE!1>=[=P2O_>C$S/S=6YLXQW^?%,YNMGM\JU2R#-@-O7AT"5 EYTP0E
M,6=< Z93"!#,;7)<0@"+54YBA2E5PMEMWQ7%V!16@S=ZJ@]&)P<IU*+!7N=7
M>_BS.\^2PYG $-SWK.;V1-@-C9A$[8P8,3867?31)C8W4_%IJ*GP.'L88DH&
M.ISH;VK\SC)NI?3B84?GAP]W&G*K_'O')3<_K*/7XO%IMGA6JG*VUO$F;8,!
MI#*84@F85!E 6&! %,M!FF<99K9!K8A]S.6S(XUMP:G/ 19U[(VG0^$LFX[>
M@A <]7UD<BHL;E<'U;@#EJ]W9B?41O[L.,/NTJ^)>[0%OWI#QS-7-9O91I9S
M^7M5K\;\?%^7ZVI# '*.)90"Z#S7 ,7"V*T98P G6&KS/A'BUIW,=<#1:0PV
M:VIR/K9X/8];KS'L>.8:D+>^M4@-M2)M S9JT/:@.URI"74">VVX88]A'84_
M.HMUO<\_U>QKL;)GO._FLOA>R#6;_;-8??NL9I7Y4WXKGKXNZB.;-XM'5LRG
M+$V5Y-R6C%$,()I*0),4 Y&K3"82Y<BM8G"'L<>F;2KX=NN[%2#ZLX;JD:3F
M.P&7-5#/M/:LC#HQZI7>UI&;&S+??$<<+"FN(Q6[^7)='W%#%\8/B_GB2=G=
MV?RA/KEH-.%4)"+G.LV!PFD"4*8%H&F,09SH),NQS&#B>71[><#Q'<[6O0>;
MP]E?FDJNOU9'M!T:-)YGVLT("L=>SUIGT^QY@[0]+/VE 7L^6:Q;]\:KK(1L
MXWA^L.'[.5X5_&1CQ^MW=5,H.V7WJLUT>;=>?5LLBW\K.>4TBX7" C!D6WYA
MG0(2)Q3$,H=9FG.(N?+92ET8:VQV35,7LZSK8M;IDA';P.V>1'F);S>=$HC%
MWEWVNX5%:Z#1%FDX9>) 1R!-<FFD0=6(@\B'.L3EEEN#X"NCQR8-+E?/7Y=L
M7C)1V4"OGO?^I8K;9IQ1AI@$&-D>\H11P'2> *X(-!NH# GIU4VP$XJQ*9W=
M / &;%2AC78%F=BP\/U_OC&LWF?B')T_?4]'WQZAOF;BAD#]#DP&#^'WP?!"
MP?T=:#H?]M_E8?[^I]_9C^)Q_=BX5RFC"G(I0)*@#*!88F#^%H-,QY#$,-9:
M.+7K.'KRV-1= \[=3;3/TW4G4&?I>]8N#:Z GN6STM[@M-E_WF NF9-B[#I<
M3E_0<??#RF]W<VG_L"V6O[.9JCKYE*ME(<SG??K?Z_"L:9[S.-$2@EA)LSVB
M$@%"S2<;IVE&="K2E'J=--T"9FS?M@59G:=4/^S ]=PMW3(_CMNI@5CO>[]U
MCO!)M)4ENG#5$%&C(;@.M9F[!<JPN[T I!UM!T,\LYO*K4M'OEXOE[:_"TI4
MGBJ: 9%GV.P#$PZH0*F-\U%,Y%S!7$Q7BQ6;N>G0O:=[*<7-&#T>[=@Q(E&#
MBU@%U4\?[I/GIN Z4]*SQFI;OC?(PFF9DP('4AO[SQY4#YP4Z_##/GU1UQSE
M+X]L-GNU+HNY*LMI(HG2A"M M.0 (4P PS$#.N:*8))D(M5^.<E[SQ^;"=.D
MSE88HQ:D;[;Q/H.7/]@ O/3\R?I1TB%O^*3@-^0)[S]OX+S@D\(<YP&?OJRC
M,_9D4EMS4O2J3DNU$;O%?%W,'S[6!TJ+>;DI)9;%*L8I8R#-$@*00@P0Q"6
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MH5X/_OP.R=-7>YOR,[U-OZKEXT+7:2^K1=OI=*I1*K00QK#FUKK.;=<I23+
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M_T/,UE5UQ-+LHTHEO[(?TRQF6%(HC&E$J/D/IX F/ $958+G21KGN?#+G^^
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MS-?ZTZ</[3?ZC]%K^/3A?U!+ P04    " "!@_94XD:K.4)N  !T_ 0 %0
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MX>UL&C:G@PY>6O02P'-N 3G"<R9%!M0K0;0-%AV(V@;U/D):.(/K&-*#Q=R
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M[)5[ZICC(3D"WFM?)I8X< DM,Z>*9\:5B:[ZK(].E W<E;<.2N[TUJVOE!_
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M2,M5"X9KK-S>/-IJ$D1.P%W T)IY!9:B)>9X@ANJ5""&=#KS=EJV&Y*>RI-
MSV)OP&:]=/,ILE2:?:PFV=]F)T5BDG .B"QWRQB$@!&&@C7.1IYT=-4[OSQ"
M4C>$/;7;_IIZ: !6*QZ>N46*SV=G9;>L$]J_;++<7T\#BGK\-96KYHNGLVQ"
M,-F6L3L*3WL,A<%%+<!IHPB7GNCJ?;/V(+,;_)[:U7_?^FH DNOYI!_=MSO1
M2K#,1QK \H!;RY4QI)1&H$%:85/D(=2>B[V-EF[@>FH/ %4DWP""WJ8_KTEH
M/IOB7\.Z*N=^7P"M="">,(B4E62 4KW%*(5D69""<<)D;63M2F,WQ#VU:_]>
M-?4#E!#4*#S><Z5CEQ0<I0#Y 1@3Y25Q=I674:KKE<4#,EBP,CA-DI2A>HI@
MCU52X7.*YY-TFK?F"GQ<S?$4AKM<]BTS$3>O+>XJ)_@E[A=O<6.[4/NRORMM
MS987[(*4._Y;'XH9\,A=S)>C]Z6AS\FW\6)$B<V:\X#!3[E/+ED"1I6$4*EX
M#,X9SCO=PN*G7D,2?G6%HAL+#@N1?G0Y.U2P+:#AUU3JED<$?^0,%2"U4V4^
M7$"_,6:045)K(LF9=LI%[(*']9+#(.( 9=U6]QZ2&UCAOXZGX[/SLPWARFAT
MPY*&D)%<$8W"L-.6F3!1,^MH-+[3Y< C*K^QZ,!*WT=ELQKR&UKQ[MLUPFGA
MD L!)/$RY,41L(39DE4=.$8"R%>GV22/*?[ZHL.4BE53_-[R:R#&WGKD88"0
M5HT$1X;D$*568&QYL@D,H9QB0GU:0U@*S)':3VB/4S7P:,(^78:>5-, V$H)
MQ\@[IJ33&FA4#@3U :R3#)QWL@RN$T;8RG JZP[K8];6Y3TE-#L)MA$P7*OG
M.5D^=_/Y=PS45D48(VH)(28'4%0G% >&:#:&,A);:\IC=L)6SP1YD*)A+<X1
M %1)&0U ZVU:KN_ W\P6BY%E.63K"7@;(PA1MH1V'DKQ1&#1.19JWPC=(&#8
M"N2>@;._J)L8D_L^K3L:7SP'GX1P?G8^*6.,7J0\#N/E2 B?A<X>J"O/;LD@
M]C,Q(!BZ]H[B#A"U)S4_3M6P=<@]8ZJR4@Z=9_6Q3C;1[[/Y'\C-<_=EO'23
MD62:6!HLZ)@9"$,B&.,C$&\D(X'*Q+JU>KSYN<-6"/<$C$/EU\"1M%4RORU2
M/I^\&><T8CHSB2X<1)DP6&"N3-W2#CAWP47&$N>U+4T'LH8M]NW9U-162P-(
MNU:"=;OPZA]I$E_-YLC;R&1%8DX&5)($@P4\J0W5 I(0J>229$%K1V&="!NV
MT+=GM-5730-X>ZBWJ7'44Y)PJT0-0D8/KO1-=8Q(2P7'H+0VR [L0=M;JD_?
M;G@=)30 I]^F\Q1FGZ;C?Z'GY;X]2U-T^<JDW)!]LD9#\!3/>^<=F, (.,ME
M\#8D6[TYP192ABW<[1E(-<3?+HJN,N/2U$U6<T]79:()E7A1J##RTBL=$@,>
M5[E))".K2@$USC))M96V=A;9 >0.7,4[#!RKZ[$!R%[RM*%_P^LH"<FU]Q9C
M'!71'<CH?BJ.@0[U.FE!-+DJ[ZB=+GN3E($+=OMVSBK(O_$)*=TR^#85S._7
M&Z\LW'O6XO8ECYV^V)'Y_O,8$6Q:$6: <8=1IP\:K(D1N.!!HW05C;7]G?[R
M&"^E>N;&Y4KO79KGV?RL#*P_]9/QIY5.R[XK_=X^CL_P5TJ)ZG*\R.NVENO7
M5,ZI"SD;W( ,MV*9)N?0@P4552#.!\M#[<XN=2AO-@=R%Y1MZ71P3*4.G"F#
M)U \#\O3^8<T_SH.ZS0Q':.P)5G$6A) 6)O 2_0ZG"!,NF3P/YTVZB,),_>M
M/2RLAM#_K*(RV@!3\5PW'"Q>S(HH1S%+]%=2!KI*(6+HLUJ#.].X+"W1B;-N
MC;R[(>HN </EX1VNT[L .5# 0Q>AOTI_7O2166Q2S*ST60:N4 *%?#38&-CX
M!-E(XJ,(D0OWF%^VY;,'5_VAVIK5$UT+"=BK#6 )UT;' !Y5"()(7N(;!HD&
MDZ@40MA.[T)5T_%[RW09^%C93^PM8&4#\22"<27H=;:DL9J,.P5=// Q.1*$
M3=EVNB]X6LGZ.REK2[+^+I(;.F?[1K*YTY009RU:2$&0>?Q;N=D'9%I3ZKUR
MO--DL*>7K+^3RK8FZ^\BOZ$5?R/9/'J52=8!M"CM@ /2;!G:/$9X"FC_A.$U
M]GJ#R?I[*WYO^35P17SPT?AAZ>;+%VZYMIG*T<QLN=G,6N 1J0PZUHX#8=';
M1$VVM%.IQS&O4VYP,&QFY8".2@. ^!&VP]7#@>;&NQ@X))4I""70G$A1FA($
M+QCCB<?:V>;UJ!\V&?1'V ;[ >%'V +X#\:S2$?.8>2;$P$ER_M^CGB4!N;0
MG<9#5DO\GZ@]7+86[4_\%G1/[-7> OL X0?HS++UO6]TZZ0[RG/GB+;SX'E;
M )=/GK\<I)8-!;AN2..OQ?3_-O7CR21=7ONYTCYT#:8-<?MH8J]UZ@G_<#8K
M/3%?$7#UZL>Y9+B?/5J6<J/N+0>O X',F&#$$:5Y?<?_#AD'78L_+M^3._*]
M:C_%; C<B(@N1LKEM@A%H8@&;U)IA,9CM.PQ@!U.QM 'UV' N''5?CQU-'WF
M[+/K5^[O7KDU!ZPVK*&[C^4>S1U+.5+&-.2,$:T@*H C$3V<K&E.*B2,+]HU
M=W=[#ER(_.ULF19O9FXU]/75>(K.'A[L5TM?FS(1M!,Q1\C*.4#\:-SA/$-0
M(2A!712Q=F71 >2V9Q=W0=#V5F']ZJV!:/2^@2>K\A;D\V)\Q?>/-UF,C#J2
M8^F2HDN7I8AQ/T\"HN&,&EMN:&MOSCW('/I)M"XD^];3#W=&7X92=_\Q_O+M
M?W] NNSQB!O6 Z@@T!X=!F5IS()K$-&7K$A%P7"7P&GAHW:>*%([Y;YV?/1Q
M[F*Z*]R1CX):F30P6II>.HFL)9$@!A%9L(09W:WL?,L"[9W=NRCS1DQ30X0-
M',H7F^DR%>H:*\SI' U+H$GI^:Q+E[I5IE4@T6HCI-&U@?X .>T=LOM@I[;<
M&X#0W4WP]WEI]Q)9]HQJ";R,E!4Y1C#91%")YM)BWJKJ,\JWD#+T2W!=Z-20
M]_ZPF2W=I YL)I/9G^4%XM5L_F)V[I?Y?'*//36Q)&T$ TZ4&H32$-[1D*"X
ME8Q83VVW],9=4-2)LJ'?52N#JKXVAN^LLWW'O$W+Y^O!B2-/,J,"-PM3LB3]
M2@%64 &:24&]L)S[VC/''Z)GV!8]_=NJ/25?S6 U%S3>^OY0X>$6,AH)!+L(
MJ<>0SRH9!?$!B(FA-%WA8&-$'Y]$;H0(U+G:Y98]W!'?=[%S>:%SL2D-E9$0
MH8"+5-(,>"PY-PJD\(&IJ%BTM>=^=:&KO<AQ%TQTN6([2!,_W)U:C9DX5=8=
MU@ >95[.?>@VS)&<LH*\:FY ;0#OLX"4I>+EL9>ZVEY1#Q;OH2B;!Q:RS 1H
M)KB]I&-@#3HX&"PQ%I,QV=<>BG/H[<91[=LN"-CE=F,7N3=PN]'-5$LB\/^A
M3ZS07@NK>&FNS0$=YAQ#<92K=V&I=F@>]<KL$%!5UT33A^9%/QMWK97-/H?@
MO9]3[U![G,Q*A]36_CZ7V(I,N<1,1$LB2H=[8<"'F(%PGFDRQ!MSM$D4M0ZP
MK0N\&"_"9+8XGU_/!Y#)V(AN(L7X' 1!*=C,.&BI+#=1JF1K)^[M0E^C,Q;V
MPD_G3K&'ZNG)V:C]$]8>^+1^[56/"6>/H\X[PIV($I37I329X8D8G8?$6([)
M1<.KSSL>SFI=[0%K Y>26:#2E/&*4H++^*7RPF9#8Z"R=GSQ.%6M6ZA=L-+9
M0NVGDR=GERZO$N_[X0&7#'NOU:]-VYW=HUF\8'+21!#@3""*A=/@D\,8P!)-
MI-2E2^-3LWB[C/SB3'E3+O5\2<PK/2AY1N8Y5Y1H2>1_S5&\=7%SR$3>SOII
MX'9B*S?/OG_$CUC5;1N1,Z?4@Q.BI).D,I[)!Y!.,4HD44X=S<.X(NOI3/7M
MCH>N1^Z>RFD9;X6A34>N@))1S)8R[=)FUV@-^$$6 N.:(U&&J*/9]RNR&K5N
M^T*ALW>WGUX:@-JK\_ETO,3 >54&\:W\[:)/&^.*!.,R!&,#LD,5F$0(2,N$
MD98RZVM7!6RGIE%@[:OX62]:: !/SV=G7\[QXRXEM&%#TI STP[42CI9I?*.
MFT%R4NZ+32#=1AKO='=_+RF-SI"LA*0:\F\ 1J?+SVG^JT-A3M/\^W4Y;?@)
MUCC&T6,P2N&V,,:"X9Z"#5%Q%K-4L;:'_QA-C<Z8K 2LJAII &$?9GGYIUM9
MW(N_ODA?TV2VXNGY;''9KS1EKIR/Y9HF:(R(O !'2^ZOCIXX)S(CM7-U.A/7
MZ S*2ICK1T<-@&]5Z/?;%+7S?#;%P/M\U?YEPXM1PC%K>)FE6"KQ&>XAC?M*
MQARXHRPS6CN2?(B>1J=95H)8-4TT@*HWR2W2Y]DDOC[[,I]]3:O98Q<;)$J?
M(^>@-2VO81'M-$%W(#%.A8LAD^K-U1X@I]%YEI4P54L/#4"JP[P?)G,*&FTM
MU\& "-Z#-T9"$C(I8F6FIO;Q^#A5PSKYP]Y[[:>:EL&VKKQ2-$<6T;>4J6R=
M1!-XH3G8TDR>V!Q=JGT?\3!%C=Y)[*G_KO#:71D-0.O&^'(D(HS=NLW:ETE:
M*6P:3\YF\^7X7ZOO;V5^E$V*2>A5X(Q\!Y2FM<[BEREI88G+M/:U:RW:&[WX
MJ /7011\:.U=OU;SLK%-6CDD[\>?/B]/\V^+M&XSDG%W;9':+6&-M,B6*D[
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MSL-%XGHPVCGI0%,JREQ7@CPX_-++H*W+[D[0OFV^S_T+-*+[?30VJRR^%B#
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MD1D@/B3#)%.:=^M:\/A:PQ2G]&4>ZHJV@5>V+7[7U1.18\%%8S,8IDD9*6G
MKOX@A@J30DK5!T0]1M.PI735/=5>5-$ M!X)!E]^"Y/SN$DKQ?_%C^[;*'LO
MI;$*5)(1!/5XR*+(@+&$VU09)JH/?MV#S"9#I3UQLMLKR,%*:_K:\,/XTW2<
MQ\%-EP<]ZM[[.?6N Q\GL];5WWCQ1SD^?YN&-%_BR;D<I\758QLS)@3K0;F
M/I&R!H,N*D!K[Y,VV?#ZKY4/$73X=%?\U +YHI:R$FZT,)DMSN?7KLACY)(S
M7VJ\F ;AC +K600, A#G5 =2?5I$%[H&OO:KAI.[$U\KZ^3)V9\#7BH>^KA^
MK5&O[Q$/@TU$JSC/P)T)($0VX+0LC0N-\4'Z1*MW-^[5*%UUT'F)G[O\_OLX
MILT9_>S[K^Y_S^:70G_V_7WZ4A*OII\^I$^KQ-*U4\H\CXH2#\0:@4XIC^"I
ME: LY0X] TE,KBR3"F0W;=)V0-GV7O?'T6@#D< =*_[L^[,T#9_/W/R/U?VM
M2A2M-EIPYDKY1>DT:LKS$#JRV6&L+D.N[?8_1E,K#?"/!)+'SMU#--8D B^X
MV5P)&6JB3HZ"3AR=%&<3.(E.BN%$BJP$E:3V,^YC- V+P+H(>!1>!ZBC 7B=
MA%#*J!?O,;@>?RV[[V(BKLA":)WPC' EYUYD\ Z=U$@4"8X8Z:OW6MM&2VMP
M.D3C=^<C'B[^!F!TSYZ['#]!O9*Q3/ 2V98.$(0A*\) EM$H8B/-MO9DH@?(
M::5-=3.GXUYZ:A%RUUJ_:VF3"2@BP4K1(Y7(BDT$#3XRJ4RP@=7N /, .:W9
MKSU5_AB4]I1_"U#:[+D[+%UT_+7$N3)^4":!%CF@U^!,Y*"8((XK*:D3M>'T
M,$F-06I?U=^&5$4]#)P ==.6KS9;-L)'DQ1PAJ>YB(J#(X)!)AAS1^XUE9W*
M_1[)?+J[<BN=E(][Y%70PL 8>NO.4&HW>-AL,K3+4@LO 66"\M!6@+,R0^9,
M^NR%=Z93"\9'H+25@.$RIP[5Z*RV>(?.F3F=I@OJ-U:2"Z(%QK*0O$(S'+,"
MJSDR$U2(BF4B>+>2]3L?/9S:*^EJ5DUP#7@M=\SI#?&\N7Q43\IRE:T!EE5<
MG\B6,H4"HS(Q%U*6M1\6.I(V;"O7H6.Q/O37 "SO.&_OTKQ\PWU*=!28(:RD
MKA5O#0,.[L$QR4$&%3,7E+GJ#SH/T3.L&]T+ !Z+TO;51M//S\]G9V?CY6I?
MNFDLZ3^X4],TC/>K 7[HX^H]/W<FNM+S\[7U3FZM=Y6;</E0J$AR/ 0#)+-0
MFD]KL"XYL)$'A1&=2+K^L\(.!!YNICHL=I6IH;E/F5(%IIAW4;:?UYJ@I^E%
MUMHE=7MFTG'$T4@>37_8NFO0>M-;Q?;#1S9R;]V\6/BOZ8"<FUT^_BA&\&&F
M!C&*CJ68O?% R_@/@3 &SX1!]%)")*.(MOJO_4<PBJN Z(&5ULZN2J7?%J40
M8S(@.,O@9/3@G2516LN(HX^AK--*3\F6[0*)&_%G57$/?%/UOC2Q75W&>.(B
M$9H"NI8)[2W58(RGH!6U(;(L6>KDX#]R,W6YX(#C)NLJ<':H-%N P.8B)9="
M0R72)HT_$@O.>0-:$$IEX"[33L]O74 P],W4GLJZK>X])#?T"\>Z<^/ETPPS
M+)?65:E,$%'*@-'1@DY61:^)"**3?_S8X\;U10=6^CXJF]60W]"*=]^N$6Z4
M#LYS#25?!023I#PA"T@Q:>N-B[G;.(Q'7[6^[:CX7HIVJRA^;_D-_=;PP(EW
M=5LE=%)>&()B\:QD&%/P&-T!T<@/53Y)Z0_U$G>[0>YGU' OQW\_8AYTKLZ&
MI0E^:S;?J.9RZ,'[V7<W67Y_E=*(Y:"<\AP\H:4#HA/@LB? E#2!!-PBKBMN
M'ENK3:=Q3]W.^A/S\/;F,78VM]FG^:+D\]U\'-*(^^!(2 %TUAQ=,5W:P>6
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M@*/U&DW>6?J "E\=@V\V+*X2,TF*5@4=@"6OD15*P1CM0'J"L3H&[AV'/.^
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MM5QA65AFGS_.KZY^G"_J#R=)$=E<IS:*>B"94E$')P=1,VX-HE9QKPL,Y["
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M9G+[Z+N,MF(6D?D2O5M3O"U?>\3E I8D4#$CE$NV];6;AQ2<NJ+\1,LET?U
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M ?WD-+:&ZZ<GP"?#&TMB)IA'+;5:49_KJ07B/0GU4*:&+8$%H LZ%E*XA:<
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M>S41*Q]MWN4?KQ6;=U7X$$FH<*M5GOC.L_P-7YWZ[U]/_@=02P,$%     @
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M;7=-AOXE<A\U1@=-;\DO2[%])<22AOU2$U2-MRUC2SYA$MG/)%6&9]M1".>
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M(RDG9N;=.P6^?_[8EV+>_1(RQX=0KO>7?./@N+P6Q]CV0/W\#U!+ P04
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M-#,P+GAS9%!+ 0(4 Q0    ( (&#]E3EW+'M=1H  +<  0 5
M  "  3,% @!C<V)R+3(P,C(P-#,P7V-A;"YX;6Q02P$"% ,4    " "!@_94
MTC@#]M<U  "27@( %0              @ ';'P( 8W-B<BTR,#(R,#0S,%]D
M968N>&UL4$L! A0#%     @ @8/V5.1&Z&UGOP  M0L( !4
M ( !Y54" &-S8G(M,C R,C T,S!?;&%B+GAM;%!+ 0(4 Q0    ( (&#]E3B
M1JLY0FX  '3\!  5              "  7\5 P!C<V)R+3(P,C(P-#,P7W!R
M92YX;6Q02P$"% ,4    " "!@_94<3T-;18#  #U"P  %
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M2P$"% ,4    " "!@_94=/A_3,4#  !2"P  $P              @ &4G ,
I8W-B<F5X-#$T,S R,#(R+FAT;5!+!08     "P + -,"  "*H ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
